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Background: Tuberculosis (TB) vaccine candidates have been mostly ineffective and it 
remains unclear as to what constitutes protective host immunity.   Despite high levels of 
IFN-γ at the site of disease, the Th1 cytokine associated with protection, many 
individuals still have progressive active TB. Whether a Th2-like immune response (IL-4; 
IL-4δ2; IL-9) can subvert protective host immunity requires clarification. 
 
Methods: Blood and/or broncho-alveolar lavage fluid (BAL) were obtained from 
individuals with confirmed pulmonary TB [TB; n=51(BAL=11; Blood=40)] and 
presumed latent TB infection [LTBI; n=38 (BAL=14; Blood=24)]. Expression of mRNA 
encoding IFN-γ (Th1), IL-4 and IL-4δ2 (Th2) from whole blood and alveolar lavage 
cells was determined by quantitative real-time PCR. Human recombinant IL-4 (rIL-4) 
and IL-4δ2 (rIL-4δ2) proteins were expressed in a baculovirus system and functionally 
validated using 3H-thymidine proliferation and B-cell flow cytometric assays. The effect 
of IL-4 on mycobacterial containment (colony-forming units (CFU)/ml) was evaluated 
by co-culturing effector T-cells (pre-primed with rIL-4 and/or PPD) with H37Rv-
infected monocyte-derived-macrophages. Flow cytometry was used to evaluate cell 
surface and intracellular biomarker expression in co-cultured cells. The impact of 
neutralizing IL-4 (anti-IL4 antibody) was also evaluated in this model. T-helper cytokine 
levels were determined in RD1-stimulated cell culture supernatants using a Luminex 
multiplex assay. TB-antigen driven IL-9 producing T-cell populations were investigated 
by flow cytometry. 
 
Results: IFN-γ and IL-4 responses in TB were compartment-specific (high IFN-γ levels 
in BAL and high IL-4 levels in blood). In whole blood, TB patients expressed higher 
median IL-4 mRNA levels (p=0.02) and a lower IFN-γ/IL-4 ratio (p=0.01) compared to 
LTBI controls. Functionally active rIL-4 increased T-cell proliferation and B-cell CD23 
expression in a dose-dependent manner. rIL-4δ2 inhibited IL-4-induced T-cell 
proliferation but protein yield  was insufficient for further downstream experiments. In 
the mycobacterial containment model, addition of rIL-4 was associated with a reduction 
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in mycobacterial containment (CFU/ml), increased levels of regulatory T-cells 
(CD4+CD25+FoxP3+; p=0.0006), decreased CD4+ Th1 cytokines (CD4+IFN-γ, 
p=0.0005; CD4+TNFα, p=0.01), and increased macrophage DC-SIGN expression 
(p=0.02) in a dose-dependent manner. Anti-IL-4 antibodies abrogated the effect of IL-4 
on mycobacterial containment and the expression of CD4+IFN-γ+ (p=0.03) and 
regulatory T-cells (p=0.03). Soluble IL-9 was increased in RD-1-stimulted BAL 
supernatants from patients with TB versus LTBI (p=0.02). CD4+ and CD8+ IL-9-
producing lymphocytes exhibited a Th9 and Tc9 phenotype (IL9+IL13negIL17neg), 
respectively and Th9 and Tc9 levels higher in TB versus LTBI in both BAL (p=0.02) 
and blood (p=0.03).  
 
Conclusions: Patients with TB from Cape Town, South Africa, have a 
compartmentalized and Th2-skewed (IL-4 and IL-9) host immune response. It is shown 
for the first time that IL-4 is associated with subversion of mycobacterial containment in 
human monocyte-derived macrophages, and this seems to occur, at least in part, through 
a regulatory T-cell-related mechanism. These data have implications for selection of 
effective vaccine candidates and the design of appropriate TB-specific 
















1.  CHAPTER 1: Literature Review 
 
1.1 Study rationale and objectives 
Tuberculosis (TB) is one of most widespread infectious diseases globally and, despite slowly 
declining incidence, still causes 9 million new cases and 1.5 million deaths every year [1]. 
This is none more apparent than on the African continent, contributing to one quarter of 
global cases, where inefficient control programmes, high levels of poverty, emerging drug 
resistance and HIV are fuelling the epidemic. Furthermore, current vaccine candidates, such 
as BCG and MVA85A, do not offer sufficient protection to prevent disease progression [2-
4]. Thus novel approaches to therapy and the design of effective vaccine candidates are 
urgently needed but will require a comprehensive understanding of the host‟s immune 
response to TB. However, despite substantial research on the subject, a definitive answer as 
to how the Mycobacterium tuberculosis (M.tb) pathogen is able to evade the immune system 
and cause active disease remains elusive.  
 
The spectrum of disease caused by M.tb is more extensive than previously thought. Indeed, 
the outcome of infection is heavily dependent on the host-pathogen interaction or, more 
precisely, the nature of the immune response evoked by M.tb, but this interaction is not well 
understood [5]. Most exposed individuals do not develop TB and the bacilli may either be 
completely eradicated from the host or remain in a latent non-replicative state under the 
control of the immune system [5, 6]. On the opposite end of the spectrum, development of 
active TB may manifest as a subclinical infection or overt cavitatory disease with extensive 
tissue damage [7, 8]. However, many of these individuals have no obvious defects in 
immunity and actually have very strong measurable Th1 responses, characterized by high 
levels of the type I cytokine IFN-γ, at the site of disease [9-15]. Indeed, the current TB 
vaccines have been designed to evoke such a response but still fail to provide adequate 
protection. Therefore a strong Th1 response, although important, is clearly not enough for a 
successful host defense and the question remains: Why do some individuals exposed to M.tb 
develop active disease whereas others, despite repeated exposure, remain healthy? The work 




 The host immune response to M.tb involves a complex cascade of innate and adaptive 
mechanisms that work in conjunction to combat the infection. Various innate responses, 
elicited mainly by macrophages, neutrophils and specialized T-cells, are the „first responders‟ 
that attempt to eliminate the pathogen, but are often circumvented by M.tb specific 
mechanisms [8]. As such, adaptive immunity is initiated to reassert immune control and 
involves an interaction of various helper T-cell subsets and cytokines responses. However, 
dysregulation of T-cell mediated immunity may also lead to immunopathological 
consequences. Indeed, there are a number of hypotheses that may explain how M.tb is able to 
evade and sabotage a protective host response. One such theory is that in TB susceptible 
patients, mycobacterial antigens induce a small but significant Th2 response within a 
dominant Th1 environment, which disrupts protective immunity allowing M.tb to evade anti-
mycobacterial cellular mechanisms [16].  Indeed, there is considerable evidence to show that 
IL-4 (the signature Th2 cytokine) is increased in TB patients and these levels correlate with 
immunopathology [9, 17-21] and disease susceptibility [22, 23]. However, IL-4 is a very low 
expressing cytokine and its measurement can be technically challenging [24-27]. Also, the 
existence of IL-4δ2, an alternatively spliced variant and natural antagonist of IL-4, must be 
considered when evaluating IL-4 responses but this cytokine has not been well described in 
TB. Evidence suggests increased IL-4δ2 mRNA expression is associated with a protective 
disease phenotype [28, 29] and response to anti-TB treatment [9, 30]. Furthermore, IL-4δ2 
may exist as a functional protein and acts like a Th1 cytokine in in vitro culture [31, 32]. 
Consequently, other studies failed to detect differences in the IL-4 levels of TB patients and 
controls, which may be due to the use of insensitive assays or failure to distinguish between 
IL-4 and IL-4δ2 [12, 33-37]. Even now, commercial immunoassays are not available to 
differentiate between the two isoforms at a protein level due to a lack of discriminatory 
antibodies and the only currently available method involves measuring mRNA by 
quantitative PCR assay. 
 
Another caveat of previous studies and more recent ones as well, is that most researchers 
tend to focus on the peripheral compartment to evaluate cytokine responses rather than the 
site of disease as blood samples are more easily acquired. This is surprising because the 
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immune profile and cellular environment of the lungs in pulmonary TB can differ 
significantly from the circulating blood due to cell migration and enhanced cellular activity at 
the site of host-pathogen interactions [38]. Indeed, only one previous study, performed in a 
low TB endemic setting, measured IL-4 and IL-4δ2 in both compartments of TB patients and 
controls [9]. There are none that have measured the compartment-specific levels of these 
cytokines in a high burden setting. 
 
Despite evidence of increased IL-4 in tuberculosis, it is still unclear whether it is causing the 
immunopathology or is merely a consequence of excessive inflammation. Some studies have 
reported an inhibitory effect of IL-4 on known anti-mycobacterial mechanisms in 
macrophages and T-cells [39-44]. However, many of these studies have been reported in 
murine models which have limited bearing in human TB. For example, most murine models 
fail to develop cavitatory disease (a hallmark of transmissible disease) and lack the structural 
complexity of granuloma formation and the wide spectrum of disease phenotypes which 
occurs in humans [6, 45, 46]. Furthermore, there are no studies that have directly assessed the 
impact of IL-4 on mycobacterial survival in a human TB model.  
 
A better understanding of the host response is important in developing new approaches to 
treating and preventing TB. The failure of current vaccines suggests that simply inducing 
protective Th1 responses may not be the only answer. If IL-4 does contribute to the 
development of immunopathology then it would be useful to identify the specific IL-4-
inducing components of M.tb so that they may be incorporated into the design of 
prophylactic and therapeutic vaccines. Additionally, immune-modulators targeting IL-4 itself 
may be useful as an immunotherapeutic intervention to decrease treatment duration or as an 
adjunct in cases where treatment options are limited, such as drug-resistant TB. 
 
Thus the overall objective of the thesis was: 
 
To determine the role of Th2 and Th-2 like cytokines in the host immune response to 




The specific objectives of this thesis were as follows: 
 
(i) To evaluate the mRNA expression levels of IFN-γ, IL-4 and IL-4δ2 in ex vivo 
bronchoalevolar (BAL) cells and peripheral whole blood of pulmonary TB 
patients and presumed latently infected controls. A multi-compartment approach 
to assessing the expression of IL-4 and IL-4δ2 in a high burden TB setting has not 
been previously performed. A compartment-specific profile of IFN-γ and IL-4 
mRNA expression was observed and increased IL-4 levels were found in TB 
patients compared to LTBI controls (Chapter 3). 
 
(ii) In order to determine if the role of IL-4 and IL-4δ2 in TB is causal or a by-
product of disease, it was first necessary to clone and express human recombinant 
IL-4 and IL-4δ2 (rIL-4 and rIL-4δ2) in a baculovirus-insect cell expression 
system. IL-4δ2 has been previously expressed in yeast [47] and mammalian cells 
[32] but never in an insect cell system. Both rIL-4 and rIL-4δ2 was successfully 
expressed in insect cells but low quantities of rIL-4δ2 were obtained which 
limited its use in downstream assays (Chapter 4). 
 
(iii) Following successful protein expression, it was essential to validate rIL-4 and rIL-
4δ2 function using a 3H thymidine proliferation assay and CD23 flow cytometric 
assay, as performed in previous studies [47, 48]. Functionality was confirmed as 
rIL-4 induced proliferation of T-cells and CD23 expression on B-cells whereas 
rIL-4δ2 inhibited IL-4-mediated T-cell proliferation. However, the low quantity 
of rIL-4δ2 obtained and the high concentrations required to produce a visible 
effect prevent further assessment of rIL-4δ2 in immunological assays (Chapter 5). 
 
(iv) The next step was to determine the effect of rIL-4 on the ability of PPD pre-
primed effector T-cells to control M.tb survival in monocyte derived macrophages 
in an in vitro TB infection model. rIL-4 subverted the ability of effector T-cells to 
contain M.tb within macrophages in an IL-4-concentration dependent manner and 




(v) The next logical step was to assess the effect of rIL-4 on various cellular 
mechanisms potentially involved in the IL-4-associated subversion of M.tb 
containment. This was determined by performing a mycobacterial containment 
assay (as performed in (iv)) where cells were stained for surface marker and 
intracellular cytokine expression and measured by flow cytometry. Addition of 
rIL-4 resulted in decreased T-cell expression of Th1 cytokines, increased 
regulatory T-cell expression and increased expression of DC-SIGN on 
macrophages. These effects were blocked upon the addition of anti-IL4 antibodies 
(Chapter 7). 
 
(vi) In parallel, the production of other Th1, Th2 and Th2-like cytokines were 
assessed in RD-1 antigen stimulated supernatants of bronchoalveolar lavage and 
peripheral blood mononuclear cells from pulmonary TB patients and LTBI 
controls by a Luminex multiplex assay. Compartment specific differences in 
cytokine expression were observed in TB patients compared to LTBI controls, 
most notably characterized by increased levels of IL-9 in BAL and decreased 
IFN-γ in blood (Chapter 8).  
 
(vii) The increased production of IL-9 observed in TB patients led to further 
investigations into the specific helper T-cell subsets that produce IL-9 using flow 
cytometry. It was recently discovered that Th9 cells were the predominant 
producers of IL-9 in allergic inflammation [49, 50] but these cells have been 
poorly characterized in pulmonary TB. Elevated levels of IL-9 were produced by 
CD4+ and CD8+ cells of TB patients compared to LTBI controls in both 
compartments (lungs and blood), and these cells exhibited a specific Th9 and Tc9 




1.2 Origins and history of TB 
The early progenitor of M. tuberculosis (M.tb) is thought to have originated in East Africa 
about 3 million years ago where it infected early hominids [51]. However, there is less 
agreement regarding the emergence of the modern members of the M.tb complex and how it 
spread to the new world. Whole genome sequencing and phylogenetic analyses suggest these 
modern strains originated about 70,000 years ago and spread together with modern humans 
migrating out of Africa [52]. However, a more recent study proposed a much later 
emergence, around 6,000 years ago, and may have been carried to the New World by 
migrating seals which then transmitted the disease to humans in the coastal regions of South 
America [53]. 
 
TB has plagued human civilizations since ancient times. The earliest evidence dates back 
5,000 years to ancient Egypt; archeological evidence of spinal tuberculosis (Pott‟s disease) 
was found in Egyptian mummies [54], which was later confirmed using DNA analysis [55]. 
Similar evidence has been found in Peruvian mummies [56]. Written records of TB have 
been described in early texts from India and China, the Old Testament of the Bible and by the 
ancient Greeks where it was known as phthisis [57].   The disease was endemic in Europe 
throughout the Middle Ages and peaked in the 18th and 19th centuries where the lack of 
treatment, overcrowding and poor sanitation likely encouraged its spread and high mortality 
rate [57]. Initial attempts to treat TB involved isolation of patients in sanatoria and alleviation 
of symptoms by pneumothorax but the exact cause of the disease remained unknown [57]. It 
was not until 1882 that Robert Koch identified Mycobacterium tuberculosis as the disease 
causing pathogen [58]. This discovery was followed by the development of the BCG vaccine 
in 1921 [59],  the use of streptomycin as the first effective chemotherapy against TB in 1943, 
then isoniazid and the rifamycins a few years later [57]. However, despite improvements in 
sanitation and the availability of effective therapies, TB remains a major cause of morbidity 




1.3 TB epidemiology 
The epidemic of TB is greater today than at any point in history. It is the second greatest 
cause of death from a single infectious agent, behind only HIV/AIDS. According to the 
WHO, there were 9 million new cases of TB and accounted for 1.5 million deaths in 2013 
[1]. The 2013 global TB incidence rates are shown in Figure 1.1. While significant 
developments have been made in reducing the burden of disease, progress remains slow and 
many countries are unlikely to achieve the 2015 United Nations Millennium Development 
Goals of reducing TB prevalence and mortality by 50% compared to 1990 levels [1].  This is 
most evident in the African region which accounts for over a quarter of the global TB cases 
(2.6 million new cases) [1]. Eight of the ten countries with the highest TB incidence rate in 
the world are located in Sub-Saharan Africa and this region has, by far, the highest mortality 
rate due to TB [1]. The HIV epidemic is the primary driving force behind the high TB 
prevalence and mortality in the African region.  
 
South Africa is a particular „hot-bed‟ of TB activity in this region, having the 5th highest 
number of TB cases worldwide, behind much larger and densely populated countries such as 
India and China [1]. Moreover, it has the highest incidence rate per capita (excluding 
Swaziland and Lesotho, which are „land-locked‟ by South Africa) in the world [1], equating 
to ~1 person out of 100 that develops TB every year. In this country, the disease is largely 
driven by the high prevalence of HIV (61% of TB cases are HIV infected), factors associated 
with a low economic status (poverty, malnutrition), an overstrained primary healthcare 





Figure 1.1. Global estimates of TB incidence rates in 2013 as reported by the World Health 
Organization [1].  
 
1.4 Pathogenesis, transmission and spectrum of TB infection 
Mycobacterium tuberculosis (M.tb) can infect any organ within the body but infection of the 
lungs is the most common accounting for ~85% of cases in high burden countries [60]. The 
bacteria are transmitted via droplet nuclei, approximately 1-5µm in size, aerosolized in the 
cough of patients with pulmonary tuberculosis [60]. The risk of infection depends on the 
bacilliary load present in the cough aerosol of the index case, the duration and intensity of 
exposure, M.tb strain-specific virulence factors and the immune status of the contact [5]. 
Upon inhalation, the droplet nuclei travel through the respiratory tract, escaping the mucosal 
barriers in the bronchi, and eventually end up in the terminal alveoli where recruited and 
resident phagocytes, such as macrophages, dendritic cells (DCs) and neutrophils engulf the 
bacteria [61-64]. During the early stages of infection, M.tb can evade the initial host innate 
immune mechanisms within infected cells and undergo intracellular replication [65]. Infected 
DCs and macrophages also travel to the local lymph where T-cells are primed and clonally 
expand in response to M.tb antigens. These T-cells then migrate back to the site of infection 
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thus signaling initiation of the cell mediated immune response, which can take 2-6 weeks 
after initial infection [66, 67]. The subsequent interaction of macrophages, T-cells and other 
cell types at the site of disease results in the formation of a granuloma. 
 
In the vast majority (~95%) of infected individuals, the bacilli are effectively contained 
within the granuloma in a persistent non-replicating state, known as latent TB infection 
(LTBI) [68]. These individuals show no clinical symptoms but may display M.tb specific T-
cell responses, as indicated by a positive tuberculin skin test (TST) and/or IFN-γ release 
assay (IGRA) [10, 69]. However, evidence suggests that the LTBI phenotype may be more 
heterogeneous than previously assumed [6]. For instance, a proportion of exposed individuals 
(may be up to 50%) show no immuno-diagnostic evidence of T-cell sensitization 
(consistently TST and IGRA negative) [70]. In a South African study 20% of highly exposed 
persons remained TST negative [71, 72]. Such individuals may have a „sterilizing immunity‟ 
phenotype where the innate response is sufficient to eliminate infection without engaging 
adaptive immunity, but this remains unproven [5]. Alternatively, the immune response may 
be highly localized to the lung without any detectable systemic responses [8]. Studies have 
also identified individuals who revert their TST and IGRA status weeks to months after 
becoming initially infected and may perhaps indicate acute resolving infection, but this is 
also unclear [73-75]. It is difficult to definitively ascertain these various LTBI phenotypes 
given the suboptimal performance of the currently available immunodiagnostic tests (TST 
and IGRA) [10]. 
 
In approximately 5-10% of exposed individuals, the immune system is not able to effectively 
contain the bacteria and results in primary active TB [5]. Furthermore, up to 5% of latently 
infected individuals may develop active TB, termed reactivation TB, if their immune system 
becomes compromised (HIV, malnutrition, etc.) [5]. Similar to LTBI, active pulmonary TB 
can present as an array of clinical phenotypes ranging from subclinical disease to cavitatory 
disease with extensive lung tissue destruction [7, 8]. These individuals represent the primary 
source of disease transmission. Molecular epidemiology studies have shown that the majority 
of TB cases in high burden countries emerge as a result of recent transmission rather than 




Thus, M.tb infection can result in a spectrum of disease phenotypes characterized by different 
immunodiagnostic, clinical and radiological profiles (Figure 1.2). But a fundamental question 
still remains: why do some people exposed to TB progress to active disease despite being 
immunocompetent whereas others remain healthy? Host immunity undoubtedly plays an 
important role in the host-pathogen interaction to determine the outcome of infection but 
what facets of the immune response control the infection or contribute to the development of 









1.5 Diagnosis of TB 
1.5.1 Active TB 
TB detection is one of the key indicators of the MDG framework but remains a challenging 
aspect of TB control particularly in high burden and resource limited settings. In 2013, over 3 
million cases were missed globally either because they were undiagnosed or not notified to 
National TB programs [1].  
 
TB diagnosis is still heavily dependent on older tools such as smear microscopy and culture. 
Sputum smear microscopy is the primary diagnostic tool in most high burden settings but 
suffers from suboptimal sensitivity, particularly in HIV infected individuals [80]. Sputum 
culture, using automated liquid culture systems, is considered the gold standard for TB 
diagnosis due to its superior sensitivity [81]. However, the test is still relatively costly and 
prone to contamination. Furthermore, detection can take weeks resulting in significant delays 
in treatment initiation [82]. 
 
Major advancements in TB diagnosis have been made recently, mainly exploiting nucleic 
acid amplification technology (NAATs). The most noteworthy being the Gene Xpert 
MTB/RIF assay, a cartridge based real-time PCR system that can detect M.tb DNA and 
genotypic rifampicin resistance in ~2 hours [83]. The performance of Xpert has been 
extensively evaluated and, in a recent systematic review, showed a pooled sensitivity and 
specificity of 88% and 98% in TB suspects, respectively and 68% sensitivity in smear 
negative cases [84]. Similar performance characteristics were shown in HIV infected cohorts 
[84]. In a large African multi-centre randomised control trial, Xpert MTB/RIF, in place of 
smear microscopy, reduced the time to diagnosis and treatment initiation but failed to reduce 
morbidity and mortality [85]. The test has also been shown to be cost-effective in TB 
endemic settings [86, 87]. As such, the Xpert MTB/RIF has been recommended by the WHO 
as the frontline diagnostic test for TB [88], and has undergone widespread rollout across all 




1.5.2 Latent TB infection 
With over one third of the world‟s population infected with TB, it is important to identify 
latently infected individuals who may progress to active TB, such as those who are HIV 
infected. Diagnosis of LTBI is difficult because it is based on the presence of an effector 
memory T-cell response to M.tb antigens rather than the direct assessment of mycobacterial 
load [8].  The tuberculin skin test, in use for over 100 years, elicits a delayed type 
hypersensitivity immune reaction at the site of injection. However, the test suffers from poor 
specificity due to previous BCG vaccination and exposure to environmental mycobacteria 
[90]. More recently, IFN-γ release assays (IGRAs) have been developed that measure 
systemic IFN-γ T-cell responses to the M.tb specific antigens early-secretory-antigen-target-6 
(ESAT-6) and culture-filtrate-protein-10 (CFP-10). Two commercial assays are available; the 
Quantiferon Gold In-Tube ELISA assay (QFT-GIT; Qiagen) and the T-SPOT.TB ELISPOT 
assay (Oxford Immunotec). They show similar sensitivities but higher specificities compared 
to TST, particularly in prior BCG vaccinated individuals [91]. Developed countries with a 
low TB burden have recommended these tests for LTBI diagnosis in certain high risk 
populations either as a replacement to the TST or in conjunction with the TST [92-94]. 
However, in low income TB endemic areas where the incidence of LTBI is high, their utility 
is limited because the test is costly and it is unable to distinguish between active TB, 
previous TB, LTBI and previous exposure to M.tb or environmental mycobacteria [10]. 
Furthermore, the IGRA and TST are unable to identify individuals with LTBI that have a 
high risk of progression to active TB, which is an important priority in TB research. 
 
1.6 Drug resistant TB 
The emergence of drug resistance is one of the most concerning aspects of the global TB 
epidemic. In 2013, the WHO reported an estimated 480,000 multi-drug resistant TB cases 
(MDR-TB; defined as resistance to the two first line TB drugs isoniazid and rifampicin) and 
an estimated 9% of these are suspected of having extensively drug resistant TB (XDR-TB; 
defined as MDR-TB with additional resistance to an aminoglycoside and at least one 
fluoroquinolone) [1]. Even more worrying is the existence of strains that are resistant to all 
known TB drugs, termed totally drug resistant TB (TDR-TB) [95, 96]. Most drug resistant 
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TB (DR-TB) cases are concentrated in India, China and Eastern Europe but South Africa is 
not far behind having the 3rd highest number of notified DR-TB  cases among 27 high 
burden countries [1]. 
 
Rapid and reliable diagnosis of drug resistant TB, particularly XDR-TB, remains elusive. 
Genotypic first-line drug susceptibility testing (DST) (Xpert MTB/RIF and Hain 
MDRTBplus Line Probe assay) for RIF and INH is well established [84, 97] but phenotypic 
methods, using MGIT liquid culture, are usually required for confirmation and to detect 
second-line drug resistance. The long waiting periods before availability of MGIT DST 
results, issues with in vitro stability of certain second line drugs and discordant phenotypic 
and genotypic DST profiles often makes diagnosis and design of effective treatment 
regimens difficult [98]. Nonthetheless, new genotypic second line DST assays, such as the 
MDRTBsl, has shown adequate performance [99] and is currently being evaluated by the 
WHO [100]. 
 
Of greater concern are the limited treatment options available for DR-TB patients. MDR-TB 
requires treatment for ~18 months with a combination therapy consisting of 5 or more drugs, 
which have toxic side effects of varying severity [101, 102]. Despite intensive therapy, 
prognosis remains poor with less than 50% of MDR-TB patients having successful outcomes 
[103]. The situation is even worse for XDR-TB patients; additional drugs with more severe 
side effects are required and favourable treatment outcomes occur in less than 20% of 
patients [103-105]. XDR-TB mortality rates were 46% after 2 years post-diagnosis but 
climbed to 73% when patients were followed up for a longer period [106]. The financial 
burden of DR-TB can also be extensive. In South Africa, DR-TB consumes 30% of the NTP 
budget despite only comprising 2.2% of TB cases [107]. Current healthcare facilities are ill 
equipped to address the growing number of newly diagnosed DR-TB patients and care for 
those patients who have failed treatment. Consequently, these individuals remain in the 
community and facilitate transmission of the disease [108]. 
 
Thus, DR-TB threatens to undermine the advances made in curbing the TB epidemic. 
Despite the availability of new (bedaquiline, delaminid) and repurposed (linezolid) drugs for 
 
 14 
DR-TB treatment, other avenues including immunotherapeutic agents, need to be explored to 
shorten treatment regimens or to augment the efficacy of existing ones. However, this will 
require an understanding of the immune response and what constitutes protective immunity 
against TB. 
 
1.7 Vaccines against TB 
Given the slow decline of global incidence rates, the ever increasing burden of drug 
resistance and the shrinking arsenal of drugs available for treatment, an effective vaccine that 
offers long-term protection may be the only way to effectively eliminate TB. However, 
currently available vaccine candidates have failed to sufficiently meet these conditions. 
 
The Bacillus Calmette-Guerin (BCG) vaccine, a live attenuated strain of M. bovis, has been 
in use for over 80 years and has been successful in prevented disseminated disease in 
children. However, the vaccine has a highly variable efficacy [109] and often fails to protect 
adults from developing active disease, particularly in TB endemic settings where the high 
burden of environmental mycobacteria is thought to interfere with vaccine activity [2]. 
Furthermore, BCG caused disseminated infection in HIV infected infants resulting in WHO 
recommendations against BCG vaccination in HIV infection [110, 111]. More recently, the 
efficacy of a Modified-Vaccinia-Ankara (MVA) 85A was assessed in phase III clinical trials 
where BCG vaccinated infants were boosted with MVA85A and followed up for 3 years. 
However, even though pre-clinical trial results were promising, the MVA85A vaccine failed 
to provide any additional protection against TB [3, 112]. Despite the lack of protective 
efficacy elicited by BCG and MVA85A, a number of prophylactic and therapeutic vaccine 
candidates that either improve or supplement BCG are at various stages of clinical trials. 
Nonetheless, such trials are expensive and are further hampered by the lack of field testing 
sites [113]. Therefore, potential candidates need to be thoroughly vetted to ensure the most 
promising candidates are selected for large scale trials. Given that these vaccines function by 





1.8 The immune response to TB 
A complex immune cascade consisting of various interacting cell types and cytokines is 
initiated in response to M.tb infection. In the majority of individuals, the immune response 
mounts a successful defense, either by completely eradicating the bacilli (sterilizing 
immunity) or effectively controlling them in a non-replicative latent state (LTBI) [5]. 
However, it is unclear which specific constituents of the immune response is the driving 
force of protective immunity. Invaluable information has been obtained from the numerous 
studies on TB-associated host immunity in in vitro systems and animal models but the 
applicability of these findings to human TB is somewhat limited. In vitro systems represent 
an artificial environment and fail to fully mimic the in vivo immune response. Furthermore, 
many studies evaluate cellular responses of the systemic circulation, as blood is easily 
acquired and high cell quantities are obtained, but may not represent the situation at the site 
of disease [38]. Animal models have been extensively used for studying in vivo responses but 
are often not equivalent to human systems due to dissimilar manifestations of disease 
pathology. For instance, mice fail to develop cavitatory disease because the granuloma lacks 
the fibrotic and hypoxic environment often observed in human TB [45, 46]. Furthermore, 
mice do not exhibit the spectrum of disease phenotypes that humans do [6]. Other animal 
systems, including guinea pigs, rabbits and non-human primates more closely resemble 
human TB [114, 115] but the scarcity of appropriate culture reagents and high cost of these 
systems often limits their feasibility in a research setting [8]. 
 
Despite these limitations, such models have provided crucial information on host-pathogen 
interactions and laid the foundation for our current understanding of TB host immunity. They 
remain essential to identify other potential immunological pathways involved in TB control 
and as a screening tool for vaccine candidates and immune-modulating therapies [8]. The 
following sections describe our current knowledge of the innate and adaptive immune 
system, including the specific cells and cytokines involved, and how they function to limit or 
promote TB-associated immunopathology. An overview of the cellular mechanisms involved 






Figure 1.3 Overview of the innate and adaptive cellular immune responses to TB. Figure was 
adapted and modified from O’Garra et al [8].  
 
1.8.1 The innate immune response 
1.8.1.1 M.tb entry into phagocytic cells 
Initiation of the innate immune response occurs immediately after infection. Once the bacilli 
enter the alveoli, they are internalized by alveolar macrophages, dendritic cells (DCs) and 
neutrophils [61-64]. Entry into these cells is facilitated by surface-expressing pattern 
recognition receptors (PRRs) such as Toll-like receptors (TLRs) and C-type lectin receptors 
(includes mannose receptor (MR), DC-specific intracellular-adhesion-molecule-3 grabbing 
non-integrin (DC-SIGN)), which recognize various components of M.tb (lipoprotein, CpG-
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containing DNA and mannose-capped lipoarabinomannan (ManLAM)) [116, 117]. The type 
of receptor and the specific antigen involved in uptake dictates the nature of the 
immunological response to M.tb. For example, entry via TLR2 activates the NF-κβ pathway 
and upregulates the vitamin-D receptor resulting in the production of protective 
proinflammatory cytokines and antimicrobial peptides, respectively [118-120]. Conversely, 
uptake of M.tb via binding of ManLAM to MR and DC-SIGN in macrophages drives 
production of IL-10 and TGFβ which suppress protective immune responses [118, 121]. 
 
1.8.1.2 Granuloma formation 
Granuloma formation is a distinct characteristic of TB infection in humans representing a 
dynamic relationship between host immunity and bacterial persistence. In this regard, the 
granuloma can effectively contain M.tb infection while simultaneously providing the bacilli 
with a suitable environment to facilitate long term survival [122]. Initial infection of 
macrophages and neutrophils initiates a cytokine and chemokine cascade that activates 
microbicidal mechanisms in infected cells and recruits additional macrophages, neutrophils 
and dendritic cells as well as natural killer and γδ T-cells to the site of infection [123]. 
Chemokines such as MCP-1, CCL12 and CCL13 recruit macrophages [124] whereas IL-17, 
produced by γδ T-cells [125], is thought to be responsible for neutrophil recruitment [126]. 
TNFα and IFN-γ production by infected macrophages is responsible for activating 
phagocytic cells and maintaining the granuloma structure [127, 128]. These cells accumulate 
around the infected cells while activated CD4+ and CD8+ T-cells arriving from the local 
lymph nodes, further surround the primary foci and mount a Th1 response resulting in 
additional cell recruitment and activation [123]. The resulting structure consists of a mass of 
infected and uninfected macrophages and neutrophils at the centre surrounded by a layer of 
lymphocytes and fibroblasts [129]. Within the granuloma, macrophages may fuse to form 
multinucleated giant cells or differentiate into foamy macrophages or epitheliodal cells [129]. 
In most cases, the M.tb bacilli are contained within the centre of the granuloma and are 
controlled by the surrounding phagocytic cells and lymphocytes. Usually, a necrotic caseum 
forms at the centre, a consequence of macrophage death, which is hypoxic and unfavourable 
for M.tb proliferation [130]. However, a dysregulated immune response may cause M.tb 
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containment to fail resulting in exposure of the pathogen to an oxygenated environment and a 
subsequent increase in bacterial proliferation [6, 131]. The bacilli are released into the 
environment and disseminate resulting in active disease. The typical structure of a caseous 





Figure 1.4. The typical structure of a caseous granuloma. Taken from Barry et al. [6]. 
 
1.8.1.3 Innate cellular immune mechanisms and evasion by M.tb 
1.8.1.3.1 Macrophages 
Macrophages, activated by cytokines IL-12, IFN-γ and TNFα, possess multiple anti-
mycobacterial mechanisms and represent the first line of defense against M.tb [132, 133]. 
Once phagocytosed, bacilli are enveloped within phagosomes that become acidified which 
eventually undergo lysosomal fusion and subsequent proteolytic degradation [134, 135]. 
Similarly, the production of reactive nitrogen and oxygen intermediates, such as nitric oxide 
(NO), exert toxic effects on M.tb [136]. However, M.tb has developed mechanisms to evade 
these intracellular killing pathways; various M.tb components, such as ManLAM, PKnG and 
lipid phosphatase can either delay or inhibit phagosome maturation or fusion with lysosomes 
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[60, 134]. M.tb prevents recruitment of inducible nitric oxide synthase (iNOS) to the 
phagosome and the lipid rich envelope of the bacilli is particularly resistant to oxidants [137, 
138]. 
 
1.8.1.3.2 Apoptosis  
Programmed cell death of infected macrophages by apoptosis is thought to be protective in 
TB infection as it limits growth and prevents dissemination of M.tb [139]. The process is 
facilitated mainly by TNFα but other mechanisms have also been shown to activate pathways 
of cell death (Fas-FasL interaction, ATP, H2O2) [140-143]. Studies in both mice and humans 
have shown that TNFα-induced apoptosis reduced M.tb viability in macrophages [140, 144, 
145]. Additionally, apoptotic vesicles containing M.tb antigens may be taken up by dendritic 
cells for more effective antigen presentation and activation of CD8 T-cells during the 
adaptive immune response [146].  
 
There is convincing evidence that M.tb inhibits apoptotic mechanisms. Virulent M.tb strains 
induce very little apoptosis allowing for uncontrolled intracellular growth [147-149]. Specific 
M.tb components drive this reduction in apoptosis. For instance, LAM inhibits apoptosis in a 
Ca2+ dependent manner [150]. Inactivation of anti-apoptitic M.tb genes secA and nuoG, that 
encode a virulence-related secretion system involved in controlling ROIs and NADH 
dehydrogenase respectively, resulted in enhanced apoptosis and antigen specific CD8+ T cell 
priming [151, 152]. Inhibition of apoptosis by M.tb skews the infected cells to cell death by 
necrosis, allowing M.tb to disseminate and infect surrounding cells [153, 154]. 
 
1.8.1.3.3 Autophagy 
Autophagy is an innate mechanism responsible for encapsulating and trafficking cytosolic 
materials, in autophagosomes, to lysosomes for degradation [155]. In macrophages, 
autophagy is an important cell survival mechanism during starvation but also plays a vital 
role in eliminating intracellular pathogens and has been suggested as one of the mechanisms 
by which the host cell overcomes the M.tb evasion tactic of inhibiting phagosomal 
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maturation [156, 157]. Autophagy effectively kills M.tb through lysosomal fusion with the 
autophagosome and can be induced by IFN-γ and TNFα through the immunity-related 
GTPase M (IRGM1) pathway [158, 159], TLR signaling [160, 161] or by cathelicidin via 
Vitamin D metabolism [162]. It also assists with antigen processing by delivering M.tb 
antigens, present in the autophagosomes, for MHC I and II presentation to CD8+ and CD4+ 
T-cells [163, 164]. However, autophagy induction is influenced by the effects of Th1/Th2 
polarization [44, 158, 159]. While Th1 cytokines induce autophagy, Th2 cytokines such as 
IL-4 and IL-13 are inhibitory and act via the starvation induced Akt signaling pathway or 
IFN-γ induced STAT-6 pathway [44]. Given its impact on promoting intracellular killing of 
M.tb in vitro, Cheallaigh et al suggested targeting autophagy, by using autophagy-inducing 
compounds or suppressing autophagy-inhibiting immune responses, may be a useful 
immunotherapeutic strategy for TB treatment [157]. 
 
1.8.1.3.4 Efferocytosis 
Efferocytosis is a recently described mechanism of antimicrobial control inherently 
associated with apoptosis [145]. Apoptotic macrophages containing M.tb are engulfed by 
non-infected surrounding phagocytes, through recognition of „eat me‟ signals present on the 
surface of apoptotic cells such as phosphatidyl serine [165] and calreticulin [166], to form a 
double membrane efferosome. The contents of the efferosome, including M.tb, are 
subsequently destroyed through lysosomal fusion or oxidative killing [145]. It is thought that 
efferocytosis is the ultimate bactericidal effect of apoptosis as the contents of apoptotic cells 
would otherwise be released in the extracellular environment leading to secondary necrosis 
and inflammation [145, 167]. However, in L. major infection, efferocytosis of infected 
neutrophils is thought to enhance spread of the parasite to macrophages [168]. Whether this 
may also occur in M.tb is not clear and much research still needs to be performed to 




1.8.1.3.5 Vitamin D and cathelicidin 
Vitamin D also plays a role in suppressing M.tb growth within macrophages. Evidence 
comes from patients with vitamin D deficiency or polymorphisms in the vitamin D receptor 
that show increased susceptibility to TB [169, 170]. Vitamin D is metabolized within 
granulomatous tissue to its active form, 1,25-dihydroxyvitamin D, resulting in the production 
of the antimicrobial peptide cathelicidin, which restricts M.tb growth directly [120] or by 
induction of autophagy [162]. However, 1,25-dihydroxyvitamin D can also downregulate 
Th1 responses which are protective in TB [171].  
 
1.8.1.3.6 NK and γδ T-cells 
NK and γδ T-cell subsets are considered part of the innate response as they are partially 
activated, respond rapidly following infection and modulate other cell types. NK T-cells in 
the innate pathway do not require MHC presentation but rather recognize antigens, mainly 
glycolipids, through the CD1 family of antigen presenting surface molecules. These cells 
exert their mycobactericidal activity through production of IFN-γ and release of cytotoxic 
granules [172]. They also induce DC maturation and recruit other inflammatory cells to the 
site of infection [173, 174]. In mice, NK T-cells directly kill M.tb and confer protection 
against aerosolized infection [175, 176]. TB patients exhibited reduced frequency and 
functionality of NK cells in peripheral blood [177]. However, a subset of NK T-cells that 
produce IL-4 were found to be increased in TB patients [178], and may contribute to a 
subversion of protective innate responses. 
 
Similar to NK T-cells, γδ T-cells respond to non-peptide phosphoantigens without the 
requirement of activation via MHC presentation. Both human and animal studies suggest a 
crucial role in M.tb immunity [179]. Vγ9Vδ2 T-cells, the predominant form found is humans, 
are rapidly recruited to site of M.tb infection and directly kill infected cells via release of 
cytotoxic molecules such as granulysin and perforin [180].These cells can also produce large 





1.8.1.3.7 Neutrophils  
Neutrophils, together with macrophages, represent the first line defense against M.tb 
infection. However, their role in TB is somewhat controversial [183]. Neutrophils are the 
predominant M.tb infected phagocytic cell type [61] and are recruited early to the site of 
infection [183] where they internalize M.tb via TLRs binding [184] or opsonisation [185]. 
The mycobactericidal effect of neutrophils are employed in a number of ways; they kill M.tb  
directly through antimicrobial peptides such α-defensins (human neutrophil peptides) and 
cathelicidin [186, 187], or indirectly by cooperating with macrophages to remove apoptotic 
neutrophils [188, 189], enhancing DC activity [190] and playing a role in granuloma 
formation [191]. In contrast, evidence suggests that neutrophils can actually contribute to the 
pathology associated with chronic TB. In mice, neutrophil deletion leads to enhanced 
protection [192, 193] and in humans, systemic neutrophilia is associated with poor prognosis 
and slow sputum conversion [187, 194]. Additionally, virulent M.tb strains can inhibit 
neutrophil apoptosis and delay T-cell responses in a similar way to macrophages [195]. A 
failure to eliminate M.tb means that neutrophils are a potential reservoir of bacilli which 
facilitate dissemination of disease [196-198]. Furthermore, neutrophil necrosis releases 
cytotoxic contents into the microenvironment and can lead to granuloma liquefaction, 
excessive inflammation and immunopathology [61, 198].  
 
1.8.1.3.8 Dendritic cells (DCs) 
Dendritic cells are the primary antigen presenting cell responsible for initiating adaptive T-
cell responses [199] and evidence suggests they enhance the immune response to TB [200, 
201]. In DC depleted mice, CD4+ T-cell responses were insufficient to control bacterial 
replication [202]. After initial infection, large numbers of DCs congregate in the lungs [203, 
204] and internalize M.tb via the TLRs and DC-SIGN [205]. Activated DCs then travel to the 
lymph nodes and facilitate T-cell priming by upregulating surface expression of MHC and 
other co-stimulatory molecules for antigen processing and presentation. They also interact 
with infected macrophages and neutrophils undergoing apoptosis resulting in enhanced DC 
migration to lymph nodes and more rapid T-cell priming [206, 207]. M.tb can impair DC 
maturation, delay DC trafficking to the lymph nodes and inhibit their ability to expand T-cell 
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population [208, 209].  For example, infected DCs were shown to be poor stimulators of 
antigen-specific CD4+ T-cells despite high levels of MHC expression [64]. DC maturation is 
also dependent on the type of receptor engaged during its interaction with M.tb. Entry of M.tb 
via TLRs induces IL-12 secretion and efficient DC activation whereas entry via DC-SIGN 
inhibits maturation by blocking NFκβ activation and subsequent IL-10 secretion [210]. 
Finally, M.tb can also influence DCs to downregulate protective responses by directing Th2 
differentiation or regulatory T-cell (Treg) expansion via induction of IL-1β or PD1, 
respectively [211, 212].  
 
1.8.2 Adaptive Immunity 
Initiation of the adaptive immune response is typically delayed, occurring ~2-6 weeks after 
initial infection [66]. Infected DCs and macrophages travel to the lymph nodes where they 
activate CD8+ and CD4+ T-cells via the MHC I and MHC II antigen presentation pathways, 
respectively. NK and γδ T-cells can also be activated in the lymph nodes via CD1 restricted 
pathways, as previously discussed. Tregs serve to modulate the immune response and have 
been described in both the CD4+ and CD8+ populations.  The cells of the adaptive immune 






          
Figure 1.5. The various CD4 and CD8 T-cell lineages of the adaptive immune response and 
their role in TB immunity. 
 
1.8.2.1 CD8+ T-cells 
Murine studies have indicated a role for CD8+ T cells in the immune response to TB. Mice 
with defective MHC I processing pathways are more susceptible to TB than wild type mice 
[213, 214]. Studies in humans support similar conclusions [215, 216]. CD8+ cytotoxic T-
cells (CTLs) exert their antimycobacterial activity directly by killing M.tb infected cells 
through the production of perforin and granulysin [217], or indirectly by producing IFN-γ 
and TNFα that recruits and activates macrophages [218]. However, CD8+ T-cells may also 
differentiate into distinct effector phenotypes based on transcription factor expression and 
cytokine secretion patterns, in a similar way to CD4+ helper T-cells [219]. In addition to the 
traditional IFN-γ producing CTLs (known as Tc1 cells), other „non-classical‟ CD8+ subtypes 
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producing IL-4 (Tc2),  IL-17 (Tc17) and IL-9 (Tc9) have been described and their induction 
is likely dependent on the cytokine microenvironment [220-223]. These subtypes have 
mainly been described in tumour immunity but less is known about their role in TB. It has 
been suggested that these cells support CD4+ T-cell mediated responses rather than promote 
cytotoxicity [224]. 
 
1.8.2.2 CD4+ T-cells 
CD4+ T-cells are indispensible to TB immunity and play a central role in the induction and 
maintenance of the cell mediated immune response. CD4+ T-cell deficient mice are unable to 
control M.tb growth and quickly succumb to disease [216]. Also, HIV infected individuals 
with reduced CD4 lymphocytes are highly susceptible to TB. CD4+ T-cells polarize into 
different subsets that secrete distinct cytokine patterns which will ultimately determine the 
outcome of cell mediated immunity in TB. These helper T-cell (Th) subsets include Th1, 
Th2, Th17, Th9 and Tregs which all have diverse functions that can either enhance or impair 
a protective response [216]. These subsets and the major cytokines they produce are 
discussed below. 
 
1.8.2.2.1 Th1 cells 
Th1 effectors differentiate under the control of the transcription factor T-bet and their 
induction is dependent on IL-12 and IL-18 [225, 226]. Th1 cells usually develop in response 
to intracellular pathogens and are the primary effector cells responsible for protective 
immune responses to M.tb [216, 227]. They are characterized by secreting high levels of 
IFN-γ and TNFα. 
 
IFN-γ 
IFN-γ is the main cytokine required for a protective immune response in TB [228]. In 
addition to Th1 cells, it is also produced by CD8+ cells, NK cells and macrophages. Its 
protective role was first exhibited in lepromatous leprosy patients where administration of 
IFN-γ to lesions resulted in T-cell and monocyte migration and a subsequent decrease in 
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bacilliary load [229]. Furthermore, humans and mice with defects in the IFN-γ or IFN-γ 
receptor genes showed increased susceptibility to M.tb infection [230-232]. IFN-γ induces 
multiple protective effects; it activates macrophages to eliminate intracellular M.tb, it 
augments antigen presentation by inducing MHC I and II expression and subsequent 
recruitment of CD4+ and CD8+ T-cells, upregulates expression of ROIs and RNIs in 
phagocytic cells, induces innate mechanisms of autophagy and apoptosis and prevents T-cell 
exhaustion [60, 158, 233-236]. Its protective effect is so apparent that aerosolized IFN-γ has 
been used as an immunotherapeutic agent to treat MDR-TB patients with some success 
[237]. Given these data, it would not be remiss to assume that active TB is associated with a 
depressed IFN-γ response. However, the extensive number of studies that have investigated 
the levels of this cytokine have produced conflicting results; some studies, using ex vivo or 
antigen stimulated cells, have reported higher levels of IFN-γ in TB patients compared to 
controls [9, 11, 238-242] whereas other have reported lower levels [33, 243-247]. 
Furthermore, studies that examined the site of disease found extremely high levels of IFN-γ 
in TB patients [9-15]. Thus, while it is undoubtedly important for protection, IFN-γ alone is 
likely not enough to prevent active disease. 
 
TNFα 
The crucial role of TNFα in TB immunity has been demonstrated in both mice and humans. 
TNFα and TNFα receptor deficient mice showed increased susceptibility to TB infection 
[248]. Similarly, LTBI subjects receiving anti-TNF treatment for autoimmune diseases 
exhibited a five-fold increase in TB reactivation rates [249, 250]. TNFα, is produced by T-
cells, macrophages, DCs and neutrophils, activates macrophages, and, like IFN-γ, has 
multiple anti-mycobacterial effects; it increases iNOS expression and activates macrophages 
in conjunction with IFN-γ [136, 233], induces apoptosis [140, 144, 145], produces 
chemokines (IL-8, MCP-1 and RANTES) which recruit immune cells to the infection site 
[124] and plays a role in granuloma maintenance [233, 251]. In contrast, TNFα may also 
cause the immunopathology often observed in active TB. In mice with progressive disease, 
treatment with TNFα enhances inflammation and tissue damage causing increased mortality 
[252]. TNFα is also associated with fever and weight loss and contributes to 
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immunopathology in human TB [253-255]. IL-4 may also be involved in the toxicity of 
TNFα as the addition of recombinant IL-4 to mixed Th1/Th2 pulmonary lesions in mice 
infected with TB exacerbated TNFα mediated inflammation [256]. 
 
1.8.2.2.2 Th17 cells 
Th17 cells have been recently described as a distinct helper T-cell subset that develops in the 
presence of IL-6 and TGFβ and characterized by the production of IL-17, IL-21 and IL-22 
[257]. They induce protective immune responses in a variety of infections, including M.tb 
[125, 126, 258], but are also involved in promoting inflammation and tissue damage, 
particularly in autoimmune diseases [259].  
 
IL-17 
IL-17 is the signature cytokine secreted by Th17 cells, although other cells may also produce 
IL-17, including γδ T cells, NK cells and neutrophils [260-262]. γδ T-cells are the primary 
source of IL-17 early in M.tb infection [125]. The foremost role of IL-17 in TB immunity is 
the recruitment and activation of neutrophils which contributed to early granuloma formation 
[126].  In IL-17 deficient mice, there was a decrease in neutrophil recruitment and increased 
disease susceptibility [263, 264]. Furthermore, there is evidence that IL-17 may also enhance 
the Th1 response in BCG infection [125]. However, excessive production of IL-17 can also 
be detrimental by causing an influx of neutrophils and subsequently providing an 
accommodating environment for M.tb replication [61]. Indeed, an accumulation of 
neutrophils is commonly observed in genetically susceptible mice [192, 193]. Furthermore, 
extensive exposure of neutrophils to IL-17 can alter their phenotype making them more 
inclined to cause immunopathology [265]. IFN-γ seems to regulate Th17 cells by limiting 
excessive production of IL-17 and improving disease outcome [266]. 
 
1.8.2.2.3 Regulatory T-cells 
Regulatory T-cells (Tregs) modulate the immune response by suppressing Th and other cell 
responses to prevent pathogen-mediated immunopathology, autoimmunity and to maintain 
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self-tolerance [267]. Tregs have been described in most lymphocyte populations including 
CD4+ [268, 269], CD8+ [270], NK T- and B-lymphocytes [271]. Within the CD4+ T-cell 
population, two main subsets have been described: natural CD4+CD25+FoxP3+ Tregs 
(nTregs), which develop in the thymus and are anergic to T-cell receptor stimulation [272] 
and inducible Tregs (iTregs), which differentiate in response to TGFβ and retinoic acid from 
effector T-cells and natural Tregs [4, 273], and exhibit less stable expression of FoxP3 [274]. 
Furthermore iTregs, which include Tr1 and Th3 cells, are thought to mediate 
immunosppresive effects partly through the production of immunomodulatory cytokines such 
as IL-10 and TGFβ (discussed below) [272, 275] but the extent of their suppressive capacity, 
at least in vitro, compared to nTregs remains contentious [276, 277]. In addition to 
immunosuppressive cytokine production, Tregs may also exert their effects by preventing 
DC maturation and subsequent T-cell activation [278] via the CLTA-4 pathway [279, 280] or 
by inducing apoptotic mechanisms via IL-2 sequestration [281, 282] or perforin/granzyme 
production [283].  However, the precise characterisation of these Treg subsets and their 
interaction to facilitate immune suppression has not yet been fully elucidated [284, 285].  
 
Since the first report of Tregs in TB almost a decade ago [286], there have been several 
subsequent studies showing increased Treg levels in the peripheral blood [287-289], pleural 
effusions [290], broncho-alveolar lavage [291-293] and lymph nodes [294] of TB patients 
compared to healthy controls. Tregs in the peripheral circulation migrate to the site of disease 
as demonstrated in a macaque model of TB [295].  The target of Treg suppression appears to 
be the Th1 response; reports in TB patients have demonstrated an inverse relationship 
between Treg expression and IFN-γ production and functional depletion of Tregs also 
resulted in increased IFN-γ levels [286, 287, 292-294]. Similarly, blocking of TNFα resulted 
in increased Treg activity and subsequently increased susceptibility to disease [296-298]. An 
in vitro model of human M.tb infection demonstrated that Tregs attenuate the ability of 
effector cells to contain M.tb growth, likely by downregulating protective immune 
mechanisms [293, 298]. Evidence suggests that Tregs mediate suppression in TB via IL-10 
[292] or cell-contact dependent [299] mechanisms. While Tregs may be required to limit 
excessive inflammation, their early expansion may delay the initiation of adaptive immunity 
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allowing for unrestricted bacterial proliferation [300].  A Th2 response can drive Treg 
expansion [301-303] but it is not known if this is occurring in TB as well. 
 
IL-10 
In addition to Tregs, the anti-inflammatory cytokine, IL-10 is produced by most Th subsets 
as well as neutrophils, macrophages and DCs [304]. In TB, IL-10 downregulates the 
production of proinflammatory cytokines such as TNFα and IL-12 [305, 306], inhibits 
phagocytosis and IFN-γ mediated production of ROIs and RNIs, which are all pivotal 
protective mechanisms against TB [304, 307, 308]. Furthermore, in addition to being 
produced by iTregs, IL-10 also enhances differentiation of iTregs [309]. IL-10 deficient mice 
exhibited reduced bacterial loads, enhanced resistance and a concurrent increase in IFN-γ 
secretion [310, 311]. Similarly in humans, neutralization of IL-10 resulted in increased T-cell 
proliferation and IFN-γ production [312, 313]. These data suggest that IL-10 prevents 
bacterial clearance early in disease by downregulating protective responses [310]. 
 
TGFβ 
Like IL-10, TGFβ has immunosuppressive effects on protective host immunity to TB; it 
decreases IFN-γ induced MHC II expression [314] and macrophage activation [315] and has 
modulatory effects on T-cell proliferation [316]. Increased levels of TGFβ are often observed 
in PBMCs and granulomas of TB patients [317]. TGFβ has been shown to enhance 
intracellular M.tb proliferation [318] and inhibit the protective effects of TNFα [319]. 
Furthermore, TGFβ is also associated with tissue damage and fibrosis [320, 321]. Existing 
data suggests that a Th2 response may drive TGFβ leading to subversion of the protective 
immune response [16]. 
 
1.8.2.2.4 Th9 cells 
Th9 is a newly described T-cell subset that produces large amounts of IL-9 but not cytokines 
from other Th lineages [49, 50]. Th9 cells may also produce IL-10 in mice but not in humans 
[322, 323]. They develop from naïve T-cells in the presence of IL-4 and TGFβ or from Th2 
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cells in the presence of TGFβ [49, 50, 322, 323]. Despite the distinct cytokine secretion 
pattern and developmental requirements, the identification of a single lineage-defining 
transcription factor remains elusive [324]. Given the need for IL-4 in their development, a 
number of Th2 related transcription factors, such as STAT-6 and GATA-3 have been shown 
to be involved in Th9 development indirectly by downregulating other IL-9 inhibiting 
transcription factors [49, 50, 325]. Convincing evidence has emerged that interferon 
regulatory factor 4 (IRF4) and the ETS transcription factor PU.1 are essential for 
development and maintenance of Th9 cells [326, 327]. Both bind directly to the Il9 promotor 
and mice deficient in either transcription factor show reduced IL-9 production and IL-9-
dependent allergic pulmonary inflammation [326, 327]. Similar results have been found in 
humans [326-328]. However, these transcription factors are also involved in the development 
of other Th subsets, including Th2 and Th17 [329, 330]. Further investigations are required 
to identify a Th9 specific transcription factor. 
 
Th9 cells play significant pro-inflammatory roles in asthma [326, 331], allergic airway 
inflammation [324, 327, 332] and autoimmune disease [49, 333]. However there is a paucity 
of data regarding their role in TB. Ye et al characterized Th9 cells in pleural TB patients 
where they differentiated in response to antigen presentation by pleural mesothelial cells 
(PMCs), stimulated PMCs and inhibited PMC apoptosis [334]. Given that these cells have 
similar functions to Th2 cells, Th9 cells may also contribute to the hypothesis that a 
dyregulatory Th2 response may be undermining protective immunity to TB. 
 
IL-9 
IL-9 was originally considered a Th2 cytokine but has been shown to be produced by other 
Th subsets (Th9, Th17, Tregs), CD8+, NK and mast cells [335]. The effects of IL-9 are 
equally diverse having both pro- and anti-inflammatory roles. IL-9 contributes to allergic 
inflammation by driving mast cell expansion and IL-13 production, stimulating mucus 
production and airway hyper-responsiveness [336, 337]. Its effect on mast cells also 
contributes to development of autoimmune disease as shown in mouse models of 
experimental autoimmune encephalomyelitis (EAE) and colitis [333, 338, 339]. IL-9 
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promotes parasite clearance by inducing eosinophila, mucus production and increased 
intestinal muscle contraction [340, 341]. In contrast, IL-9 has also been shown to promote 
Treg suppression in transplantation tolerance [342]. In APCs, IL-9 induces TGFβ secretion 
resulting in decreased production of TNFα and ROIs [343]. 
 
Very few studies have investigated IL-9 in TB [11, 334, 344, 345] but evidence suggests that 
IL-9 impairs protective Th1 responses. IL-9 reduced IFN-γ expression in PBMCs of 
pulmonary TB patients [344] and inhibited IFN-γ induced apoptosis of pleural mesothelial 
cells in TB pleuritis patients [334]. These data suggest a detrimental role for IL-9 in TB as it 
seems to undermine protective Th1 responses.   
 
1.8.2.2.5 Th2 cells 
As already stated, a Th1 response, while necessary for protection against M.tb infection, is 
not sufficient to prevent disease progression and other mechanisms are likely involved in 
disrupting protective immunity. This thesis postulates that one of these subversive 
mechanisms is an underlying Th2 response. Th2 cells are characterized by the secretion of 
IL-4, IL-5 and IL-13 and drive expansion and differentiation of B-cells, eosinophils and mast 
cells [346]. They have important roles in clearance of intestinal parasitic infections and 
inducing inflammation in allergic diseases and asthma [346]. There is a significant body of 
evidence suggesting a subversive role for Th2 cells in TB (discussed later) but many studies 
have been observational and it is unclear if a Th2 response is the cause of reduced protection 
and immunopathology or an inconsequential by-product of active disease. IL-4 is the 
signature cytokine that facilitates Th2 functions. Another Th2 cytokine, IL-13, has similar 
properties to IL-4 and bind to receptors that share the IL-4 receptor  chain [44]. IL-13 is 
upregulated in active TB patients and correlates with IL-4 levels [18]. Furthermore, IL-13 
can also downregulate Th1 responses and protective mechanisms such as autophagy [44].  
 
The following sections describe the properties of IL-4 and the current evidence investigating 
the presence and role of IL-4 in TB, including the putative mechanisms by which IL-4 may 
subverts protective responses. 
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1.9 IL-4 and IL-4δ2 
1.9.1 Biological functions of IL-4 
IL-4 is a pleiotropic cytokine which exert their functions on multiple cellular targets as IL-4 
receptors are widely distributed on these cells. IL-4 is a potent inducer of T-cell proliferation 
[47] and drives Th2 differentiation from naïve T-cells [347]. Due to the reciprocal 
relationship of Th1 and Th2 cell activation, IL-4 inhibits Th1 responses in T-cells including 
downregulation of IL-2 receptor expression [348] and IFN-γ production. IL-4 can also 
inactivate macrophages by decreasing CD14 and Fcγ receptor expression [349, 350] or 
polarize macrophages toward an alternatively activated form characterized by increased IL-
10 and TGFβ expression [351]. In LPS induced monocytes, IL-4 inhibits PGE2 production 
[47], a potent inducer of apoptosis in innate immune cells [352]. These functions suggest that 
IL-4 can downregulate protective mechanisms against TB. In addition, IL-4 stimulates and 
recruits eosinophils, mast cells and basophils to the site of infection or in response to 
allergens thus promoting mucus production and airway hyper-responsiveness [347]. In B-
cells, IL-4 enhances MHC class II expression, induces CD23 (low affinity IgE receptor) and, 
together with IL-13, IgE class switching [347].  
 
1.9.2 Sources of IL-4 and Th2 differentiation 
It was previously thought that only IL-4 was able to induce the development of a Th2 
response via IL-4Rα binding and STAT-6 (signal transducer and activator of transcription-6) 
activation. However, the initial production of IL-4 by non T-cell (granulocytes) or 
specialized T-cell (NK, γδ T-cells) populations was not essential for induction of CD4+ 
specific IL-4 responses [353]. Indeed, Th2 differentiation can occur through pathways 
independent of IL-4. For example, Th cell polarization is dependent on the interaction of 
pathogen specific PAMPS and PRRs expressed on DCs [354]. S. mansoni protein extract 
induced the development of Th2 cell-promoting effector DCs that drive Th2 development by 
an OX40-ligand dependent mechanism [355]. M.tb and its various components are also 
capable of polarizing DC to induce Th2 responses. Dendritic cells derived from BCG-
infected precursors are able to promote a Th2 response [356].  Similarly, the 30- and 38-kDa 
M.tb antigens partially mature dendritic cells to stimulate development of IL-4 producing 
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CD4+ T-cells [357]. RD1 antigens and virulent M.tb, but not BCG, induce IL-1β production 
in DCs and subsequently drive the development of Th2 cells [211]. However it is likely a 
number of other factors may also influence the outcome of Th polarization including tissue 
specific factors, physical interaction with other cell types and length of TCR engagement 
[358]. Furthermore, IL-4/STAT-6 independent pathways can also drive Th2 differentiation 
(discussed below) but whether M.tb is able to induce these pathways is unclear. 
 
1.9.3 IL4 receptors and Th2-inducing signaling pathways 
1.9.3.1 Membrane bound IL4 receptors 
The IL-4 receptor (IL-4R) is widely distributed on various cell types and exists in two forms. 
The type 1 receptor is a heterodimer complex consisting of IL4Rα and the cytokine receptor 
common γ chain, γc. This receptor is predominantly found on T-cells and mast cells and, as a 
result, these cells respond strongly to IL-4 rather than IL-13 [359]. In contrast, the type 2 
receptor, commonly found on both haemopoeitic and non-haemopoeitic cells such as 
macrophages, is comprised of IL-4R with IL-13R1 and binds both IL-4 and IL-13 [359]. 
The IL-13R2 alone can bind IL-13 and may act as a „decoy‟ receptor or activate IL-13-
mediated fibrosis pathways [360]. 
 
1.9.3.2 Soluble IL-4 receptors 
The soluble extracellular form of the IL-4R (sIL-4R) is produced by proteolytic cleavage of 
the membrane bound IL-4R [361] and appears to have opposing effects at different IL-4 
concentrations. At high IL-4 concentrations, sIL-4R has a neutralizing effect by blocking 
binding of IL-4 to membrane bound receptors. In contrast, sIL-4R can prolong the half-life 
and enhance the bioactivity of IL-4 at low IL-4 concentrations, which has been convincingly 
shown in in vitro T-cell culture [362]. Given that sIL-4R has a lower affinity for IL-4 
compared to its membrane bound counterpart, circulating IL-4 is protected from degradation 
and can be released in a delayed fashion [362]. Elevated sIL-4R has been observed in 
patients with leishmaniasis and malaria [363, 364]. Surprisingly, the opposite is observed in 
asthmatic children [365] and patients with allergic rhinitis [366] or pulmonary TB [367], 
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where sIL-4R levels were much lower compared to healthy controls. As such, further studies 
into the function of sIL-4R and its relevance in TB disease is required. 
 
1.9.3.3 IL-4R dependent and independent signaling pathways 
The most well characterized signaling cascade for inducing a Th2 response is the 
IL4R/STAT6 pathway [368]. STAT-6, bound to the intracellular domain of IL4Rα, becomes 
activated by Janus kinase (JAK1 and 3) mediated phosphorylation. As a result, STAT6 
dimerizes and translocates to the nucleus where it binds directly to the Th2 transcription 
factor gene, GATA-3 thus facilitating IL-4 and IL-13 expression and subsequent Th2 
differentiation [369].  Alternatively, IL-4/IL4R binding can initiate the insulin receptor 
substrate pathway (IRS; most commonly IRS-2) mediated by the phosphatidylinositol-3-
kinase (PI3K) cascade. Murine studies suggest that both pathways work in conjunction to 
promote IL-4 induced proliferative responses [370]. 
 
Studies have shown that STAT6-/- mice are still able to induce Th2 responses [371] 
suggesting that alternative signaling pathways independent of IL4R/STAT6 can also 
contribute to Th2 differentiation. The Notch signaling pathway involves phosphorylation-
mediated activation of Notch proteins (expressed by CD4+ cells) and subsequent 
upregulation of IL-4 and GATA3 genes, via RBPJ (recombination-signal-binding protein for 
immunoglobulin-κ J region) proteins [369]. Mice deficient in Notch 1, Notch 2 or RBPJ 
exhibited impaired Th2 responses to parasite antigens [372]. The mammalian target of 
rapamycin complex 2 (MTORC2) forms part of the IRS pathway and acts by downregulating 
suppressor of cytokine signaling 5 (SOCS5), an inhibitor of STAT6 activation [369, 373]. 
Finally, Th2 responses can be induced via an IL-2-induced STAT5 activation pathway [374], 





1.9.4.1 Alternative splicing 
Alternative splicing is an important mechanism for regulating gene expression and promoting 
functional diversity within the eukaryotic proteome by the generation of multiple mRNA 
transcripts from a single gene [376]. The subsequent protein isoforms which are produced 
differ from their native counterparts in terms of structural and biological properties, including 
binding affinity, enzymatic activity, intracellular localization, stability and bioactivity [376]. 
In humans, over 90% of multi-exon genes are alternatively spliced. However, the splice 
variant isoforms are normally expressed at much lower levels (~7 times lower) compared to 
the full-length protein [377, 378]. In addition to IL-4, alternatively spliced variants of IL-2 
[379], IL-6 [380], IL-7 [381], IL-15 [382] and IL-33 [383] have been described and, in some 
cases, function antagonistically to the wild type isoform [384]. 
 
1.9.4.2 IL-4δ2 structure and function 
IL-4δ2 is a naturally occurring splice variant of IL-4 generated by deletion of exon 2, a 48 
base pair region encoding a stretch of 12 amino acids (positions 22 to 37). The resulting 
protein structure lacks a double stranded anti-parallel β-sheet and a disulfide bond, due to 
deletion of a cysteine residue, but still retains the majority of the native IL-4 structure [385, 
386]. The modification in structure means that IL-4δ2 only binds to the IL-4Rα chain and 
subsequently has a reduced binding affinity for the IL-4R [385]. 
 
In addition to humans, IL-4δ2 mRNA transcripts have been detected in non-human primates, 
rabbits, woodchucks, mice and cattle [387, 388] and was found to be expressed in various 
cell types and tissues [389-391]. However, data regarding IL-4δ2 protein is limited because 
assays using commercially available antibodies are unable to discriminate between IL-4 and 
IL-4δ2. Nonetheless, recombinant IL-4δ2 has been successfully expressed in yeast [47] and 
mammalian cell systems [32] and functional characterization has shown that it is an IL-4 
antagonist suppressing IL-4-driven responses in vitro. IL-4δ2 inhibits IL-4-induced T-cell 
proliferation, CD23 and IgE expression in B-cells and blocks the IL-4-mediated inhibitory 
effects on COX-2 expression and PGE2 production in monocytes [47, 48, 392]. IL-4δ2 also 
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stimulated production of IFN-γ, IL-6, IL-10, MCP-1 and TNFα in cultured T-lymphocytes 
[31]. The in vivo effects of IL-4δ2 have been demonstrated in a murine gene delivery model 
where it induced inflammation independent of IL-4 causing T- and B-cell recruitment, 
collagen deposition and induction of IFN-γ suggesting IL-4δ2 was associated with a Th1 
response [32, 393]. Luzina et al recently developed antibodies which were able to effectively 
discriminate between IL-4 and IL-4δ2 and demonstrated that IL-4δ2 was produced naturally 
as a functional protein by activated T-cells [31]. However, the predominant Th subset (Th1, 
Th2 or Th17) that produced the majority of IL-4δ2 could not be definitively identified [31]. 
 
1.9.4.3 IL-4δ2 in disease 
IL-4δ2 has been investigated in systemic sclerosis [394], asthma [395], gastritis [389], 
transplantation [396] and tuberculosis [397], mostly at the transcriptional level. IL-4δ2 
mRNA was upregulated in systemic sclerosis patients along with IL-4 probably because both 
IL-4 and IL-4δ2 have stimulatory effects on fibrosis [394], a characteristic feature of this 
disease.  Asthma patients expressed significantly elevated levels of IL-4 mRNA whereas IL-
4δ2 increased only slightly [395]. IL-4δ2 protein was also found to be increased in PMA 
stimulated T-cells of asthma patients compared to healthy controls [31]. Studies investigating 
IL-4δ2 in tuberculosis are discussed later.  
 
1.9.4.4 Other IL-4 splice variants 
In addition to IL-4δ2, other IL-4 splice variants have been described in humans and other 
mammalian species. IL4δ3, where exon 3 is deleted, has been described in rabbits [398] and 
cattle infected with Fasciola hepatica [388] or M. bovis [399]. IL4δ3 was found to be 
associated with protection in BCG vaccinated cattle infected with M. bovis [399]. Yuan et al 
demonstrated another splice variant, termed VIL-4, in cynomolgus macaques that induced 
expansion of Vγ2Vδ2 T-cells [400]. However, these variants have never been investigated in 
humans. Interestingly an IL-4 mRNA variant, IL-4alt3, was identified in human mononuclear 
cells where exon 3 was partially deleted but the function and significance of this splice 
variant in unknown [401]. 
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1.9.5 Challenges in measuring of IL-4 and IL-4δ2 
The biological properties of IL-4 often make its detection in biological samples difficult at 
the transcript and protein levels. IL-4 is active at very low concentrations and is commonly 
expressed ~3 logs below that of IFN-γ at the mRNA level [24, 25]. It also has a very short 
half-life (~60 minutes) [402] so any delays in sample processing, which is often the case 
under field conditions, can result in undetectable levels [26]. Furthermore, IL-4 protein is 
rapidly internalized via membrane bound receptors [403, 404] or sequestered by soluble 
receptors [405]. For these reasons, immunoassays such as ELISA and flow cytometry lack 
the sensitivity to detect levels of biologically active IL-4 [27] and cells often require 
mitogenic pre-stimulation, which is Th1 biased and may downregulate IL-4 responses [406]. 
These issues extend to the measurement of IL-4δ2 as well, which tends to be expressed at 
even lower levels compared to IL-4. In any case, IL-4 and IL-4δ2 cannot be distinguished 
using currently available immunoassays due to the lack of antibodies specific to each 
isoform. These factors may be the reason why earlier TB studies, which did not measure IL-
4δ2, failed to observe differences in IL-4 expression or detect IL-4 altogether (discussed 
below). Currently, the most reliable and sensitive method involves quantitative PCR using 
specific primers that can amplify the mRNA sequences of each isoform separately. 
 
1.10 IL-4 and IL-4δ2 in tuberculosis infection 
1.10.1 Studies in active TB using blood 
The literature relating to the measurement of IL-4 in human TB is substantial but results have 
been conflicting so the issue remains contentious. Early reports of increased IL-4 in TB came 
from studies conducted in the USA and UK [241, 407, 408]. IL-4 mRNA was detected in a 
proportion of TB patients by conventional RT-PCR [407, 408]. Surcel et al reported strong 
IL-4 ELISPOT responses in M.tb antigen stimulated PBMCs of pulmonary TB patients 
compared to controls [241]. Given the difficulty in measuring IL-4 (discussed in 1.9.5), it 
was interesting to find that a number of studies, mostly in developing countries, observed 
very high IL-4 levels in TB patients compared to controls, to the extent that it was detectable 
in the serum by ELISA [17, 409, 410]. In similar studies performed in India [243], Indonesia 
[21], The Gambia [411], South Africa [412] and Mexico [413], researchers observed that TB 
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patients expressed a higher proportion of IL-4 secreting cells in response to M.tb or non-
specific antigen stimulation when measured by flow cytometry, which has a similar 
sensitivity to ELISA [414]. 
 
In later studies, the notion that a Th2 response may be related to TB became more apparent 
with the use of PCR techniques that were more sensitive and were also able to effectively 
distinguish between IL4 and IL-4δ2. In a UK study, Seah et al used a nested semi-
quantitiative PCR assay to demonstrate that both IL4 and IL-4δ2 were increased in TB 
patients compared to TST positive controls [18]. Another UK study performed by Dheda et 
al, using quantitative PCR,  also found that both IL-4 and IL-4δ2 was increased in TB 
patients compared to controls and in HIV infected TB patients compared HIV uninfected 
patients which correlated with disease severity [9, 415]. Similar results were reported in 
Ethiopia [28, 416] and The Gambia [29] where increased IL-4 and IL-4δ2 mRNA levels in 
TB patients were strongly associated with responses to the M.tb specific antigen, ESAT-6. 
Demissie et al also found that Ethiopians subjects expressed higher IL-4 compared to Danish 
subjects [28]. Subsequent studies from other research groups in high TB burden settings 
found a distinct pattern of increased IL-4 and IL-4δ2 which correlated with more severe 
disease and changed in response to anti-TB treatment [30, 288, 417, 418]. 
 
In contrast, some studies, mostly performed before the year 2000, failed to detect any 
differences in IL-4 expression between TB patients and healthy controls. Studies in the USA, 
Portugal and The Netherlands did not observe any changes in IL-4 levels when measured by 
RT-PCR [12, 37, 419], immunohistochemistry [34] or ELISA [35]. Similar findings were 
obtained in studies of TB patients from Mexico [33], China [420] and South Africa [36]. 
These conflicting results may be attributed to the technical difficulties in measuring IL-4 
(discussed earlier). Furthermore, studies which used conventional PCR did not use primers to 




1.10.2 Studies in active TB using broncho-alveolar lavage 
Systemic responses in pulmonary TB can differ significantly from those at the site of disease. 
For instance, the presence of specialized tissue specific cells with distinct morphological and 
functional characteristics and the migration of M.tb-specific immune cells to the site of 
infection results in a compartmentalized immune response that is not normally present in the 
peripheral circulation [38].  However, most studies tend to use peripheral blood because of its 
ease of acquisition. Consequently, only a handful of studies in pulmonary TB patients have 
investigated Th2 cytokine responses in the lungs [9, 11, 14, 15, 19, 20, 253, 421, 422] and 
even fewer have examined both compartments (blood and lungs) [9, 11, 15, 19]. Some 
studies failed to find differences in IL-4 in BAL samples by in situ hybridization [14], 
immunohistochemistry [422] or ELISA [253]. Schwander et al measured IL-4 protein in PPD 
stimulated PBMCs and alveolar lavage cells but failed to find differences between TB 
patients and healthy controls [15]. In contrast, other studies found significantly increased 
levels of IL-4 in the BAL of TB patients when measured by Luminex [11, 19] and qPCR [9]. 
Herrera et al observed increased IL-4 in M.tb supernatants of alveolar cells but not PBMCs 
[11].  Surprisingly, only one study demonstrated increased mRNA expression of IL-4 and IL-
4δ2 in BAL and blood [9]. This study was performed in the UK and none, where both 
compartments were investigated for expression of the two isoforms, have been performed in 
a high TB burden setting. 
 
1.10.3 Disease extent and response to therapy 
In some studies, increased IL-4 levels were often observed in patients with more severe 
pulmonary TB, based on radiological and microbiological correlates of disease extent such as 
the presence and degree of cavitation [21, 421], unilateral vs bilateral disease [409], AFB 
sputum positivity [20], conversion of smear status [17] or a combination of these factors [9, 
18, 19]. A higher proportion of IL-4 secreting cells were associated with cavitatory disease 
compared to non-cavitatory disease [21, 421]. Studies conducted in the UK [9, 18] and 
Ethiopia [19], using a chest X-ray scoring system which graded the extent of radiological 
involvement, found that increased IL-4 strongly correlated with disease extent. Finally, 
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Nolan et al observed that higher IL-4 levels in the BAL was found in smear positive 
compared to smear negative TB patients [20]. 
 
Researchers have also reported that IL-4 and IL-4δ2 levels change in response to anti-TB 
treatment. Most studies have found that IL-4 was significantly decreased at the end of 
treatment compared to the levels at diagnosis [9, 30, 288, 412, 417]. Siawaya et al showed 
that this decrease can occur as soon as one week after treatment initiation [30]. Studies which 
also measured IL-4δ2 (using quantitative/semi-quantitative PCR) found that expression of 
this isoform increased with treatment [9, 30]. In contrast, others found IL-4δ2 levels were 
unchanged [288] and even decreased following successful TB chemotherapy [417]. 
 
1.10.4 Contacts of TB patients and LTBI 
As discussed previously, latent TB infection represents the majority of M.tb exposed 
individuals where the infection is established but contained by the host immune system and is 
characterized by IFN-γ responses to M.tb specific antigens such as ESAT-6. Expression of 
IL-4δ2 mRNA was increased in LTBI donors from Ethiopia and The Gambia but not TB 
patients suggesting that IL-4δ2 may be associated with a protective phenotype in M.tb 
infection [28, 29]. On the other hand, evidence suggests that IL-4 may also be involved in 
disease progression. A study in Portugal found that healthcare workers with pre-existing IL-4 
responses to M.tb antigens in vitro went on to develop TB within 2–4 years [23]. Similarly, a 
Pakistani study found that increased IL-4 responses were associated with household contacts 
of index cases that developed disease compared to those that remained disease free within the 
same household [22]. It has also been suggested that the IL-4/IL-4δ2 ratio may serve as an 
indicator of disease progression [16]. 
 
1.10.5 What do increased IL4 and/or IL-4δ2 indicate? 
A number of conclusions can be made from the literature presented above. Firstly, there is 
convincing evidence that IL-4 is upregulated in TB and that it correlates with disease 
susceptibility and immunopathology whereas the IL-4 splice variant, IL-4δ2 is associated 
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with protective responses. Secondly, IL-4 levels are raised to a greater extent in TB patients 
from countries close to the equator, which may be partly due to the Th2-priming adjuvant 
effect of helminth infection or exposure to environmental mycobacteria [423]. However, it is 
still unclear if IL-4 causes the immunopathology in TB or is merely a by-product of 
excessive inflammation.  Indeed, evidence of a causal relationship has been demonstrated in 
a mouse model where adoptive transfer of Th2 cells in infected mice resulted in increased 
immunopathology [424]. However, whether this is also occurring in humans is unclear. A 
number of immune mechanisms known to be protective in TB are downregulated by Th2 
responses and these are discussed in more detail in the next section. 
 
1.11 Putative effects of a Th2 response on host immunity in TB 
1.11.1 Induction of Th2 response by M.tb 
M.tb has evolved a number of mechanisms by which it manipulates the host immune 
response to its benefit, allowing the bacteria to survive and, in some cases, undergo 
unrestricted growth. One such M.tb evasion mechanism may involve the induction of a Th2 
response.  There is ample evidence that IL-4 is increased in TB patients and certain M.tb 
specific components, such as ESAT-6, tend to drive IL-4 expression [28, 29]. Dwivedi et al 
demonstrated that the virulent H37Rv strain induces both Th1 and Th2 responses in murine 
DCs whereas BCG preferentially induces Th1 responses. Furthermore this effect was driven 
mainly by the RD1 proteins ESAT-6 and CFP-10 [211]. Induction of IL-4 by M.tb appears to 
be strain specific [425] and some studies suggest that virulent M.tb strains are strong inducers 
of IL-4 expression [426, 427]. BALB/c mice infected with highly virulent Beijing strains 
induced significantly higher IL-4 expression compared to less virulent strains [426]. Infection 
of human monocytes in vitro with Beijing isolates preferentially induced IL-4 and IL-13, 
through cellular interaction with various M.tb lipid components [427]. Additionally, the 
16kDa heat shock protein of M.tb contains specific epitopes that are recognized by Th2 cells 




1.11.2 Putative effects of IL-4 on the immune response to M.tb 
A number of putative Th2 inducing mechanisms have been instigated in downregulating 
antimycobacterial mechanisms of protection and promoting immunopathology. Some of 
these mechanisms are discussed below and shown in figure 1.6. 
 
1.11.2.1 Downregulation of a Th1 response 
The protective role of a Th1 response, through the various effects of IFN-γ and TNFα on 
macrophage activation and other innate mechanisms, in TB is unquestionable. However, the 
relationship between a Th1 and Th2 response is antagonistic, in that these subsets cross-
regulate each other so that one predominates over another [429]. For example, IFN- (Th1) 
inhibits murine Th2 cell proliferation whereas Th2 cells inhibit cytokine synthesis of Th1 
cells [430]. Thus, increased IL-4 may very well lead to an undermining of Th1 immunity in 
TB by downregulating IFN-γ mediated responses. In leprosy, ineffective immunity is 
characterized by a Th2 profile whereas protective immunity is associated with a Th1 profile 
[431]. Indeed, the downregulatory effects of IL-4 on apoptosis, iNOS production and 
macrophage activation have been observed in TB models (discussed below). However, the 
caveat to this notion is that a Th1 response is usually dominant in TB and very high levels of 
IFN-γ are often observed in the lungs of patients despite exhibiting increased IL-4 responses. 
Thus, it is unlikely that a simple two way regulation occurs but rather that an IL-4 response is 
undermining host immunity within the prevailing Th1 environment [16]. 
 
1.11.2.2 Alternative activation of macrophages 
Macrophages become polarized depending on the cytokine environment in much the same 
way as T-cells. Th1 cytokines, IFN-γ in particular, drive classical activation of macrophages 
(termed M1) resulting in increased pro-inflammatory responses and mycobactericidal activity 
through the production of iNOS, TNFα, IL-6 and IL-12. In contrast, IL-4 and IL-13 drive 
alternative activation of macrophages (termed M2) which have anti-inflammatory functions, 
characterized by increased expression of surface receptors MR and DC-SIGN as well as 
production of IL-4 and IL-10 [351]. The M2 phenotype has been shown to modulate immune 
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mechanisms that promote intracellular M.tb survival [432]. For instance, M2 macrophages 
increase the intracellular availability of iron, a key requirement for M.tb proliferation [433], 
through the upregulation of transferrin receptor expression [39]. Furthermore, 
downregulation of iNOS, a well described mechanism of intracellular M.tb killing in M1 
macrophages, have been demonstrated in M2 macrophage of murine infection models [39, 
40]. Kahnert et al found that IL-4 activated macrophages exhibited reduced iNOS expression 
but also increased arginase-1 expression which competes for L-arginine, the key substrate 
required by iNOS to produce NO [39]. Redente et al found that macrophages in M.tb infected 
mice underwent a switch from M1 to M2 polarization late in infection, characterized by high 
arginase-1 and low iNOS production [40]. In a similar murine model, Ito et al showed that 
the switch to M2 polarization was TLR-9 dependent [434].  
 
1.11.2.3 Inhibition of autophagy and apoptosis 
In addition to iNOS production, alternatively activated macrophages also have 
downregulatory effects on innate mechanisms of apoptosis and autophagy. TNFα induced 
apoptosis of infected macrophages is inhibited by virulent M.tb strains through the secretion 
of high levels of soluble TNF receptors which form inactive TNFα-TNF receptor complexes 
[147, 435]. IL-4 is thought to enhance this effect because it downregulates TNFα production 
in human monocytes and macrophages [41, 42] and increases the expression of soluble TNF 
receptors [41]. Indeed, infection of THP-1 cells with the virulent Erdmann strain of M.tb 
resulted in reduced expression of TNFα and the surface receptor TNFR1 when IL-4 was 
added exogenously [436]. Apoptosis inhibition may also occur by upregulation of an anti-
apoptotic molecule Bcl-2, via the IL-4/STAT6 signalling pathway [370]. Additionally, 
Abebe and colleagues found that M.tb infected THP1 cells, in the presence of IL-4, induced 
significantly more necrosis than apoptosis compared to cultures without IL-4, suggesting that 
IL-4 may not simply inhibit apoptosis but rather preferentially promote necrotic cell death 
[436].  Indeed, virulent strains of TB can alter the balance of the lipid mediator eiconasoids in 
infected cells by inducing lipoxin A4 (LXA4; pronecrotic) and inhibiting prostaglandin E2 
(PGE2; proapoptotic) resulting in reduced apoptosis and increased necrosis [207, 437]. 
Interestingly, IL-4 is known to downregulate PGE2 production in phagocytic cells [43, 438] 
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and this may represent another pathway by which IL-4 impairs apoptosis of M.tb infected 
cells. 
 
Autophagy is considered a rescue mechanism initiated by the host immune response to 
counteract the M.tb mediated inhibition of phagolysosomal fusion [439]. However, evidence 
suggests that Th2 cytokines (IL-4 and IL-13) are able to block autophagy in infected 
macrophages via 2 separate pathways; IFN-γ induced autophagy is inhibited via the IL-
4/STAT6 pathway while starvation induced autophagy is blocked via the IL-4/IRS-1 
pathway [44]. In addition to blocking apoptosis, STAT-6 signaling induction of Bcl-2 also 
leads to sequestration and subsequent inactivation of Bcl-1, which is essential for autophagy 
induction [440, 441]. IL-4 induction of IRS-1 and Akt upregulates mTOR which inhibits 
autophagy induced by starvation [44, 442] 
 
1.11.2.4 Promotion of Treg development 
There is increasing evidence that Tregs can play a detrimental role in TB (discussed in 
1.8.2.2.3). However, whether IL-4 is involved in driving the expansion and maintenance of 
Tregs is unclear. Evidence in both humans and mice suggests that Th2 cells are more 
resistant to Treg suppressive functions and IL-4 can promote the development of Tregs but 
data is conflicting. Pace et al showed that IL-4 preserves murine CD4+ T-cell proliferation in 
the presence of CD4+CD25+ Tregs and drives their proliferation via IL-4Rα signaling [443].  
In humans, CD4+ and CD8+ Tregs generated from thymocytes abrogated Th1 proliferation 
but had a much lower suppressive effect on Th2 proliferation, which was reduced even 
further with the addition of IL-4 [444]. IL-4 also induced the generation of Tregs in an IL-10 
and TGFβ independent but antigen-specific stimulation-dependent manner [303]. In contrast, 
Wei et al found that TGFβ induced Foxp3+ Treg development from naïve T-cells is inhibited 
by Th1/Th2 polarizing cytokines [445]. Similarly, the addition of IL-4 inhibited Treg 
mediated expression in an adoptive transfer murine model of allergic inflammation [302]. 
Despite these finding, there have been no studies investigating the link between IL-4 and 





Figure 1.6. Possible pathways and mechanisms by which IL-4 subverts the protective host 
immune response to M. tuberculosis. Taken from Rook [439]. 
 
1.12 The implication of Th2 responses in TB vaccines 
1.12.1 Inefficacy of BCG 
BCG efficacy exhibits wide variability depending on the geographical location but its failure 
to confer protection against TB is most apparent in high TB burden developing countries 
where it is greatly needed [446]. Although there is not a definitive explanation for this 
phenomenon, individuals from these countries tend to have a background Th2 response 
against mycobacterial antigens. For example, Malawian BCG vaccinated infants induced 
significantly more IL-4, IL-13, IL-5 and IL-9 in PPD-stimulated blood cells, compared to 
matched BCG-vaccinated UK infants [447]. This notion is also supported by the observation 
that IL-4 is easily detectable in biological samples of TB patients from equatorial regions 
whereas more sensitive techniques and the use of prestimulation protocols are often required 
to observe measurable IL-4 levels in TB patients from developed countries [423]. It has been 
suggested that pre-exposure to non-tuberculous mycobacteria (NTM) and chronic helminth 
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infection may contribute to the reduced efficacy of BCG, which are common in these 
developing countries. Exposure to NTM may boost background levels of immunity which 
either blocks or masks the ability of BCG to induce a protective response [2, 448]. This may 
occur through the induction of a Th2 or regulatory responses. Vaccinated mice exposed to 
live M. avium via the oral route exhibited increased IL-4 levels and reduced BCG efficacy 
[449]. Also, pre-exposure to NTM reduced BCG efficacy in Gambian neonates via a 
mycobacterial-specific Treg mechanism and subsequent reduction in Th1 and Th17 
responses [450]. A similar effect is likely to occur as a result of chronic helminth infections 
which are potent inducers of Th2 cytokines and regulatory T-cell responses. Helminth-
infected Ethiopian subjects showed reduced immune responses to BCG compared to those 
treated with anti-helminthics [451].  Indeed, helminth infection can downregulate protective 
responses to M.tb. Filariasis patients showed exaggerated IL-4-specific memory responses 
and reduced IGRA responses compared to uninfected patients [452] and mice infected with 
N. brasiliensis exhibited impaired resistance to M.tb infection due to increased M2 
macrophage polarization [453].  However, it should be noted these organisms can induce a 
Th1 response as well [454] and it may be the Th1/Th2 balance that is the crucial factor in 
determining efficacy. 
 
These data suggest that failure of BCG in developing countries is due to the priming of a 
Th1+IL-4 mixed response by NTM exposure or the presence of helminth infections. The 
immunity gained through these environmental influences likely impairs the ability of BCG to 
replicate and mount a sufficient protective response. This background response may also 
explain why a high dose of M.tb is required to cause disease. Laboratory mice from 
developing countries which have previously been exposed to environmental mycobacteria, 
required ~105-106 organisms to overcome the background immunity and cause disease 
whereas pathogen free mice from countries such as the USA, develop disease at a much 
lower dose [455, 456]. In humans from these countries where a background mixed Th1+Th2 
response exists, this partial immunity is able to control the low dose infection. In contrast, 
infection with a large dose or virulent IL-4-inducing M.tb strains may be initially controlled 
but eventually, the preexisting IL-4 (Th2) response will increase to a point where it can 
subvert Th1 mediated protective immunity and cause progressive disease [16, 256, 439]. 
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1.12.2 Vaccine design in the context of a Th2 response 
There are a large number of vaccine candidates currently in various stages of development 
and clinical trial phases which use preparations of inactivated whole cell extracts, M.tb genes 
in viral vectors, fusion proteins and live recombinant BCG or attenuated M.tb [457].  It is not 
feasible to test every candidate in large scale efficacy trials so it is of paramount importance 
to select the most promising ones at preclinical development or an early stage of clinical 
testing. Firstly, vaccine preparations should be tested in animal models within the context of 
helminth infection or NTM exposure, using a high dose challenge so as to mimic the 
situation in developing countries where a new vaccine is most needed [439]. Secondly, if IL-
4 is indeed causing impairment of protective immunity, then it may be more appropriate to 
screen vaccines based on their ability to downregulate Th2 responses rather than just induce 
more Th1. Indeed, MVA85A induced strong IFN-γ ELISPOT responses but failed to be 
efficacious [3]. Such preparations may be useful as a prophylactic vaccine to prevent 
infection pre-exposure or as a therapeutic vaccine to supplement chemotherapy after 
development of active disease (Figure 1.7). Two vaccines candidates have been shown to 
downregulate Th2 responses with promising results in preclinical and clinical trials. The 
hsp65 DNA vaccine was found to be protective as a therapeutic vaccine in mice where it 
downregulated IL-4 and promoted CD8+ CTL and Th1 production [458]. In another murine 
model, the vaccine showed strong therapeutic effects against MDR- and XDR-TB [459]. 
Similarly, heat killed M. vaccae drives regulatory T-cells that target Th2 cells while 
simultaneously inducing CTL responses [460]. It has shown protective efficacy as a 
therapeutic vaccine in mice [461, 462] but its effect was more variable in human trials. It had 
limited or no additional benefit to standard therapy in trials performed in Southern Africa 
[463, 464]. In contrast, single or multiple doses were associated with bacteriological and 
radiological improvement compared to the placebo group in two other trials [465, 466].It has 





Figure 1.7. The role of the subversive Th-2-like response in progressive TB and its implications 
of vaccine design. Taken from Rook et al. [468]. 
 
1.13 Conclusion 
The data outlined in Chapter 1 provides an outline of the immunological events during TB 
infection, the possible mechanisms of disease progression, biological attributes of IL-4 and 
IL-4δ2, a review of the literature regarding the role of IL-4 and IL-4δ2 in TB and how it 
relates to vaccine design.  
 
However, there are still some issues regarding the IL-4 hypothesis that remain unclear. 
Indeed, the foremost question is whether IL-4 is causative or a consequence of TB disease in 
humans. The role of IL-4δ2 within this context also needs further clarification. Furthermore, 
the compartment specific expression of human Th1 and Th2 cytokines (lung and blood) in 
human TB, particularly in a high burden setting, and the interaction with other T-cells subsets 
has not been fully elucidated.  The experiments performed in this thesis will attempt to 





2. CHAPTER 2: General methods and demographic data 
 
2.1 Study Design and ethical considerations 
The design of the study was cross sectional. The study was approved by the University of 
Cape Town Research Ethics Committee (UCT REC). Samples were obtained from 
participants undergoing bronchoscopy and venepuncture as part of previous and existing 
ethically approved studies being conducted at the Lung Infection and Immunity Unit, 
University of Cape Town. Informed consent was obtained from all study participants in 
accordance with UCT REC guidelines.  
 
2.2 Participant selection and recruitment 
2.2.1 Pulmonary tuberculosis patients 
Pulmonary tuberculosis (TB) patients were recruited at part of ongoing studies from primary 
care clinics in and around the Cape Town area including Langa Clinic, Chapel Street Clinic, 
Gugulethu Clinic and Vanguard Clinic. All recruited patients were HIV uninfected, more 
than 18 years old and were not pregnant. TB diagnosis was microbiologically confirmed by 
sputum smear microscopy and/or culture at the time of recruitment. Auramine fluorescence 
microscopy and Bactec MGIT 960 liquid culture were performed by the National Health 
Laboratory Service as part of routine diagnostic testing. All patients were receiving anti-TB 
treatment for less than 2 weeks at the time of recruitment. Any patients with chronic 
immunosuppressive diseases, Th2-related conditions or receiving immunosuppressive 
medications were excluded from the study, as determined by a review of medical records and 
interviews conducted by the recruiting nurse. All inclusion criteria are listed in table 2.1. 
 
2.2.2 Presumed latently infected controls 
Presumed latently infected (LTBI) controls were defined as asymptomatic individuals with 
no previous history of TB and were both tuberculin skin test (TST) and interferon-gamma 
release assay (IGRA) positive. There is no reliable method to determine latent infection and, 
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in our opinion, these criteria best represented exposure to M.tb and subsequent control of 
infection. LTBI controls were close contacts of TB index cases, healthcare workers recruited 
from ongoing studies and laboratory personnel. All LTBI controls were HIV uninfected, 
more than 18 years old and not pregnant. As with TB patients, LTBI controls were excluded 
if they had any chronic immunosuppressing or Th2-related conditions. Inclusion criteria for 
LTBI controls are listed in table 2.1. 
 
Table 2.1: Inclusion criteria for the recruitment of study participants. 
 
Pulmonary tuberculosis patients (TB) 
 
Latent TB Infected controls (LTBI) 
• HIV uninfected 
• ≥18 years old 
• Not pregnant 
• Microbiologically confirmed 
diagnosis (sputum smear and/or TB 
culture positive) 
• ≤ 2 weeks of anti-TB 
chemotherapy 
• No concurrent immunosuppressive 
conditions (diabetes, malignancy) 
and not currently on 
immunosuppressive medications 
• No concurrent Th2 -related 
conditions (asthma, allergic 
rhinitis, autoimmune disorders, 
worm infestation 
• HIV uninfected 
• ≥18 years old 
• Not pregnant 
• Asymptomatic 
• No previous radiological evidence of 
active TB 
• Tuberculin Skin Test (TST) positive 
• IGRA (Quantiferon Gold In-Tube) 
positive 
• No concurrent immunosuppressive 
conditions (diabetes, malignancy) and 
not currently on immunosuppressive 
medications 
• No current Th2-related conditions 
(asthma, allergic rhinitis, autoimmune 
disorders, worm infestation) 
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2.3 Clinical procedures 
2.3.1 Venipuncture 
Venipuncture was performed by a qualified research nurse. A maximum of 45ml whole 
blood was collected in 9 ml sodium heparin vacutainer tubes (Lasec) for PBMC isolation and 
other immunological assays. 2.5ml of whole blood was also collected directly into PAXgene 
blood RNA tubes (Qiagen) to preserve the mRNA profile for qPCR analysis (chapter 3). 
 
2.3.2 Tuberculin skin test (TST) 
The TST was performed on all potential LTBI controls according to standard protocols. 
Briefly, 0.1ml of tuberculin PPD RT 23 (Statens Serum Institute) was intradermally 
administered into the participant‟s forearm by a qualified research nurse. The induration size 
was measured 48-72 hours post-injection. The TST was considered positive if the induration 
size was >10mm.  
 
2.3.3 Bronchoscopy  
Bronchoscopy was performed on TB patients and LTBI controls as part on on-going 
immunological studies being conducted at the Lung Infection and Immunity Unit. Informed 
consent was obtained from all participants prior to participation in the study and were 
compensated according to local ethical policy. Prescreening blood tests were performed to 
identify any possible bleeding tendencies and a CXR were performed to exclude participants 
with other respiratory illnesses. Bronchoscopy was not performed if participants had any of 
the following: asthma, uncontrolled hypertension, ischaemic heart disease, diabetes, 
pregnancy and immunosuppression.  
 
An experienced pulmonologist performed all bronchoscopy procedures. The participants‟ 
medical history, blood test results and CXR were reviewed to evaluate their suitability to 
undergo the procedure. Bronco-alveolar lavage (BAL) fluid was collected according to 
standard procedures and proper safety protocols were strictly followed. Briefly, after 
administration of lignocaine anesthaetic, the bronchoscope was passed through the airway 
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and the tip was wedged into the right middle lobe bronchus. A 300ml lavage using sterile 
saline, in 60 ml aliquots was performed under low suction (<20cm H20). The lavage fluid 
was aspirated into a sterile glass container and then transported on ice directly to the 
laboratory for processing as described in section 2.4.3.  
 
2.4 Laboratory Methods 
2.4.1 Quantiferon Gold In-tube 
A Quantiferon-Gold-In-Tube IGRA assay (Qiagen) was performed on all potential LTBI 
participants according to the manufacturer‟s instructions. Briefly, 3ml of blood was collected 
directly into Quantiferon blood tubes containing (i) no antigen (Nil control), (ii) M. tb 
specific antigens ESAT-6, CFP-10 and TB7.7 (TB antigen) and (iii) PHA (Mitogen control) 
and incubated at 37°C for 16 hours. After centrifugation of the tubes, the plasma was 
collected and used to determine the levels of IFN-γ (IU/ml) by ELISA, according to the 
manufacturer‟s instructions. An IFN-γ detection level of > 0.35 IU/ml was considered a 
positive result. 
 
2.4.2 PBMC isolation 
PBMCs were separated from whole blood by density gradient centrifugation as per standard 
protocols. Briefly, whole blood was centrifuged at 1800 rpm for 10 minutes and the plasma 
was removed. The uppermost layer of the remaining cells, which contained leucocytes 
(„buffy coat‟), was collected and mixed with 1xPBS (Lonza) in a 1:1 ratio. The entire 
suspension was layered on Ficoll Histopaque (Sigma-Aldrich) at a 3:1 ratio (cell suspension: 
ficoll) and centrifuged in a swing bucket rotor at 1800 rpm for 25 minutes with the centrifuge 
brakes turned off. The subsequent mononuclear cell layer was harvested, washed twice in 1x 
PBS, and re-suspended in growth media [RPMI 1640 containing glutamine (Lonza) and 10 % 
human AB serum (Western Province Blood Transfusion Services), 100U/ml penicillin/ 
streptomycin (Sigma-Aldrich) and 0.1% Fungin (Invivogen)]. Cells used in the 
mycobacterial containment assay were resuspended in growth media without 
penicillin/streptomycin. An aliquot of cells were stained using Turks solution and counted on 
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a Neubauer haemocytometer counting chamber. Cells were then seeded in tissue culture 
plates for various immunological assays (chapter 5-9). 
 
2.4.3 BAL cell isolation 
After the bronchoscopy procedure in the respiratory clinic (section 2.3.3), the BAL fluid was 
immediately transported on ice to the laboratory. The BAL fluid was filtered through sterile 
2-ply gauze to remove any mucus and particulate debris. The filtered BAL fluid was then 
transferred to a 50ml tube and centrifuged at 1200rpm for 10 minutes. The BAL supernatant 
was removed and the resulting pellets were combined, washed twice in 1xPBS and 
resuspended in growth media. Cell viability was determined by Trypan blue exclusion 
staining and cells were counted using a Neubauer haemocytometer counting chamber. Cells 
were either stored in RLT lysis buffer (Qiagen) to preserve the RNA profile (qPCR analysis 
in chapter 3) or seeded in tissue culture plates and stimulated with TB antigens for 
downstream Luminex (chapter 8) or flow cytometry (chapter 9) assays.  
 
2.4.4 Generation of monocyte derived macrophages 
Monocyte derived macrophages were generated from PBMCs as previous described [293, 
469]. PBMCs (isolated as described in section 2.4.2) were seeded at 2x106 cells/well in a 96 
well flat bottom plate or at 6x106 cells/well in a 24 well plate for CFU counting and flow 
cytometric analysis in the mycobacterial stasis assay, respectively. The cells were incubated 
at 37°C with 5% CO2 for 5 days to allow adherent monocytes to differentiate into 
macrophages. On day 3, wells were replenished with growth media. Non adherent cells were 
removed by washing with warm RPMI after 5 days. Adherent monocytes were presumed to 
be at 2x105/well in the 96 well plate and 6x105/well in the 24 well plate as ~10% of PBMCs 
are composed of monocytes [293, 470, 471].  
 
2.4.5 Preparation of H37Rv stocks 
H37Rv (donated by State Laboratory) was grown in Middlebrook 7H9 broth (Difco) 
supplemented with 10 % OADC (oleate-albumin-dextrose-catalase) enrichment media (BD 
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Biosciences) and 0.02% glycerol (Merck). Cultures were grown in a tissue culture flask 
(Corning) at 37°C and 5% CO2 in a humidified incubator and shaken daily. Growth was 
assessed periodically until cultures reached mid-log phase. 1ml aliquots of culture were then 
snap frozen in 10% glycerol using liquid nitrogen and stored at -80°C. 
 
Colony forming units (CFU)/ml, were determined using three randomly selected frozen 
H37Rv tubes. The bacterial suspension was homogenised by aspiration using a 1ml insulin 
syringe. 10-fold serial dilutions were made from the stock and the three lowest dilutions (102, 
101, 100 CFUs) were plated in replicates of 6 onto Middlebrook 7H10 gridded agar plates 
(BD Biosciences) supplemented with 10% OADC. Plates were incubated in a 37oC oven for 
10-16 days or until visible colonies were formed. Colonies were counted using an inverted 




2.4.6 Immunofluorescence staining and flow cytometry 
Cells were stained with fluorescently labelled antibodies for analysis by flow cytometry 
(chapter 5, 7 and 9). Cells were harvested into 15x75mm 5ml polystyrene tubes (BD 
Biosciences), washed in 2ml FACS buffer (0.01% sodium azide, 10% human AB serum, 
1xPBS) and centrifuged at 1200rpm for 5 minutes. The supernatants were removed and the 
cell pellet was resuspended in 100ul of FACS buffer. Appropriate fluorescently conjugated 
antibodies for cell surface markers were added at previously titrated volumes to the cells and 
incubated in the dark for 15 minutes at room temperature. Cells were then washed to remove 
unbound antibodies and fixed in 100μl of BD Cell Fix diluted 1:10 in H2O (BD Biosciences) 
for 15 minutes in the dark. After another wash step, cells were permeabilized in 500ul PERM 
II solution diluted 1:10 (BD Biosciences) for 10 minutes in the dark. In panels measuring 
FoxP3 (chapter 7), fixation and permeabilization was performed using Human FoxP3 buffer 
set (BD Biosciences), according to the manufacturer‟s instructions. Appropriate fluorescently 
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conjugated antibodies for intracellular markers was added to each tube at previously titrated 
volumes and incubated for 30 minutes in the dark. The cells were then washed to remove 
unbound antibodies and 100ul of 4% paraformaldehyde solution was added to each tube for 
at least 30 minutes. All antibodies used in flow cytometry experiments are listed in table 2.2. 
 
Flow cytometric analysis was performed using a BD LSRII Flow Cytometer (BD 
Biosciences).  Fluorescence compensation was performed prior to data acquisition to 
eliminate any spectral overlap that may occur between fluorophores with similar emission 
spectra.  BD compensation beads (BD Biosciences) were used to make compensation 
controls where the appropriate beads were stained with a single fluorescently conjugated 
antibody, according to the manufacturer‟s instructions. Voltages for each fluorescent channel 
was adjusted until the mean fluorescent intensity of the different cell population were equal. 
 
Following data acquisition, the numbers of cells expressing the appropriate makers were 

























Source Catalogue No Used in  
CD3  Alexa fluor 
700 




CD4  APC H7 BD Pharmingen  560837 
CD8  PeCy5 Biolegend  300914 
CD19 PE eBiosciences 12-0199-42 CD23 expression 
assay (Chapter 5) CD23 APC eBiosciences 17-0238-42 
CD14 PE Cy7 Biolegend 301814 




 (chapter 7) 
CD16 PE Cy7 Biolegend 302016 
CD25  PE BD Pharmingen  557138 
IFNγ PE Biolegend 506507 
IFNγ  PeCy7 eBiosciences 505826 
TNFα  APC BD Pharmingen  5513841 
DC-SIGN PerCP Biolegend 330110 
LC3B Alexa 488 Cell Signalling 
Technologies 
3868S 
FOXP3  Alexa fluor 
647 
BD Pharmingen  560045 
IL10  Alexa fluor 
488 
Biolegend  505013 
IL-9 PE BD Pharmingen 560807 
Expression of IL-9 
in T-cells 
 (chapter 9) 
IL-17A  PerCP eBiosciences 45-7179-42 
IL-13 FITC R&D Systems Inc. IC2131F 







2.5 Statistical analysis 
Data sets were evaluated for normality using the Shapiro-Wilk test. The Mann Whitney test 
was used to determine differences between participant groups and between the different 
biological compartments that were sampled. The Wilcoxon matched-pairs signed rank test 
was used to determine differences in samples before and after addition of recombinant IL-4. 
In all tests, a p-value of <0.05 was considered significant. Statistical analyses were performed 
using GraphPad Prim version 5.0 (GraphPad) and Microsoft Excel (Microsoft). 
 
2.6 Demographics and clinical characteristics of study participants 




























































Black African  
Mixed Ancestry  

























Smear status (%) 




            Smear negative  























TB sputum culture (%) 51 (100%) - - 
≥1 previous episode of TB 
(%) 
16 (31) - - 
Median length of time from 
start of treatment to 











3. CHAPTER 3: Expression of mRNA encoding IFN-γ, IL-4, and 
IL-4δ2 using cells from peripheral blood and the lungs 
 
3.1 Introduction 
Protective immunity to tuberculosis (TB) is known to require a Th1 response. Strong 
evidence comes from genetic studies in mice where mutations in the IFN-γ gene resulted in 
granuloma formation and disseminated growth of bacilli [228, 472]. In humans, genetic 
defects in the IFN-γ receptor 1 gene is associated with increased susceptibility to tuberculosis 
[473]. Despite strong Th1 responses in TB patients, particularly at the site of disease [9, 11-
15], some exposed individuals still progress to active disease. Moreover, BCG and newer TB 
vaccine candidates, including MVA85A, have poor efficacy in developing countries despite 
inducing strong IFN-γ responses [112]. These observations suggest that this Th1 response is 
only part of the answer and there is some other underlying mechanism which, even in the 
presence of a potent Th1 response, is undermining TB immunity.  
 
One hypothesis is that an underlying Th2 immune mechanism is subverting the protective 
Th1 response, leading to progressive TB. A number of studies have shown that the levels of 
IL-4, the principal Th2 cytokine, are elevated in TB and correlate with disease severity [9, 
17, 18, 21]. In one study, increased IL-4 levels in healthcare workers were able to predict 
progression to active disease [23]. Furthermore, IL-4 has been shown to have deleterious 
effects on protective host response mechanisms in TB, including the downregulation of iNOS 
production [39, 40], autophagy [44] and apoptosis [41, 436] in macrophages as well as 
contributing to tissue damage and fibrosis [256].  
 
 The study of IL-4 is not meaningful without studying IL-4δ2, a naturally occurring 
alternatively spliced variant of IL-4 where exon 2 is deleted. IL-4δ2 is a functional antagonist 
of IL-4 and dampens the effects of IL-4 on T cell proliferation, CD23 expression on B cells 
and LPS-induced cycloxygenase-2 expression and prostaglandin E2 secretion in monocytes 
in vitro [47, 48]. IL-4δ2 mRNA has been detected in asthma [474] and is increased in 
scleroderma [394] suggesting it may have an inflammatory role.  Only recently,  it was found 
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that IL-4δ2 is not only expressed on a transcriptional level but is also produced as a protein in 
vivo, and is associated with the production of pro-inflammatory cytokines by T-lymphocytes 
including IFN-γ, IL-6 and TNF-α [31, 393]. Current data suggests that it is associated with a 
protective phenotype in TB as IL-4δ2 levels are increased in healthy controls compared to 
TB patients[28, 29, 416] and also increase following successful anti-TB chemotherapy [9, 
30]. However, its precise role in relation to IL-4, in the host immune response to TB is not 
clear. 
 
Only one study has investigated IL-4 and IL-4δ2 simultaneously in the peripheral blood and 
site of disease [9] but not in a TB endemic setting. In pulmonary TB, the study of cytokine 
expression in the lungs is important as it accurately reflects the innate and adaptive immune 
response to host-pathogen interactions [38]. Furthermore, accumulation and activation of 
immune cells at the site of infection can be significantly different from the peripheral 
circulation (reviewed in [38]). Thus, analysis of both compartments can provide clinically 
relevant insights into cytokine expression patterns.  
 
The aim of this chapter was to determine the mRNA expression levels of IFN-γ, IL-4 and IL-
4δ2 in cells obtained from peripheral blood and broncho-alveolar lavage (BAL) in TB 
patients and presumed LTBI controls using a validated quantitative PCR (qPCR) assay. 
qPCR was chosen for cytokine determination as it is more sensitive, compared to other 
conventional assay methods (ELISA), for measurement of low expressing cytokines. 
Furthermore, it is the only available method to distinguish IL-4 and IL-4δ2. Nonetheless, 
soluble levels of IL-4 and other cytokines were assessed in these samples and will be 
discussed in chapter 8. 
 
3.2 Methods 
3.2.1 Sample collection and processing 
Whole blood and broncho-alveolar lavage (BAL) fluid was obtained from TB patients and 
presumed LTBI controls as described in sections 2.3.1 and 2.3.3, respectively. 
Approximately 2.5ml of whole blood was obtained from participants and immediately 
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transferred to a PreAnalytiX PAXgene Blood RNA tube (Qiagen) in order to preserve the 
mRNA profile. PAXgene tubes were incubated at room temperature for 16-24 hours to 
ensure complete lysis of blood cells, followed by storage at -80oC. BAL cells were isolated 
from BAL fluid as described in section 2.4.3. A total of 350μl RLT lysis buffer 
(supplemented with β-mercapto-ethanol) from the RNeasy Plus Mini kit (Qiagen) was added 
to ~1-2x106 BAL cells followed by storage at -80 oC. 
 
3.2.2 Choice of primers, hydrolysis probes and amplification targets used for 
quantitative PCR  
The primer and hydrolysis probes sequences used in this study were taken from published 
sequences in the literature [9, 288] and are shown in Table 3.1. The primers were designed to 
span exon-exon boundaries so as not to amplify genomic DNA and thus increase assay 
specificity. Furthermore, the design of intro-spanning primers was an absolute requirement to 
differentiate between the IL-4 and IL-4δ2 transcripts. Primer binding sites and amplification 
target size and locations are shown in Figure 3.1. Primers and probes were synthesized by 
IDT (Integrated DNA Technologies Ltd.) on a scale of 25nM and 100nM, respectively. 
Primers were purified by standard desalting whereas probes underwent HPLC purification. A 
fluorophore (FAM) and two fluorescent quencher (FQ) molecules (an internal ZEN FQ and 
IOWA BLACK FQ at 3‟-end) were incorporated into the hydrolysis probes. Primer sequence 
specificity was confirmed by melt curve analysis on the Rotor-Gene 6000 (Qiagen) using the 
Rotor-Gene SYBER Green PCR kit (Qiagen) assay, according to the manufacturer‟s 











Table 3.1: Primer and probe sequences, taken from the literature [9], to determine cytokine 
mRNA levels.  




○ Forward primer 5‟ - 3‟ 
● Reverse primer 5 ‟- 3‟ 



















































Figure 3.1 Primer binding sites and amplicon location and sizes for (A) HuPO (B) IFN-γ 
(C) IL-4 and (D) IL-4δ2. In (A), (C) and (D), the forward (sense) primer spans the exon-exon 
boundary. The numbers indicate the base pair position of the exon-exon boundary. The size of the 
amplicon is indicated in parentheses. In (C), the forward primer crosses the exon 2-exon 3 boundary 
for detection of full length IL-4. In (D), an alternative splicing event removes exon 2 in IL-4δ2 so the 
forward primer is designed to cross the exon1-exon3 boundary.  
 
3.2.3 RNA extraction and assessment of RNA quality 
RNA was extracted from whole blood in PAXgene tubes using the PreAnalytiX PAXgene 
Blood RNA kit (Qiagen), according to manufacturer‟s instructions. DNaseI treatment was 
performed to remove genomic DNA. RNA extraction from BAL cells was performed using 
the RNeasy Plus Mini Kit (Qiagen) according to manufacturer‟s instructions. Genomic DNA 
was removed using a gDNA eliminator column. All standard protocols for cleaning, handling 
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and storage during RNA isolation procedures were strictly followed. Quality (and quantity) 
assessment of isolated RNA was performed on an Agilent Bioanalyzer 2100 (Agilent) using 
the Agilent RNA 6000 Nano kit, according to manufacturer‟s instructions. Total RNA 
obtained ranged from 0.5-5μg. Samples were only used in reverse transcription reactions if 
an RNA Integrity Number (RIN) of ≥7.5 was obtained. 
 
3.2.4 Reverse Transcription and qPCR 
The iScript cDNA synthesis kit (BioRad) was used to convert RNA samples to cDNA, 
according to manufacturer‟s instructions. The kit uses a modified MMLV-derived RNase H+ 
transcriptase. RNA quantity limited the amount of input RNA to 500ng per reaction. A 20μl 
reaction was set up containing 500ng of sample RNA, reverse transcriptase, nuclease free 
water and iScript mastermix (containing a proprietary mixture of oligo(dT), random 
hexamers and RNase inhibitor). The reaction was performed in a G-Storm thermal cycler (G-
Storm) using following conditions: 5 minutes at 25ºC; 30 minutes at 42ºC; 5 minutes at 85ºC.  
Appropriate control reactions containing no reverse transcriptase enzyme were also included. 
 
Amplification of cDNA was performed on a Rotor-Gene Q real-time PCR machine (Qiagen). 
Reactions were set up manually using the Rotor-Gene probe PCR kit, according to the 
manufacturer‟s instructions. The 2x Rotor-Gene probe PCR Master Mix contained HotStar 
Taq Plus DNA Polymerase, dNTP mix and Rotor-Gene Probe PCR buffer (containing a 
proprietary mixture of Tris-Cl, KCl, NH4Cl, MgCl2 and Q-Bond). Primers were used at pre-
validated concentrations of 500nM for HuPO and IFN-γ and 250nM for IL-4 and IL-4δ2. 
Probes were used at concentrations of 250nM for all analytes, as previously described [9]. 
2μl of sample cDNA and 5μl of 10-fold serial dilutions of linearized plasmid standards 
(described in section 3.2.5) were added to the appropriate sample and standard tubes, 
respectively. The final PCR reaction volume was 20μl. The amplification conditions were as 
follows: initial step of 95°C for 10 minutes, followed by 40 cycles of 95°C for 10 seconds 
and 60°C for 30 seconds. Standards were run in triplicate and samples were run in duplicate. 
Appropriate no template controls (NTC) and no reverse transcriptase controls were includes 
in each qPCR run. 
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3.2.5 Method of mRNA quantification  
Absolute quantification, where the mRNA copy number in a sample is expressed in relation 
to a standard curve containing known numbers of nucleic acid copies, was chosen as the 
method of mRNA quantification. It allows for greater control of inter-assay variation in PCR 
efficiency and experimental reproducibility. This is beneficial especially when large sample 
numbers are assayed over a period of time from different study sites [475]. As such, an 
external standard curve using recombinant DNA inserted into a plasmid was chosen because 
of its long term stability, high reproducibility and its ability to more appropriately mimic the 
length of native mRNA. Furthermore it shows higher sensitivity compared to recombinant 
RNA standards [476]. 
 
3.2.5.1 Generation of cDNA targets of interest 
PBMCs from a healthy control were isolated (described in section 2.4.2) and 1x106 cells 
were stimulated for 16 hours with 10μg/ml of phytohaemmaglutinin (PHA) in a 96-well 
round bottom plate. Total RNA was extracted and reverse transcribed using 1μg of RNA, as 
described in section 3.2.3 and 3.2.4. cDNA was amplified using the Kappa Taq PCR kit 
(Kappa Biosystems) and cloning primers (listed in Table A1 of the Appendix), according to 
the manufacturer‟s instructions. The cloning primers were designed to amplify a region of the 
cDNA containing the target qPCR sequence for IFN-γ and HuPO. The PCR reaction 
conditions were as follows: initial step of 95°C for 2 minutes, followed by 30 cycles of 95°C 
for 1 minute 30 seconds, 50°C for 1 minute, 72°C for 1 minute and a final extension step of 
72°C for 10 minutes. The amplified PCR product was run on a 1% Agarose gel at 200V for 1 
hour (described in section 4.2.1.3). The bands of interest were excised and purified using 
Zymoclean Gel DNA Recovery Kit (Zymo Research), according to manufacturer‟s 
instructions. IL-4 and IL-4δ2 cDNA containing plasmids were generated during cloning 




3.2.5.2 Sub-cloning of cDNA into pGEM-T Easy plasmid 
Purified cDNA was ligated into the pGEM-T Easy plasmid (Promega) at a vector:insert ratio 
of 3:1, transformed in JM109 chemically competent E. coli cells (Promega) and purified 
using the GeneJet Plasmid Miniprep kit (Thermo Scientific), according to the manufacturer‟s 
instructions (more detailed description in chapter 4). Plasmids were sequenced by Inqaba 
Biotech Ltd using an ABI 3500XL DNA sequencer to confirm the successful insertion of the 
target DNA into the plasmid.  
 
3.2.5.3 Linearization and serial dilutions of the plasmid standards 
The HuPO, IFN-γ, IL-4 and IL-4δ2 plasmids were linearized using SacI FastDigest enzyme 
(Thermo Scientific), according to the manufacturer‟s instructions. The plasmids were 
linearized because circular plasmid standards tend to overestimate copy numbers and reduce 
PCR efficiency [477]. Each plasmid was identified to have a single SacI restriction site 
outside the target cDNA sequence. Linearized plasmid concentrations were re-measured and 




10-fold serial dilutions containing down to 101 copies were made in nuclease-free H2O and 
added to appropriate PCR tubes (Qiagen) for qPCR amplification reactions. 
 
3.2.6 Data Analysis and Normalization strategy 
Data analysis was performed using the Rotor-Gene Q series software 2.0 (Qiagen). The cycle 
threshold (Ct) was automatically determined by the software for each qPCR run. Samples 
that were not reproducible (technical replicates with variations in Ct values >0.5 were 
considered outliers) or that were below the detection limit of the assay were given an 
arbitrary value of 1 copy in the final analysis, as previously described [9]. Copy numbers 
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were determined by absolute quantification and normalized using HuPO as a reference gene. 
The suitability of HuPO as a reference gene in pulmonary tuberculosis gene expression 
studies has been pre-validated [478] and used in similar study settings [30, 288]. Gene of 
interest copy numbers are expressed per million copies of HuPO. Coefficient of variance was 
used to assess inter- and intra-assay variation. Inter-group and inter-compartmental 
differences in cytokine mRNA expression were determined using Mann-Whitney U-test. All 
statistical analyses were performed using GraphPad Prism 5 (GraphPad Software Inc.) and 
Microsoft Excel (Microsoft). 
 
3.3 Results 
3.3.1 Validation of qPCR assay 
qPCR assay validation was performed on plasmid standards prior to analysis of samples. The 
limit of detection of the assay was determined to be 10 copies as the replicate Ct values 
below 10 copies were very variable (difference in Ct replicates >0.5). In most experiments, 
PCR efficiency approached 100% and R2 value was >0.99. No transcripts were detectable in 
the „no template‟ controls (NTC) or in the „no reverse transcriptase‟ controls (no RT 
controls) indicating a lack of genomic DNA contamination. The coefficient of variance 
between technical replicates within a single assay (intra-assay variation) was <~20% at each 
concentration. Figure 3.2 shows an example of IL-4 copy number determination by absolute 
quantification in a validated qPCR assay. PCR efficiency, copy numbers and Ct values were 
measured in 5 separate experiments and compared in order to assess inter-assay variation. 
The mean PCR efficiency was 100% (95% CI; 96.1-103.9) and the coefficient of variance at 






Figure 3.2. Generation of IL-4 standard curve to determine unknown values by absolute 
quantification method using Rotor-Gene Q software. Serial 10-fold dilutions of IL-4 plasmids 
standard (blue) and 2 unknown samples (red) were amplified in a qPCR assay. No reverse 
transcriptase (no RT; green) controls and no template controls (NTC; black) and were also included. 
The fluorescence plot (top) was used to generate the standard curve (bottom right). PCR efficiency 
was 100% and R2 value was 0.9995 for this assay. The calculated copy numbers (Calc conc) for the 
samples (red), no RT control (Green) and NTC (black) derived from the standard curve are shown in 
the adjacent table. The variance (%Var) for individual standards was <22% and coefficient of 








Figure 3.3. Inter-assay variability in (A) copy number and (B) Ct value of quantitative PCR 
(qPCR) assay to determine IL-4 plasmid standard copy number. qPCR amplification was 
performed on serial 10-fold dilution of linearized IL-4 plasmid standard in five separate runs. Each 
circle represents a single experiment. The x-axis show the expected copy numbers and the y-axis 
show the expected copy numbers in (A) and Ct values in (B). Lines and error bars represent mean 
values and 95% confidence intervals, respectively. In (A), the coefficient of variance at each dilution 





3.3.2 mRNA expression levels of IFN-γ, IL-4 and IL-4δ2 in TB patients compared to 
presumed LTBI controls in BAL and peripheral blood 
Messenger RNA (mRNA) levels in peripheral blood were assessed in 23 tuberculosis (TB) 
patients and 22 presumed latently infected (LTBI) controls, after RNA samples with low RIN 
values were excluded.  BAL cells (BAL) were obtained from 8 TB patients and 7 presumed 
LTBI controls. 
 
There were no significant differences in IFN-γ mRNA expression levels (per 106 copies of 
HuPO) between TB patients compared to LTBI controls in the peripheral blood or in BAL 
(Figure 3.4A). However, median IFN-γ expression levels in BAL was ~6-fold higher 
compared to peripheral blood in both TB patients (6783 vs. 1721, respectively; p=0.005) and 
LTBI controls (6281 vs. 1871, respectively; p=0.02). 
 
TB patients had significantly higher peripheral blood IL-4 mRNA expression levels 
compared to LTBI controls (126 vs. 42; p=0.02) but these differences were not observed in 
BAL (Figure 3.4B). In contrast to the observed IFN-γ expression profile, median IL-4 mRNA 
expression levels were significantly reduced in BAL compared to the blood in both TB 
patients (126 vs. 10, respectively; p=0.003) and LTBI controls (42 vs. 3, respectively; 
p=0.005).  
 
There were no observed differences in IL-4δ2 expression between TB patients or LTBI 
controls either in BAL or peripheral blood (Figure 3.4C). TB patients did have slightly higher 
IL-4δ2 levels in the blood compared to BAL (6 vs. 1, respectively; p=0.04) but no other 
differences in IL-4δ2 expression levels were observed between the two different 
compartments. Median expression levels of IL-4δ2 were generally low and expression in 
some samples, particularly from BAL, was below the detection limit of the assay. Median 
cytokine expression levels are shown in Table 3.2. 
 
When TB patients were stratified by smear grade, there were no significant differences in 
IFN-γ or IL-4 levels (IL-4δ2 not analyzed due to low expression) between smear negative 
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and the smear positive samples (+1 to +3) in peripheral blood (Appendix; Figure A2). Gene 
expression in BAL was not analyzed by smear grade due to the small sample numbers. 
 
 
Figure 3.4. mRNA expression levels of (A) IFN-γ (B) IL-4 and (C) IL-4δ2 in cells of broncho-
alveolar lavage (BAL; blue circles) and peripheral whole blood (Blood; red squares) from 
patients with pulmonary tuberculosis (TB; BAL n=8, Blood n=23) and presumed latently 
infected controls (LTBI; BAL=7, Blood n=22) as measured by quantitative real-time PCR. Data 
is shown on a log10 scale and copy numbers are expressed per million copies of HuPO. Statistical 




3.3.3 IFN-γ:IL-4 and IL-4δ2:IL4 expression ratios in BAL and whole blood of TB 
patients and presumed LTBI controls 
The ratio of IFN-γ:IL-4 expression, thought to represent the Th1:Th2 balance, was 
significantly lower in peripheral blood of TB patients compared to LTBI controls (22 vs. 53; 
p=0.01). In BAL, there were no significant differences in the IFN-γ:IL-4 between TB patients 
and LTBI controls (999 vs. 1098, respectively; p=0.78) (figure 3.5A). When the different 
compartments were compared, the median IFN-γ:IL-4 ratios were significantly higher in 
BAL compared to peripheral blood of TB patients (p=0.0001) and LTBI controls (p=0.0001), 
which was mainly attributable to the very high expression levels of IFN-γ in BAL. There 
were no differences in the IFN-γ:IL-4 ratio when TB patients were stratified by smear grade 
(Appendix; Figure A2). 
 
There were no significant differences in the IL-4δ2:IL4 ratio in BAL or whole blood of TB 
patients compared to LTBI controls. Similarly, no differences were detected when the 











Figure 3.5.  Cytokine mRNA expression ratios of (A) IFN-γ:IL-4 and  (B) IL-4δ2:IL-4 in cells of 
broncho-alveolar lavage (BAL; blue circles) and peripheral blood (Blood; red squares) from 
patients with pulmonary tuberculosis (TB; BAL n=8, Blood n=23) and presumed latently 
infected controls (LTBI; BAL=7, Blood n=22) as measured by quantitative real-time PCR. Data 
is shown on a log10 scale. Statistical analysis between groups was performed using the Mann-Whitney 















Table 3.2. Median cytokine mRNA expression levels and ratios of mRNA levels in broncho-
alveolar lavage (BAL) and peripheral blood of tuberculosis (TB) patients and presumed latently 
infected controls (LTBI) as measured by quantitative real-time PCR. mRNA levels are expressed 
as median copies per 106 copies of HuPO  and interquartile range (IQR) in parentheses. Statistical 
analysis between groups was performed using the Mann-Whitney test and a p-value of <0.05 (bold) 
was deemed significant.  
mRNA Analyte 














































































p-values compare the median copy number/ratio in  aTB BAL vs. LTBI BAL, bTB blood vs. LTBI 





The cytokine mRNA expression levels of IFN-γ, IL-4 and IL-4δ2 were determined in the 
peripheral blood and BAL of TB patients and LTBI controls using a validated qPCR assay. 
In peripheral blood, IL-4 mRNA levels were significantly higher in TB patients compared to 
LTBI controls but no differences were observed in IFN-γ or IL-4δ2 expression levels. In 
BAL, there were no significant differences in the mRNA expression of IFN-γ, IL-4 or IL-4δ2 
between TB patients and LTBI controls. When the different compartments within the same 
group were compared, higher IFN-γ and lower IL-4 was observed in the BAL compared to 
peripheral blood in both TB patients and LTBI controls. Significantly lower IL-4δ2 
expression was also observed in the BAL compared to the blood of TB patients but not in 
LTBI controls. Overall, IL-4δ2 expression levels were very low. The IFN-γ:IL4 ratio in 
peripheral blood was significantly lower in TB patients compared to LTBI controls. No 
differences were observed in the IL-4δ2:IL-4 ratio between the two groups. 
 
3.4.1 Inter-group and compartment-specific differences in cytokine expression 
3.4.1.1 IFN-γ 
There is extensive evidence confirming the protective role of IFN-γ in TB (discussed in 
section 3.1). IFN-γ, produced by activated T-cells, natural killer (NK) cells and macrophages, 
exerts its mycobactericidal activity by activating macrophages and inducing phagosomal 
maturation, autophagy [158] and the production of reactive nitrogen and oxygen 
intermediates [235, 479]. It also plays a role, together with TNF-α, in granuloma formation 
[68].  
 
In the data presented here, there were no differences in IFN-γ mRNA expression levels 
between TB patients and presumed LTBI controls either in the peripheral blood or BAL, 
which is consistent with other gene expression studies using unstimulated cells [9, 18, 417, 
480]. Conversely, other studies have found either lower [33, 243-247] or higher IFN-γ levels 
[9, 11, 238-240, 242] in TB patients compared to controls. These discrepancies most likely 
reflect differences in the study geographical location or the experimental design, including 
the use of cell pre-stimulation protocols and method of detection (qPCR vs. ELISA or flow 
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cytometry). Indeed, recall responses of T-cells to M.tb antigens shows a decrease in IFN-γ 
levels in TB patients compared to healthy controls ([33, 246, 247] and results reported in 
chapter 8). Disease severity may also play a role as patients with more extensive disease are 
associated with higher IFN-γ production and levels decrease after anti-TB treatment [35, 240, 
481]. Few studies have directly compared IFN-γ expression in the periphery and site of 
disease in a high burden setting [11, 15, 19]. While I found no inter-group (TB vs. LTBI) 
differences, there was a six-fold increase in IFN-γ expression in the lungs compared to the 
peripheral blood. Peripheral blood is commonly used to measure cytokine responses because 
samples can be easily acquired, but may not reflect the immune response at the site of 
infection [8, 38]. High IFN-γ levels at the disease site is not uncommon and has been 
previously shown in the BAL [9, 11, 14, 15], pleural fluid [13, 482, 483] and lymph nodes 
[12] of TB patients. These results, and data presented in this chapter, may reflect the 
accumulation of IFN-γ-producing effector cells to the site of tissue inflammation, through 
both active recruitment and local expansion of T-cells. As a result, there is a subsequent 
decrease in peripheral circulating T-cells [8, 38]. These results suggest that TB patients are 
still able to produce a potent Th1 response, particularly at the site of disease, and there may 
be another underlying mechanism that is causing disease progression. 
 
3.4.1.2 IL-4  
I found significantly higher IL-4 mRNA expression in peripheral blood of TB patients 
compared to LTBI controls. IL-4, the prototype Th2 cytokine, is traditionally considered an 
anti-inflammatory cytokine that can down-regulate the protective Th1 response, but evidence 
suggests that it may also have immunopathological consequences in disease [16]. For 
instance, its role in asthma-associated airway inflammation is well described [484-486]. In 
the last two decades, there has been an increasing body of evidence that a Th2 response is 
associated with M.tb disease. Indeed, despite a strong Th1 response in progressive TB, IL-4 
levels are found to be increased compared to healthy controls [9, 29, 487] and correlate with 
disease severity [9, 418, 488]. Furthermore, these levels decrease following anti-TB 
treatment [9, 30, 417]. The data presented here is in agreement with a number of studies [9, 
30, 288, 417]. However, some earlier studies failed to detect any differences in IL-4 levels 
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[12, 33, 35, 419]. These failures may reflect the use of insensitive detection methods. IL-4 
protein levels, as measured by Luminex, in antigen driven culture supernatants approached 
the detection limit of the assay (Chapter 8). IL-4 detection is challenging, even in Th2 driven 
diseases, as it is physiologically active at concentrations 3 logs below that of IFN-γ [24, 25]. 
Additionally, the short half-life of IL-4 [9, 402, 489, 490], the rapid cellular internalization of 
IL-4 [403, 404], the sequestration of IL-4 by soluble IL-4 receptors [405] and the use of pre-
stimulation protocols that favor a Th1 response [406] also contribute to the difficultly in 
measuring IL-4. Furthermore, many of these studies failed to distinguish IL-4 and IL-4δ2, 
which can have significant effects on study conclusions [30]. As such, I chose a probe-based 
quantitative PCR approach to measure IL-4 because of its superior sensitivity and the fact 
that it is currently the only reliable method to distinguish IL-4 and IL-4δ2. 
 
Investigation of the lung compartment revealed marginally higher IL-4 levels in the BAL of 
TB patients compared to LTBI controls but these levels were not significant. However, IL-4 
mRNA expression levels were significantly lower (~12-fold) in BAL compared to peripheral 
blood. Few human studies have investigated IL-4 levels in both the peripheral blood and the 
site of disease [9, 11, 482]. Barnes et al [482] found a comparable relationship in pleural TB, 
where IL-4 levels were significantly higher in the blood compared to pleural fluid. 
Conversely, other investigators found similar levels of IL-4 in both peripheral blood and 
BAL [9, 11]. In addition to reasons discussed previously, these discrepancies in 
compartment-specific IL-4 expression profiles may be explained by differences in Th1 and 
Th2 cellular and cytokine trafficking. Indeed, the high IFN-γ levels seen in BAL is likely due 
to Th1 cellular recruitment to the site of disease [8, 491] and these CD4+T-cells tend to 
express high levels of the Th1 homing receptors CXCR3 and CCR5 [492]. However, less is 
known about the extent of Th2 cell migration to the site of infection. One possible 
explanation may be that the recruitment of Th1 cells to the lungs results in fewer of these 
cells circulating in the periphery. As a result, this allows for a greater expansion of the IL-4 
producing T-cell population in the peripheral blood.   
 
Another reason for these observed differences is the uncertain contribution of other cell types 
producing IL-4. In pulmonary TB, IL-4 appears to be predominantly expressed by T-cells, 
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but production by non T-cells can be significant [9]. Alveolar macrophages remain the most 
abundant cell type at the site of infection [493], despite substantial lymphocytic infiltration 
into the alveolar space. Macrophages normally polarize to an M1 phenotype (classical 
activation), and produce IFN-γ [494], early in TB disease [495] but M2 (alternative 
activation) polarization, driven by IL-4, also occurs in some TB patients [493]. IL-4 can be 
produced by these M2 macrophages [391] but the frequency of these cells early in disease 
and the extent to which they produce IL-4 is unclear. Other IL-4 producing cell types, 
including mast cells, neutrophils and eosinophils, have also been shown to migrate to the 
lungs in both murine [192, 496] and human TB [183, 497]. However, lung mast cells produce 
very little IL-4 [498] and the contribution of neutrophils and eosinophils to IL-4 production 
has not been fully elucidated. Given these data, it is possible that the proportion of cells in 
the lung lavage, obtained by bronchoscopy, contain fewer IL-4 producing cells compared to 
the blood and result in the observed lower mRNA expression in BAL. 
 
Other factors that may have played a role in the low IL-4 expression levels in the BAL 
include the time of recruitment. IL-4 levels tend to be highest at the onset of disease but as 
little as 1 week of therapy can significantly reduce IL-4 levels [30]. Furthermore, cytokine 
detection will also be dependent of the level of inflammation and disease extent in the lung 
section that is lavaged [499]. 
 
My findings of elevated IL-4 levels in TB patients compared to controls, in the presence of a 
potent Th1 response, does favour the hypothesis that a dysregulating Th2 response may be 
undermining immunity to TB. 
 
3.4.1.3 IL-4δ2 
This is the first study to investigate the levels of IL-4δ2 in both the lungs and the peripheral 
blood in the context of a TB endemic setting. Most TB studies investigated IL-4δ2 in 
peripheral blood [30, 288, 397, 417] and only one, conducted in the UK, compared IL-4δ2 
expression levels in both BAL and blood of pulmonary TB patients and controls [9]. These 
studies found either increased levels [9, 418] or no difference in expression between the two 
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groups [288, 417]. Studies, which measured IL-4δ2 mRNA pre- and post-treatment, found 
these levels to increase after therapy [9, 30, 417]. My study did not find any significant 
differences in IL-4δ2 between TB and LTBI either in the BAL or blood. However, IL-4δ2 
was significantly higher in blood compared to BAL where it was mostly undetectable. These 
discordant results may be explained by the use of pre-stimulation protocols [418] or 
differences in the study setting (low vs. high burden TB settings) where non-tuberculin 
reactors were used in the control group [9]. However, even in these studies, IL4δ2 expression 
was very low. This is not surprising given that splice variant expression can be as little as 
15% of the parent cytokine [377, 378].  
 
The role of IL-4δ2 in relation to IL-4 has not been well characterized in the context of TB. 
Evidence suggests that their relationship is not a simple antagonistic one. Alternative splicing 
is a versatile regulatory mechanism that produces protein isoforms with differential 
expression patterns in various tissues and may well have different biological properties 
compared to the full-length protein [376, 500]. For example, IL-4δ2 mRNA stability is 
decreased compared to IL-4 mRNA in TB [501]. Recent evidence has shown that IL-4δ2 is 
produced as a functional protein and can act much like a Th1 cytokine, stimulating 
lymphocyte recruitment and production of pro-inflammatory cytokines [32, 393, 502].These 
effects are different and independent of IL-4 [502]. However, its role in tuberculosis is 
unclear. Some studies have shown increased IL-4δ2 levels post-treatment, which, suggests 
that it is associated with a protective immune response during TB infection [9]. It may down-
regulate the effects of IL-4, have an additive effect on Th1 type cells, including promotion of 
IFN-γ expression, or both. Conversely, much like IL-4, it also stimulates collagen production 
in fibroblasts and may contribute to fibrosis seen during TB infection [256]. Low expression 
levels of IL-4 (mRNA and protein) suggest it is functional at picomolar levels in vivo [24, 25, 
27], but we do not know the concentrations at which IL-4δ2 is biologically active. In in vitro 
cultures, at least 100 fold higher concentrations of IL-4δ2 compared to IL-4, are required to 
see an effect on T-cell proliferation (Chapter 5 and [47, 392]). My study and previously 
published work, have demonstrated that the levels of IL-4δ2 mRNA in samples from TB 
infected patients, approaches the detection limits of the assay and similar levels are seen in 
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asthma patients [474]. Thus further studies are required to elucidate the significance and 
exact role of IL-4δ2 during TB infection.  
 
3.4.2 Significance of the Th1:Th2 balance  
3.4.2.1 IFN-γ:IL-4 ratio 
I found a lower IFN-γ:IL-4 ratio in peripheral blood, but not BAL, of TB patients compared 
to LTBI  controls. The finding that TB patients have elevated levels of IL-4 but similar IFN-γ 
levels, compared to LTBI controls, suggest a mixed Th1:Th2 response during infection. It is 
clear that the Th1 response remains dominant and the Th2 response may be playing a 
subversive role by not necessarily downregulating the Th1 response but perhaps by 
contributing to immune dysregulation, leading to the observed immunopathology and 
subsequent disease progression. The results presented here are consistent to other studies [9, 
416-418, 503, 504] that correlate this ratio with disease severity [9, 418] and response to anti-
TB treatment [9, 503]. A mixed Th1:Th2 response in TB infection has been shown in murine 
models of TB where TNF-α toxicity may be causing the observed immunopathology [256]. 
However, I did not observe differences in this ratio in the BAL which, could be explained by 
compartment-specific differences in cytokine expression similar to what was observed with 
IL-4 expression. 
 
3.4.2.2 IL4δ2:IL-4 ratio 
I found no difference in the IL4δ2:IL-4 ratio between those with TB and LTBI, either in the 
BAL or peripheral blood. Similar to the IFN-γ:IL-4 ratio, the IL4δ2:IL-4 ratio has also been 
associated with protection against active TB and has been reported to increase in response to 
treatment [9, 30]. Data about the IL4δ2:IL-4 ratio in TB are conflicting; some reports found a 
lower IL4δ2:IL-4 ratio [29, 417], whereas others found no difference in those with active TB 
versus LTBI [9, 288].  My findings are consistent with the latter. The discordance may be 
explained by the variations in the ratio during the course of disease. The IL4δ2:IL4 ratio is 
likely to be lower during early onset of disease (when IL-4 is highest) and higher during and 
at the end of treatment (lower IL-4 and higher IL4δ2) [9, 417]. Furthermore, the exact 
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function of IL4δ2 in TB and its relationship with IL-4 is unknown. The clinical relevance of 
the ratio in predicting disease progression requires clarification. 
 
3.4.3 Limitations 
There were a number of limitations to the study. Unavoidable delays in transporting samples 
from the clinic to the laboratory sometimes prevented BAL fluid samples from being 
processed immediately. Delayed sample processing can significantly affect detection of low 
expressing cytokines [26], due to the presence of intrinsic RNases in biological samples, and 
could explain the low mRNA expression levels of IL-4 and IL-4δ2 observed in the BAL. 
This was not an issue with peripheral blood because the RNA profile was immediately fixed 
when blood was drawn in PAXgene tubes. Nonetheless, only samples with RNA of sufficient 
quality (RIN>7.5) were included in the study.  
 
The small BAL sample size may have contributed to the lack of significant differences in 
mRNA expression between the TB and LTBI groups and subsequent interpretation of the 
data. Recruitment of participants to undergo an invasive bronchoscopy procedure was 
difficult and limited cell recovery often meant that immune assays needed to be prioritized 
based on the amount of alveolar cells that were available. Furthermore, the BAL collection 
procedure and delays in sample processing (discussed above) sometimes resulted in recovery 
of low quality RNA and warranted exclusion of these samples from qPCR analysis. 
Nonetheless, additional participants will be recruited from other ongoing studies to increase 
the number of BAL samples in both the TB and LTBI groups 
 
Resource constraints prevented the collection of radiological data to assess the severity of 
disease in pulmonary TB patients. A number of previous studies showed that higher IL-4 
levels were associated with more severe disease, such as those with more extensive cavitation 
[9, 18, 19, 21]. However, I used the degree of sputum positivity as an estimate of disease 
severity, as done in another study [18], but I found no correlation between sputum smear 
status and cytokine expression levels.  Similar constraints and high attrition among patients 
prevented collection of samples for assessment of cytokine levels post-TB treatment. 
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The helminth infection and exposure status in the participant groups was not assessed in this 
study. Concurrent helminth infection can prime Th2 responses resulting in high IL-4 levels 
[452]. However, the effect of helminths would presumably be equally distributed between the 
groups as both TB patients and LTBI controls were recruited from the same communities and 
reside in the same environment. Furthermore, the clinical diagnosis of helminth infection is 
challenging and requires both serological testing (worm specific IgE) and analysis of faecal 
samples (presence of eggs) to distinguish between past and current infection. These tests 
were not performed due to resource and ethical restrictions and, in any case, they are not 
considered reliable „rule out‟ tests. Additionally, diagnosis is further complicated as exposure 
to helminths is not only dependent on time but may require a genetic component which 
determines the immune response (Professor Gerhard Walzl, personal communication and in 
[505]). However, I did attempt to determine the exposure status by asking participants and 
reviewing medical records about any previous or current helminth infection.  
 
3.5 Conclusion 
I have shown that IFN-γ and IL4 mRNA expression profiles in TB are compartment-specific. 
IFN-γ expression in the lungs was higher compared to the peripheral blood but no differences 
were observed between TB patients and presumed LTBI controls. This suggests that a strong 
Th1 response exists at the site of disease but this response is not sufficient to contain the 
infection. Additionally, significantly increased IL-4 levels were observed in the peripheral 
blood of TB patients compared to controls driving a skewed Th1:Th2 response in TB 
patients. This was evident by the lower IFN-γ:IL-4 ratio in TB patients compared to controls.  
However, it is not known if this skewed Th2 response is actually driving the 
immunopathology associated with TB or is merely a bystander effect due to inflammation. 
Furthermore, the exact role of IL-4δ2 in TB remains unclear. In order to investigate these 
effects further, I will attempt to generate recombinant IL-4 and IL-4δ2 protein and directly 





4. CHAPTER 4: Cloning & protein expression of recombinant 
IL-4 and IL-4δ2 
 
4.1 Introduction 
Efficient strategies for the production of recombinant proteins remain an important aspect of 
the medical research, biotechnology and pharmaceutical industries. The choice of the 
expression system used is essential to produce correctly folded and functional proteins that 
best mimic their native counterparts. Recombinant cytokines have been expressed in a 
variety of systems depending on their ultimate use. 
 
E. coli is one of the most versatile and widely used hosts for recombinant protein expression 
due to its well described physiology and genetic makeup, rapid growth rate, low setup costs 
and high protein yields [506, 507]. However, the utility of E. coli systems is limited in the 
expression of eukaryotic proteins, particularly mammalian proteins. Proteins expressed in 
prokaryotic systems lack post translational modifications, such as such as glycosylation and 
disulfide bond formation (depending on the compartment where folding occurs), which can 
have important functions in protein stability and bioactivity [507-509]. E. coli also lacks 
appropriate chaperone molecules to stabilize eukaryotic proteins leading to protein 
misfolding and formation of inclusion bodies. Protein refolding often requires harsh 
conditions and often results in non-functional proteins [507, 510]. Additionally, high levels 
of endotoxin inherent in bacterial expression can affect downstream immunological assays 
[506, 507]. 
 
Baculovirus protein expression systems are ideal for recombinant expression of mammalian 
proteins as it allows for proper protein folding, correct signal peptide cleavage and post 
translational modifications [506, 511, 512]. The non-reducing environment within the insect 
cell cytoplasm also allows for disulfide bond formation, which is essential to the 
conformational structure of IL-4. Furthermore, there is no risk of endotoxin contamination 
which can affect downstream immunological assays [507, 513]. As such, recombinant 
proteins produced in this system are much more likely to be functional. However, 
baculovirus systems do have their drawbacks. The reagents are costly and the process of 
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producing high titre baculovirus stocks can be lengthy.  While high protein expression levels 
of up to 30% of total cell protein have been reported using this system [506], yield can be 
considerably lower and usually requires extensive optimization of infection and culture 
conditions to produce sufficient amounts of protein. Improper protein folding and formation 
of intracellular aggregates has also been reported to occur in this system, although not to the 
same extent as in prokaryotic expression systems [514, 515]. Furthermore, glycosylation in 
baculovirus expressed proteins, such as the addition of sialic acid deficient N-linked glycans, 
is not equivalent to mammalian glycosylation patterns and can lead to different levels of 
bioactivity [506, 507]. Nonetheless, functional cytokines from various mammalian species, 
including humans, have been successfully expressed in a baculovirus system [516-518]. For 
these reasons and others described in Table 4.1, a baculovirus system was chosen for the 
expression of IL4 and IL-4δ2. 
 
The IL-4 protein has been extensively studied. The mature protein contains 129 amino acid 
residues consisting of 4 exons. The protein is glycosylated on Asn38 [519] and contains 3 
disulfide bonds (Cys3-127, Cys24-65, Cys46-99) [520]. IL-4 has been previously expressed in E. 
coli [521, 522], yeast [47, 523], insect cells [524] and mammalian cells [32, 393] for 
structural  and functional studies. In IL-4δ2, exon 2 is deleted by alternative splicing to 
produce a protein consisting of 113 amino acid residues. The protein is similar in structure to 
IL-4 but contains only 2 disulfide bonds (Cys3-127, Cys46-99) and a free cysteine (Cys65) 
residue as a result of the deletion  [385]. Recent evidence suggests that IL-4δ2 is produced in 
vivo [31]. However, few studies have previously attempted to express recombinant IL-4δ2 
[47, 393, 525] and none in a baculovirus system.  
 
The aim of this chapter is to clone and express functional recombinant IL-4 and IL-4δ2 in a 
baculovirus-insect cell expression system. These proteins were assessed for function and 






Table 4.1: Advantages and disadvantages of a baculovirus insect cell system and an E. coli 
expression system for recombinant protein expression. Adapted from [506, 507].  
 
 Advantages Disadvantages 









 Simple, fast (3 days) 
 Inexpensive 
 Very high protein yields 
 Well described physiology 
and genetic make-up. 
 
 Formation of inclusion bodies  
and may require protein 
denaturation and refolding 
leading to non-functional 
proteins 
 Endotoxin contamination of 
proteins 















 Properly folded and 
functional proteins usually 
produced 
 Eukaryotic post-translational 
modification  
 Higher protein yields than 
other eukaryotic systems 
 
 Complex optimisation of 
expression conditions 
 Slow (3-4 weeks) 
 Relatively expensive 
 Post-translational modifications 
may not be equivalent to 
mammalian systems 
 Viral proteases present in insect 










4.2.1 General recombinant cloning methods 
4.2.1.1 IL-4 sequence and primer design 
Full length human IL-4 cDNA sequence (Accession No: NM_000589.2) was purchased from 
Origene (Origene Technologies Ltd) and was used in all subsequent cloning steps to generate 
the IL-4 and IL-4δ2 constructs described in this chapter. 
 
All primers were designed using DNAMAN and vector NTI Advance 11.0 (Invitrogen) and 
were synthesized by Integrated DNA Technologies (IDT) (Listed in Appendix section B).  
Primers incorporated restriction sites in their design to facilitate restriction digestion and 
subsequent cloning into appropriate vectors. Some primers were designed to add sequences 
coding decahistidine (10x His) affinity tags or Tobacco Etch Virus (TEV) protease 
recognition sites to enable affinity purification of expressed proteins and subsequent removal 
of the affinity tag following purification. Inverse primers were designed to amplify DNA 
regions flanking a specific sequence to be deleted, such as exons and signal peptides, within 
the constructed vectors, where necessary. These primers were phosphorylated on their 5‟ end 
to allow for efficient ligation.  
 
4.2.1.2 PCR amplification 
PCR were performed using the Kappa HiFi DNA polymerase kit (Kappa Biosystems), 
according to the manufacturer‟s instructions. Briefly, a 50μl reaction mixture was made 
consisting of 1x Kappa HiFi Fidelity buffer (containing 2mM Mg2+), 0.25mM dNTPs, 0.5μM 
primers, 50U of Kapa HiFi DNA polymerase, 10-50ng of DNA template and nuclease-free 
H2O. PCR amplification was performed on a G-Storm thermal cycler (G-Storm). A typical 
PCR amplification consisted of an initial denaturation step of 95°C for 2 min, followed by 30 
cycles of denaturation at 95°C for 1 minute 30 seconds, annealing at 50-60°C for 30 seconds, 
extension at 72°C for 30seconds/kb and a final extension step at 72°C for 5 minutes. Inverse 
PCR [526], using appropriate inverse PCR primers, was performed to remove unwanted 
coding regions from nucleotide sequences. Gradient PCR was performed to identify the 
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optimal annealing temperature based on the Tm of each primer set and minimize nonspecific 
binding. 1-5% DMSO was added in reactions to minimize the formation of primer-dimers 
when necessary. PCR products were pooled and purified using the GeneJet PCR purification 
kit (Thermo Scientific), according to manufacturer‟s instructions, and subsequently 
quantified using UV spectroscopy at A260 with a Nanodrop spectrophotometer (Thermo 
Scientific). 
 
4.2.1.3 Agarose gel electrophoresis and DNA extraction 
Agarose gel electrophoresis analyses was performed to determine the purity and yield of 
PCR products or to determine the size of DNA fragments generated by restriction enzyme 
digestion (described in 4.2.1.4). A 0.8-2% DNA gel was prepared containing 1x GelRed 
(Biotium Inc.) and run in 1x Tris‐acetate buffer (TAE, pH 8.0) at 100-120V for 1-2 hours. 
Gels were visualized in a Syngene GBOX F3 system (Syngene Inc.). 5μl of Generuler 1kb 
DNA ladder (Thermo Scientific) was included for size determination of PCR products and 
restriction fragments. For downstream cloning procedures, DNA bands of interest were 
excised and purified using the GeneJet Gel Extraction kit (Thermo Scientific).  
 
4.2.1.4 Restriction Enzyme Digestions 
PCR products and plasmid vectors, containing the relevant restriction sites, were cleaved 
with appropriate restriction enzymes (REs) to facilitate ligation of the PCR product and 
vector. Restriction fragment analysis was also performed on ligated constructs using specific 
REs as an initial screening step, prior to DNA sequencing, to determine correct insertion of 
the target DNA into the plasmid vector. For products generated by inverse PCR, parental 
DNA sequences were eliminated post inverse PCR using DpnI. Amplified DNA generated 
using PCR is not methylated, therefore resistant to DpnI digestion. REs (Thermo Scientific) 
were used to perform restriction digestions according to the manufacturer‟s instructions.  
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4.2.1.5 Additional DNA modifications 
In cases where self-ligation was to be avoided, such as after RE digestion of plasmid DNA 
required for ligation with an insert, DNA was treated with FastAP thermosensitive alkaline 
phosphatase (Thermo Scientific) according to the manufacturer‟s instructions.  
 
4.2.1.6 DNA ligation 
T4 DNA ligase (Thermo Scientific) was used to re-ligate an inverse PCR product or to ligate 
a PCR product and linearized vector according to the manufacturer‟s instructions. 5μl of each 
reaction was used in subsequent transformations. 
 
4.2.1.7 DNA transformations and plasmid preparations 
Chemically competent JM109 E. coli cells were obtained from commercial sources 
(Promega) and used for all DNA transformations, according to manufacturer‟s instructions. 
Briefly, 5μl of ligation mixture was added to a 100μl aliquot of competent, gently mixed and 
incubated on ice for 30 minutes. Appropriate negative controls (containing no ligation 
mixture) were included. The cells were heat shocked at 42°C for 90 seconds and then placed 
on ice for 2 minutes. The entire mixture was then added to 900μl of pre-warmed Luria broth 
(LB) media and incubated at 37°C for 1 hour 30 minutes in a shaking incubator. 10μl and 
100 μl aliquots of each transformation mixture were plated onto LB agar plates containing 
100μg/ml Ampicillin (Sigma Aldrich) and incubated at 37°C overnight. Individual colonies 
were chosen randomly to inoculate 5 ml LB media containing 100μg/ml Ampicillin and 
incubated for 16-20 hours at 37°C in a shaker incubator. Plasmids were extracted from the 
cultures and purified using the GeneJet Plasmid Miniprep kit (Thermo Scientific), according 
to manufacturer‟s instructions. The insertion or deletion of target sequences was determined 




4.2.1.8 Restriction fragment analysis 
Following cloning, plasmids were screened to determine if a specific target sequence was 
inserted (insertion of PCR product into plasmid) or deleted (by inverse PCR). Vector NTI 
11.0 (Invitrogen) was used to identify differences in the presence and number of restriction 
sites between the recombinant and parent plasmid. The selected restriction enzymes were 
used to digest both the recombinant and parent plasmids (section 4.2.1.4) and subsequently 
visualized on an agarose gel (section 4.2.1.3) to determine the sizes of the fragments 
produced. The final plasmid constructs that generated restriction fragments consistent with 
insertion or deletion of the target sequence were sent for DNA sequencing. 
 
4.2.1.9 DNA sequencing 
Following initial screening of recombinant plasmids by restriction fragment analysis, 
plasmids were sent for DNA sequencing to Inqaba Biotech Ltd. to verify the sequence of the 
target. Sequencing was performed using an ABI 3500 XL sequencer. 10 μM of sequencing 
primers and a minimum of 200ng of plasmid were supplied for each sequencing reaction.  
Sequence alignment to the DNA sequence of interest was performed using Bioedit v7.2.5 
(Ibis Biosciences). 
 
4.2.2 Protein expression methods 
Protein expression was performed in a baculovirus system where Spodoptera frugiperda 
(Sf21) insect cells were infected with baculovirus. An outline of the steps required for protein 








Figure 4.1. Steps illustrating transfection, generation of high viral titre baculovirus stocks and 
subsequent protein expression 
 
4.2.2.1 Preparation of Linearized Bacmid DNA 
H5996 cells containing bacmid pBAC10:KO1629 were plated on LB agar for isolation of 
single colonies. For plasmid maintenance within the host cells, all growth media was 
supplemented with 10ug/ml kanamycin (Sigma-Aldrich) and 30ug/ml chloramphenicol 
(Sigma-Aldrich). Colonies were obtained on LB plates after incubation overnight at 37oC. A 
single colony was used to inoculate 5ml LB broth incubated at 37°C for ~8 hours in a 
shaking incubator. This culture was subsequently used to re-inoculate 500ml of LB broth and 
incubated at 37°C for ~16 hours in a shaking incubator. Cells were harvested and centrifuged 
at 3000rpm for 30 minutes at 4°C and bacmid DNA was subsequently isolated and purified 
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using the BAC100 Plasmid purification kit (Macherey Nagel). Bacmid DNA was linearized 
using the Bsu36I restriction enzyme (New England Biolabs) in a 500μl reaction containing 
~350μl bacmid DNA, 1 x NEB buffer 3, 300 units of Bsu36I and nuclease-free H2O. The 
reaction was at 37°C for 5 hours followed by heat inactivation at 80°C for 20 minutes. The 
bacmid DNA was precipitated using isopropanol and centrifugation. The pelleted DNA was 
resuspended in 100μl TE buffer and quantified on a Nanodrop spectrophotometer. 
Linearization of bacmid DNA was confirmed by running both undigested and digested 
bacmid DNA on a 1% agarose gel (section 4.2.1.3). Linearized bacmid DNA was then stored 
at -20°C. 
 
4.2.2.2 Growth and maintenance of Sf21 cells 
Sf21 cells were grown from frozen glycerol stocks by first thawing an aliquot of cells on ice 
for 30 minutes. Once thawed, the entire aliquot was added to 20-30ml of Insect-Xpress media 
supplemented with 2% fetal bovine serum (FBS; Lonza) in a 100ml shaker flask. Cells were 
then incubated at 28°C in a shaker incubator. Cells were counted regularly by Trypan blue 
(Sigma-Aldrich) exclusion staining to monitor cell growth rate and viability. Cells were sub-
cultured periodically if the cell concentration exceeded 3x106/ml.  
 
4.2.2.3 Transfection of Bacmid and Transfer vector 
The baculovirus pBAC10:KO1629 has been previously described elsewhere [527]. The 
pBAC10:KO1629 has the following attributes: an F replicon from E. coli, which allows the 
viral genome to be amplified in E. coli; a chloroamphenicol acetyl transferase (cat) cassette 
in the essential ORF1629 and a single Bsu36I restriction site to linearize the bacmid DNA. 
Co-tranfection of the pAP01 transfer vector and linearized bacmid DNA pBAC10:KO1629 
allows for recombination between the homologous DNA regions (603 and 1629) so that the 
gene of interest between the homologous sites is transferred from the pAP01 vector to the 
bacmid DNA. The presence of the cat cassette ensures that baculovirus will only replicate if 
a homologous recombination event occurs (Figure 4.2).   
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A 24μl transfection mixture was made for each plasmid construct, consisting of 500ng of 
pPR30 vector (containing the gene of interest), 500ng of linearized bacmid DNA, 12ul of 
Lipofectin (Invitrogen; diluted 2:1 in sterile H2O) and sterile H2O. Appropriate lipofectin 
only and bacmid DNA only controls were included. Additionally, a pPR30 vector containing 
no insert was also transfected with bacmid DNA. Transfection mixtures were incubated for 
30 minutes at room temperature. A 6-well plate was seeded with 1x106 Sf21 cells in 2ml of 
serum free Insect-Xpress media (Lonza) and incubated at 28°C for 1 hour to allow cell 
adherence. After removal of spent media, the transfection mixture was added to the cells and 
incubated at 28°C overnight. The spent media was again removed and 2ml of Insect-Xpress 
media supplemented with 2% fetal bovine serum (FBS; Lonza) was added to the cells. The 
cells were incubated at 28°C for 5 days after which virus-containing supernatant stocks (P0 
viral stocks) were harvested and stored at 4°C. Viral DNA was isolated from 200μl of each 
P0 viral stock using the High Pure Viral Nucleic Acid Kit (Roche) according to 
manufacturers‟ instructions. PCR amplification of the viral DNA and subsequent agarose gel 










Figure 4.2. Recombination event that occurs during co-transfection of insect cells with 
baculovirus. Adapted from Blackburn et al. [527]. 
 
4.2.2.4 Amplification of viral stocks  
High-titre viral stocks were required for scale-up of protein expression. A 6-well plate was 
seeded with 1x106 Sf21 cells in 2ml of serum free Insect-Xpress media (Lonza) and 
incubated at 28°C for 1 hour to allow cell adherence. After removal of spent media, 500μl of 
P0 virus and FBS supplemented Insect-Xpress media was added and incubated at 28°C for 6 
days. Virus-containing supernatants (P1 viral stocks) were harvested and stored at 4°C. For 
the production of P2 and P3 virus stocks, a T150 tissue culture flask was seeded with 5 x 107 
Sf21 cells, the spent media removed and replaced with 30ml of FBS supplemented media. 
500μl of P1 virus in 3ml of FBS containing media was added to the cells and incubated at 
28°C for 6 days. Virus-containing supernatants (P2 and P3 viral stocks) were harvested and 
stored at 4°C. Viral titres of P3 stocks were determined by a viral qPCR assay (described in 
section 4.2.2.5). P4 and P5 viral stocks were produced in suspension cultures. Sf21 cells were 
grown in 500ml flasks to a concentration of 1-1.5x106/ml. Cells were infected with P3 viral 
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stock at an MOI of 0.1 at 28°C for 4-5 days in a shaker incubator. Supernatants were 
harvested and viral titres were determined as above.  
 
4.2.2.5 Quantitative PCR to determine titres of viral stocks 
Determination of titres of viral stocks was performed by the Centre for Proteomic and 
Genomic Research (CPGR). Viral DNA was purified from viral stocks using the High Pure 
Viral Nucleic Acid kit (Roche) according to the manufacturer‟s instructions. Viral DNA was 
quantified in a SybrGreen quantitative PCR assay against a standard curve of DNA obtained 
from virus with a known titre, as determined by plaque assay. The titres of viral stocks 
ranged from 106-108 plaque forming units (pfu)/ml. 
 
4.2.2.6 Protein expression in Sf21 cells 
IL-4 and IL-4δ2 proteins were expressed in Sf21 suspension cultures using high-titre P4 and 
P5 baculovirus stocks. Similarly, viral stocks produced from empty transfer vector were used 
as an expression control. Preliminary small scale expression experiments were performed to 
determine the recombinant protein location (intracellular or secreted), optimal day of harvest 
and multiplicity of infection (MOI) for each construct. Typically, Sf21 cells were grown to 1-
1.5x106/ml in shaker flasks and infected at an MOI of 5-20, depending on the construct used. 
Cells were then incubated for 48-72 hours at 28°C in a shaker incubator. Cell morphology 
and viability were periodically assessed by trypan blue exclusion staining and examination 
under a microscope to confirm infection of cells.  
 
4.2.2.7 Preparation of cell supernatants and clarified cell lysates 
Both Sf21 cells and cell supernatants were harvested to determine if the recombinant protein 
was secreted into the media or remained intracellular. For secreted proteins, cell supernatants 
were collected in 50ml tubes followed by the addition of 1% Benzonase (Novagen) and 1x 
EDTA-free protease inhibitor cocktail (Roche) to each tube. These were stored on ice prior to 
protein purification. For recombinant proteins expressed intracellularly, infected Sf21 cells 
were pelleted by centrifugation at 1000rpm for 10 minutes at 4°C followed by 3 washes in  
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cold 1xPBS (Lonza). Cells were then re-suspended in lysis buffer containing 50mM sodium 
phosphate buffer pH7.7, 50mM KCl, 20% glycerol, 2mM CaCl2, 10mM MgCl2, 0.1% Triton 
X-100, 1mM TCEP, 1% Benzonase, 1x EDTA-free protease inhibitor cocktail and sterile 
H2O. Approximately 1ml of lysis buffer was added per 10x106 cells. The cells in lysis buffer 
were incubated on ice for 30 minutes with gentle shaking followed by vortexing and 
sonication in a water bath sonicator for 1 minute. Cell lysates were centrifuged at 13000rpm 
for 30 minutes at 4ºC. The clarified lysates were collected, pooled and placed on ice before 
protein purification. 
 
4.2.2.8 Protein purification and concentration 
His-tagged proteins, as well as the expression control were purified using the His-Spin 
Miniprep Kit (Zymo Research) according to the manufacturer‟s instructions. However, 
adjustments were made to the protocol to accommodate for larger sample volumes. ~40ml 
aliquots of cell supernatants or ~10ml aliquots of clarified lysates were evenly split into 50ml 
tubes. In order to mimic the buffer conditions of the His-binding buffer, the following 
components were added to the cells supernatants or clarified cell lysates to a final volume of 
50ml: 50mM Sodium phosphate buffer  at pH7.7, 300mM NaCl, 0.03% Triton-X and 10mM 
Imidazole. 300-350μl of His affinity gel, consisting of Ni2+ agarose beads, was added to each 
50ml tube and placed on a tube rotator at 4ºC for 30-45 minutes to allow binding of the His-
tagged proteins to the beads. The samples containing beads were then centrifuged at 800rpm 
for 1 minute to pellet the beads and the supernatants were removed taking care not to disturb 
the beads. The beads were then resuspended in His-Binding buffer and carefully transferred 
to a Zymo-spin P1 column. Beads were then washed 3 times in His-Wash buffer (50mM 
Sodium phosphate buffer pH7.7, 300mM NaCl, 0.03% Triton-X, 50mM Imidazole) followed 
by incubation in His elution buffer (50mM Sodium phosphate buffer pH7.7, 300mM NaCl, 
0.03% Triton-X, 500mM Imidazole) for 10 minutes and collection of the eluate. 
 
GST-tagged proteins were purified from clarified cell lysates using Glutathione Magnetic 
Beads (Thermo Scientific), according to the manufacturer‟s instructions. As with His 
purifications, adjustments were made to the protocol to accommodate for larger sample 
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volumes. ~10ml aliquots of clarified lysates were evenly split into 50ml tubes. In order to 
mimic the buffer conditions of the GST-binding buffer, the following components were 
added to the clarified cell lysates to a final volume of 30ml: 125mM Tris buffer at pH8.0, 
150mM NaCl, 0.03% Triton-X. 150μl of Glutathione magnetic Beads, consisting of iron 
oxide beads attached to reduced glutathione, were added to each  tube, placed on a tube 
rotator at 4ºC for 1-1.5 hours to allow binding of the GST-tagged proteins to the beads. A 
magnet was applied to the tubes to immobilize the magnetic beads and the supernatants were 
removed by pipetting. The beads were then carefully transferred to 1.5ml microcentrifuge 
tubes and washed 4 times in GST-binding buffer using a MagnaBind Magnet (Thermo 
Scientific). Beads were then incubated in GST Elution buffer (12 5mM Tris buffer at pH8.0, 
150mM NaCl, 50mM reduced glutathione) for 5 minutes and the eluates were collected. 
 
Protein eluates, both from His or GST purifications, were concentrated and buffer exchanged 
using Amicon Ultra 0.5ml centrifugal filters (Millipore) with a molecular weight cut-off of 
3kDa. The filters were centrifuged at 13000 rpm at 4°C in 20 minute intervals. All of the 
eluate was added to the centrifugal filter to concentrate the sample. This was followed by 
RPMI 1640 (Lonza) for buffer exchange. The final volume of the protein in RPMI ranged 
from 50-150μl. An aliquot was collected for determination of protein concentration. Aliquots 
of each fraction in the purification process were collected for SDS-PAGE and Western Blot 
analysis. Proteins were stored at -80oC in low-bind microcentrifuge tubes (AEC Amersham) 
in single-use aliquots supplemented with 2% endotoxin-free BSA (Sigma Aldrich). 
 
4.2.2.9 Determination of protein concentration 
Protein concentration was determined by the Bradford method using Protein Assay Dye 
(BioRad), according to the manufacturer‟s instructions. The microassay method was 
performed in a 96-well flat-bottom plate using a bovine serum albumin (BSA) standard curve 
ranging from 0-500μg/ml. Samples were diluted as appropriate. The standard curve analysis 




4.2.2.10 SDS-PAGE gel electrophoresis and Western Blot analysis 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot 
were used to analyze the size, purity and immunoreactivity of expressed protein and were 
performed according to standard guidelines [528]. Either a 12% (GST-tagged proteins) or 
15% (His-tagged proteins) polyacrylamide gel were cast and protein sizes were determined 
using the PageRuler Plus Prestained protein ladder (Thermo Scientific). Gels were typically 
run at ~100-120V and were either stained overnight using Acqua Stain (Vacutec) or used for 
Western Blot transfer. The purity of the recombinant protein was estimated from the eluted 
protein fraction band of the SDS-PAGE gel by densitometry using Image J scientific image 
processing software (Wayne Rasband) and expressed as a percentage of total protein present 
in the eluted fraction. Gels for Western Blot were transferred onto Hybond-C nitrocellulose 
membrane (GE Healthcare). Protein transfer was confirmed by staining with Ponceau S 
solution (Sigma Aldrich) for 1 minute followed by 3 washes with 1 x TBST buffer (100 ml 
10 x TBS [0.5 M Tris, 0.66 M NaCl, pH 7.6], 10 ml 10% Tween-20, 890ml H2O) to remove 
the stain. The membranes were then blocked in 5% fat‐free milk powder in 1 x TBST buffer 
for 1 hour and probed overnight at 4°C using the following antibodies: 1:5000 dilution of 
HRP‐conjugated Anti‐His antibody (Sigma Aldrich) for His-tagged proteins; 1:1000 dilution 
of HRP‐conjugated Anti‐GST antibody (Santa Cruz Biotech) for GST-tagged proteins; 
1:2500 dilution of HRP-conjugated Anti-IL-4 antibody (Abcam) for IL-4 and IL-4δ2. 
Membranes were then washed 3 times with 1xTBST buffer for 5 minutes with shaking. 
Proteins were detected using the Super Signal West Pico Chemiluminescent HRP Substrate 
(Thermo Scientific) and visualized using a G:BOX chemiluminescent reader (SynGene).  
 
4.2.2.11 TEV cleavage 
In order to remove the protein affinity tag, proteolytic cleavage of the 7 amino acid TEV 
recognition site within the fusion protein was performed using ProTEV protease (Promega), 
according to the manufacturer‟s instructions. A 100μl reaction was set up containing 10 units 
of ProTEV enzyme, 1mM of DTT, 1x ProTEV buffer, sterile H2O and up to 20μg of protein. 
Protein to be cleaved were first buffer exchanged in 1xProTEV buffer, as described in 
section 4.2.2.8. The reaction mixture was incubated for 1, 4 and 16 hours at 30oC. Fractions 
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were analysed by SDS-PAGE gel electrophoresis (section 4.2.2.10) and the remaining 
reaction mixture was purified as described in section 4.2.2.8. Cleaved protein was present in 
the supernatants after incubation with the beads whereas the ProTEV protease and cleaved 
His tag remained bound to the beads. The fractions containing the cleaved protein were 
buffer exchanged in RPMI 1640, their concentrations were measured and stored as described 
in section 4.2.2.8. 
 
4.3 Results 
4.3.1 pPR030 vector characteristics 
The pPR030 transfer vector is a modified plasmid derived from the pTriEx 1.1  E. coli 
transfer vector (Figure 4.3). The pPR030 vector has a late phase viral polyhedron promotor, 
polh, which controls protein expression; an attR1 gene which is required for homologous 
recombination; β-lactamase coding sequence which confers ampicillin resistance; bacmid 
603 and 1629 DNA regions that flank the insertion sequence and are homologous to regions 
in the bacmid genome. The presence of the cat cassette in the essential 1629 region in 
pBAC10:KO1629 means that replication competent virus will only be produced if a successful 
homologous recombination event occurs (described in section 4.2.2.3 and Figure 4.2). The 
pPR030 construct was originally constructed with a biotin carboxyl carrier protein (BCCP) 
tag to produce fusion proteins for immobilization applications such as microarray assays 
[527]. Due to the strong dissociation constant between biotin and streptavidin, the tag is not 
compatible with affinity purification and was subsequently removed by inverse PCR using 







Figure 4.3. pPR030 plasmid backbone used as transfer vector for transfection into Sf21 insect 
cells   
 
4.3.2 Cloning and protein expression of IL-4 
4.3.2.1 Cloning of His-tagged IL-4 construct 
The cloning procedure for the construction of pAP01 containing His-tagged IL-4 construct is 
described in figure 4.4A and as follows: the IL-4 cDNA was amplified from the Origene 
construct in 2 PCR reactions; the first PCR reaction, using primers AP2_F and AP2_R1 
(Appendix section B), added a BamH1 restriction site at the 5‟-end of the IL4 cDNA 
sequence and the codons for TEV cleavage sequence and the first 6 histidine residues at the 
3‟- end of the IL-4 sequence. The second PCR, using primers AP2_F and AP2_R2, added 
codons for the last 4 histidine residues, a stop codon (TAG) and an AvrII site at the C-
terminal end. The final PCR product (IL-4-TEV-His) was ligated between cohesive 
restriction enzyme sites BamHI and AvrII in the parent vectors.  pAP01-IL4-TEV-His 
(nucleotide sequence in section B of Appendix) was the resultant plasmid of this cloning 
strategy,  and was used for transfection and expression of His-tagged IL-4 protein.  
 
The structure and translated amino acid sequence of IL4-TEV-His is shown in Figure 4.4B 
and contains the following components: the full IL-4 cDNA sequence including the 24 amino 
acid signal peptide; a Tobacco Etch Virus (TEV)  protease cleavage site for removal of the 








Figure 4.4 (A) The cloning steps to produce the pAP01-IL-4-TEV-His construct and (B) the 
structure and translated amino acid sequence of IL-4-TEV-His  
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4.3.2.2 Protein expression & nickel chelate affinity chromatography purification of 
His-tagged recombinant IL-4 protein 
The pAP01-IL4-TEV-His construct was transfected with linearized pBAC10:KO1629 bacmid 
DNA in Sf21 cells to produce P0 viral stocks. The presence of the IL-4-TEV-His construct 
was determined by PCR amplification of P0 viral DNA and visualization of the amplified 
inserts by agarose gel electrophoresis. After several rounds of viral amplification, high titre 
P5 viral stocks were produced in the range of 108 pfu/ml and used for protein expression. 
Initial small scale expression experiments were performed using an MOI of 5, 10 and 20 and 
harvesting cells 2 days and 3 days post infection. An MOI of 10 and harvesting 3 days post 
infection (PI) produced the optimal yield of recombinant IL-4 (rIL-4) protein. Furthermore, 
the majority of protein was found to be present in the cell supernatants. These conditions 
were chosen to infect Sf21 cells in a 500ml shaker flask culture at a cell concentration of 
1.5x106/ml. At 3 days PI, cells were elongated and enlarged at ~50-60% viability indicating 
viral infection of cells. Cell supernatants were harvested and purified as described in section 
4.2.2.8. Analysis of the protein fractions by SDS-PAGE gel electrophoresis indicated the 
presence of 2 bands at ~19kDa and ~16kDa in the purified and concentrated fractions (Figure 
4.5A). The expected size of His-tagged rIL-4 is ~17-18kDa and these two bands could 
represent different glycosylated forms of IL-4, which has also been shown to occur in 
baculovirus expressed swine rIL-4 [518].  However, this may not be the case given that only 
a single band was observed in the Western blots (Figure 4.5 B and C). The purity in this 
fraction was ~85% as determined by band densitometry using Image J software (lanes 5 and 
6 of Figure 4.5A). Expression and purification using empty pPR30 vector did not produce 
equivalent bands of this size. Western blot analysis using anti-His and anti-IL-4 antibodies 
produced similarly sized bands confirming that this protein was indeed His-tagged rIL-4 
(Figure 4.5 B and C). Protein yield from a 500ml culture ranged between 60-120μg. 
Cleavage of the His tag using ProTEV (described in section 4.2.2.11) was attempted but the 
majority of protein was lost during the cleavage and subsequent purification process (Figure 
4.5 D). Due to the low recovery yield after cleavage, it was decided not to remove the His 







Figure 4.5. Purification of His tagged recombinant IL-4 (rIL-4) using Ni+ affinity column and 
cleavage of His tag using TEV protease.(A) 15% SDS PAGE gel of rIL-4 purification fractions  
showing (1) post-infection Sf21 insect cell supernatant (2) flow-through after column binding (3) 1st 
wash with 50mM imidazole (4) 2nd wash with 50mM imidazole (5) elution of rIL-4 at 500mM 
imidazole (6) elution of rIL-4  at 750mM imidazole. The eluted protein had a size of ~17kDa (arrow). 
Western blot analysis of the purified rIL-4 fraction probed with (B) anti-His antibody at 1:5000 and 
(C) anti-IL4 antibody at 1:2500. (D) 15% SDS-PAGE gel of purified rIL-4 (1) before cleavage with 
TEV protease and (2) after cleavage with TEV protease. Low protein yield was obtained post 
cleavage (arrow). Molecular weight markers are shown on the left in kiloDaltons (kDa). 10-15μl of 
each fraction was loaded onto the gel. 
 
4.3.3 Cloning and protein expression of IL-4δ2 
4.3.3.1 Cloning of His-tagged IL-4δ2 construct 
In humans, an alternative splicing event results in the deletion of exon 2 from the IL-4 gene 
to produce the IL4δ2 splice variant. Here, exon 2 within the IL-4 cDNA sequence of the 
pAP01-IL4-TEV-His construct was deleted by inverse PCR. The inverse PCR was performed 
using the primers AP3_Inv1 and AP3_Inv2 (Appendix section B), which flanked the exon 2 
sequence. Parental DNA was removed using DpnI treatment, and the amplified PCR product 
was re-ligated. The successful deletion of exon 2 is confirmed by the absence of HincII 
restriction site that falls within this deleted nucleotide sequence. The final construct, pAP01-
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IL4δ2–TEV-His was used for protein expression. However, based on the results of initial 
rIL-4δ2 protein expression experiments (reported in section 4.3.3.2), the signal peptide of IL-
4δ2 was deleted from the pAP01-IL4δ2-TEV-His construct by inverse PCR using the primers 
AP4_Inv1 and AP4_Inv2, as described above. This new construct, called pAP01-NSIL4δ2-
TEV-His, was used in subsequent protein expression of His-tagged rIL-4δ2. The cloning 
procedure is described in figure 4.6A. The nucleotide sequence of the pAP01-IL4δ2-TEV-
His is shown in section B of the Appendix. The structure and translated amino acid sequence 











Figure 4.6 (A) the cloning steps to produce the pAP01-IL-4δ2-TEV-His and pAP01-NSIL-4δ2-
TEV-His construct and (B) The structure and amino acid sequence of IL-4δ2-TEV-His 
sequence inserted into pAP01. The NSIL-4δ2-TEV-His sequence is identical to the IL-4δ2-TEV-
His sequence except that the signal sequence, which comprises the first 24 amino acids (shown in 
red), are deleted. 
 
4.3.3.2 Protein expression and nickel chelate affinity chromatography purification of 
His tagged recombinant IL-4δ2 protein 
Transfection of pAP01-IL-4δ2-TEV-His and production of high titre viral stocks were 
performed as previously described (section 4.2.2.3). Initial expression experiments using 
conditions similar to rIL-4 (MOI of 10 and harvesting of cell supernatants at 3 days PI) 
resulted in no expression of protein. Small scale experiments revealed that His tagged-IL4δ2 
was present in the cell lysates but not the supernatants suggesting that the expressed IL4δ2 
was not secreted but remained intracellular (Figure 4.7). The signal peptide (the first 24 
amino acids) in IL-4, and probably in IL4δ2 as well, is required for protein secretion and is 
cleaved to produce the mature functional protein. However, it was difficult to determine if 
the signal peptide was cleaved in the IL4δ2-TEV-His protein expressed here because the 
difference in size (~1-2 kDa) of rIL4δ2 before and after signal peptide cleavage was too 
small to resolve on an SDS PAGE gel. Given that proper protein function requires removal of 
the signal sequence, another construct was created where the signal peptide was removed 
(pAP01-NSIL-4δ2-TEV-His; section 4.3.3.1). This construct was used for subsequent His-
tagged rIL4δ2 protein expressions. Optimized conditions (an MOI of 10 and 2 days PI) were 
used to infect a ~500ml insect cell culture at a concentration of 1.5x106/ml. Given the 
intracellular location of the rIL4δ2 protein, cells were harvested, lysed and purified as 
described in section 4.2.2.8. SDS-PAGE gel electrophoresis and Western blot analysis using 
anti-His and anti-IL-4 antibodies confirmed the presence of His-tagged rIL4δ2 (~14kDa) in 
the concentrated eluted fraction (Figure 4.8). However, the purity  of the rIL4δ2 protein was 
only ~30-40% based on band densitometry analysis (Lane 7 in figure 4.8A) A number of 
strategies [529] were employed in an attempt to improve purity including: increasing 
imidazole concentrations in the wash buffer up to 100mM or varying imidazole 
 
 106 
concentrations in the elution buffer to differentially elute the nonspecific proteins;  increasing  
NaCl concentration up to 500mM and Triton-X 100 up to 1% in the binding buffer; 
performing affinity purification utilizing Co2+ (Thermo Scientific) rather than Ni2+ as the 
metal-ion affinity matrix [530, 531]. However, none of these substantially improved the 
purity, and in some cases, even reduced the yield of rIL4δ2. Furthermore, the Western Blot 
analysis revealed that most of the protein was insoluble (Lane 3 of Figure 4.8B). Attempts to 
improve solubility by varying the constituents of the lysis buffer (varying buffers, salt 
concentrations and detergents), using harsher cell lysis methods (sonication) or commercial 
lysis buffers (IPER lysis reagent, Thermo Scientific) were unsuccessful (Figure 4.9A-D).  
rIL4δ2 protein yield (~5μg from a 500ml culture) was much lower compared to rIL-4. 




Figure 4.7. Cellular (intracellular vs extracellular) localization and optimization of conditions 
for the expression His tagged recombinant IL-4δ2 (rIL-4δ2). (A) Western blot analysis of crude 
cell lysates and cell supernatants at different days of harvest post infection (PI) and different 
multiplicity of infections (MOI) – Lanes 1c-4c show crude cell lysates and lanes 1s-4s shows cell 
supernatants at (1) Day 2 PI and MOI 5 (2) Day 2 PI and MOI 10 (3) Day 3 PI and MOI 5 (4) Day 3 
PI and MOI 10.   IL-4δ2 has a size of ~15kDa (arrow). (B) Western blot analysis of purified and 
concentrated IL4δ2 (Day 2 PI and MOI 10) in (1) cell supernatants and (2) crude lysates show that 
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protein is not secreted and remains intracellular. Molecular weight markers are shown on the left in 
kiloDaltons (kDa). Anti-His antibody was used at a 1:5000 dilution. 15μl of each fraction was loaded 




Figure 4.8. Purification of His tagged recombinant IL-4δ2 (rIL-4δ2). using Ni+ affinity 
column.(A) 15% SDS PAGE gel and (B) Western blot analysis (anti-His antibody at 1:5000 dilution) 
of rIL-4δ2 purification fractions  showing (1) clarified rIL-4δ2 cell lysate (2) clarified cell lysate of 
negative control (uninfected Sf21 cells) (3) Insoluble fraction (4) Insoluble fraction of negative 
control (5) rIL-4δ2 flow-through after column binding  (6) rIL-4δ2 wash with 500mM imidazole (7) 
eluted and concentrated rIL-4δ2 fraction.  In lane 7, a band migrating just below the 15kDa molecular 
weight marker (~14kDa) represented the partially purified rIL-4δ2 protein (arrow). Based on the 
Western blot, most of the rIL-4δ2 protein is located in the insoluble cellular fraction (lane 3 in B) (C) 
Western blot analysis of (1) clarified rIL-4δ2 cell lysate and (2) Insoluble fraction using anti-IL4 
antibody (1:2000) confirms the identity of rIL-4δ2 at ~14kDa (arrow). Molecular weight markers are 





Figure 4.9. Optimization of cell lysis buffer parameters to increase the solubility of His-tagged 
recombinant IL-4δ2 (rIL-4δ2). Western blot analysis (A-D) of IL4δ2 soluble (s) and insoluble (i) 
cellular fractions using the following in the cell lysis buffer (1) NaPO4 at pH6 (2) NaPO4 at pH7 (3) 
NaPO4 at pH8 (4) Tris at pH7.5 (5) HEPES at pH 7.5 (6) KCl 10mM (7) KCl 100mM (8) KCl 
500mM (9) 0.1% Triton X-100 (10) 0.5% Triton X-100 (11) 1% Triton X-100 (12) IPER commercial 
lysis buffer (13) 0.1% sodium deoxycholate (14) 0.5% sodium deoxycholate (15) 1% sodium 
deoxycholate (16) 1% CHAPS. Anti-His antibody was used at 1:2000. Molecular weight markers are 
shown on the left in kiloDaltons (kDa). 15 μl of each fraction was loaded onto the gel.  
 
4.3.3.3 Cloning of GST-tagged IL-4δ2 construct 
A Glutathione-S-Transferase (GST) tag has been shown to increase the solubility of fusion 
proteins in a number of expression systems [532]. As such, a GST-tagged IL4δ2 construct 
was generated in an attempt to improve the solubility of IL4δ2. Initial cloning experiments to 
produce this construct were unsuccessful. Generation of this construct was therefore 
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outsourced to ExonBio (ExonBio, USA), where GST was introduced into the pAP01 vector 
followed by the IL4 cDNA sequence at the C-terminus of the GST tag and a TEV cleavage 
site between the GST tag and IL-4 cDNA. The subsequent construct, called pAP01-GST-
TEV-IL-4, was further manipulated to produce the IL4δ2 construct. However, the position of 
the GST tag at the N-terminus of the IL-4 sequence prevents cleavage of the signal peptide 
by the insect cell machinery during protein expression. As a result, an inverse PCR was 
performed, using primers AP5_Inv1 and AP5_Inv2 (Appendix section B), to delete the IL-4 
signal peptide and create the pAP01-GST-TEV-NSIL-4 construct, as previously described. 
Once DNA sequencing confirmed the removal of the signal sequence in pAP01-GST-TEV-
NSIL-4, this construct was used in a second inverse PCR (using primers AP3_Inv1 and 
AP3_Inv2) to delete exon 2 and generate the pAP01-GST-TEV-NSIL-4δ2 construct. The 
cloning steps used to generate pAP01-GST-TEV-NSIL-4δ2 are shown in Figure 4.10A and 
the cDNA sequence of this construct is shown in section B of the Appendix. The structure 







Figure 4.10 (A) the cloning steps to produce the pAP01-GST-TEV-IL4δ2 construct and (B) the 
structure and translated amino acid sequence of GST-TEV-IL4δ2. 
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4.3.3.4 Protein expression and purification of GST tagged recombinant IL-4δ2 protein 
using magnetic beads 
Transfection of pAP01-GST-TEV-IL4δ2 and production of high titre viral stocks were 
performed as previously described (section 4.2.2.3). Small scale expression experiments 
revealed that an MOI of 20 and harvesting at 3 days PI was optimal for protein expression. 
Given the lack of a signal peptide, GST-tagged IL4δ2 was expressed in the intracellular 
compartment. These optimized conditions were used to infect a ~500ml insect cell culture at 
a cell concentration of 1.5x106/ml. Cells were lysed, harvested and purified as described in 
section 4.2.2.8. SDS-PAGE and Western analyses using anti-GST antibody confirmed the 
presence of 2 proteins in the purified fractions; a band at ~41 kDa, which corresponded to the 
size of the GST-tagged IL4δ2, and a second band at ~25kDa (lane 4 of Figure 4.11A). 
Purification of uninfected insect cell lysates revealed that this 25kDa protein was also present 
in uninfected cells (lane 8 of figure 4.11A) suggesting that it is an intrinsic insect cell protein 
that is being co-purified along with the GST-tagged IL4δ2. A previous study [533] has also 
reported the co-purification of this glutathione binding protein (GluBP) during GST 
purification. The large amount of GluBP in the uninfected cells suggests that this protein is in 
much larger quantities than the GST- IL4δ2 protein and is likely competing for available 
binding sites leading to a reduced IL4δ2 yield. This competing effect is maintained even if 
increasing amounts of magnetic beads are added to the lysates during purification. Pichet et 
al [533] suggested that GluBP has a lower affinity for glutathione than GST and will elute at 
a lower concentration of glutathione. As a result, differential elution of the contaminating 
protein was attempted by gradually increasing the concentration of glutathione in the elution 
buffer from 5mM to 50mM. However, the GluBP eluted at all concentration of glutathione 
that were tested (figure 4.11B). Also, initial attempts to cleave the GST tag using ProTEV, in 
order to release the IL4δ2 protein from the beads while leaving the GluBP attached, were 
unsuccessful due to the almost nil recovery of cleaved IL4δ2. Use of size exclusion 
chromatography or further optimization of cleavage conditions may be necessary to isolate 
IL4δ2 protein but, at this point, protein expression using this construct was not pursued 





Figure 4.11. Purification of GST tagged recombinant IL-4δ2 (GST-IL-4δ2; ~41 kDa) using 
glutathione magnetic beads and attempts to remove a contaminating intrinsic Glutathione 
binding insect cell protein (Glu-BP; ~24 kDa) (A) 12% SDS PAGE gel of GST-IL-4δ2 and 
uninfected Sf21 insect cells purification fractions  showing the presence of the Glu-BP 
“outcompeting” GST-IL-4δ2  for available binding sites on the beads (1) GST-IL-4δ2 clarified cell 
lysate (2) GST-IL-4δ2 flow-through after bead incubation (3) GST-IL-4δ2 wash (4) eluted GST-IL-
4δ2 fraction (5) uninfected Sf21 clarified cell lysate (6) uninfected Sf21 control flow-through after 
bead incubation (7) uninfected Sf21 wash (8) eluted uninfected Sf21 fraction. (B) A 12% SDS-PAGE 
gel showing purified GST-IL-4δ2 fractions in an attempt to remove GluBP by using differential 
glutathione elution conditions [533]. Elution at (1) 5mM glutathione (2) 10mM glutathione (3) 20mM 
glutathione (4) 50mM glutathione failed to reduce the amount of Glu-BP present in the pure fraction. 
Molecular weight markers are shown on the left in kiloDaltons (kDa). 15μl of each fraction was 










This chapter described the attempt to express recombinant IL-4 and IL-4δ2 using a 
baculovirus expression system. His-tagged rIL-4 and rIL-4δ2 was successfully expressed and 
purified by affinity purification in sufficient amounts for functional assessment. However, 
His-tagged rIL-4δ2 protein recovery and purity were low post-purification and the majority 
of protein was insoluble. Attempts to increase solubility and purity were unsuccessful. A 
GST-rIL-4δ2 construct was used to successfully express N-terminus GST-tagged rIL-4δ2. 
However, competitive binding with an intrinsic glutathione binding insect cell protein 
(GluBP) during the purification process resulted in low rIL-4δ2 recovery. 
 
4.4.1 Expression of rIL-4 in baculovirus infected insect cells 
In the above experiments, rIL-4 was cloned with its native signal peptide and the expressed 
protein was secreted into the extracellular media suggesting that the insect cell machinery 
was able to effectively recognize and cleave the signal peptide and fold the protein in its 
native conformation. Similar secretory expression of mammalian rIL-4 has been 
demonstrated in a baculovirus system [518, 534] and is also commercially available for a 
range of species. A His-tagged fusion protein was constructed to obtain purified protein by 
affinity purification rather than the use of virus-containing supernatants [534] for functional 
and immunological assays. A His-tag was chosen because of its small size and non-
immunogenicity and usually does not affect protein folding or require removal following 
purification [535, 536]. Nonetheless, cleavage of the His tag was attempted but, due to low 
protein recovery post-cleavage, was not pursued. Two distinct bands were observed on the 
SDS-PAGE gel which may represent alternatively glycosylated forms of the protein [518], 
but this is unlikely given that only a single band was observed in the Western blot. IL-4 
undergoes N-linked glycosylation in the mature protein. However, N-linked glycans in insect 
cells are not equivalent to mammalian cells as they have high mannose content and lack 
sialic acid [537]. Inappropriate glycosylation can have significant effects on protein stability, 
conformation and bioactivity [508, 509]. Functional assays were performed to determine rIL-




4.4.2 Expression of rIL-4δ2 in baculovirus infected insect cells  
To my knowledge, this is the first study to attempt expression of the IL-4 splice variant, IL-
4δ2, in a baculovirus system. Unlike IL-4, IL-4δ2 was not secreted into the culture 
supernatant but remained in the intracellular compartment, suggesting an incompatibility of 
IL-4δ2 secretion in the insect cell secretory pathway. In eukaryotes, protein secretion is 
mediated by the signal peptide which, through binding to a signal recognition protein, directs 
the precursor protein to the endoplasmic reticulum (ER). Here, it is cleaved by signal 
peptidases, properly folded and glycosylated before transport to the Golgi apparatus for 
additional modifications and subsequent extracellular secretion [538, 539]. The efficiency of 
this process is a function of the host expression system and the protein itself [539]. In IL-4 
and IL-4δ2, the signal peptide comprises the first 24 amino acids of the precursor protein 
which is cleaved to produce the mature protein. The observation that IL4, but not IL-4δ2, is 
secreted into the media under the direction of the same signal peptide suggests that the 
sequence and/or structure of IL-4δ2, rather than an inappropriate signal peptide, may be 
interfering with the insect cell secretory mechanisms. The IL-4 structure consists of 4 α-helix 
bundles with a short two-stranded anti-parallel β-sheet and is stabilized by 3 disulfide 
bonds[385, 386]. The omission of exon 2 in IL-4δ2 resulted in a protein structure which lacks 
the β-sheet and a disulfide bond due to deletion of a cysteine residue [385, 386]. Despite 
these structural differences, IL-4δ2 retains the majority of the hydrophobic core and native 
structure of IL-4 [386]. Furthermore, IL-4δ2 seems to exists as a naturally occurring protein 
in mammals [31] suggesting that the protein is stable in its natural environment and these 
effects on secretion may be specific to expression in a baculovirus system. There is evidence 
indicating that protein structure can influence the secretory pathway. Choo et al 
demonstrated that recognition of signal sequences by signal peptidase can extend into the 
mature protein sequence and subsequently affect signal peptide cleavage in various 
expression hosts [540]. Furthermore, studies of deletion mutants in different expression 
systems have demonstrated that protein structure can reduce the ability of the signal peptide 
to direct translocation to the ER [541, 542]. This effect may be due to a reduced affinity of 
the signal recognition protein for the signal peptide, interference with signal peptidase 
activity or a combination of the two [541]. A similar effect may be occurring with IL-4δ2 
expression in this system. It was difficult to determine if the signal peptide was cleaved 
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because the difference in size (~1-2 kDa) of rIL4δ2 with or without the signal peptide was 
too small to adequately resolve on an SDS PAGE gel. Given that proper protein function 
requires removal of the signal sequence, rIL4δ2 was subsequently expressed using a 
construct where the signal peptide sequence was deleted (pAP01-NSIL-4δ2-TEV-His; 
section 4.3.3.1). However, it cannot be ruled out that the use of the intrinsic human IL-4 
signal peptide may be suboptimal for expression in the baculovirus-insect cell system. 
Atamas et al successfully expressed IL-4δ2 in  P. pastoris using a yeast specific α-factor 
secretory signal that directs extracellular secretion of the protein within this system [47]. In 
future experiments, replacement of the human IL-4 signal sequence with one more 
appropriate for a baculovirus system, such as the honey bee mettilin sequence [543], will be 
attempted to improve secretion of the protein. 
 
While IL-4δ2 was successfully purified from cell lysates, the amount of recovered protein 
was low as a significant quantity remained as insoluble aggregates. Protein aggregation in a 
baculovirus system has been previously reported [514, 515], and is likely a direct 
consequence of failed protein secretion. In insect cells, the secretory pathways can be 
hindered by overproduction of protein due to the strong polyhedron promotor, a lack of 
appropriate chaperone molecules or deterioration of infected cells, all resulting in 
accumulation of proteins and subsequent aggregation within the infected cells [544]. Protein 
overexpression and cellular localization has been shown to cause aggregation of GFP in a 
baculovirus system [539]. In the rIL-4δ2 expression described here, removal of the signal 
sequence inevitably resulted in protein accumulation within the cell and likely led to the 
observed formation of insoluble aggregates. A probable mechanism of protein aggregation 
involves the formation of specific intermolecular interactions between partially folded 
protein intermediates [545]. Mutations in native proteins may also form similar interactions 
due to alterations in protein folding.  Studies have shown that point mutations in human 
proteins expressed in different systems have a dramatic effect on the production of protein 
aggregates [546, 547]. In the case of IL-4δ2, which contains a free cysteine residue, 
intermolecular disulfide bonds may form between adjacent protein molecules [548] leading 




The low yield of IL-4δ2 also probably explains the low purity after protein purification, 
which is particularly evident when proteins are expressed intracellularly. Secreted proteins 
tend to be easier to purify because the majority of protein in the supernatant consists of the 
target recombinant protein [549]. Indeed, rIL-4 protein obtained from cell supernatants had a 
purity of >85%. In contrast, the large number of histidine-rich proteins in eukaryotic cells 
(including insect cells) makes it difficult to obtain His-tagged recombinant proteins of 
sufficient purity. A decahistidine tag was used to increase the affinity of IL-4 and IL-4δ2 
fusion protein to Ni2+ beads during binding. However, IL-4δ2 still only consisted about 30% 
of the purified fraction. Similar purity issues occurred with the GST-tagged protein due the 
presence of an intrinsic GluBP.  
 
4.4.3 Limitations and future investigations 
Sufficient levels of rIL-4 were obtained from expression in the baculovirus system, whereas 
rIL-4δ2 expression proved to be more problematic and resulted in low protein yield. Due to 
time and resource constraints, further optimization of IL-4δ2 expression was not possible and 
additional investigations, detailed below, will be required to obtain sufficient amounts of IL-
4δ2. 
 
As stated above, IL-4δ2 protein was not secreted into the media even under the direction of 
the intrinsic IL-4 signal peptide. This was unexpected given that IL-4 was successfully 
processed and secreted into the media using the same signal peptide. Future experiments will 
replace the intrinsic IL-4 signal peptide with a sequence that directs secretion of proteins in 
baculovirus infected insect cells, such as the honey bee metillin leader sequence, which has 
been shown to significantly increase protein secretion and yield [543]. 
 
The presence of the His-tag on the C-terminal end of the protein may have affected rIL-4δ2 
protein expression. Optimal placement of the tag, either on the C-terminal or the N-terminal 
end, is usually protein specific [536]. However, this is unlikely given that this did not affect 
rIL-4 expression, which has a similar protein structure. Furthermore, the His tag is small and 
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uncharged under physiological conditions so it usually does not interfere with protein folding 
and compartmentalization [536]. Nonetheless, movement of the His tag to the N-terminal end 
of the IL-4δ2 sequence will be attempted to determine if tag placement has a significant 
effect on expression levels, solubility or protein localization. 
 
Cleavage of the affinity tag from expressed proteins was performed to try to improve the 
purity of the eluted proteins, particularly in the case of His- and GST-tagged rIL-4δ2. 
However, these efforts were unsuccessful because IL-4δ2 expression levels were very low 
before cleavage and were further reduced post-cleavage.  Attempts to increase the expression 
levels of IL-4δ2 or further optimize the TEV cleavage conditions will be performed to 
remove the affinity tag without compromising protein yield. 
 
The use of another expression system may be required if sufficient quantities of IL-4δ2 
cannot be produced in the baculovirus system. Functional IL-4δ2 has been previously 
produced in yeast [47] and mammalian cells [32, 393]. The mammalian expression system is 
most likely optimal for IL-4δ2 expression because it best mimics the native environment. 
However, expression levels here are usually lower than insect cells and the use of adenovirus 
constructs requires additional biosafety considerations. In the P. pastoris system, Atamas et 
al used a yeast-specific leader sequence to express IL-4δ2 [47]. This system is a viable 
option but was not feasible when this study was being conducted. Expression of IL-4δ2 in E. 
coli has been previously reported [525] but was not used for reasons stated in Table 4.1. 
Indeed, most of the protein was expressed as insoluble inclusion bodies in this study. 
However, optimization of reaction conditions, the use of an appropriate promoter and signal 
peptides sequences specific for a prokaryotic system and efficient endotoxin removal 
techniques may produce IL-4δ2 protein suitable for immunological assays. Further 






Human rIL-4 was successfully cloned and expressed in a baculovirus insect cell expression 
system in adequate amounts for further downstream analyses. rIL-4δ2 was also successfully 
expressed but the protein yield was much lower compared to IL-4. Further investigations 
need to be performed to optimize IL-4δ2 expression in this system. In the following chapter, 
rIL-4 and rIL-4δ2 will be used in immunological assays to determine the activity of these 









5. CHAPTER 5: Characterization of recombinant IL-4 and IL-
4δ2 amino acid sequence and protein function 
 
5.1 Introduction 
IL-4 is a pleiotropic cytokine with multiple effects on different cell types including T and B-
lymphocytes, monocytes, macrophages, and fibroblasts [347]. The effects of IL-4 in in vitro 
cultures have been well described. These include inducing T-cell proliferation [47, 392], 
driving Th2 differentiation [550], inducing CD23 expression and IgE production in B cells 
[48, 392] and inhibiting LPS-induced cyclooxygenase-2 expression and subsequent 
prostaglandin E2 secretion in monocytes [47, 48]. IL-4δ2, the naturally occurring splice 
variant of IL-4, is an IL-4 antagonist and suppresses IL-4-driven responses. For example, IL-
4δ2 downregulates IL-4-induced T cell proliferation and CD23 expression on B lymphocytes 
and activates the production of pro-inflammatory cytokines IFN-γ, IL-6 and TNFα in human 
T-cell cultures [32, 47, 48, 392, 393]. Recently IL-4δ2 has been shown to be a naturally 
occurring protein and is associated with pulmonary inflammation in mice [502]. Like IL-4, 
IL-4δ2 binds to the IL-4 receptor (IL-4R) but at a lower affinity. Furthermore, it is presumed 
the binding of IL-4δ2 to the IL-4R does not induce a signal cascade in the cell [392]. 
 
The aim of this chapter is to confirm the amino acid sequence, by mass spectrometry, and 
function of recombinant IL-4 and IL-4δ2 expressed in a baculovirus-insect cell system using 
specific in vitro assays. 
 
5.2 Methods 
5.2.1 Mass spectrometry 
The rIL-4 protein was analyzed by mass spectrometry (MS), performed by Dr. Brandy 
Young-Gqamana at the Blackburn Lab in the Department of Medical Biochemistry, 
University of Cape Town. 20μg of purified rIL-4 was used for MS analysis. The lysis buffer 
(8% SDS, 200mM Tris-HCl, 0.2M TCEP) was added to purified protein (chapter 4) followed 
by sonication for 1 minute. The sample was heated at 90oC for 3 minutes then loaded onto a 
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0.5ml 3kDa MWCO centrifugal filter (Millipore) pretreated with 50mM Ammonium 
Bicarbonate (ABC) and proteolysed on the MWCO centrifugal filter using a  FASP protocol 
[551]. In short, the sample was reduced, alkalyated and digested using lysis buffer, 
iodoacetamide and trypsin respectively. The sample was incubated overnight at 37oC and the 
peptides were collected and further analyzed by product ion scan using a TSQ Vantage mass 
spectrometer (ThermoFisher). The data was processed using Skyline software.  
 
5.2.2 PBMC isolation 
Whole blood was obtained by venipuncture from 10 healthy controls. PBMCs were isolated 
by density centrifugation as described in section 2.4.2. 
 
5.2.3 3H thymidine assay to measure T-cell proliferation 
A total of 5x104 PBMCs suspended in RPMI 1640 (Lonza) (supplemented with 10% pooled 
human AB serum and 1:100 penicillin and streptomycin) were seeded in 96-well round 
bottom plates. Cells were stimulated with anti-CD3 antibody (eBiosciences) at 250ng/ml and 
incubated at 37oC and 5% CO2 for 3 days. On day 3, specified amounts of rIL-4 (5-
100ng/ml), rIL-4δ2 (100-1000ng/ml) or a combination of both were added to appropriate 
wells. In order to test the effect of neutralizing IL-4, anti-IL4 antibody (Abcam) was added at 
concentrations of 0.5-20μg/ml to wells containing rIL-4. Appropriate controls were also 
included; phytohaemagglutinin (PHA; Sigma Aldrich) at 10μg/ml was used as a positive 
control and the negative control used His-purified fractions of the pAP01 expression control 
(section 4.2.2.6). All controls and interventions were performed in triplicate at a final volume 
of 200μl. Cells were incubated for a further 3 days at 37oC and 5% CO2. After 3 days, 1μCi 
of 3H-Thymidine (AEC Amersham) was added to each well and incubated at 37oC for 18 
hours. The cells were then harvested using the Wesbart 2020 Maxi cell harvester (Wesbart) 
and counted by liquid scintillation spectrophotometry using a Tri-Carb 2100 TR liquid 
scintillation counter (Packard). The mean counts per minute (CPM) for each condition was 
used to calculate the % proliferation, in the case of rIL-4, and the % suppression in the case 






5.2.4 Flow cytometry to measure CD23 expression on B-cells 
A total of 1.5x106 PBMCs were seeded in 24 well plates. Cells were stimulated with rIL-4 at 
specified concentrations (0.5-50ng/ml) and incubated at 37oC and 5% CO2 for 3 days. Cells 
were then harvested and stained for specific surface markers using fluorescently labeled 
antibodies (Table 2.2) and subsequently analyzed on a BD LSR II flow cytometer (BD 
Biosciences) as outlined in section 2.4.6. 
 
5.2.5 Data analyses 
Statistical differences between controls and the different interventions were determined using 
the Wilcoxon matched-pairs signed rank test. A p value of <0.05 was deemed significant. 
Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad) software and 
Microsoft Excel (Microsoft). 
 
5.3 Results 
5.3.1 Confirmation of rIL-4 amino acid sequence by mass spectrometry 
Trypsin specifically cleaves polypeptides at the carboxy terminus of lysine (K) and arginine 
(R) residues. Trypsin digest of the rIL-4 protein and subsequent analysis of the mass 
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spectrum identified 3 peptide fragments; a 9 amino acid peptide at lysine position 36 
(TLNSLTEQK), a 6 amino acid peptide at arginine position 71 (AATVLR) and a 4 amino 
acid peptide at lysine position 101 (QLIR). An acceptable signal intensity was produced for 
each peak in the mass spectrum (signal:noise was >~10). The identified peptides were 
compared to a database of known protein sequences using the NCBI BLAST sequencing tool 
(http://blast.ncbi.nlm.nih.gov/) and all fragments were 100% homologous to the human IL-4 
protein sequence. The observed fragment ions for each identified peptide are shown in figure 
5.4. The masses of the fragment ions allow the sequence of each peptide to be determined. 
This data, as well as the expected size observed on the SDS-PAGE gel and the reactivity with 
anti-IL-4 antibody by Western blot (Chapter 4), provides sufficient evidence to confirm the 




Figure 5.1. The confirmation of the recombinant IL-4 (rIL-4) protein using tandem mass 
spectrometry. Trypsin digestion of rIL-4 produced 3 peptide fragments. (A) The location of each 
fragment in the IL-4 protein sequence is shown above in red and the IL-4 signal peptide is crossed out 
as it is absent in the mature protein. (B) The fragment ion masses (m/z shown in blue) observed in the 
mass spectra provide the amino acid sequence for each peptide. 
 
5.3.2 The effect of rIL-4 and rIL-4δ2 on T-cell proliferation  
The addition of rIL-4 to anti-CD3 stimulated PBMCs (n=10) induced T-cell proliferation in a 
concentration dependent manner. Proliferation was 350% at 5ng/ml rIL-4 (p=0.002), 490% at 
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10ng/ml rIL-4 (p=0.002) and 670% at 20ng/ml rIL-4 (p=0.002) compared to the negative 
control (Figure 5 .2A). Proliferation in response to PHA (10μg/ml) stimulation was also 
observed. Neutralization of IL-4 using anti-IL-4 antibody (n=3) suppressed the observed T-
cell proliferation. Addition of anti-IL-4 antibody (Ab) at 0.5, 5 and 20μg/ml suppressed T-
cell proliferation induced by 20ng/ml rIL-4, by 65%, 88% and 94%, respectively. A similar 
pattern of suppression was observed when antibody was added to PBMCs stimulated with 
100ng/ml rIL-4 (mean suppression was 26% at 0.5μg/ml anti-IL-4 Ab, 77% at 5μg/ml anti-
IL-4 Ab and 82% at 20μg/ml anti-IL-4 Ab; Figure 5.2B). However the differences were not 
statistically significant.  
 
Sufficient rIL-4δ2 was produced (Chapter 4) to assess its effect on IL-4-induced T-cell 
proliferation. The addition of rIL-4δ2 suppressed T-cell proliferation induced by 5ng/ml rIL-
4 (mean suppression was 55% at 1000ng/ml rIL-4δ2, 44% at 500ng/ml rIL-4δ2 and 10% at 
100ng/ml rIL-4δ2) and 10ng/ml rIL-4 (mean suppression was 30% at 500ng/ml rIL-4δ2 and 
11% at 100ng/ml rIL-4δ2). The addition of rIL-4δ2 (100ng/ml) alone did not have any effect 
on proliferation as the CPM value was similar to the negative control (Figure 5.3). Results 












Figure 5.2. (A) Recombinant IL-4 induces proliferation of T-cells pre-activated with anti-CD3 
in peripheral blood mononuclear cells of healthy participants (n=10) in a concentration 
dependent manner. (B) The addition of anti-IL-4 neutralization antibodies reduces the IL-4-
mediated T-cell proliferation (n=3) in a concentration dependent manner. Proliferation was 
measured in a 3H-Thymidine proliferation assay. Statistical analysis was performed using the 




Figure 5.3. IL4δ2 reduces the IL-4-mediated proliferation of T-cells pre-activated with anti-
CD3 antibody in peripheral blood mononuclear cells of healthy participants (n=2) in a 
concentration dependent manner. Proliferation was measured in a 3H Thymidine proliferation 
assay. Statistical analysis was performed using the Wilcoxon matched-pairs signed rank test and 




5.3.3 The effect of rIL-4 on CD23 expression in B-cells 
The gating strategy used to identify CD23+ expressing B-cells in PBMCs is shown in Figure 
5.4A. Lymphocytes were acquired based on cell size (FSC) and granularity (SSC). Cells 
were gated on CD3-CD19+ population to identify the B-lymphocyte population CD23+ cells 
were then identified within the B-lymphocyte (CD3-CD19+ population). CD23 expression 
was determined before and after the addition of rIL-4. The percentage (%) CD3-
CD19+CD23+ was expressed relative to the B-lymphocyte population (CD3-CD19+). 
 
rIL-4 induced CD23 expression on B-cells in healthy controls (n=6) in a concentration 
dependent manner. Median CD3-CD19+CD23+ levels increased when rIL-4 was added at 
0.5ng/ml (29.9%, IQR 10.6-41.1; p=0.03), 1ng/ml (31.0%, IQR: 15.5-61.0; p=0.03), 5ng/ml 
(50.2%, IQR: 30.5-64.2; p=0.03), 10ng/ml (67.1%, IQR: 61.8-74.0; p=0.03) and 50ng/ml 
(69.7%, IQR: 64.6-75.2; p=0.03) compared to the negative control (3.1%, IQR: 0.9-8.0) 
(Figure 5.4B). PHA stimulation of PBMCs also resulted in increased levels of CD3-
CD19+CD23+ cells.  rIL-4δ2 was not assessed in this assay due to the limited amount of 







Figure 5.4. Recombinant IL4 induces expression of CD23 on B-cells (CD3+CD19+) in 
peripheral blood mononuclear cells of healthy participants (n=6) in a concentration dependent 
manner as measured by flow cytometry. The gating strategy for identification of CD3-
CD19+CD23+ cells is shown in (A). The median frequency (%) and interquartile range of CD3-
CD19+CD23+ cells at different concentrations of rIL-4 are shown in (B). Statistical analysis was 
performed using the Wilcoxon matched-pairs signed rank test and p<0.05 was deemed significant.  
 
5.4 Discussion 
The identity of the purified rIL-4 protein was confirmed by mass spectrometry. rIL-4 was 
shown to induce T-cell proliferation in a concentration dependent manner and this 
proliferation was suppressed by the addition of anti-IL-4 neutralizing antibody. rIL-4 also 
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induced CD23 expression on B-cells in a concentration dependent manner. IL-4δ2 
suppressed the observed IL-4-induced T-cell proliferation and had no effect on proliferation 
when added alone. The function of IL-4δ2 was not assessed in the B-cell CD23 assay or 
analyzed by mass spectrometry due to the limited amounts of recombinant protein available. 
 
5.4.1 Assessment of IL-4 and IL-4δ2 function 
The effects of IL-4 and IL-4δ2 on T-cell proliferation and B-cell CD23 expression confirms 
the bioactivity of rIL-4 and rIL-4δ2 proteins expressed in a baculovirus-insect cell system. 
Similar results were observed when these proteins were produced in a P. pastoris expression 
system [47, 48]. In the previous chapter (Chapter 4), rIL-4 and rIL-4δ2 were expressed and 
purified with the His affinity tag still attached to the mature protein because removal of the 
His tag resulted in insufficient protein recovery. As a result, His-tagged proteins were used 
and the data provided here shows that protein function remained intact, suggesting that the 
His-tag did not interfere with binding to IL-4 receptors. However, future investigations will 
determine if bioactivity is altered when the affinity tag is removed.  
 
Very high concentrations of IL-4δ2 (~100-200 times the amount of IL-4) were found to be 
required to suppress IL-4-induced T-cell proliferation in PBMCs. Structural studies suggest 
that IL-4 contains 2 binding sites for its receptor (IL-4R) [552, 553]. Deletion of exon 2 in 
IL-4δ2 alters the protein structure and results in the loss of one of these binding sites [48]. 
Subsequently, the IL-4δ2 binding affinity for the IL-4R on T-cells is presumably reduced and 
much higher concentrations of IL-4δ2 are therefore required to „out-compete‟ IL-4 for the IL-
4R binding sites.  
 
IL-4 significantly increased CD23 expression, a low affinity IgE receptor, expression on B-
cells at a lower concentration compared to what was needed for induction of T-cell 
proliferation.  In a similar study, low concentrations of IL-4 effectively induced CD23 
expression and required ~1000 times more IL-4δ2 than IL-4 to suppress this effect [48]. The 
apparent higher sensitivity of B-cells to IL-4 compared to T-cells, may be a reflection of the 
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different assay systems used or differences in the receptor systems on B-cells compared to T-
cells.  
 
Other studies have used similar concentrations of IL-4 and IL-4δ2 to test their bioactivity in 
vitro [47, 48, 392]. However, the effective concentrations of IL-4 and IL-4δ2 in vivo are 
significantly lower and may reflect differences in the stability and bioactivity of 
recombinantly expressed proteins compared to their native counterparts. Luzina et al [393] 
observed differences in the bioactivity of adenovirus-mediated gene delivery of IL-4δ2 in 
mice compared to in vitro assays using IL-4δ2 expressed in mammalian cells. One plausible 
explanation is the presence of chaperone proteins in vivo, which preserve protein stability and 
bioactivity, but are absent in vitro [393]. Co-expression of chaperone proteins in conjunction 
with the recombinant protein in an appropriate expression system can sometimes enhance 
protein folding and bioactivity [537]. The extent of recombinant protein bioactivity is also 
dependent on the expression system used. As discussed in chapter 4, N-linked glycosylation 
patterns in insect cell expressed proteins are different from those expressed in mammalian 
cells due to their high mannose content and lack of sialic acid [507, 537]. Inappropriate 
glycosylation can have a significant impact on protein stability and function [508, 509]. For 
example, human erythropoietin is 1000 times more active in vivo compared to its de-
sialylated form [554]. Naturally occurring IL-4, and probably IL-4δ2 as well, undergoes N-
glycosylation. Atamas et al [47] demonstrated that de-glycosylated IL-4 and IL-4δ2 still 
retain their function in vitro. However, other evidence suggests that inappropriate 
glycosylation can impact bioactivity to a greater extent than non-glycosylated forms. Two 
studies [555, 556] found that glycosylated forms of IL-4 expressed in P. pastoris and COS 
cells have lower bioactivity compared to their de-glycosylated forms. This may be explained 
by the presence of mannose on N-glycans which allows for rapid uptake of these isoforms by 
cultured cells and subsequent cellular degradation [555]. Also, the lack of sialic acid residues 
means these proteins are more prone to proteolytic attack [557, 558]. The ultimate 
consequence of reduced recombinant protein stability and bioactivity in in vitro experiments 





The effect of glycosylation on the function of IL-4 or IL-4δ2 was not tested. As mentioned 
above, inappropriate glycosylation, which occurs in insect cells, can affect protein function 
[508, 509]. However, rIL-4 and rIL-4δ2 were found to be active at concentrations similar to 
those used in functional assays in other studies [48, 392]. Further investigations will be 
required, where the proteins are de-glycosylated using PNGase and their function compared 
to untreated protein, to determine if differential glycosylation has any effect on protein 
bioactivity. 
 
High concentrations of IL-4δ2 were required to reduce IL-4-induced T-cell proliferation. 
Given low protein yield obtained for IL-4δ2 (Chapter 4), it was not possible to assess its 
effect on CD23 expression in B cells or for mass spectrometric analysis. Once IL-4δ2 
expression has been optimized and sufficient amounts are produced, these assays will be 
performed to confirm the structure and function of the protein. 
 
5.5 Conclusion 
The data presented here demonstrates that rIL-4 and rIL-4δ2 expressed in a baculovirus 
system are functional based on their ability to modulate T-cell proliferation and CD23 
expression on B-cells. The role of rIL-4 on mycobacterial survival was subsequently 
investigated in an in vitro infection model. However, due to the low yield of rIL-4δ2 and the 
high concentrations required to produce an effect on IL-4-induced T-cell proliferation, it was 
not possible to assess the effect of IL-4δ2 in subsequent assays. Further studies will have to 
be performed in order to address the above.  
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6. CHAPTER 6: Effect of IL-4 on mycobacterial containment 
 
6.1 Introduction 
Innate and adaptive immune responses are required for effective control of M.tb. Innate 
mechanisms, facilitated by infected macrophages and possibly neutrophils [183], represent 
the first line of defence against M.tb infection [235, 479, 559, 560]. In some exposed 
individuals, the innate system may presumably be able to completely eliminate infection 
without initiation of adaptive immune mechanisms [5]. In the majority of exposed 
individuals however, the adaptive immune response, mediated principally by CD4 IFN-γ 
producing T-cells, plays a key role in control of infection [559]. As discussed previously, 
IFN-γ is responsible for activation of macrophages [228], CD8 mediated cytotoxicity [561-
563] and recruitment of additional T-cells to the site of infection [559]. Despite high levels of 
IFN-γ at the site of disease [9, 11, 13-15, 482, 483], some individuals still progress to active 
TB. Preliminary evidence suggests that a subversive Th2 response may be undermining 
protective Th1 mediated immunity [16]. However, the direct relationship between IL-4 and 
host mycobactericidal activity remains unclear. In chapter 3, I have demonstrated that TB 
patients have higher IL-4 mRNA levels compared to presumed LTBI controls in peripheral 
blood and the IFN-γ:IL-4 ratio, which has been proposed as a surrogate marker for disease 
progression, is lower in TB patients compared to controls. These results have been confirmed 
in other studies [9, 21, 29, 416-418, 487, 504]. However, it is unknown if these high IL-4 
levels is a by-product of excessive inflammation (irrelevant epiphenomenon) or plays an 
active role in causing TB progression. A number of mechanisms, that are associated with 
protection against TB, are downregulated by IL-4 [16]. To my knowledge, there have been 
no published studies that directly assessed the impact of IL-4 on mycobacterial containment. 
In the previous chapters, I have expressed and functionally assessed recombinant IL-4 (rIL-4) 
protein in a baculovirus insect cell expression system. The aim in this chapter is to assess the 
effect of adding rIL-4, either to effector cells and/or macrophages on mycobacterial survival 




6.2.1 Mycobacterial containment assay overview 
A mycobacterial containment assay was used to determine the effect of rIL-4 on the ability of 
effector cells and macrophages to control the intracellular containment of M.tb within 
monocyte derived macrophages (MDMs). Approximately 70ml of peripheral blood was 
collected from patients with active pulmonary TB and presumed LTBI controls. Peripheral 
blood mononuclear cells (PBMCs) were isolated as previously described (section 2.4.2). 
Monocytes were cultured for 5 days to generate monocyte derived macrophages (section 
2.4.4). Simultaneously, PBMCs were cultured and stimulated with PPD (Statens Serum 
Institute) for 6 days to generate pre-primed effector cells. On day 5, previously grown stocks 
of H37Rv (section 2.4.5), a virulent laboratory strain of M.tb, were used to infect MDMs for 
18 hours at a multiplicity of infection (MOI) of 3:1. On day 6, non-ingested H37Rv was 
removed by washing with warm RPMI and the pre-primed effector cells were co-cultured 
with infected MDMs for 48 hours followed by lysis of the infected MDMs. Serial dilutions of 
cell lysates (containing H37Rv) were made and plated on 7H10 Middlebrook agar. Colonies 
were counted and expressed as colony forming units/ml (CFU/ml). Appropriate controls 
containing infected MDMs but no effector cells (both with and without removal of non-
ingested H37Rv by washing) were included. In order to assess the effect of IL-4 on 
mycobacterial growth, rIL-4 (expressed and tested as described in chapter 4 and 5) was 
added at several concentrations at multiple time points during the assay. Infected MDMs 
were harvested at 48 hours and 120 hours post co-culture to determine the optimal time to 
harvest T-cells. These preliminary experiments were performed on presumed LTBI controls 
and are shown in section C of the Appendix. Based on these results, M.tb containment assays 
were then performed on samples from additional LTBI controls and TB patients. 
Descriptions of experimental controls and interventions are given below. An outline of the 
assay is shown in Figure 6.1 and details on stimulant concentrations and cell numbers are 
given in Table 6.1. Detailed descriptions of each step in the assay are provided in sections 
6.2.1.1 to 6.2.5. 
 
 132 
6.2.1.1 Experimental controls 
6.2.1.1.1 MDMs infected with H37Rv 
MDMs are generated (section 6.2.2) for 5 days and infected with H37Rv at an MOI of 3:1 for 
18 hours. After 18 hours, the infected MDMs are either washed with warm RPMI to remove 
non-ingested bacteria (❷ in Figure 6.1 and Table 6.1) or not washed thus leaving the non-
ingested bacteria in the well (❶ in figure 6.1 and Table 6.1). No effector cells were added to 
these wells. The % difference in CFU/ml between these two controls gave an indication of 
H37Rv uptake by MDMs (see Figure 6.2). The washed H37Rv infected MDM control was 
used as the baseline to determine the % M.tb containment. 
 
6.2.1.1.2 PPD effectors 
MDMs were generated, infected and washed as described in section 6.2.2. Concurrently, 
autologous PBMCs were stimulated with PPD (12μg/ml) for 6 days to generate PPD 
potential effector cells. On day 6, these PPD effectors were co-cultured with the infected 
MDMs (❸ in Figure 6.1 and Table 6.1). 
 
6.2.1.2 Experimental interventions using rIL-4 
6.2.1.2.1 PPD/IL-4 effectors  
MDMs were generated, infected and washed as described in section 6.2.2. Concurrently, 
PBMCs were stimulated with PPD (12μg/ml) and IL-4 at concentration of 5, 20 and 100 
ng/ml for 6 days to generate PPD effector cells. On day 6, these PPD effectors were co-
cultured with the infected MDMs (❹ in Figure 6.1 and Table 6.1). 
 
6.2.1.2.2 Exogenous IL-4 
MDMs were generated, infected and washed as described in section 6.2.2. Concurrently, 
PBMCs were stimulated with PPD (12μg/ml) for 6 days to generate PPD effector cells. On 
day 6, these PPD effectors were co-cultured with the infected MDMs and rIL-4 was added at 




6.2.1.2.3 Neutralization of IL-4  
„PPD/IL-4 effectors‟ wells were setup as stated in section 6.2.1.2.1 (❹ in Figure 6.1 and 
Table 6.1). However, anti-IL-4 neutralizing antibody at 20μg/ml (Abcam) was added, 
together with PPD and rIL-4 (20 and 100ng/ml) to PBMCs for 6 days to generate effector 



























Figure 6.1. Overview of the mycobacterial containment assay to determine the effect of 
recombinant IL-4 (rIL-4) on M.tb containment within monocyte-derived macrophages. Culture 
conditions and stimulant concentrations of controls and interventions (labeled ❶ - ❺ in diagram) 
are further described in table 6.1 
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Table 6.1. Details of experimental setup including cell and stimulant concentrations in the 
mycobacterial containment assay (as described in Figure 6.1). 
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6.2.2 Generation of MDMs 
MDMs (~2x105) were generated in 96-well flat bottom plates as described in section 2.4.4.  
 
6.2.3 Culture and stimulation of PBMCs 
PBMCs were isolated (section 2.4.2) and 2x105 were seeded in 96-well round bottom plates 
(Nunc). Cells were stimulated with PPD (12μg/ml), PPD + rIL-4 (5, 20 and 100ng/ml) or 
PPD + rIL-4 (20, 100 ng/ml) + anti-IL-4 antibody (20μg/ml) in a final volume of 200 μl/well. 
Cells were incubated at 37oC in a 5% CO2 humidified chamber for 6 days. 
 
6.2.4 Infection of MDMs with H37Rv and co-culture of pre-primed effector cells and 
infected MDMs 
Following generation of MDMs after 5 days, non-adherent T-cells removed by gentle 
washing with warm RPMI 1640 (Lonza). Adherent MDMs were infected with H37Rv, at an 
MOI of 3:1. This MOI was chosen based on preliminary optimization experiments, but 
additionally as a low MOI has been shown to reduce bacterial clumping during infection and 
maintains MDM viability in vitro [564]. Based on this MOI, a total of 6x105 CFUs were 
added to each well and incubated at 37oC and 5% CO2 for 18 hours. Cells were then washed 
with warm RPMI to remove non-ingested H37Rv (except in the H37Rv-infected MDM 
control that was not washed; ❶ in figure 6.1 and Table 6.1). The pre-primed effector cells, 
generated by stimulation of PBMCs, were harvested and washed in RPMI. These effector 
cells were then added to the well containing H37Rv infected MDMs in a final volume of 
250μl. The co-cultured cells were incubated at 37oC and 5% CO2 humidified chamber for 48 
hours. In the „Exogenous IL-4‟ intervention (section 6.2.1.2.2 and ❺ in Figure 6.1 and 
Table 6.1), rIL-4 was added to the co-cultured cells at concentrations of 5, 20 and 100ng/ml. 
 
6.2.5 Lysis of infected cells and plating of cell lysates 
Following co-culture, cells were washed with warm RPMI and the supernatants discarded to 
remove cell debris and extracellular H37Rv (except in the H37Rv-infected MDM control that 
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was not washed; ❶ in figure 6.1 and Table 6.1). 200μl of H2O was then added to each well 
to lyse infected cells and release intracellular bacteria. These lysates were then harvested and 
four 10-fold serial dilutions were made in 0.25% Tween-80 solution (0.25 % Tween 80 
(Merck) in PBS). Six 10μl replicates of each dilution was pipetted onto each grid of a gridded 
7H10 Middlebrooks agar plate. The plates were incubated at 37°C for 10-14 days or until 
visible colonies had formed. Colonies were counted using an inverted microscope. 
 
6.2.6 Data analysis 
Colonies were counted and expressed as colony forming units per ml (CFU/ml). Controls 
were performed in duplicate and the average CFU/ml was reported. In order to normalize the 
data to account for inter-patient variability, the percentage (%) mycobacterial containment 
relative to the MDM only control was also reported. An increase in % mycobacterial 
containment represents decreased M.tb survival whereas a reduction in % mycobacterial 
containment represents an increase in M.tb survival. The % mycobacterial containment was 




Differences between experimental controls and interventions, in terms of absolute CFU/ml 
and % mycobacterial survival, were determined using the Wilcoxon matched-pairs signed 
rank test and Mann-Whitney U test. A p value of <0.05 was deemed significant. Statistical 






6.3.1 Mycobacterial uptake by monocyte derived macrophages 
As stated in section 6.2.1.1.1, after infection of MDMs with H37Rv, non-ingested bacteria 
were either removed by washing (❷ in Figure 6.1 and Table 6.1) or were not washed and 
left in the well (❶ in figure 6.1 and Table 6.1). The „unwashed‟ H37Rv infected MDM 
control represents the total amount of bacteria added to the well and the difference between 
these 2 controls represents the M.tb uptake by MDMs. When all participants (Figure 6.2A; 
n=10) were considered, the CFU/ml decreased from 268.4x103 in the „unwashed‟ control to 
76.7x103 in the washed control, representing a 34% uptake of H37Rv by macrophages.  
Viable mycobacterium decreased from 268.4x103 to 51.5x103 CFU/ml in TB patients (n=6) 
and 316.5 x 103 to 109.5x103 CFU/ml in presumed LTBI controls (n=4) in „unwashed‟ 
compared to „washed‟ MDM controls, representing a median M.tb uptake of 19% and 34% 




Figure 6.2 Median uptake of H37Rv by monocyte derived macrophages (MDMs) in (A) all study 
participants and (B) in patients with tuberculosis (n=6) and latently infected controls (n=4). In 
the „ingested and non-ingested H37Rv‟ column, MDMs were not washed after infection with H37Rv 
and thus represent the total amount of H37Rv added to each well for infection. In the “ingested 
H37Rv only” column, MDMs were washed after 18 hours of infection to remove any non-ingested 
bacteria and therefore represent only the H37Rv that was engulfed by the MDMs. 
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6.3.2 Effect of recombinant IL4 on mycobacterial containment in TB patients and 
LTBI controls 
6.3.2.1 PPD effectors  
The mycobacterial containment assay was performed in a total of 5 presumed LTBI controls 
and 8 TB patients. There was a significant decrease in median CFU/ml when the infected 
MDM‟s were co-cultured with PPD effectors in TB patients (n=8) compared to „H37Rv 
infected MDM only‟ control (30.7x103 vs. 15.7x103 CFU/ml; p=0.008) (Figure 6.3A; blue 
circles). Additionally a significant increase in mycobacterial containment (decreased M.tb 
survival) of 48% (p=0.008) was demonstrated (Figure 6.4A). A similar CFU/ml reduction 
was observed in LTBI controls (101.7x103 vs. 28.0x103 CFU/ml) which equated to a 72% 
increase in mycobacterial containment (decreased M.tb survival)  (Figure 6.3B and 6.4B) 
although this did not reach statistical significance (p=0.06). However, this lack of 
significance could be a result of the small sample size in the LTBI group (n=5). 
 
6.3.2.2 PPD/IL-4 effectors  
In the „PPD/IL-4 effectors‟ interventions, rIL-4 was added together with PPD to PBMCs to 
generate PPD/IL-4 effectors, which were co-cultured with infected MDMs (section 
6.2.1.2.1). In TB patients, compared to the „PPD effectors‟ control, there was a significant 
increase in the median CFU/ml when rIL-4 was added at 5ng/ml (29.1x103; p=0.008), at 
20ng/ml (42.5x103; p=0.008) and at 100ng/ml (43.8x103; p=0.008) (Figure 6.3A; red 
squares). Subsequently there was a significant decrease in mycobacterial containment 
(increased M.tb survival), at each concentration (1%, -73% and -33%, respectively), 
compared to the „PPD effectors‟ control (48%) (Figure 6.4A; red squares). Absolute CFU/ml 
and % mycobacterial containment were significantly higher at 100ng/ml rIL-4 compared to 
5ng/ml rIL-4 (43.8x103 vs. 29.1x103 and -32% vs. 1%; p=0.008) indicating that the observed 
effect was dependent on the concentration of rIL-4 added. A similar concentration-dependent 
increase in absolute CFU/ml and decrease in % mycobacterial containment (increased M.tb 
survival) was observed in presumed LTBI controls when rIL-4 was added (45.6x103 CFU/ml 
and 64% at 5ng/ml; 70 x 103 CFU/ml and 18% at 20ng/ml; 108.3x106 CFU/ml and -6% at 
100ng/ml) (Figure 6.3B and 6.4B; red squares). However, there were no significant 
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differences compared to the „PPD effectors‟ control in this group. Furthermore, while the % 
mycobacterial containment was generally lower in TB patients compared to LTBI controls in 
equivalent wells (for example, -32.5% in TB vs. -6% in LTBI at 100ng/ml rIL-4), these 
differences were not statistically significant (p=0.06). As stated in the previous section, the 
lack of statistical significance may be attributable to the small sample size in the LTBI group 
(n=5). 
 
6.3.2.3 Exogenous IL-4  
In the „Exogenous IL-4‟ intervention, rIL-4 was added when PPD effectors were co-cultured 
with infected MDMs (section 6.2.1.2.2). In TB patients (n=6), compared to the „PPD 
effector‟ control, there was a significant increase in median CFU/ml when rIL-4 was added at 
5ng/ml and 20ng/ml (71.7x103 and 60x103 CFU/ml respectively; p=0.03) (Figure 6.3A; 
green circles). However, when data was normalized to the MDM only control, the % 
mycobacterial containment was significant decreased at rIL-4 concentrations of 5ng/ml and 
100ng/ml (-8% and 13%, respectively; p=0.03) (Figure 6.4A; green circles). In contrast to the 
„PPD/IL-4 effectors‟ intervention, the CFU/ml and % mycobacterial containment was similar 
in all concentrations of rIL-4 suggesting that this effect was not concentration-dependent. 
Similarly, higher CFU/ml and lower % mycobacterial containment (increased M.tb survival) 
was observed in presumed LTBI controls (Figure 6.3B and 6.4B; green circles). However, 










Figure 6.3. The effect on IL-4 on mycobacterial containment in monocyte derived macrophages 
(MDMs) of pulmonary tuberculosis patients (TB; n=8) and latently infected controls (LTBI; 
n=5) expressed as absolute CFU/ml. H37Rv-infected MDMs plated by themselves (black squares) 
or were co-cultured with peripheral blood mononuclear cells pre-primed with purified protein 
derivation (PPD) alone (blue circles) or PPD and rIL-4 at concentrations of 5, 20 and 100ng/ml (red 
squares). PPD effectors were also added together with rIL-4 to infected MDMs (green circles) 
Median colony forming units (CFU/ml) are expressed for (A) TB patients and (B) LTBI controls. 
































Figure 6.4. The effect on IL-4 on mycobacterial containment in monocyte derived macrophages 
(MDMs) of (A) pulmonary tuberculosis patients (TB; n=8) and (B) latently infected controls 
(LTBI; n=5) expressed as % mycobacterial containment. H37Rv-infected MDMs plated by 
themselves (black squares) or were co-cultured with peripheral blood mononuclear cells pre-primed 
with purified protein derivation (PPD) alone (blue circles) or PPD and rIL-4 at concentrations of 5, 20 
and 100ng/ml (red squares). PPD effectors were also added together with rIL-4 to infected MDMs 
(green circles; TB, n=5). The % mycobacterial containment was expressed relative to the „H37Rv 
infected MDM only‟ control. Increased M.tb containment indicates reduction M.tb survival whereas 
decreased M.tb containment indicates an increase in M.tb survival. Statistical analysis was performed 
using the Wilcoxon matched-pairs signed rank test and p<0.05 was deemed significant. 
 
6.3.2.4 Neutralization of IL-4  
Given the more pronounced and concentration-dependent increase in CFU/ml and decrease 
in % mycobacterial containment that was observed in the „PPD/IL-4 effector‟ intervention, I 
attempted to determine the effect of neutralizing rIL-4 in this intervention in TB patients 
(n=6) by adding anti-IL-4 antibody (20μg/ml) at the same time as rIL-4 (as described in 
section 6.2.1.2.3). As already shown, addition of rIL-4 at 20ng/ml and 100ng/ml resulted in 
an increase in CFU/ml compared to the „PPD effectors‟ control (76.5x103 and 62.4x103 vs. 
34.8x103, respectively; Figure 6.5A) and a subsequent decrease in % mycobacterial 
containment (-20% and 5.5% vs.  48.5%; Figure 6.5B). Addition of anti-IL-4 antibody to the 
wells containing 20ng/ml rIL-4 significantly reduced the CFU/ml to levels similar to the 
„PPD effectors‟ control (32.4x103 CFU/ml; p=0.03). Addition of anti-IL-4 antibody also 
reduced CFU/ml in 100ng/ml rIL-4 wells but to a lesser extent (49.6x103 CFU/ml). 
Furthermore, the % mycobacterial containment increased in the anti-IL-4 antibody 
containing wells with rIL-4 at 20ng/ml (60%) and 100ng/ml (42%) to levels similar to the 
„PPD effectors‟ control (48.5%). However, the difference was only significant in the 20ng/ml 






Figure 6.5 The effect of neutralizing IL-4, using anti-IL-4 antibodies, on mycobacterial 
containment in monocyte derived macrophages (MDMs) of pulmonary tuberculosis (TB) 
patients (n=6). H37Rv-infected MDMs were co-cultured with peripheral blood mononuclear cells 
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pre-primed with purified protein derivation (PPD) alone (blue circles), PPD + rIL-4 (20 and 
100ng/ml; red squares) or PPD+ rIL-4 + anti-IL4 antibody (20μg/ml; brown circles). Median colony  
forming units (CFU)/ml are expressed in (A) and the % mycobacterial containment i.e. change in 
CFUs relative to the „H37Rv-infected MDM only‟ reference control is expressed in (B). Statistical 




There is substantial evidence that IL-4 is associated with progression to active TB but 
whether IL-4 can directly cause the observed immunopathology or is merely a by-product of 
inflammation remains unclear. In the preceding experiments, I have shown that IL-4 has the 
ability to subvert mycobacterial containment within monocyte derived macrophages. This 
effect is observed when rIL-4, together with PPD, is used to pre-prime effector T-cells 
(„PPD/IL-4 effectors‟) or when rIL-4 is added to infected macrophages in the presence of 
PPD pre-primed effector T-cells („Exogenous IL-4‟). The subversive effects in the former 
occur in an IL-4 dose-dependent manner. Furthermore, the IL-4 driven subversive effect was 
reversed with the addition of anti-IL-4 antibody in the „PPD/IL-4 effectors‟ intervention.  
 
6.4.1 PPD pre-primed effector cells enhance mycobacterial containment 
In the mycobacterial containment assay, macrophages were infected and co-cultured with 
effector T-cells, generated by pre-stimulating PBMCs with PPD. I observed a ~50% increase 
in mycobacterial containment with PPD effectors compared to no effectors (MDM only 
control) in TB patients. Similar levels of containment were observed in other in vitro co-
culture infection models of TB [293, 564]. The in vitro infection model used here primarily 
assesses the role of adaptive immunity in restricting M.tb growth. This is largely mediated by 
IFN-γ-producing CD4 Th1 cells [559], which are essential for the initial [565-567] and long 
term control [568] of bacterial growth in mice, and are equally important  in humans [569]. 
In vitro stimulation of PBMCs with PPD, which is a mixture of mycobacterial antigens, 
activates both resting and central memory CD4 T-cells [570, 571], usually toward a Th1 
phenotype with the production of pro-inflammatory cytokines. These cytokines, including 
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IFN-γ, activate macrophages and cytotoxic CD8 T-cells [572] to restrict M.tb growth. In 
similar in vitro models of infection, Silver et al. demonstrated the importance of  CD4 cells 
in restricting M.tb growth in peripheral monocytes [569] whereas Carranza et al. found that 
CD8 T-cells were more effective than CD4 cells in eliminating M.tb in alveolar macrophages 
[564]. These results highlight the important contribution of an antigen-specific Th1 response 
in TB immunity. Mycobacterial containment was somewhat higher in presumed LTBI 
controls (72%), which could indicate that their T-cell recall responses are more effective, 
compared to TB patients, in terms of their ability to control M.tb replication.  
 
6.4.2 PPD and IL-4 pre-primed effectors subvert mycobacterial containment 
The co-culture of PPD/IL-4 effectors and infected macrophages exhibited a reduction in M.tb 
containment by 50-120% compared to co-culture with PPD effectors alone, depending on the 
IL-4 concentration used. The addition of IL-4 at this point in the assay i.e. prior to pre-
priming of T-cells, may be inhibiting differentiation of naïve T-cells to become Th1 effectors 
and driving them toward a Th2 phenotype as T-cell polarization is heavily influenced by the 
cytokine microenvironment [227]. Under Th2 polarizing conditions, IL-4 downregulates 
IFN-γ expression of naïve T-cells by inhibiting STAT6 activation and subsequently 
increasing the expression of GATA-3 [573, 574]. This downregulation of IFN-γ is possibly 
occurring in our model as well as leading to a reduction in mycobactericidal activity within 
macrophages. The Th1/Th2 paradigm not only applies to CD4 T-cells but extends to CD8, 
NK and γδ T-cells [575, 576] and IL-4 may be polarizing these cells in a similar manner to 
CD4 Th cells. The IL-4-concentration dependent effect on mycobacterial containment in this 
intervention suggests that there is some level of competitive inhibition between Th1 and Th2 
activation. At increasing IL-4 concentrations, IL-4, which drives Th2 polarization, is 
outcompeting PPD, which drives Th1 polarization, to produce a predominant Th2 response. 
Furthermore, neutralization of IL-4, using anti-IL-4 antibodies, reverses this effect, most 
likely by restoring a predominantly Th1 driven phenotype among the T-cell population. 
However, IL-4 is highly pleiotropic and can have additional effects both on T-cells and 
macrophages (reviewed in [16]). A number of these mechanisms were investigated and will 
be discussed in chapter 7. 
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6.4.3 Exogenously added IL-4 to PPD pre-primed effectors subverts mycobacterial 
containment 
In the „Exogenous IL-4‟ intervention, where IL-4 is added to the co-cultured PPD effectors 
and infected macrophages, mycobacterial containment was reduced by 35-56% compared to 
the „PPD effectors‟ control. This was less than the „PPD/IL4 effectors‟ intervention. In 
contrast to the „PPD/IL4 effectors‟, where addition of IL4 had a direct effect on development 
of a Th1 effector response, IL-4 added at this stage in the assay is likely to have a lesser 
impact on effector cells given that these cells would have fully differentiated in response to 
PPD to become predominantly Th1 effectors. Murine data suggests that, after 96 hours of 
stimulation under Th1 polarizing conditions, cells are fully committed to the Th1 lineage 
and, even if subjected to Th2 polarizing conditions, are unable revert to a Th2 phenotype 
[574]. Indeed, PBMCs are stimulated with PPD alone for 6 days (no IL-4 is added) in this 
assay suggesting that these are fully differentiated cells of a predominantly Th1 phenotype. 
However, these Th1 cells may still retain responsiveness to IL-4 [574] and are able to 
modulate IFN-γ expression, but to a lesser extent than in the „PPD/IL4 effector‟ intervention. 
This may explain the smaller decrease in mycobacterial containment in the „Exogenous IL-4‟ 
compared to „PPD/IL-4 effectors‟ intervention.  Furthermore, rIL-4 may also directly affect 
macrophages in this model. IL-4 drives alternate activation of macrophages, which have anti-
inflammatory functions and downregulate protective mycobactericidal mechanisms such as 
iNOS production [39, 40], TLR expression [434], autophagy [44] and apoptosis [41, 436]. 
The degree to which this occurs will be dependent on the plasticity of macrophages and to 
what extent they can switch between the classical and alternative phenotype. This has been 
shown in an in vitro model of C. neoformans infection [577] but may also occur in 
progressive TB in vivo [40]. 
 
6.4.4 Biological significance of IL-4 mediated subversion of mycobacterial 
containment 
In our infection model, particularly in the „PPD/IL-4 effectors‟ intervention, addition of IL-4 
artificially skews the Th1/Th2 balance to favour a Th2 response. This is most probably due to 
a dampening of mycobactericidal activities by both lymphocytes and macrophages leading to 
the observed reduction in mycobacterial containment. Whether this is occurring in vivo as 
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well will be dependent on the Th1/Th2 balance within the cellular environment, which is 
influenced by the pathogen, environmental factors and the genetic background of the host 
[227]. Evidence suggests that a pre-existing mixed Th1/Th2 response, induced by 
environmental mycobacteria, is present in individuals from developing countries [16]. 
Furthermore, M.tb infection is known to downregulate protective Th1 mechanisms [8]. 
Certain bacterial components, such as ManLAM, of virulent M.tb strains can also stimulate 
IL-4 production [427]. These factors may all be contributing to a disrupting Th2 response.  
This is further supported by the data presented in chapter 3 and previously published studies 
[9, 416-418, 503, 504] which show high IL-4 levels and a low Th1:Th2 ratio in TB patients 
compared to healthy controls. Impaired Th1 immunity is most apparent in the early stages of 
infection where an inadequate Th1 response fails to contain M.tb within the granuloma and 
leads to active disease. 
 
6.4.5 Limitations 
This in vitro model of mycobacterial infection assessed the capacity of lymphocytes and their 
soluble mediators to modulate the growth of M.tb within monocyte derived macrophages. 
However, the model is a „closed system‟ and lacks the milieu of cytokines, recruitment and 
involvement of other cell types and granuloma formation that occurs at the site of disease. 
Nonetheless, the aim of these experiments was to specifically assess the effect of IL-4 on the 
immune activities of lymphocytes and macrophages, as these cells are the most important in 
the immune response to TB and the pleiotropic effects of IL-4 are most evident on these 
cells. 
 
It is unknown if mycobacterial containment is a result of direct killing of M.tb or an 
inhibition of its replicative state. Counting of CFUs was performed at ~14 days after plating 
for optimal assessment of colony numbers, as extensive overgrowth occurred after this 
period. Further growth may have occurred after this period if organisms were in a non-
replicating state. However, previous optimization experiments in our lab did not find any 




The biological relevance of the observed decrease in mycobacterial containment after co-
culture for 48 hours is unclear. Similar studies have used different time periods ranging from 
18 hours to 7 days [293, 564, 569].  However, given the 24 hour doubling time of M.tb, a 48-
hour period allows for sufficient intracellular replication of M.tb to observe an effect on CFU 
counts while still maintaining MDM survival. Trypan blue exclusion staining of infected 
MDMs at this time point confirmed the viability of these cells. Furthermore, in my own 
optimization experiments, a 120-hour co-culture time period resulted in a significant drop in 
CFU counts, compared to 48 hours, which is most likely due to lysis of infected 
macrophages. As such, the choice of experimental conditions is justified.   
 
The concentrations of IL-4 used in these assays may not be biologically relevant given that 
IL-4 is active at picomolar levels in vivo. The rIL-4 concentrations used here were derived 
from the concentrations used in the rIL-4 T-cell proliferation assay that produced a 
significant effect (chapter 5). Recombinant proteins can act differently to their naturally 
produced counterparts and is heavily dependent on the expression system used. For instance, 
certain proteins expressed in insect cells undergo inappropriate N-glycosylation resulting 
attachment of much simpler N-glycan sugars compared to mammalian expressed 
counterparts leading to reduced protein bioactivity [578] (discussed in chapter 4). Indeed, 
proteins expressed in a mammalian system do show improved stability compared to insect 
cell counterparts [506, 507]. Also, protein quantification methods, including Bradford and 
ELISA, fail to assess proper protein function and a portion of the measured IL-4 may be non-
functional. Furthermore, the in vivo environment has mechanisms that increase bioactivity 
and maintain the effect of certain proteins. For example, human erythropoietin is 1000-fold 
more active in vivo compared to when it is used in in vitro experiments [554]. Similar 
mechanisms may also prolong the effect of IL-4. IL-4 has a very short half-life (<20 minutes) 
but soluble IL-4 receptors are able to sequester free IL-4 and prolong its activity. No IL-4 
bioactivity could be determined in supernatants of T-cells activated in the presence of IL-4 
for 6 days but bioactivity was markedly increased the presence of sIL-4R [362]. These 
findings justified the IL-4 concentrations used in my assays. Indeed, other in vitro 
stimulation experiments used similar IL-4 concentrations [47, 48, 392, 579], likely for the 




Considerable variation was observed in mycobacterial uptake by MDMs of TB patients and 
presumed LTBI controls. This variation may be explained by inter-participant biological 
variability, inherent variability in mycobacteria stocks or a result of the small sample size 
which, due to experimental and time constraints, was unavoidable.  
 
Monocyte derived macrophages may have different phagocytic capacities and anti-
mycobacterial properties compared to their tissue specific counterparts [580, 581]. It may 
have been more appropriate to use alveolar macrophages in the assay to better reproduce 
M.tb infection at the site of disease.  However, blood, compared to BAL, is much more easily 
acquired and high PBMC numbers usually obtained. Furthermore, BAL can be prone to 
contamination with resident respiratory tract flora. Additionally, in a similar assay used to 
assess the effect of Tregs on M.tb containment, similar outcomes were obtained either using 
MDMs or alveolar macrophages [293].  
 
The use of PPD to pre-activate PBMCs tends to favour CD4 activation over other T-cells, 
including CD8, γδ and NK T-cells. Perhaps the use of live bacteria or whole cell sonicates 
may better mimic the T-cell activation responses in vivo, as these antigen induce stronger 
activation of  CD8, γδ and NK T-cells compared to soluble antigens such as PPD [570, 582].   
 
Unfortunately, due to limited protein yields, the effect of IL4δ2 could not be assessed in this 
model. Given the limited data on its precise role in TB, it would have been interesting to 
perform these assays using both IL-4 and IL4δ2. However, IL4δ2 expression will be 
attempted in more appropriate systems to increase protein yield and we will attempt to 
determine the effect of IL4δ2 on mycobacterial containment as part of future work. 
 
6.5 Conclusion 
The ability of IL-4 to subvert mycobacterial containment within monocyte derived 
macrophages suggests that a subversive Th2 response can undermine protective immunity, 
likely by a downregulation of the Th1 response. However, it is unknown what other TB-
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associated immune mechanisms, which can impact mycobacterial survival, may be affected 
by IL-4. In the next chapter, specific mechanisms of IL-4 mediated mycobacterial subversion 










The observation of  high IL-4 levels in active TB has been documented [9, 15, 30, 288, 417, 
418] and my results in chapter 3 support these findings. Furthermore, I have shown that, in 
an in vitro macrophage infection model, IL-4 is associated with a subversion of 
mycobacterial containment (chapter 6). However, the mechanisms involved in this 
subversion have not been fully elucidated. One possible mechanism is the IL-4-mediated 
downregulation of Th1 effector cells. In a murine model, this occurs through STAT-6 or 
STAT-6-induced regulation of T-bet and IFN-γ expression [574]. The anti-mycobacterial 
effects of IFN-γ on both T-cells and macrophages have been well described and include the 
induction of ROI and RNI species [235, 479], CD8 cytotoxicity [218], autophagy [158, 583] 
and apoptosis of infected cells [236].  
 
IL-4 can also directly affect the ability of macrophages to kill M.tb. Harris et al showed that 
IL-4 inhibits starvation-induced autophagic control of M.tb in infected macrophages via Akt 
upregulation [44]. IL-4 polarizes macrophages to become alternatively activated and express 
high levels of pattern recognition receptor (PRRs), such as mannose receptor and DC-SIGN, 
which facilitate uptake of M.tb into these cells [432]. Alternatively activated macrophages 
can also downregulate M.tb killing mechanisms [39]. 
 
Regulatory T-cells (Tregs) have been implicated to be detrimental in M.tb infection as a high 
frequency of Tregs has been observed in TB patients compared to healthy controls [287, 288, 
291-294] and Tregs have been shown to be associated with attenuated mycobacterial stasis 
[293]. However, the role of IL-4 in Treg development and maintenance is less clear, with 
studies, mostly performed in mice, suggesting that IL-4 can either stimulate [301, 303, 443, 




Thus, IL-4 has the potential to modulate multiple immune mechanisms involved in 
controlling M.tb infection. The aim of this chapter was to explore specific immune 
mechanisms (Treg and Th1 downregulation) that may be involved in the IL-4-associated 
subversion of mycobacterial containment observed in chapter 6. These data would provide a 




7.2.1 Mycobacterial containment assay overview 
A mycobacterial containment assay was performed, similar to that described in chapter 6, to 
determine the possible mechanisms involved in the observed IL-4 associated subversion of 
mycobacterial containment (Chapter 6).  In contradistinction to chapter 6 however, cells were 
analyzed by flow cytometry to determine the expression levels of lymphocyte- and 
macrophage-specific surface and intracellular biomarkers, rather than lysing them to culture 
and grow intracellular H37Rv. Briefly, ~50ml of whole blood was obtained from TB patients. 
MDM generation and infection, PBMC stimulation and cell co-culture for 48 hours were 
performed as summarized in section 6.2.1.  Infected MDMs and lymphocytes were then 
harvested, stained with fluorescently-labelled antibodies against specific cell surface and 
cytokine markers (outlined in table 7.2) and analyzed by flow cytometry. Appropriate 
controls were included in the assay, as outlined below. Based on the results in chapter 6, and 
due to cost and sample volume limitations, only the effect of IL-4 on biomarker expression in 
the „PPD/IL-4 effectors‟ intervention, was assessed as described in section 6.2.1.2.1 and 
below. Descriptions of experimental controls and interventions are given below. An outline 
of the assay is shown in Figure 7.1 and details on stimulants and cell numbers are given in 




7.2.1.1 Experimental controls 
7.2.1.1.1 Uninfected MDMs and MDMs infected with H37Rv 
The H37Rv infected MDM control was performed as described in section 6.2.1.1.1 (❷ in 
Figure 7.1 and Table 7.1).  A control well containing uninfected MDMs was also included. 
(❶ in figure 7.1 and Table 7.1). No effector cells were added to these wells.  
 
7.2.1.1.2 PPD effectors 
PBMCs were stimulated with PPD for 6 days to generate PPD effectors, and subsequently 
co-cultured with infected MDMs as described in section 6.2.1.1.2 (❸ in Figure 7.1 and 
Table 7.1). 
 
7.2.1.2 Experimental interventions using rIL-4 
7.2.1.2.1 PPD/IL-4 effectors  
PBMCs were stimulated with PPD and rIL-4 at concentrations of 20 and 100ng/ml for 6 days 
to generate „PPD/IL-4 effectors‟. These „PPD/IL-4 effectors‟ were then co-cultured with 
infected MDMs, as described in section 6.2.1.2.1. (❹ in Figure 7.1 and Table 7.1) 
 
7.2.1.2.2 Neutralization of IL-4 with anti-IL4 or anti-IL-4R antibody 
„PPD/IL-4 effectors‟ wells were setup as stated in section 7.2.1.2.1(❹ in Figure 7.1 and 
Table 7.1). However, anti-IL-4 neutralizing antibody (20ug/ml; Abcam) or anti-IL-4 receptor 
neutralizing antibody (20μg/ml; Abcam) was added, together with PPD and rIL-4 (100ng/ml) 
to PBMCs for 6 days to generate effector cells. On day 6, these effectors were co-cultured 






Figure 7.1. Overview of mycobacterial containment assay to determine the mechanisms 
involved in the IL-4-associated subversion mycobacterial containment within monocyte-derived 
macrophages in TB patients. Culture conditions and stimulant concentrations of controls and 








Table 7.1. Details of experimental setup including cell and stimulant concentrations in the 
mycobacterial containment assay to determine mechanisms involved in the IL-4 associated 
subversion of mycobacterial containment in TB patients (as described in Figure 7.1). 
 
No.* Condition 




































































*corresponds to the controls/interventions shown in figure 7.1 
 
7.2.2 Generation of MDMs 
MDMs were generated as described in section 2.4.4. A total of 6x105 MDMs were assumed 
to be plated in 24-well flat bottom plates as previous optimization experiments showed that 




7.2.3 Culture and stimulation of PBMCs 
PBMCs were isolated (section 2.4.2) and 2x105 were cultured in triplicate in 96-well round 
bottom plates (Nunc). Cells were stimulated and incubated as described in section 6.2.3. 
 
7.2.4 Infection of MDMs with H37Rv and co-culture of pre-primed effector cells and 
infected MDMs 
MDMs were infected and co-cultured with pre-primed effector cells as described in section 
6.2.4.  An MOI of 3 equated to a total of 1.8x106 CFUs being added to each well for 
infection. Triplicate wells of effector cells were harvested and pooled. These cells (6x105) 
were then added to the well containing H37Rv infected MDMs in a final volume of 1ml and 
incubated for 48 hours. 
 
7.2.5 Cell harvesting, immunofluorescence staining and flow cytometry 
All staining procedures were performed in a Biosafety level 3 laboratory. Golgi-stop, 
containing monensin (0.6μl/ml), was added to each well at least 5 hours before harvesting of 
cells in order to block the release of cytokines and proteins from the Golgi complex within 
the cell cytoplasm. Non-adherent cells were harvested and transferred to a 5ml FACS tube. 
Adherent cells were treated with 100ul of cold 0.5% EDTA (50ul EDTA (Sigma Aldrich) in 
9.95ml of 1xPBS) for 30 minutes at room temperature followed by gentle scraping to lift 
MDMs from the plate. The wells were observed under an inverted microscope to establish 
whether all the cells had been removed. These cells were added to the same 5ml FACS tube. 
Cells were then stained for specific surface and extracellular markers using fluorescently-
labelled antibodies (Table 7.2), as outlined in section 2.4.6. Cells were left in 4% para-
formaldehyde overnight to kill any remaining H37Rv not removed during the staining 







Table 7.2. Fluorescently-labelled antibodies used to determine the mechanisms associated with 







CD3  Alexa fluor 700 Lymphocyte marker 
1 & 2 
CD4  APC H7 Th cell marker 





DC-SIGN PerCP Marker for alternative 
activation of macrophages 
IFNγ PE  
Th1 cytokines 
TNFα  APC 
LC3B Alexa fluor 488 Autophagy marker 
CD25  PE Lymphocyte activation/Treg 
marker 
2 FOXP3  Alexa fluor 647 Treg transcription factor 
IL-10  Alexa fluor 488 Regulatory cytokine 
IFNγ PECy7 Th1 cytokine 
 
7.2.6 Data analysis 
The frequency of specific cell populations expressing biomarkers was determined using 
FACSDiva software (BD). Cells expressing the target biomarker were reported as a % of the 
total lymphocyte (CD3+CD4+ and CD3+CD8+) and macrophage (CD14+CD16+) 
populations. Differences in expression levels between experimental controls and 
interventions were determined using the Wilcoxon matched-pairs signed rank test and Mann-
Whitney U test. A p-value of <0.05 was deemed significant. Statistical analyses were 




7.3.1 Gating strategy for identification of lymphocytes and macrophages 
The gating strategies for identification of biomarker expressing cells in the lymphocyte and 
macrophage populations are shown in figure 7.2. Lymphocytes and macrophages were 
acquired based on cell size (FSC) and cell granularity (SSC). Cells were gated on the 
CD14+/CD16+ populations for macrophages and CD3+ population for lymphocytes. CD4+ 
and CD8+ populations were identified within the CD3+lymphocyte populations. Cells 
expressing the target biomarkers were then identified in the gated macrophage (CD14+/16+), 
CD4+ and CD8+ lymphocyte (CD3+) populations. All subpopulation percentages displayed 




Figure 7.2 Gating strategies for identification of lymphocytes and macrophages expressing 
biomarkers 
 
7.3.2 The effect of IL-4 on regulatory T-cell expression  
The gating strategy for identification of Tregs (CD4+CD25+FoxP3+) in the lymphocyte 
population is shown in figure 7.3A. Lymphocytes were acquired based on cell size (FSC) and 
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cell granularity (SSC). Cells were gated on CD3+CD4+ T-cells and then within that gate on 
CD4+CD25+ cells. FoxP3 + cells (Tregs) were identified within this population (figure 7.3).  
All subpopulation percentages displayed in the graphs were plotted relative to the total CD3+ 
cell count (lymphocytes). 
 
There was a significant increase in median % Treg (CD4+CD25+FoxP3+) expression in 
„PPD/IL-4 effectors‟ (100ng/ml) compared to the „PPD effectors‟ control (p=0.0006) (Figure 
7.3B). The expression of IL-10 by Tregs was also assessed. In the majority of patients, Tregs 
produced very little IL-10 either in the „PPD effectors‟ (median 3.3%) or the „PPD/IL-4 
effectors‟ at 20ng/ml rIL4 (median 4.6%) and 100ng/ml (median 1.1%) (Table 7.3). There 







Figure 7.3. (A) The gating strategy for identification of regulatory T-cells (Tregs; 
CD4+CD25+FoxP3+) cells within the lymphocyte population and (B) the frequency (%) of 
CD4+CD25+Foxp3+ Tregs in the co-cultured lymphocyte population of the mycobacterial 
containment assay as measured by flow cytometry in pulmonary TB patients (n=16). H37Rv-
infected MDMs were co-cultured with peripheral blood mononuclear cells pre-primed with purified 
protein derivation (PPD) alone (blue circles) or PPD and rIL-4 at concentrations of 20ng/ml (n=10) 
and 100ng/ml (n=16) (red squares). Statistical analysis was performed using the Wilcoxon matched-
pairs signed rank test and p<0.05 was deemed significant.  
 
 
Table 7.3 Median frequency of Regulatory T-cell (Tregs) expressing IL-10 in control (PPD 
effectors) and intervention (PPD/IL-4 effectors at 20 and 100ng/ml rIL-4) wells of the 
mycobacterial containment assay. Values are expressed as the median % of CD4+CD35+FoxP3+ 













% Tregs that express    
IL-10 










7.3.3 The effect of IL-4 on IFN-γ expression 
There was significantly lower median CD4+IFN-γ expression in the „PPD/IL-4 effectors‟ 
well at 20 and 100ng/ml rIL-4 compared to the „PPD effectors‟ well (p=0.01 and p=0.0005, 
respectively). IFN-γ expression was significantly higher in the CD8+ lymphocyte population 
compared to the CD4+ population in the equivalent wells (PPD effectors, p=0.04; PPD/IL-4 
effectors at 20ng/ml rIL-4, p=0.015; PPD/IL-4 effectors at 100ng/ml rIL-4, p=0.001). 
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However, there were no significant differences in CD8+IFN-γ expression between „PPD 
effectors‟ and „PPD/IL-4 effectors‟ (Figure 7.4A). 
 
IFN-γ expression in the macrophage (CD14+CD16+) population was generally higher than in 
the lymphocyte (CD3+) population. Furthermore, IFN-γ expression was higher in uninfected 
MDMs compared to infected macrophages alone (p=0.04) and „PPD effectors‟ (containing 
infected MDMs and PPD effector cells; p=0.02). However, there were no significant 
differences in IFN-γ expression within the macrophage population between „PPD effectors‟ 







Figure 7.4. Frequency (%) of IFN-γ expressing cells in the co-cultured (A) CD4 and CD8 
lymphocyte and (B) Macrophage (CD14/CD16) populations of the mycobacterial containment 
assay as measured by flow cytometry in TB patients. H37Rv-infected MDMs were co-cultured 
with peripheral blood mononuclear cells pre-primed with purified protein derivation (PPD) alone 
(blue circles) or PPD and rIL-4 at concentrations of 20ng/ml (n=8) and 100ng/ml (n=16) (red 
squares). Uninfected and H37Rv-infected macrophages alone (n=12) were also cultured. Flow 
cytometry dot plots of the IFN-γ+ cells in the CD4+ (top), CD8+ (middle) and CD14+/16+ (bottom) 




7.3.4 The effect of IL-4 on TNFα expression 
There was significantly lower median CD4+TNFα+ expression in the „PPD/IL-4 effectors‟ 
well at 100ng/ml rIL-4 compared to the „PPD effectors‟ well (p=0.02). TNFα expression was 
similar in the CD4+ and CD8+ lymphocyte population. There were no significant differences 
in CD8+TNFα+ expression between „PPD effectors‟ and „PPD/IL-4 effectors‟ (p=0.8; Figure 
7.5A). 
 
TNFα expression in the macrophage (CD14+CD16+) population was similar to that in the 
lymphocyte (CD3+) population. There were no significant differences in TNFα expression 










Figure 7.5. Frequency (%) of TNFα expressing cells in the co-cultured (A) CD4 and CD8 
lymphocyte and (B) H37Rv infected macrophage (CD14/CD16) populations of the 
mycobacterial containment assay as measured by flow cytometry in TB patients. H37Rv-infected 
MDMs were co-cultured with peripheral blood mononuclear cells pre-primed with purified protein 
derivation (PPD) alone (blue circles) or PPD and rIL-4 at concentrations of 20ng/ml (n=8) and 
100ng/ml (n=16) (red squares). Uninfected and H37Rv-infected macrophages alone (n=12) were also 
cultured. Flow cytometry dot plot graphs of TNFα+ cells in the CD4+ (top), CD8+ (middle) and 
CD14+16+ (bottom) populations are shown to the right of the corresponding graphs.  
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7.3.5 The effect of IL-4 on DC-SIGN expression 
Expression of CD4+DC-SIGN+ was generally very low and there were no significant 
differences between „PPD/IL-4 effectors‟ and „PPD effectors‟. DC-SIGN expression was up 
to 27 times higher in CD8+ compared to CD4+ lymphocytes in equivalent wells (PPD 
effectors, p=0.0006; PPD/IL-4 effectors at 20ng/ml rIL-4, p=0.015; PPD/IL-4 effectors at 
100ng/ml rIL-4, p=0.0005). However, there were no significant differences in CD8+DC-
SIGN+ expression between „PPD effectors‟ and „PPD/IL-4 effectors‟ (Figure 7.6A). 
 
In macrophages (CD14+16+), DC-SIGN expression was significantly higher in „PPD/IL-4 
effectors‟ at 100ng/ml rIL-4 compared to PPD effectors (p=0.02). DC-SIGN expression was 
also higher in uninfected MDMs compared to „PPD effectors‟ (containing infected 















Figure 7.6. Frequency (%) of DC-SIGN expressing cells in the co-cultured (A) CD4 and CD8 
lymphocyte and (B) H37Rv infected macrophage (CD14/CD16) populations of the 
mycobacterial containment assay as measured by flow cytometry in TB patients (n=16). H37Rv-
infected MDMs were co-cultured with peripheral blood mononuclear cells pre-primed with purified 
protein derivation (PPD) alone (blue circles) or PPD and rIL-4 at concentrations of 20ng/ml (n=8) 
and 100ng/ml (n=16) (red squares). Uninfected and H37Rv-infected macrophages alone (n=12) were 
also cultured. . Flow cytometry dot plots of the DC-SIGN+ cells in the CD4+ (top), CD8+ (middle) 
and CD14+/16+ (bottom) populations are shown to the right of the corresponding graphs.  
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7.3.6 The effect of IL-4 on LC3B expression (Autophagy) 
The autophagy marker, LC3B was significantly higher in the CD8+ lymphocyte population 
compared to the CD4+ population in the equivalent wells (PPD effectors, p=0.01; PPD/IL-4 
effectors at 20ng/ml rIL-4, p=0.008; PPD/IL-4 effectors at 100ng/ml rIL-4, p=0.009). There 
were no significant differences in CD4+LC3B+ or CD8+LC3B+ expression between „PPD 
effectors‟ and „PPD/IL-4 effectors‟ (Figure 7.7A). 
 
LC3B expression in the macrophage (CD14+CD16+) population was generally higher than 
in the lymphocyte (CD3+) population. However, there were no significant differences in 
LC3B expression within the macrophage population between „PPD effectors‟ and „PPD/IL-4 











Figure 7.7. Frequency (%) of LC3B expressing cells in the co-cultured (A) CD4 and CD8 
lymphocyte and (B) H37Rv infected macrophage (CD14/CD16) populations of the 
mycobacterial containment assay as measured by flow cytometry in TB patients (n=16). H37Rv-
infected MDMs were co-cultured with peripheral blood mononuclear cells pre-primed with purified 
protein derivation (PPD) alone (blue circles) or PPD and rIL-4 at concentrations of 20ng/ml (n=8) 
and 100ng/ml (n=16) (red squares). Uninfected and H37Rv-infected macrophages alone (n=12) were 
also cultured. . Flow cytometry dot plots of the LC3B+ cells in the CD4+ (top), CD8+ (middle) and 
CD14+/16+ (bottom) populations are shown to the right of the corresponding graphs.  
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7.3.7 Neutralization of IL-4 and its effect on biomarker expression  
In a subset of TB patients (n=6), the effect of blocking IL-4 was assessed by the addition of 
neutralizing anti-IL-4 antibody in the „PPD/IL-4 effectors‟.  As expected, there was a 
significant increase in Treg expression (p=0.03) and decrease in IFN-γ expression (p=0.03) 
in „PPD/IL-4 effectors‟ at 100ng/ml rIL-4 compared to „PPD effectors‟. When anti-IL-4 
antibody (20μg/ml) was added, there was a significant decrease in Treg expression (p=0.03; 
Figure 7.8A) and increase in IFN-γ expression (p=0.03; Figure 7.8B), compared to „PPD/IL4 
effectors‟, to levels similar to the „PPD effectors‟ control. Addition of anti-IL-4R antibody 
(20μg/ml) produced similar results but there were no significant differences compared to the 
„PPD/IL-4 effector‟, most likely due to the low samples numbers in this intervention. There 
were no significant differences in the expression of TNFα, DC-SIGN or LC3B in the 










Figure 7.8. The effect of adding anti-IL-4 antibody on the frequency (%) of (A) regulatory T-
cells (CD25+FoxP3+) and (B) IFN-γ expressing cells in the co-cultured CD4 lymphocyte 
population used in the mycobacterial containment assay as measured by flow cytometry in TB 
patients (n=6). H37Rv-infected MDMs were co-cultured with peripheral blood mononuclear cells 
pre-primed with purified protein derivation (PPD) alone (blue circles); PPD and rIL-4 at a 
concentration of 100ng/ml (red squares); PPD, rIL-4 and anti-IL4 antibody at a concentration of 




Table 7.4. Median frequency (%) of biomarker expressing lymphocytes (CD4, CD8) 
and macrophages (CD14/CD16+) in co-cultured cell populations of the mycobacterial 
killing assay with and without anti-IL-4 antibody as measured by flow cytometry. 
Peripheral blood mononuclear cells were obtained from pulmonary TB patients (n=6). 
H37Rv-infected MDMs were co-cultured with peripheral blood mononuclear cells pre-
primed with purified protein derivation (PPD) alone or PPD and rIL-4 (100ng/ml) or PPD, 
rIL-4 (100ng/ml) and anti-IL4 antibody (20μg/ml). Statistical analysis was performed using 





In chapter 6, I showed that pre-priming effector T-cells with PPD, in the presence of IL-4, 
results in a subversion of mycobacterial containment within infected monocyte derived 
macrophages. In the preceding experiments, the possible mechanisms that may drive this IL-
4-mediated subversive effect on mycobacterial containment were investigated by flow 
cytometry. The addition of IL-4 resulted in a significant increase in Treg 
(CD4+CD25+FoxP3+) expression in the „PPD/IL-4 effectors‟ wells compared to „PPD 
effectors‟. Concurrently, there was a significant decrease in CD4+ T-cell expression of IFN-γ 
and TNFα and DC-SIGN expression on macrophages (CD14+CD16+). The addition of anti-
IL-4 antibody reversed the expression patterns of CD4+IFN-γ and Tregs to levels similar to 
the „PPD effectors‟ control. Expression of the autophagy marker, LC3B, was not affected by 
the addition of IL-4, either in the macrophage or lymphocyte populations. Thus, IL-4-
mediated subversion of M.tb containment is characterised by increased Treg expression, 
decreased CD4+ lymphocyte expression of Th1 cytokines (IFN-γ and TNFα) and increased 
DC-SIGN expression in macrophages. 
 
7.4.1 IL-4 increase Treg expression 
The pre-priming of PBMCs with PPD, in the presence of IL-4, resulted in a significant 
increase in the number of CD4+CD25+FoxP3+ regulatory T-cells (Tregs). IL-4 has been 
implicated in the development and maintenance of Tregs but the data are conflicting. Some 
studies have shown that IL-4 induces CD4+CD25- cells to become Tregs in both mice [301, 
302, 443] and humans [303] whereas others have shown IL-4 inhibits Treg proliferation 
through the blocking of TGF-β [445]. Furthermore, IL-4 can either maintain Tregs [301, 444, 
584] or suppress their function [302]. The data presented supports a proliferative role for IL-
4 in Treg development and the observed differences, compared to other studies, are likely 
due to the in vitro model used (human vs murine), the timing of exposure to IL-4 and the 
type of antigen stimulation. 
 
Tregs play a major role in the control of autoimmunity and immunopathological responses by 
downregulating inflammatory Th responses [267]. Traditionally, two major types of CD4+ 
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Tregs have been described. Natural Tregs (nTregs), produced in the thymus, are anergic and 
are secreted into the periphery where they exert their suppressive effect. Inducible Tregs 
(iTregs), on the other hand, expand in response to antigenic stimulation and secrete 
immunomodulatory cytokines such as TGF-β and IL-10 [585]. Recent evidence suggests that 
nTregs can also expand in response to antigenic stimulation [586, 587]. Furthermore, a subset 
of nTregs, in response to IL-4 and antigen stimulation, undergoes clonal expansion to 
become antigen specific nTregs, termed Ts2. These are distinct from conventional nTregs, 
not only in their ability to respond to antigen but also in the expression of IL5Rα. These cells 
are able to suppress Th1, Th17 and macrophages [588, 589]. The presented data suggests that 
PPD stimulation, in the presence of IL-4, drives development of FoxP3+ nTregs as they 
produce very little IL-10 (Table 7.2).  
 
The role of Tregs in TB has been extensively described. A number of studies have found that 
Tregs are high in TB patients [291-294, 590-593], tend to accumulate at the site of disease 
[291-294, 298] and decrease following anti-TB treatment [591, 593]. A Th1 response is the 
likely target of suppression by these Tregs, as Treg levels either correlate with reduced IFN-γ 
expression or functionally downregulate IFN-γ in these cells [287, 292-294, 592]. This is a 
likely scenario in my model as IFN-γ was also downregulated with the addition of IL-4. 
Additionally, Anti-TNF therapy is associated with increased Treg function and subsequent 
susceptibility to TB [296-298]. Two studies have directly demonstrated that Tregs favour 
mycobacterial survival by downregulation of anti-mycobacterial responses [293, 298]. In 
contrast, a murine model found that TB pathogen load was unaffected by Treg mediated 
depression of antigen specific cytokine responses [594]. However, none have previously 
shown a direct involvement of IL-4. 
 
In my model, the addition of IL-4 results in increased Treg and decreased IFN-γ expression 
whereas neutralization of IL-4 simultaneously reverses these effects. Furthermore, blocking 
of the IL-4 receptor produces similar results to blocking of IL-4 protein suggesting that these 
effects are facilitated through signalling via the IL-4 receptor.  IL-4-driven Treg effects have 
been shown to be mediated via the IL-4Rα in mice [443].  Taken together, these data suggest 
IL-4 may be promoting the expansion of nTregs which suppress the protective Th1 response 
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and result in a subversion of mycobacterial containment (chapter 6). However, the 
mechanism by which Tregs suppress the Th1 response, whether by a direct cell-to-cell 
contact mechanism [278] or through the production of regulatory cytokines [595, 596], is 
unknown. My data suggests the former, given that these Tregs produce very little IL-10. 
Nonetheless, further investigation is required to elucidate these mechanisms. 
 
7.4.2 IL-4 downregulates the Th1 response  
The addition of rIL-4 resulted in decreased expression of IFN-γ and TNFα in the CD4 T 
lymphocyte population but not in the CD8 or macrophage populations suggesting that the 
most significant effect of IL-4 in this model was a downregulation of the CD4 Th1 response. 
In a similar in vitro infection model, IFN-γ was produced primarily by CD4 T-cells but was 
less effective at restricting M.tb growth compared to CD8 T-cells, which mainly produced 
TNFα [564]. While IFN-γ production by other T-cells (including CD8, NK and γδ T-cells), is 
important, production of IFN-γ by these cells, cannot compensate for a deficiency in CD4+ 
T-cells [568, 597]. The vital role of IFN-γ in M.tb control has been discussed earlier, and 
includes activation of mycobactericidal activity in macrophages [228] and cytotoxic 
mechanisms in CD8 cells, through production of granzyme and perforin and Fas-FasL 
mediated apoptosis [217, 598], as well as further recruitment of T-cells [559]. 
 
TNFα is also an essential mediator in TB immunity as it recruits monocytes to the site of 
infection [124], is a strong inducer of apoptosis [140, 144, 145] in infected macrophages and 
is essential in granuloma formation as demonstrated in both murine and human TB [599, 
600]. Indeed, anti-TNFα therapy can result in increased susceptibility to TB [249]. Previous 
studies have shown that TNFα is primarily produced by phagocytic cells, particularly at the 
site of disease [250], but also by T-lymphocytes [601]. In a murine model, a deficiency in 
myeloid derived TNFα caused early susceptibility to disease but was then controlled by 
recruitment of TNFα producing T-cells, which sustained protection during the later stages of 
infection [602]. In the model presented here, IL-4 reduced TNFα expression in CD4+ T-cells 
suggesting that IL-4 may undermine the effects of TNFα during the early stages of infection. 
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Given the importance of these cytokines, it is not surprising that the reduced Th1 response is 
consistent with the decrease in mycobacterial containment observed in chapter 6.  
 
The downregulation of Th1 cytokines, in response to IL-4, may be occurring either by the 
increase in Treg activity (discussed in 7.4.1) and/or the skewing of the Th1/Th2 balance. T-
cell priming with PPD alone primarily induces a Th1 response, most likely through MHC 
processing and activation of the IL-12/STAT4 signalling pathway [603]. However, the effect 
of adding IL-4, together with PPD, to un-primed T-cells before commitment to a specific T-
cell lineage, may drive these cells toward a Th2 phenotype [574]. As a result, there is a 
concomitant reduction in the number of Th1 effectors and subsequently, reduced IFN-γ and 
TNFα expression. This result is most notable at higher rIL-4 concentrations suggesting that 
there is a competitive effect between Th1 and Th2 activation. Th2 activation, driven by IL-4, 
is perhaps outcompeting Th1 activation, via PPD stimulation, to produce a predominant Th2 
response. Given that blocking of the IL-4 receptor, using anti-IL4R antibody, restored IFN-γ 
levels in a similar manner to blocking of IL-4, it is likely that Th2 polarization is occurring 
via an IL-4R signalling pathway.  
 
There were no significant differences in IFN-γ or TNFα production in macrophages, with or 
without the addition of IL-4, suggesting that polarized Th2 effector cells did not affect the 
production of these cytokines in macrophages. However, IFN-γ expression was significantly 
decreased in infected compared to uninfected macrophages. This was similar to another 
H37Rv infection model of resting macrophages [604] and may indicate a decrease in 
macrophage numbers post-infection as a result of apoptosis or a downregulation of 
proinflammatory cytokine production by these macrophages. Indeed, M.tb inhibits classical 
Th1-mediated macrophage activation, because it blocks phagosome maturation [605], 
lysosome fusion [156], presentation via MHC Class I [606] and triggering via the IFN-γ 




7.4.3 IL-4 increases DC-SIGN expression on macrophages 
DC-SIGN is a C-type lectin expressed on the surface of phagocytes and facilitates entry of 
M.tb into phagocytic cells through binding of lipoarabinomanan (LAM). While M.tb entry 
into macrophages occurs predominantly through mannose receptors [608], it can also occur 
via DC-SIGN [609]. Increased expression of DC-SIGN was found in alveolar macrophages 
of TB patients and is thought to facilitate the spread of infection [205, 609]. Increased DC-
SIGN expression is also a hallmark of alternative macrophage activation, and results in a 
downregulation of macrophage anti-mycobacterial mechanisms [39]. 
 
The addition of PPD/IL-4 driven effector T-cells results in increased DC-SIGN expression on 
macrophages. This is not surprising given that IL-4 is a potent inducer of alternate 
macrophage activation [351]. In this model, IL-4 polarizes T-cells to a predominantly Th2 
response. The secretion of IL-4 by these polarized Th2 cells during co-culture with infected 
macrophages is likely to drive alternative activation of macrophages, characterized by, in this 
case, upregulation of DC-SIGN. In addition to increased surface expression of these pattern 
recognition receptors (PRRs), such as DC-SIGN and mannose receptor, alternatively 
activated macrophages exhibit increased production of arginase and subsequent 
downregulation of iNOS [39, 40]. The cytokine expression profile of these macrophages also 
changes with decreases in IFN-γ and TNFα production and increases in IL-10 and soluble 
TNF receptor secretion, leading to the formation of inactive TNFα-TNF receptor complexes 
[147, 435]. 
 
FoxP3+ Tregs can also induce alternative activation of macrophages in vitro [610]. If this is 
the case, then the increased Treg expression observed here may also be contributing to the 
increase in DC-SIGN levels. However, there was no decrease in IFN-γ or TNFα expression 
in macrophages with the addition of PPD/IL-4 driven effectors. This suggests that perhaps 
these macrophages are in a transition state where they express some markers of alternative 
activation but still retain their ability to express M1 associated pro inflammatory cytokines. 
This will depend on the plasticity of macrophages and their ability to switch between 
classical and alternate activation. Indeed, plasticity of macrophages has been demonstrated in 




An interesting finding is the high expression of DC-SIGN on CD8+ T-cells. DC-SIGN 
expression is usually restricted to DCs and macrophages. However, DC-SIGN-expressing B-
cells have also been described, which facilitate HIV-1 infection of T-cells and increase in 
response to IL-4 [611]. However, there was no increased expression of DC-SIGN on CD8+ 
cells when stimulated in the presence of IL-4. This is the first study to provide evidence of 
DC-SIGN expression on CD8+ T-cells. M.tb binds to DC-SIGN and facilitates entry into 
macrophages and DCs but it is highly unlikely that it has the same function on CD8+ T-cells 
given that these cells have accessory cytotoxic functions and do not internalize M.tb. It is 
possible that DC-SIGN facilitates M.tb infection of macrophages or DCs in a way similar to 
B-cell-mediated HIV-1 infection [611] or its cytotoxic activity is activated by directly 
binding to mycobacterial PAMPs, such as ManLAM, independent of MHC I presentation. 
However, DC-SIGN expression was only assessed in TB patients and it is unknown if this 
receptor is highly expressed on CD8+ T-cells in other disease conditions or in healthy 
individuals. Further investigation is required to determine the significance of DC-SIGN 
expression on CD8+ T-cells in TB and whether it extends to other diseases as well. 
 
7.4.4 LC3B production 
Autophagy is a lysosomal degradation pathway for cytoplasmic materials and damaged 
organelles and involves the formation of autophagosomes and subsequent fusion with 
lysosomes. There is extensive evidence on the role of autophagy as a protective mechanism 
against M.tb (reviewed in [155]). Autophagy directly kills M.tb within macrophages in 
response to pro-inflammatory cytokines such as IFN-γ and TNFα [158, 159], vitamin D via 
cathelicidin [162] or through TLRs [160, 161]. In contrast, IL-4 and IL-13 can inhibit 
autophagy via two different mechanisms; starvation induced autophagy is blocked by 
upregulation of Akt whereas IFN-γ induced autophagy is inhibited via the STAT-6 pathway 
[44].  
 
The most common measure of autophagy is the microtubule-associated protein light chain 3 
(LC3), which localizes to autophagosomal membranes. Upon synthesis, unprocessed LC3 
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undergoes a C-terminal cleavage event to yield the cytosolic form, LC3-I. When autophagy 
is induced, LC3-I undergoes lipidation to form LC3-II, which then becomes associated with 
autophagosomes. Lysosomal fusion with the autophagosome results in degradation of the 
vesicle contents along with LC3-II. Thus, the presence of LC3 in autophagosomes, as well as 
the conversion of LC3-I to LC3-II, indicates autophagic induction. A fluorescently 
conjugated antibody against LC3B, the most commonly measured human LC3 isoform, was 
used in this assay to measure endogenous levels of LC3 protein. No difference in the level of 
LC3B with or without the addition of IL-4 in macrophages or in lymphocytes was found. 
This is in contrast to other studies which found that IL-4 caused a reduction in starvation-
induced autophagy [44] and Vitamin D-mediated autophagy [612] within macrophages. 
These differences may be due to the method of LC3B quantification: confocal microscopy to 
determine the level of LC3 punctate cells [612] or immunoblotting to determine the LC3-II to 
LC3-I ratio [44]. Indeed, LC3B level is a good indicator of autophagy, as it correlates with 
the number of autophagosomes [613], but it does have its limitations. Variations in 
expression levels of LC3-I and LC3-II in different cell types, different antibody affinities of 
LC3-II compared to LC3-I as well as the degradation of LC3-II during autophagy can result 
in false conclusions concerning the extent of autophagy [614, 615]. This may be the reason 
why no differences in the IL-4 interventions were observed. It has been suggested that 
measurement of static levels of autophagy may not be sufficient and rather determining the 
level of „autophagic flux‟, which measures the rate of removal by autophagy, is a more 
sensitive technique [614, 615]. 
 
7.4.5 The biological significance of these findings 
Using an in vitro M.tb infection model, I have shown the multiple subversive effects of IL-4 
on cellular anti-mycobacterial mechanisms. A similar situation may also be occurring in vivo. 
At the site of disease, IFN-γ and TNFα are important for restricting M.tb growth and 
granuloma formation but excessive production has immunopathological consequences and 
can lead to tissue necrosis and cavity formation [8, 601]. Tregs function to prevent such 
immunopathology but also counteract these protective Th1 responses. High 
CD4+CD25+FoxP3+Tregs levels have been found in granulomas of both humans and 
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experimental animal TB models [291, 298, 616]. Furthermore, an early induction of Tregs 
results in delayed T-cell responses in the lung [300], likely by a direct suppression of effector 
T-cells. If IL-4 is indeed a driver of Treg proliferation, then a Th2 response in TB will likely 
disrupt the effector T-cell/Treg balance leading to a reduced Th1 response. The effect of 
alternate macrophage activation in the downregulation of protective responses in TB has 
been shown in mice in vivo [39, 40]. Evidence also suggests that a switch in macrophage 
polarization occurs from iNOS-producing classically activated macrophages to arginase-
producing alternatively activated macrophages in progressive TB [40]. A shift in this 
macrophage ratio within the granuloma, likely driven by IL-4, reduces Th1 responses and 
promotes Treg expansion resulting in enhanced M.tb survival within these macrophages 
[597]. 
 
In contrast, a zebrafish model of M. marinum infection demonstrated that a complete lack of 
a Th2 response can lead to progressive infection [617]. This finding is interesting given the 
extensive evidence supporting the detrimental role of a Th2 response in TB. However, it does 
suggest that, to some extent, a Th2 response, including induction of Tregs, is probably 
necessary to prevent an uncontrolled inflammatory response and subsequent 
immunopathology. 
 
Taking these data together, a delicate balance between the proinflammatory responses of 
macrophages and Th1 effector T-cells and immunoregulatory responses of Tregs at the site 
of disease is necessary to contain M.tb within the granuloma and simultaneously prevent 
excessive inflammation. A Th2-skewed response, which myself and others [9, 416-418] have 
shown to be present in TB, is likely disrupting this balance leading to a compromised  
immune response that cannot control the M.tb infection [38, 618]. 
 
7.4.6 Limitations 
A number of assay limitations have already been presented in chapter 6 in addition to those 




These mechanistic studies were performed in „PPD/IL-4 effectors‟ interventions but not the 
„Exogenous IL-4‟ interventions. The number of PBMCs required in the above assay (to study 
mechanisms of IL-4 mediated subversion of M.tb containment) was much greater than what 
is needed for the mycobacterial containment assay to assess CFUs (chapter 6), mainly due to 
the high cell number requirements for flow cytometric analysis. As such, it was not possible 
to perform flow cytometry on both interventions and the „PPD/IL-4 effector intervention was 
chosen as it produced the most significant effect on mycobacterial containment, in terms of 
CFU/ml. However, „Exogenous IL-4‟ interventions will be investigated in future work to 
determine if these same mechanisms are at work when IL-4 is added at such a late stage to 
the model.  
 
In addition to Tregs, activated T-cells produce low levels of FoxP3 [619, 620] and this may 
account for a rise in the number of Tregs (CD4+CD25+FoxP3+) in response to PPD and/or 
IL-4 stimulation. This is unlikely to have skewed the results given that expression of these 
cells was downregulated with the addition of anti-IL4 antibody even in the presence of PPD, 
suggesting the effect is truly an IL-4-driven expansion of Tregs. Future work will be 
performed to determine the identity, function and mode of suppression of these IL-4 induced 
Tregs. 
 
Measurement of other markers of alternate macrophage activation, including arginase and 
mannose receptor was limited by cell numbers and the number of cytokines that could be 
effectively measured in each flow cytometry panel.  It is likely that these markers would also 
have been increased and provided more supporting evidence. However, given that DC-SIGN 
is a well described marker of alternate macrophage activation, the data remain valid. 
 
As discussed above, measurement of autophagy may have been more precise by measuring 
autophagic flux or immunoblotting techniques, rather than flow cytometric analysis of LC3B 
[614, 615]. However, PBMC isolation did not yield sufficient cells to perform separate 
experiment for measurement of autophagy.  Furthermore, given the lack of antibodies to 
effectively distinguish between LC3-I and LC3-II, it was not possible to determine this ratio 
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by flow cytometry. Future experiments, which are beyond the scope of this study, will 
incorporate autophagic flux to more accurately determine the effect of IL-4 on autophagy. 
 
7.5 Conclusion 
The observed IL-4-associated subversion of mycobacterial containment within monocyte 
derived macrophages is mediated by a downregulation of a protective Th1 response 
(decreased IFN-γ and TNFα), likely through increased Treg activity, and alternatively 
activated macrophage polarization. In addition to IL-4, other Th2 and Th2-like cytokines 
may also be involved in undermining TB immunity. These data provide insights into immune 
mechanisms that can disrupt protective immunity and aid in identifying potential targets, 
such as a Th2 response, for design of future vaccines and immunotherapeutic agents. This 
prompted the work presented in the next chapter, where various Th1, Th2 and Th2-like 
cytokines and chemokines will be measured in TB and presumed LTBI samples from the 






8. CHAPTER 8: Levels of soluble Th1 and Th2-like cytokines 
and chemokines in supernatants from RD-1 antigen-driven 
peripheral blood and lung cells 
 
8.1 Introduction 
The data presented in the previous chapters provides evidence that a Th2 response, typified 
by IL-4, is present during TB infection and that it undermines protective Th1 mechanisms. 
However, it is unlikely that IL-4 alone drives this immune dysregulation given the complex 
cellular interactions and cytokine milieu found in the immune response to TB. Other 
cytokines and chemokines, which are thought to be detrimental in TB, are associated with a 
Th2 response. For example, IL-9, which has similar functions to IL-4, was recently shown to 
be produced by a distinct Th9 subset [49, 50] and is upregulated in active TB [344, 345]. 
Monocyte chemoattractant protein-1 (MCP-1) is considered a Th2 chemokine because of its 
role in the development and recruitment of Th2 cells [621-623] and high levels have been 
reported in TB patients compared to controls [624-627]. IL-10, an immunosuppressive 
cytokine produced by various Th subsets and alternatively activated macrophages, is often 
found to be upregulated in TB [33, 628, 629]. In contrast to the above mentioned cytokines, 
IL-17, similar to IFN-γ and TNFα, may have a protective role in TB as it is responsible for 
recruitment of neutrophils and early development of the granuloma [125, 630].  
 
Studies have looked at these and other biomarkers in an attempt to identify a cytokine 
expression profile that distinguishes TB infected individuals from healthy controls. However, 
the data have been disparate. Studies have shown that IFN-γ and TNFα may either be 
increased [238, 240, 244, 631] or decreased [33, 243, 245-247, 632] in active TB. Studies 
measuring IL-10 [11, 15, 33, 246, 628, 629, 633] and MCP-1 [36, 624, 625, 627] levels have 
shown similar contrasting results. Furthermore, very few studies have investigated IL-9 in 
TB disease. Most reports examining the levels of soluble cytokines in response to antigenic 
stimulation focused primarily in the peripheral blood compartment. However, few have 
investigated both the site of disease and the periphery particularly in the context of a Th2 
response. It is important to determine the local immune response at the site of disease in TB 
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as M.tb specific T-cells tend to accumulate here and, along with the highly activated resident 
tissue macrophages and other infiltrating cell types, produce a cytokine profile that can be 
different from the peripheral circulation [38]. Such investigations would provide useful 
information in identifying specific biomarker profiles which can aid in TB diagnosis or be 
used as targets in vaccine design and immunotherapeutic agents. Moreover, it is important to 
measure the soluble cytokines because, in contrast to mRNA, these proteins directly exert 
their effects on cells to generate immune responses. 
 
The aim of this chapter was to identify specific cytokines and chemokines in M.tb-specific 
antigen stimulated cell cultures from the site of disease, specifically the lungs, and peripheral 
blood in TB patients and presumed LTBI controls. 
 
8.2 Methods 
8.2.1 PBMC and BAL cell isolation 
Whole blood was obtained by venipuncture from 18 TB patients and 11 presumed LTBI 
controls. Broncho-alveolar lavage (BAL) fluid was collected from 10 TB patients and 8 
presumed LTBI controls, as described in section 2.3.3. Peripheral blood mononuclear cells 
(PBMCs) were isolated by density centrifugation and BAL cells were isolated from BAL 
fluid as described in sections 2.4.2 and 2.4.3 respectively. 
 
8.2.2 Cell culture 
A total of 2.5x105 BAL cells and PBMCs were plated in 96-well round bottom plates in 
triplicate. Cells were stimulated with the RD1 antigens ESAT-6 and CFP-10 (Oxford 
Immunotec) using manufacturer recommended concentrations (which are proprietary and 
cannot be disclosed) for 5 days in a final well volume of 200μl. Triplicate wells were pooled 
and harvested by centrifugation at 1200 rpm for 5 minutes. Supernatants were collected and 
stored in 1.5ml tubes at -80oC. 
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8.2.3 Luminex MAP assay 
A 7-plex Milliplex Human Cytokine MAP assay (Millipore) was performed for the following 
cytokines– IFN-γ, TNFα, IL-4, IL-9, MCP-1, IL-10 and IL-17 according to the 
manufacturer‟s instructions. Cell culture supernatants were assayed undiluted or diluted 10-
fold in RPMI 1640 (Lonza). All samples were run in duplicate. Antibody-immobilized beads, 
quality controls and cytokine standards were prepared as per manufacturer‟s instructions. The 
standard curve of each analyte ranged from 1.6 – 10,000 pg/ml for each kit. 25μl of 
standards, quality controls and samples was added to appropriate wells of a 96-well filter 
plate. A mixture of fluorescent beads, conjugated to antibodies specific for the cytokines of 
interest, was added to each well and incubated with shaking at room temperature. The well 
contents were then washed with wash buffer using a vacuum manifold. Biotinylated 
detection antibody was added to the beads in the wells and incubated with shaking followed 
by another wash step. Phycoerythrin-conjugated streptavidin was then added to the well 
followed by a third incubation period and wash step. Beads were then resuspended in sheath 
fluid within the wells and immediately analyzed on a Bioplex Luminex 100 reader (Bio-
Rad). Standard curve generation and quantification of analytes was performed using Bioplex 
Manager 6.0 (Bio-Rad). 
 
8.2.4 Data analysis 
Differences in median soluble cytokine and chemokine levels between the different groups 
(TB patients and LTBI controls) and different compartments (BAL vs peripheral blood) were 
determined using the Mann-Whitney U test. A p-value of <0.05 were deemed significant. 




IFN-γ levels were significantly lower in PBMC supernatants of TB patients compared to 
LTBI controls (433.0 pg/ml vs. 3757.0 pg/ml, respectively; p=0.02). In BAL supernatants, 
median IFN-γ levels were generally low and not significantly different in TB vs. LTBI (47.7 
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pg/ml vs. 1.0 pg/ml, respectively). IFN-γ was significantly higher in supernatants of PBMCs 
compared to BAL cells in LTBI controls (3757.0 pg/ml vs. 1.0 pg/ml, respectively; 
p=0.0006). (Figure 8.1A and Table 8.1). 
 
8.3.2 TNFα 
No significant differences in TNFα levels were observed in PBMC supernatants between TB 
patients and LTBI controls. Median TNFα levels were lower in BAL cell supernatants of TB 
vs. LTBI controls but these differences were not statistically significant (562.0 pg/ml vs. 
2102.0 pg/ml, respectively; p=0.07). TNFα levels were significantly higher in supernatants of 
BAL cells compared to PBMCs in LTBI controls (2102.0 pg/ml vs. 847.0 pg/ml respectively; 
p=0.02) (Figure 8.1B and Table 8.1).  
 
8.3.3  IL-9 
IL-9 levels were not significantly different in the PBMC supernatants of TB patients and 
LTBI controls. IL-9 levels were significantly higher in BAL cell supernatants of TB vs. LTBI 
controls (3.5 pg/ml vs. 1.4 pg/ml, respectively; p=0.02). In TB patients, IL-9 levels were 
higher in the supernatants of BAL cells compared to PBMCs (3.5 pg/ml vs. 1.0 pg/ml, 
respectively; p=0.003) (Figure 8.1C and Table 8.1). 
 
8.3.4 IL-4 
IL-4 was mostly undetectable in TB patients vs. LTBI controls in PBMC (0.0pg/ml vs. 
0.0pg/ml, respectively) and BAL cell supernatants (0.5pg/ml vs. 2.5pg/ml, respectively) 
(Figure 8.1D and Table 8.1). 
 
8.3.5 MCP-1 
Median MCP-1 levels were not significantly different in the PBMC supernatants of TB 
patients compared to LTBI controls. In BAL supernatants, MCP-1 was generally higher in 
TB vs. LTBI controls but these differences were not significant (15448 pg/ml vs. 7308 pg/ml, 
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respectively). MCP-1 was also higher, but not significant, in BAL compared to PBMC 




No significant differences in IL-10 levels were observed in TB vs. LTBI controls either in 
PBMC or BAL cell supernatants. However, median IL-10 levels were significantly higher in 
PBMC compared to BAL supernatants of LTBI controls (35.5 pg/ml vs. 2.7 pg/ml; p=0.01) 
(Figure 8.1F and Table 8.1). 
 
8.3.7 IL-17 
IL-17 expression was generally low in both groups. There were no significant differences in 
median IL-17 levels between TB patients and LTBI controls either in PBMC (2.8 pg/ml vs. 
2.5 pg/ml, respectively) or BAL cell supernatants (4.8 pg/ml vs. 4.9 pg/ml, respectively) 






Figure 8.1. Soluble cytokine levels of (A) IFN-γ (B) TNFα (C) IL-17 (D) IL-4 (E) IL-9 (F) IL-10 
(G) MCP-1 in ESAT-6 and CFP-10 stimulated broncho-alveolar lavage (BAL; blue circles) and 
peripheral blood mononuclear cell (Blood; red squares)  culture supernatants  from patients 
with pulmonary tuberculosis (TB; BAL= 10, Blood=18) and latently infected controls (LTBI; 
BAL=8, Blood=11) as measured by Luminex multiplex assay. Statistical analyses between group 
medians were performed using the Mann-Whitney test and p<0.05 was deemed significant. 
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8.3.8 Ratio of Th2 or Th2 related cytokines/chemokines to Th1 cytokines 
The ratio of IL-9:TNFα (Figure 8.2A) and MCP-1:TNFα (Figure 8.2B) was significantly 
higher in RD1-stimulated BAL cell supernatants  of TB patients compared to LTBI controls 
(p=0.001 and p=0.03, respectively). In PBMC supernatants, the IL-9:IFN-γ ratio (Figure 
8.2C) and MCP-1:IFN-γ (Figure 8.2D) ratio was significantly higher in TB patients 
compared to LTBI controls (p=0.049) but no significant differences were observed in the IL-
10:IFN-γ (p=0.07), IL-9:TNFα (p=0.58) and MCP-1:TNFα (p=0.43) ratios (Figure 8.2E-G). 
IL-4 was not assessed in these ratios as it was undetectable in most samples. Additionally, 
the IL-9:IFNγ, MCP-1:IFN-γ and IL-10:IFN-γ ratios were not assessed in the BAL 






Figure 8.2. Cytokine ratios of (A)IL-9:TNFα and (B)MCP-1:TNFα in RD1-stimulated broncho-
alveolar lavage (BAL; blue circles)  cell culture supernatants; (C) IL-9:IFN-γ, (D) MCP-1:IFN-
γ, (E) IL-10:IFN-γ, (F) IL-9:TNFα and (G) MCP-1:TNFα in RD1-stimulated peripheral blood 
mononuclear cell (Blood; red circles)  culture supernatants  from patients with pulmonary 
tuberculosis (TB; BAL= 10, Blood=18) and latently infected controls (LTBI; BAL=8, 
Blood=11). Statistical analyses between group medians were performed using the Mann-Whitney test 
and p<0.05 was deemed significant. 
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Table 8.1. Median cytokine levels (pg/ml) of IFN-γ, TNFα, IL-9, IL-4, MCP-1, IL-10 and IL-17 
in RD1 (ESAT-6 and CFP-10) stimulated broncho-alveolar lavage and peripheral blood cell 
culture supernatants  from patients with pulmonary tuberculosis (TB) and latently infected 
controls (LTBI) as measured by Luminex multiplex assay. Cytokines are expressed in pg/ml and 
the interquartile range (IQR) is shown in parentheses. Statistical analyses between group medians 





































































































































p-values compare the median pg/ml in aTB vs. LTBI BAL, bTB vs. LTBI blood, cBAL vs. Blood TB, 




A Luminex multiplex assay was performed to determine the levels of various cytokines and 
chemokines in RD1-stimulated PBMC and BAL cell culture supernatants of TB patients and 
presumed LTBI controls.  
 
When cytokine levels between the different groups (TB vs. LTBI) within the same 
compartment were compared, increased IL-9 and decreased TNFα were observed in the BAL 
cell supernatants of TB patients compared to LTBI controls. However, although a definite 
trend was observed, the differences in TNFα levels were not significant. In PBMC 
supernatants, IFN-γ levels were lower in TB patients compared to LTBI controls. There were 
no significant differences in levels of IL-17, IL-4, IL-10 or MCP-1 between TB and 
presumed LTBI controls.  
 
Comparison of cytokine levels between the different compartments (lung vs. peripheral 
blood) revealed significantly higher IL-9 and lower IFN-γ in the RD-1 stimulated cell 
supernatants of BAL compared to PBMCs in TB patients. In LTBI controls, higher TNFα 
and lower IL-10 was observed in the supernatants of BAL cells compared to PBMCs. 
 
Analysis of various cytokine ratios revealed that the IL-9:TNFα and MCP-1:TNFα ratios 
were significantly higher in the BAL culture supernatants of TB patients compared to LTBI 
controls. Similarly, the IL-9:IFN-γ and MCP-1:IFN-γ ratios were significantly higher in 
PBMC supernatants of TB patients vs. LTBI controls. These results suggest that TB patients 
produce a distinct cytokine expression profile compared to LTBI controls and these 
differences are compartment-specific. 
 
8.4.1 IFN-γ and TNFα 
As discussed previously, Th1 cytokines, including IFN-γ and TNFα, activate 
mycobactericidal mechanisms to mount a protective immune response in M.tb infection [68]. 
Previous studies that measured IFN-γ in response to in vitro antigenic stimulation in PBMCs 
have been conflicting; some studies have reported significantly decreased IFN-γ levels in 
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active TB disease [33, 243-247], whereas others have demonstrated an increase in IFN-γ 
responses [238, 240-242] compared to healthy controls. The data presented here supports the 
former suggesting that there is a suboptimal Th1 response in TB patients. The differences in 
other studies may be due to variations in the experimental design including the specific 
antigen used for stimulation (M.tb whole sonicates vs. purified antigen) [240-242] or the 
length of the stimulation period [240, 242] which can have significant effects on cytokine 
expression [26, 634]. The extent of disease severity may also play a role as more severe 
disease is associated with lower IFN-γ levels in TB patients [240, 245, 635]. Possible 
explanations for the observed decrease in IFN-γ responses are the increased susceptibility of  
antigen specific T-cells to apoptosis  in TB patients [636] or that IFN-γ secreting T-cells are 
recruited to the lungs during disease resulting in fewer circulating cells in the periphery [8]. 
 
IFN-γ levels in RD1-stimulated BAL cell culture supernatants were much lower compared to 
PBMCs. Studies assessing soluble cytokine levels from antigen-stimulated cells at the site of 
disease reported either lower [15] or higher production of IFN-γ [11, 482] compared to the 
periphery. These observed differences may be a reflection of the hyper-activated state of T-
cells from the site of disease. Isolated T-cells from TB pleural effusions demonstrate 
accelerated proliferation and enhanced cytotoxicity [637, 638] and exhibit increased 
apoptosis [636] compared to peripheral blood T-cells. This effect is also observed in other 
chronic lung inflammatory diseases [639]. As such, further stimulation of hyper-responsive 
cells may result in enhanced cell death and decreased cytokine production. Another 
possibility is the relative abundance of T-cells present in the lung compared to the periphery. 
Despite lymphocytic infiltration into the lungs during pulmonary TB disease, peripheral 
blood usually has a higher proportion of T-cells compared to lung lavage, which consists 
mostly of alveolar macrophages [15]. Given that T-cells are the primary source of IFN-γ [11, 
15], this disparity may also explain the low levels of IFN-γ secreted by RD1 stimulated cells 
from BAL.  
 
As observed with IFN-γ, data on TNFα responses in TB has been disparate with studies 
reporting either increased levels [240, 244, 631] or decreased levels [411, 632] in antigen-
driven PBMC and BAL cell supernatants of TB patients compared to healthy controls. I 
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found significantly higher levels in RD-1 stimulated supernatants of BAL cells compared to 
PBMCs of presumed LTBI controls. Furthermore, median TNFα levels were higher in BAL 
supernatants of presumed LTBI controls compared to TB patients, although these differences 
were not significant. The inconsistencies between these results and others studies may be due 
to technical variations in experimental design (discussed earlier) or the clinical status of the 
patient [632]. TNFα is thought to have a dual role in TB and the relative abundance of TNFα 
at various stages of disease may influence the disease outcome: low levels of TNFα result in 
suboptimal mycobactericidal activities and granuloma formation whereas high levels can 
cause enhanced inflammation and subsequent immunopathology [601]. The reduced TNFα 
levels in TB patients compared to presumed LTBI controls observed here, support the 
former. Low TNFα expression can also be a result of infection with hyper-virulent strains of 
M.tb [640] or increased expression of TNF receptors which sequester and inactivate TNFα 
[641]. 
  
TNFα was considerably higher than IFN-γ in RD1-stimulated BAL cell culture supernatants. 
As discussed above, BAL T-cells were most likely hyper-activated and died as a result of 
overstimulation, leading to low detectable levels of IFN-γ.  However, this was not observed 
with TNFα and could be a reflection of the different cellular sources of these cytokines in 
lung lavage. In the lung, the dominant source of TNFα is phagocytic cells [250], whereas 
IFN-γ is mainly produced by CD4+ T cells [11, 15]. As such, the majority of TNFα being 
produced is probably from alveolar macrophages in the BAL.  
 
8.4.2 IL-9 
 IL-9 was traditionally considered a Th2 cytokine but recent studies suggest that it can also 
be produced by Th17 [339, 642], Tregs [342] and the recently described Th9 cells [49, 50]. 
IL-9 functions in a similar manner to IL-4 as it promotes allergic airway inflammation in 
asthma and atopic allergy, eosinophil recruitment, IgE production and modulation of Treg 
activity (reviewed in [643]). There are few studies investigating IL-9 in TB [11, 334, 344, 
345], most of which reported increased levels in response to M.tb stimulation either in 
PBMCs [344, 345] or pleural mesothelial cells [334]. My data is in agreement with these 
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studies as significantly increased IL-9 was found in RD1-stimulated BAL supernatants of TB 
patients compared to presumed LTBI controls. IL-9 was also significantly higher in the BAL 
supernatants compared to PBMC supernatants of TB patients. This finding of increased IL-9 
production at the site of disease is similar to Ye et al, who reported a higher frequency of IL-
9 producing cells in pleural effusion compared to blood in TB patients [334]. This may be the 
result of IL-9 producing cells being recruited from the periphery and accumulating at the site 
of disease [334].   
 
A possible consequence of increased IL-9 in TB patients is the downregulation of the 
protective Th1 response and subsequent dampening of protective anti-mycobacterial 
mechanisms. Wu et al observed reduced IFN-γ mRNA expression upon the addition of 
exogenous IL-9 to PBMCs in vitro [344]. IL-9 also inhibited apoptosis in pleural mesothelial 
cells [334] and production of ROIs and TNFα in LPS stimulated monocytes [343]. The 
higher IL-9:TNFα cytokine ratio in stimulated BAL supernatants and IL-9:IFN-γ ratio in 
stimulated PBMC supernatants that was observed in TB patients compared to presumed 
LTBI controls support this notion (Figure 8.2A and C). Therefore, it is possible that IL-9 acts 
synergistically with IL-4 to bring about a Th2-associated disruption of the immune response. 
However, it is not known which T-cell subsets (Th2 or Th9) contribute to the observed IL-9 
increase in TB patients. Further investigations on the cellular source of IL-9 were performed 
and will be discussed in chapter 9. 
 
8.4.3 IL-4  
IL-4 levels were mostly undetectable in both the PBMC and BAL supernatants of TB 
patients and presumed LTBI controls. This result is likely attributable to the difficulty in 
measuring IL-4, particularly at the protein level. Other studies have reported similar findings 
in serum, BAL fluid and M.tb antigen-stimulated supernatants [9, 35, 36, 629, 631]. As 
discussed in chapter 4, IL-4 is difficult to detect as it is physiologically active at low 
concentrations, it is rapidly internalized and can be sequestered by sIL4R. Even IL-4 mRNA 
levels detected by qPCR, which has superior sensitivity to Luminex, were low (chapter 3 and 
[9]). In contrast, other studies have reported higher levels of soluble IL-4 in TB patients 
 
 199 
compared to healthy controls [11, 20, 241]. This may be due to the length of stimulation, 
method of detection and the use of pre-stimulation protocols. It is possible that IL-4 levels 
peaked earlier during stimulation and decreased to undetectable levels by day 5. ELISA, 
which has a similar range of detection to Luminex, is not as sensitive for measuring low 
expressing cytokines such as IL-4 [26], compared to ELISPOT and qPCR. Furthermore, RD1 
antigens tend to be Th1 biased and may downregulate production of IL-4 [644]. 
 
8.4.4 MCP-1 
MCP-1, also known as CCL2, is a chemokine responsible for recruiting monocytes and T-
cells to the site of infection. It is required for effective granuloma formation and macrophage 
activation in the early stages of disease [645, 646]. However, high levels of MCP-1 can be 
detrimental to TB. Studies in Mexican, Korean and Zambian TB patients revealed that 
polymorphisms in the MCP-1 gene promotor region resulted in excessive production of 
MCP-1 and was associated with increased susceptibility to TB [647, 648]. Furthermore, 
MCP-1 is associated with the development of Th2 responses [621, 622, 649] and enhanced 
secretion of IL-4 [623].   
 
In the data presented here, high levels of MCP-1 were mainly found in the BAL, which is 
expected given that the majority of MCP-1 is produced by macrophages [650]. MCP-1 levels 
were variable but median levels were higher in RD-1 stimulated BAL cell supernatants of TB 
patients compared to controls, although these differences were not significant. High levels of 
MCP-1 expression have been found in both the periphery and site of disease in TB patients 
compared to controls [624-627, 651]. Increased MCP-1 can downregulate the Th1 response, 
by inhibiting production of IL-12 [648] and IFN-γ [652]. A higher MCP-1:TNFα ratio was 
noted in stimulated BAL supernatants and MCP-1:IFN-γ in stimulated PBMC supernatants in 
TB patients compared to presumed LTBI controls, which supports this notion (Figure 8.2B 





IL-10 is an anti-inflammatory cytokine produced by numerous cell types including T cells, B 
cells, neutrophils, macrophages and DCs [653]. Multiple CD4+ T-cell phenotypes also 
produce IL-10, including Th1, Th2, Th17 and certain types of Tregs [310]. In TB, IL-10 
dampens protective immune responses by inhibiting production of pro-inflammatory 
cytokines, such as TNFα and IL-12 [305, 306], and enhancing iTreg differentiation [309]. IL-
10 can also directly affect macrophages by inhibiting phagocytosis and production of ROIs 
and RNIs [307, 308]. However, IL-10 is also thought to limit excessive inflammation by 
downregulating these mechanisms [654].  
 
In the data presented here, no significant differences were observed in IL-10 levels between 
TB patients and presumed LTBI controls either in RD1-stimulated BAL or PBMC culture 
supernatants. This is in contrast with other studies that found TB patients expressed higher 
levels of IL-10, compared to healthy controls, in response to antigenic stimulation of cells 
from the site of disease or peripheral blood [11, 33, 246, 628, 629]. In these TB patients, 
increased IL-10 production was often associated with lower levels of IFN-γ [33, 246]. 
However, the IL-10:IFN-γ ratio was not significantly different between TB patients and 
presumed LTBI controls (Figure 8.2E). The lack of statistical significance may be due to 
differences in experimental design (type of antigen, length of stimulation), or that the 
observed downregulation of Th1 responses was not dependent on production of IL-10 alone.  
 
8.4.6 IL-17 
IL-17 is a proinflammatory cytokine that is produced by various T-cells (CD4+, CD8+,γδ) 
including the recently described Th17 subset. In TB, IL-17 recruits and activates neutrophils, 
promotes secretion of inflammatory mediators including TNFα, IL-6 and MIP-2 [630] and 
contributes to early granuloma formation [125]. However, excessive IL-17 can lead to 
accumulation of large numbers of neutrophils in the lungs, alter their phenotype and cause 




Low expression of soluble IL-17 levels was noted, which was not different in TB patients 
compared to presumed LTBI controls, either in the RD1 stimulated cell supernatants of BAL 
or PBMCs. This is in contrast to other studies which found that TB patients expressed 
increased levels of IL-17-producing cells, compared to healthy controls, in stimulated BAL 
cells [655] and PBMCs [293, 656]. However, these studies, which measured intracellular 
production of IL-17 by flow cytometry, still detected very few IL-17-producing CD4+ or 
CD8+ T-cells. Measurement of soluble IL-17 protein tends to be challenging as it is present 
at even lower concentrations and, similarly to IL-4, may be the result of rapid degradation of 
IL-17 protein or the inactivation of IL-17 by binding to IL-17 receptors [657]. 
 
8.4.7 Summary of findings in relation to a Th2 response  
M.tb antigen-specific cells from TB patients exhibit a distinct cytokine expression profile 
compared to presumed LTBI controls and these cytokine secretion patterns are compartment-
specific.  TB patients showed increased IL-9 production and a higher IL-9:TNFα ratio at the 
site of disease compared to presumed LTBI controls. A similar effect occurred in the blood, 
where lower IFN-γ expression and a higher IL-9:IFN-γ ratio was observed. These data 
suggests a mixed Th1:Th2 response in TB patients and confirm the results obtained by qPCR 
(chapter 3). IL-4 is the principal cytokine produced by Th2 cells but, due to limitations in 
Luminex assay sensitivity, IL-4 was undetectable. As a result, no conclusions could be drawn 
on the effect of IL-4 in relation to expression of other cytokines in this assay. However, given 
that IL-4 and IL-9 have similar functions [643], it is possible that IL-9 acts in conjunction 
with IL-4 to subvert the protective Th1 response.  
 
The ratio of MCP-1 to Th1 cytokines in the BAL (MCP-1:TNFα) and blood (MCP-1:IFN-γ) 
was higher in TB patients compared to presumed LTBI controls and suggests MCP-1 may 
also be involved in driving the Th2 response. MCP-1 is considered a Th2 chemokine in mice 
and humans because it is involved in Th2 polarization and recruitment [367]. In lepromatous 
leprosy, increased MCP-1 and lower TNFα resulted in unrestricted growth and dissemination 
of M. leprae [658]. A plausible scenario involves the recruitment of IL-9 producing T-cells to 
the site of disease, driven by MCP-1, and subsequent downregulation of protective Th1 
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The choice of antigen used to stimulate cells in vitro and the length of stimulation can have a 
significant impact on cytokine production [26, 634]. Soluble antigens such as PPD and 
ESAT-6 are presented via the exogenous antigen processing pathway and primarily stimulate 
CD4+ T-cells, but not other T-cells [471]. PPD contains a mixture of mycobacterial antigens 
and responses to these proteins are not specific to M.tb, particularly in a setting such as South 
Africa where exposure to environmental mycobacteria and BCG vaccination is common. The 
RD1 antigens were chosen because they are M.tb specific and a combination of ESAT-6 and 
CFP-10 was used as it was shown to maximize the M.tb specific responses [659]. ESAT-6 
and CFP-10 drive IL-4 production in PBMCs from TB patients [503]. In contrast, RD1 
antigens have also been shown to be Th1 biased and downregulate Th2 responses [644].  
 
A 5 day stimulation period was chosen as it was optimal for detection of soluble cytokines by 
ELISA [634] and previous studies have used similar incubation periods [238, 240, 241, 244, 
247, 480]. However, a shorter stimulation time may have been more suitable for alveolar T-
cells as these cells tend to be hyper-responsive and overstimulation may have caused 
enhanced cell death. Given that T-cells are the primary source of IFN-γ [11, 15], this could 
account for low IFN-γ levels in stimulated BAL cell supernatants. Furthermore, the optimal 
culture times for antigen induced responses can vary depending on the cytokine [634]. Given 
the complexity and limits of obtaining BAL cells, it was not feasible to do variable –cytokine 
specific time points optimized for each cytokine.    
 
The small BAL sample size may have contributed to the lack of significant differences in 
cytokine levels between the TB and LTBI groups and subsequent interpretation of the data. 
Recruitment of participants to undergo an invasive bronchoscopy procedure was difficult and 
limited cell recovery often meant that immune assays needed to be prioritized based on the 
amount of alveolar cells that were available. Nonetheless, additional participants will be 
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recruited from other ongoing studies to increase the number of BAL samples in both the TB 
and LTBI groups. 
 
8.5 Conclusion 
M.tb antigen-stimulated cells from TB patients exhibit a distinct cytokine expression profile 
compared to presumed LTBI controls, characterized by increased IL-9 and reduced Th1 
cytokine levels, and these secretion patterns are compartment-specific. These data suggest 
that cytokines and chemokines, apart from IL-4, may contribute to a Th2-associated 
disruption of the Th1 response. The IL-9 secretion pattern observed here prompted further 







9.   CHAPTER 9: Analysis of IL-9 producing subpopulations of 
cells in lungs and peripheral blood 
 
9.1 Introduction 
IL-9 was traditionally considered a Th2 cytokine as it is associated with various Th2 
responses and has a prominent role in Th2-associated diseases [660]. However, recent studies 
have demonstrated the multifunctional role of IL-9 and its production by different T-cell 
subsets. Of particular significance is the discovery of an IL-9 producing CD4 T-cell subset, 
known as Th9, which is distinct from other Th subsets including Th1, Th2 and Th17 cells 
[49, 50]. Th9 cells produce IL-9 as its signature cytokine and develop from naïve T-cells in 
response to IL-4 and TGFβ [49, 50, 322, 323]. Th9 cells can also develop from Th2 cells in 
the presence of TGFβ [50].  A number of transcription factors, such as PU.1, IRF4, STAT6 
and GATA3, have been identified as necessary for Th9 development [49, 50, 326, 327] but 
these transcription factors are also required for the development of other T-cell subsets. Thus, 
the discovery of a single lineage defining Th9 transcription factor remains elusive. Th9 cells 
appear to contribute towards the immune response in allergic airway disease [326, 327, 332], 
asthma [661-663], autoimmune disease [49, 339, 642, 664] and parasitic infections [665-
668]. Most of these data come from in vitro studies or from murine models and the 
significance of these cells in the immune response to human infection in vivo, particularly in 
the context of TB, have been under-explored. 
 
A handful of studies have investigated IL-9 in TB [11, 334, 344, 345] and only one has 
attempted to define the phenotypic and functional characteristics of Th9 cells [334]. In the 
previous chapter, increased IL-9 measured by Luminex, was found at the site of disease in 
TB patients compared to LTBI controls. The aim of this chapter was to define the phenotypic 




9.2.1 PBMC and BAL cell isolation 
Whole blood was obtained by venipuncture from 15 TB patients and 10 presumed LTBI 
controls. PBMCs were isolated by density centrifugation as described in section 2.4.2. 
Broncho-alveolar lavage (BAL) fluid was collected from participants (6 TB patients and 3 
presumed LTBI controls) as previously described in section 2.3.3. BAL cells were isolated 
from BAL fluid as described in section 2.4.3. 
 
9.2.2 Cell culture and immunofluorescence staining 
A total of 1.5x106 BAL cells and PBMCs were plated in 24 well plates. PBMCs and BAL 
cells were stimulated with PPD (12ug/ml) for 18 hours in a final well volume of 500µl. In a 
subset of TB patients and LTBI controls, PBMCs were stimulated either with PPD (12µg/ml) 
or RD1 antigens, ESAT-6 and CFP-10 (Oxford Immunotec), at manufacturer recommended 
concentrations (which are proprietary and cannot be disclosed) for 18 hours. Golgi-stop, 
containing monensin (0.6μl/ml), was added to each well 5 hours before harvesting. Cells 
were harvested and stained for specific surface and intracellular markers using fluorescently 
labeled antibodies (Table 2.2), and subsequently analyzed on a BD LSR II flow cytometer, as 
outlined in section 2.4.6. 
 
9.2.3 Data analysis 
The frequency of specific lymphocyte populations expressing IL-9 and other biomarkers was 
determined using FACSDiva software (BD) and were reported as a % of the total CD4+ and 
CD8+ lymphocyte populations. Differences in expression levels between TB patients and 
presumed LTBI controls in the different compartments were determined using the Mann-
Whitney U test. A p-value of <0.05 were deemed significant. Statistical analyses were 





9.3.1 Gating strategy for CD4+ and CD8+ lymphocytes expressing IL9  
The gating strategy used to identify IL-9 expressing cells in the lymphocyte population is 
shown in Figure 9.1. Lymphocytes were acquired based on cell size (FSC) and granularity 
(SSC). Cells were gated on the CD3+CD4+ population for CD4+ lymphocytes and on 
CD3+CD8+ for CD8+ lymphocytes. Cells expressing IL-9 (IL9+) were identified within 
each of these populations. The frequency of CD4+IL9+ and CD8+IL9+ expressing cells were 




Figure 9.1 An example of the gating strategy used to identify CD4+IL9+ and CD8+IL9+ cells 
within the lymphocyte population by flow cytometry. 
 
9.3.2 Expression of IL-9 in CD4+ and CD8+ lymphocytes 
Median expression of IL-9 by CD4+ lymphocytes (CD4+IL9+) were significantly higher in 
TB patients compared to presumed LTBI controls in PPD-stimulated cells of BAL (median 
expression of 2.2% vs. 0.1% respectively; p=0.03) and peripheral blood (median expression 
of 1.8% vs. 0.7% respectively; p=0.02) (Figure 9.2A). A similar expression pattern of IL-9 
was observed in CD8+ lymphocytes. Expression of CD8+IL9+ cells in TB patients, 
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compared to presumed LTBI controls,  was significantly higher in peripheral blood (median 
expression of 1.7% vs. 0.2% respectively; p=0.047) but not in BAL (median expression of 
3.6% vs. 0.6% respectively; p=0.3) (Figure 9.2B). Two presumed LTBI controls had very 
high CD8+IL-9+ levels (>15% expression) in the peripheral blood but not in BAL (<1% 
expression) (Figure 9.2B). There were no significant differences in IL-9 expression between 





Figure 9.2. Frequency (%) of (A) CD4+ and (B) CD8+ lymphocytes (CD3+) expressing IL-9 in 
PPD-stimulated cells of broncho-alveolar lavage (BAL; blue circles) and peripheral blood 
(Blood; red squares) from patients with pulmonary tuberculosis (TB; BAL n=6, Blood n=15) 
and presumed latently infected controls (LTBI; BAL=3, Blood=10) as measured by flow 
cytometry. Statistical analyses between groups were performed using the Mann-Whitney test and 
p<0.05 was deemed significant. 
 
9.3.3 IL-9 expression in peripheral blood cells stimulated with PPD and RD1 antigens 
There were no differences in IL-9 expression in CD4+ or CD8+ lymphocytes of matched 
samples when PBMCs were stimulated with either PPD or RD1 antigens. However, in CD4+ 
lymphocytes, IL-9 expression was significantly higher in TB patients compared to presumed 
LTBI controls when cells were stimulated with PPD (median expression of 1.8% vs. 0.6% 
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respectively; p=0.03) but not when stimulated with RD1 antigens (median expression of 
2.3% vs. 1.5% respectively; p=0.47) (Figure 9.3A). TB patients had higher IL-9 expression in 
CD8+ lymphocytes, compared to presumed LTBI controls, when cells were stimulated either 
with PPD (median expression of 1.0% vs. 0.2%, respectively; p=0.006) or, to a lesser extent, 





Figure 9.3. Frequency (%) of (A) CD4 and (B) CD8 lymphocytes (CD3+) expressing IL-9 in 
peripheral blood mononuclear cells stimulated with purified protein derivative (PPD; red) or 
RD1 (ESAT-6 and CFP-10; pink) antigens from patients with pulmonary tuberculosis (TB; 
n=7) and presumed latently infected controls (LTBI; n=6) as measured by flow cytometry. 
Statistical analyses between groups were performed using the Mann-Whitney test and p<0.05 was 
deemed significant. 
 
9.3.4 Gating strategy for determining cytokine expression in IL-9 producing CD4+ 
and CD8+ cells 
The gating strategy used to identify cells co-expressing IL-13, IL-17 and PU.1 within the 
CD4+IL9+ and CD8+IL9+ populations is shown in figure 9.4. The CD4+IL9+ and 
CD8+IL9+ populations were identified as described in section 9.3.1 and figure 9.1. The cells 
expressing, IL-13 and IL-17 were identified within the IL9+ population. Expression of PU.1 
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was determined in the CD4+IL9+ and CD8+IL9+ populations not co-expressing IL-13 and 
IL-17 (CD4+IL9+IL13negIL17negPU1+ and CD8+IL9+IL13negIL17negPU1+). The frequency 
of IL-13, IL-17 and/or PU.1 being co-expressed by IL-9-producing CD4+ and CD8+ 




Figure 9.4. The gating strategy used to identify co-expression of IL-13, IL-17 and PU.1 within 




9.3.5 Co-expression of IL-13, IL-17 and PU.1 by IL-9 expressing CD4 and CD8 
lymphocytes in peripheral blood and BAL 
Further investigations were performed to ascertain the helper T-cell (Th) and cytotoxic T-cell 
(Tc) lineage of IL-9-producing CD4+ and CD8+ lymphocytes in PPD-stimulated PBMCs 
and BAL cells of TB patients. The co-expression of IL-13 (Th2/Tc2), IL-17 (Th17/Tc17) and 
the transcription factor PU.1 were analyzed and reported as a % of total CD4+IL9+ and 
CD8+IL9+ cells (Figure 9.5A and B). Co-expression was not assessed in LTBI controls due 
to the low number of IL-9 producing cells present in this participant group. 
 
A small subset of CD4+IL9+ cells in the peripheral blood and BAL produced IL-13  (Th2 
phenotype; median CD4+IL9+IL13+ expression was 3.2% and 6.9%, respectively) and IL-17 
(Th17 phenotype; median CD4+IL9+IL17+ expression was 2.9% and 15.8%, respectively). 
The median expression of IL-13 and IL-17 was generally higher in the BAL CD4+IL9+ cells 
compared to peripheral blood, but did not reach statistical significance. The majority of 
CD4+IL-9+ expressing cells exhibited a Th9 phenotype as they did not co-express IL-13 and 
IL-17 (median CD4+IL9+IL13negIL17neg expression was 93.1% and 95.2% in BAL and 
peripheral blood, respectively). The frequency of these cells also expressing the transcription 
factor PU.1, was higher in BAL compared to blood but still generally low (median 
CD4+IL9+IL13negIL17negPU.1+ expression was 8.3% and 1.0% in the BAL and peripheral 
blood, respectively; p=0.006) (Figure 9.5A).  
 
Similar to  CD4+ cells,  IL-9-producing CD8+ cells in peripheral blood and BAL produced 
small amounts of  IL-13 (Tc2 phenotype; median CD8+IL9+IL13+ expression was 1.7% and 
7.0%, respectively) and IL-17 (Tc17 phenotype; median CD8+IL9+IL17+ expression was 
4.5% and 13.5%, respectively). Most CD8+IL9+ cells did not co-express IL-13 or IL-17 and 
exhibited a Tc9 phenotype (median CD8+IL9+IL13negIL17neg expression was 93.9% and 
91.8% in BAL and peripheral blood, respectively). Of these Tc9 cells, very few expressed 
PU.1 (median CD8+IL9+IL13negIL17negPU.1+ expression was 5.0% and 1.6% in the BAL 
and peripheral blood, respectively). None of these differences in expression between BAL 









































Figure 9.5 Frequency of cytokines (IL-17 and IL-13) and transcription factors (PU.1) that are 
co-expressed by (A) CD4+IL9+ cells and (B) CD8+IL9+ cells in the blood and broncho-alveolar 
lavage (BAL) of TB patients. Bar height represent median values and error bars show the 
interquartile range. „+‟ indicates co-expression; „-‟ indicates no co-expression; „   ‟ indicates that the 
cytokine/transcription factor was not analyzed for co-expression. The pie charts below each bar chart 
indicate the contribution of the various CD4+ and CD8+ Th-cell subtypes to the production of IL-9. 
 
9.4 Discussion 
In the previous experiments, the frequency and specific lineage of IL-9 producing T-cells in 
TB patients and presumed LTBI controls was assessed by flow cytometry. CD4+IL9+ cells 
were significant higher in the PBMCs and BAL cells of TB patients compared to LTBI 
controls. CD8+IL9+ cells were significantly higher in the blood, but not the BAL, of TB 
patients compared to LTBI controls. These results were comparable whether PBMCs were 
stimulated with M.tb antigens, RD1 or PPD. In TB patients, the co-expression of lineage-
specific cytokines was analyzed in PPD-stimulated PBMCs and BAL cells to determine the 
Th and Tc phenotype of IL-9 producing CD4+ and CD8+ cells, respectively. In the 
CD4+IL9+ population, a limited number of cells expressed IL-13 (Th2) or IL-17 (Th17) and 
most (>90%) exhibited a Th9 phenotype (CD4+IL9+IL13negIL17neg). PU.1 expression in 
these Th9 cells (CD4+IL9+IL13negIL17negPU.1+) was higher in BAL cells compared to 
PBMCs (p=0.006) but still generally very low. A similar expression pattern was observed in 
the CD8+IL9+ population. Most of these cells (~90%) displayed a Tc9 phenotype 
(CD8+IL9+IL13negIL17neg) but few produced the transcription factor PU.1. 
   
9.4.1 Increased IL-9 expression in TB 
The data presented here show that CD4+ and CD8+ T-cell production of IL-9 was higher in 
the BAL and blood of TB patients compared to LTBI controls and support the results 
obtained by Luminex in chapter 8. Increased IL-9, measured either as soluble protein or 
mRNA, has been observed in M.tb antigen stimulated PBMCs of TB patients in previous 
studies [344, 345]. However, investigations of IL-9 expression at the site of disease have 
been less conclusive. Herrera et al found no differences in IL-9 levels in M.tb stimulated 
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BAL cells of pulmonary TB patients and healthy controls [11]. In contrast, Ye et al, using 
PMA and ionomycin stimulated CD4+ T-cells, observed higher expression of CD4+IL9+ 
cells in pleural effusions compared to the peripheral blood of TB pleuritis patients [334]. 
However, this study did not include healthy controls as a comparative group. As such, my 
study is the first to show increased IL-9 in the CD4+ and CD8+ populations of TB patients 
compared to presumed LTBI controls at the site of disease and the periphery.  
 
9.4.2 CD4+IL9+ cells express a predominantly Th9 phenotype 
The co-expression of other Th lineage specific cytokines was analyzed to determine the Th 
phenotype of these IL-9 producing CD4+ cells. I found that the majority of CD4+IL9+ cells 
in TB patients did not co-express IL-13 (Th2) or IL-17 (Th17) (>90% of CD4+ T-cells were 
CD4+IL9+IL13negIL17neg in blood and BAL) suggesting that these were in fact Th9 cells. A 
similar phenotypic profile of Th9 cells has been described in the peripheral blood of both 
pulmonary allergy and melanoma patients [332, 669].  Th9 cells are a newly described subset 
of Th cells which develop from naïve T-cells after antigenic stimulation in the presence of 
IL-4 and TGFβ [49, 50, 322, 323]. These cells are characterized by the production of large 
amounts of IL-9 but not cytokines from other lineage specific T-cell subsets, including IFN-γ 
(Th1), IL-17 (Th17), IL-4 or IL-13 (Th2). Th9 cells have been described in allergic airway 
inflammation [326, 327, 332] and parasitic infections [665-668] but little is known about 
their role in TB and will be discussed later.  
 
IL-9 production is not restricted to Th9 cells and can also be produced by Th2 [322, 326, 
670] and Th17 [339, 642, 664] cells. Th9 cells are closely related to Th2 cells as their 
development from naïve T-cells is dependent on IL-4 and Th2 cells can differentiate to Th9 
cells in the presence of TGFβ [49, 50]. In early stages of Th2 differentiation, Th2 cells can 
produce both IL-4 and IL-9 [671]. It has been suggested that only a small fraction of fully 
differentiated Th2 cells continue to express IL-9 and those that lose the ability to express Th2 
cytokines develop into Th9 cells [50, 672]. In my study, Th2 expression (CD4+IL13+) was 
very low and only a small proportion of CD4+ cells co-expressed IL-13 and IL-9 (3% in 
blood and 7% in BAL). A similar population has been shown in CD4+ T-cells under Th2 
 
 214 
polarizing conditions [326, 670]. It is possible that these CD4+IL9+IL13+ cells may 
represent a proportion of naïve T cells undergoing Th2 differentiation or Th2 cells at an 
intermediate stage of development into Th9 cells.  
 
Evidence also suggests that Th17 cells are capable of producing IL-9. In a murine 
autoimmunity model of EAE, large amounts of IL-9 are produced by Th17 cells and Th17 
development can be induced by IL-9 and TGFβ [339, 642]. In humans, repeated stimulation 
under Th17 polarizing conditions can drive Th17 cells to co-produce IL-9 and IL-17, which 
is further enhanced in the presence of Th17 mediators such as IL1β and IL-21 [664]. 
Furthermore, these IL9+IL17+ cells are found in greater numbers in diabetic patients 
compared to healthy controls suggesting that these cells may be associated with 
inflammatory disorders [664]. In the data presented here, I observed a small but noteworthy 
population of IL9+IL17+ cells in the BAL of TB patients (16% of CD4+IL9+ produced IL-
17). However, it is unknown if these cells have any significance in the context of TB and 
further investigations will be required to determine if these cells contribute to TB-associated 
inflammation. 
 
9.4.3 Expression of PU.1 in Th9 cells 
Th9 cells are considered a distinct lineage as they do not express other subset-specific 
transcription factors such as T-bet (Th1), GATA3 (Th2), RORγt (Th17) or Foxp3 (Tregs) at 
levels comparable to their respective T-cell subsets [324].  However, the identification of a 
single master regulator, which is thought to define a committed lineage for Th9 cells, has 
remained elusive. Instead, multiple transcription factors have been instigated in Th9 
induction and most of these are mediators in the signaling pathways of IL-4 and TGFβ, the 
two cytokines required for Th9 development. For example, STAT6 and its downstream 
target, GATA3, are mainly expressed by Th2 cells but also by Th9 cells, albeit at lower 
levels [49, 325]. However, these are thought to act indirectly by downregulating T-bet and 
FoxP3, which inhibit IL-9 production [49, 50, 325]. Two of the more convincing candidates 
are IRF4 and the ETS transcription factor, PU.1. Both of these transcription factors are 
induced by TGFβ and directly bind to the il9 locus [326, 327]. In mice, ectopic expression of 
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PU.1 increases IL-9 production and OVA sensitized PU.1 deficient mice showed less IL-9 
production and reduced allergic lung inflammation [326]. In humans Th9 cells, increased 
PU.1 expression correlated with IL-9 expression in atopic allergy patients and blocking of 
PU.1 with siRNA reduced IL-9 expression [326, 328]. In similar experiments, IRF4 
displayed the same effect on Th9 differentiation as PU.1 [327]. However, IRF4 also drives 
Th2 and Th17 development [329, 330] whereas PU.1 represses Th2 cytokine production 
[673, 674]. Given these data, PU.1 is the only transcription factor identified that is involved 
in converting a Th2 lineage to a Th9 lineage. 
 
 In the data presented here, only a small percentage of Th9 cells expressed PU.1 
(CD4+IL9+IL13negIL17negPU.1+). This result is similar to another study which reported PU.1 
expression in a proportion of Th9 cells from allergic donors [332]. While PU.1 is necessary 
for Th9 development, continued PU.1 expression may not be required for fully committed 
Th9 cells. As such, it is unlikely that PU.1 is the lineage defining transcription factor for Th9 
cells. Given the antagonistic relationship of PU.1 in Th2 and Th9 cells, it would have been 
useful to compare PU.1 expression in these two helper T-subsets. Unfortunately, this was not 
possible because the overall PU.1 expression (CD4+PU.1+) was generally low. The low 
PU.1 expression, compared to other human studies, may be explained by the use of isolated 
Th9 cells [332] or cells differentiated in vitro under Th9 and Th2 polarizing conditions [326]. 
Interestingly, Th9 cells expressing PU.1 in BAL was significantly higher compared to blood. 
Given that induction of PU.1 also turns off IL-4 production and turns on IL-9 production, it is 
possible that an upregulation of PU.1 in cells at the site of disease may represent stage of 
differentiation where Th2 cells „switch‟ to Th9 cells or naïve T-cells develop a Th9 
phenotype.   
 
9.4.4 Function of Th9 cells and possible role in TB 
The multifunctional effects of Th9 cells are exemplified by their interaction with different T-
cell lineages and their role in different diseases. Th9 cells are pro-inflammatory and, together 
with Th2 cells, seem to drive allergic inflammation and immunity to parasitic infections. In 
mice, adoptive transfer of Th9 cells to the lungs resulted in allergic inflammation 
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characterized by increased eosinophil recruitment, mast cell numbers, mucus production, IgE 
production and collagen deposition [324, 327, 332, 673, 675]. In humans, IL-9 expression 
was increased in the lungs of asthma patients and atopic infants [326, 331, 661, 676]. Th9 
cells also contribute to parasite clearance in a similar manner to Th2 cells [665, 666]. Th9 
cells also function in association with Th17 to drive autoimmunity in murine models of EAE 
and colitis [49, 333, 339]. In diabetic patients, increased levels of IL-9 produced by Th17 
cells were observed compared to healthy controls [664]. In contrast, IL-9, produced by Tregs 
and Th9 cells, may also have anti-inflammatory functions in skin allograft tolerance by 
recruiting and promoting Treg suppression at the graft site [342]. However, there is a paucity 
of data regarding the role of Th9 cells in TB.  
 
Evidence suggests that IL-9 can modulate protective anti-mycobacterial mechanisms and 
may be detrimental to TB immunity in a similar manner to IL-4. One such mechanism is the 
downregulation of a protective Th1 response. The addition of exogenous IL-9 to in vitro 
PBMC cultures of TB patients resulted in reduced IFN-γ mRNA expression [344]. IL-9 also 
inhibited IFN-γ-induced apoptosis in pleural mesothelial cells of patients with TB pleuritis 
[334] and the production of TNFα and ROIs in LPS stimulated monocytes [343]. Addition of 
rIL-9 also enhances Treg suppression in vitro [642], which can directly subvert 
mycobacterial containment in monocyte derived macrophages in vitro [293]. Furthermore, 
IL-9 can inhibit the suppressive activity of Tregs on Th2 cells [444] resulting in Th2 
polarization [677]. 
 
Th9 cells may also contribute to the lung remodeling associated with TB. Fibrosis is thought 
to be driven by TGFβ and the Th2 cytokines, IL-4 and IL-13 [16]. Similarly, IL9 seems to be 
critical for collagen deposition and extensive lung fibrosis in chronic allergic lung 
inflammation and blocking IL-9 reduced this airway remodeling [678, 679]. Thus, in a TGFβ 
rich environment, which is commonly observed in the tuberculous lung [16], it is possible 
that Th2 as well as Th9 responses may contribute to pulmonary fibrosis in active TB. 
 
Given the clear developmental relationship between Th2 and Th9 cells and their overlapping 
functions in allergic and parasitic diseases, it is likely that Th9 cells collaborate and even 
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augment Th2 responses in TB. However, this is only speculative and further investigations 
are required into the precise regulatory and effector mechanisms of Th9 cells and their 
interactions with other Th subsets, particularly Th2 cells, to influence TB disease outcome. 
These experiments were outside the scope of this thesis but will be the objective of future 
studies. 
 
9.4.5 Expression of CD8+ Tc9 cells and possible role in TB 
CD8+ T-cells show similar phenotypic patterns as Th cells and include traditional cytotoxic 
cells (Tc1), as well as IL-4 (Tc2) and IL17 (Tc17) expressing CD8+ T-cells [219]. 
Interestingly, I found a distinct CD8+ T-cell subset which expressed IL-9, but not IL-13 or 
IL-17, and was higher in TB patients compared to LTBI controls. These cells, termed Tc9, 
develop under Th9 polarizing conditions and express the same transcription factors as Th9 
cells [222, 224, 680]. Such non classical CD8+ T-cells are thought to develop under TGFβ 
rich conditions to support CD4+ mediated inflammatory responses rather than drive 
cytotoxicity [224]. Tc9 cells are distinct from traditional cytotoxic T cells (Tc1) as they 
produce much more IL-9 than IFN-γ and cytotoxic molecules such as granzyme B [222, 224, 
680]. In an adoptive transfer model of Rag2-/- mice, Tc9 cells are thought to play a supportive 
role in Th2 mediated allergic airway inflammation by driving recruitment of eosinophils, 
mucus producing cells and inflammation [224]. Surprisingly, these cells were shown to have 
greater tumorcidal activity compared to classical Tc1 cells. In an adoptive cell transfer 
murine model, Tc9 cells were able to target tumor cells and differentiate into effector Tc1 
cells, producing IFN-γ and other cytotoxic molecules for effective tumor killing [222, 680]. 
However, Tc9 cells have never been described in TB. One possible function of Tc9 cells is to 
augment Th2 activity in TB, similar to allergic airway inflammation. Further investigations 
are required to elucidate the role of these cells in TB. 
 
9.4.6 Limitations 
IL-13 was chosen as a surrogate marker of Th2 cells rather than IL-4 due to the difficulties 
associated with measuring IL-4 (discussed in chapter 4). However, IL-13 shares receptors 
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and functions with IL-4 and previous studies used a similar phenotypic profile for describing 
Th9 cells [332]. As such, the use of IL-13 as a Th2 marker is justified and the data remains 
valid. 
 
Only the transcription factor PU.1 was analyzed in Th9 cells. However, other transcription 
factors, such as IRF4, STAT6 and GATA3, have been proposed as regulatory proteins 
involved in the development and maintenance of Th9 cells. Due to limitations in sample 
quantity and the number of analytes that could be included in the Th9 flow cytometry panel, 
it was not possible to measure these additional markers. Future investigations will include 
these transcription factors to determine their role in Th9 induction in the context of TB. 
 
Only three BAL samples were obtained in the LTBI control group and may explain the lack 
of significance in the CD8+IL-9+ expression levels between this group and TB patients. 
Recruitment of participants to undergo an invasive bronchoscopy procedure was difficult and 
limited cell recovery often meant that immune assays needed to be prioritized based on the 
amount of alveolar cells that were available. However, additional participants will be 
recruited from other ongoing studies in the future to increase the LTBI BAL numbers. 
 
9.5 Conclusion 
IL-9 expression in CD4+ and CD8+ T-cells was significantly increased in the BAL and 
blood of TB patients compared to LTBI controls. The majority of these IL-9 producing cells 
exhibited a Th9 (CD4+IL9+IL13negIL17neg) and Tc9 (CD8+IL9+IL13negIL17neg) phenotype. 
These data suggest that a Th9 response may also contribute to dysregulated TB immunity 
perhaps by augmenting a subversive Th2 response. However, further investigations are 








10. CHAPTER 10: General discussion, implications and future 
direction 
 
Despite declining global TB rates, the burden of TB in Sub-Saharan Africa, particularly 
South Africa, remains a major public health threat. South Africa has one of the highest TB 
incidence rates in the world, driven by a weak primary healthcare system, HIV co-infection 
and the emergence of drug resistant TB [1].The development of effective vaccines is a key 
aspect of efficient TB control but current vaccine candidates, such as BCG and MVA85A, 
have limited protective efficacy [2-4]. These vaccine candidates have been selected based on 
their ability to induce a Th1-specific IFN- response. However, patients who get TB often 
have strong Th1 responses at the site of disease [9-15]. Successful vaccine design requires an 
in-depth understanding of the specific immune pathways that not only promotes protective 
immunity, but also those that are subversive.  
 
One such subversive pathway that may have a corrupting influence on TB immunity involves 
a Th2 response, driven by the prototype Th2 cytokine, IL-4. A number of studies have 
reported increased IL-4 in pulmonary TB patients [9, 17-21, 243, 409-413] which correlate 
with disease susceptibility [22, 23] and immunopathology [9, 17-21].  Furthermore, IL-4δ2, a 
naturally occurring splice variant and antagonist of IL-4, was found to be associated with a 
protective phenotype in TB disease [9, 28-30]. Despite these findings, none have attempted 
to determine if IL-4 and IL-4δ2 have a direct causal relationship on anti-mycobacterial 
activities and protective host immunity in a human model of TB. This thesis attempts to 
describe the host immune response of pulmonary TB patients in the context of a Th2 
response and to further elucidate the role of IL-4 and IL-4δ2 in an in vitro human TB 
infection model. 
 
There are several limitations to the current study including the difficulty in measuring IL-4 
and IL4d2 and the concentrations of IL-4 used in the mycobacterial containment assay. These 




10.1 Is IL-4 expression increased in patients with active TB? 
There have been several studies that have interrogated the levels of IL-4 and IL-4δ2 in active 
TB [9, 18, 30, 288, 417]; only one compared expression of these cytokine in the peripheral 
and disease compartments [9] and none in a high burden TB setting. Similarly, in the current 
study, analysis of mRNA expression encoding Th1 (IFN-γ) and Th2 (IL-4 and IL-4δ2) 
cytokines both at the site of disease and the peripheral circulation using a validated qPCR 
assay revealed a distinct cytokine profile in TB patients that was specific to the compartment 
being analyzed (chapter 3). The high levels of IFN-γ mRNA observed in the lung 
compartment of TB patients likely reflect an accumulation of Th1 effector cells at the site of 
inflammation [38] and, given the similar levels observed in LTBI controls, suggest that a 
potent Th1 response is not the only immune component necessary to confer protection.   
 
The higher IL4 expression and lower Th1:Th2 (IFN-γ:IL-4) ratio observed in the peripheral 
blood of TB patients compared to LTBI controls in the current study confirms results from 
previous reports [9, 21, 416, 417, 504] and support the notion that a Th2 response is 
associated with a deficient immune response to M.tb (chapter 3). Comparable results were 
not observed in BAL though, probably due to very low IL-4 expression. The antagonistic 
Th1/Th2 relationship may explain this observation in the lungs where the accumulation of 
IFN-γ producing Th1 cells may have subsequently downregulated the Th2 response. 
However, the technical difficulties associated with measuring low expressing cytokines 
cannot be ruled out. IL-4 expression is generally low as it is active at concentrations ~1000 
fold below that of IFN-γ [24, 25]. Delayed BAL sample processing, which can reduce 
detectable mRNA levels due to RNase activity [26], may have further contributed to the 
already low detectable IL-4 mRNA observed in the lungs. These challenges were particularly 
evident when IL-4δ2 was measured; its expression can be up to ~7 times lower than that of 
IL-4 expression [377, 378]. This is likely why IL-4δ2 was mostly undetectable across all 




10.2 Does IL-4 have a causal role in TB or is it just an epiphenomenon? 
In order to test the in vitro effect of IL-4 and IL-4δ2 on mycobacterial containment (chapter 
6) and mechanisms of host immunity (chapter 7), it was first necessary to clone and express 
recombinant IL-4 and IL-4δ2. A baculovirus expression system was chosen for reasons stated 
in table 4.1. rIL-4 was successfully expressed as a secreted His-tagged fusion protein 
(chapter 4). The amino acid sequence was confirmed by mass spectrometry and bioactivity 
was verified by the ability of rIL-4 to induce T-cell proliferation and CD23 expression on B 
cells (chapter 5). Similar conditions were used for rIL-4δ2 expression but proved to be more 
problematic as protein yield was very low and purity was sub-optimal. In contrast to rIL-4, 
His-tagged rIL-4δ2 remained intracellular likely because the protein structure of IL-4δ2, 
which is slightly altered compared to IL-4, interfered with the protein secretory pathway in 
insect cells [540-542]. As a result, protein overexpression, under the control of a strong 
baculovirus polyhedron promoter, and the subsequent intracellular accumulation of protein 
led to the formation of insoluble aggregates [544].  Furthermore, the higher proportion of 
intrinsic hisitidine-containing insect cell proteins in the cell lysate, compared to the 
supernatants, resulted in co-purification of non-specific proteins and low IL-4δ2 purity. 
Nonetheless, enough IL-4δ2 was obtained to confirm protein function by the ability of IL-
4δ2 to inhibit IL-4 induced T-cell proliferation (chapter 5). However, due to the high 
concentrations required to observe an effect on IL-4-induced functions in vitro, rIL-4δ2 
protein yield was insufficient to test in the mycobacterial containment model.  
 
Despite increased IL-4 being found in TB patients, it was not known whether IL-4 plays an 
active role in subverting a protective immune response or is a by-product of TB-associated 
chronic inflammation. Previous murine studies have shown that IL-4 has a direct cause/effect 
relationship in TB but the animal model may not be entirely relevant in human tuberculosis 
[256, 424]. In order to answer this question, a mycobacterial containment assay was 
performed in this study to assess the effect of rIL-4 on the ability of effector cells to contain 
H37Rv within monocyte derived macrophages (in terms of CFU/ml; chapter 6).  Effector T-
cells generated in response to PPD and IL-4 had a reduced ability to contain H37Rv within 
MDMs compared to effectors generated in response to PPD alone and this effect was IL-4 
dose-dependent. Furthermore, subversion of M.tb containment was abrogated if IL-4 was 
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blocked (using anti-IL-4 antibodies). IL-4 is essential for Th2 development and likely 
polarizes unprimed T-cells toward a Th2 effector phenotype which subsequently 
downregulated the Th1 response [574]. A similar subversive effect was observed if IL-4 was 
added to infected macrophages in the presence of PPD pre-primed effector T-cells but the 
extent of this subversion was less pronounced. Effector T-cells that develop in response to 
PPD are predominantly of a Th1 phenotype [603] and may not be as responsive to the Th2 
polarizing effect of IL-4 added at such an advanced stage of Th1 differentiation [574]. IL-4 
also exerts its effects directly on macrophages by driving alternative activation [351] and 
downregulating anti-mycobacterial responses [16] and may have also contributed to the 
reduced M.tb containment observed in both of these interventions. To my knowledge, this is 
the first study to directly evaluate the effect of IL-4 on a human model of TB infection. 
 
The observed IL-4 associated subversion of M.tb containment in vitro suggests that a Th2 
response can impair protective immunity in TB. IL-4 can modulate protective mechanisms of 
T-cells and macrophages, by downregulating a Th1 response [430, 431], inducing an 
alternatively activated macrophage phenotype [351, 432] and inhibiting autophagy [44]  and 
production of reactive intermediate species [44]. A role for IL-4 in the development of Tregs, 
which directly attenuates mycobacterial stasis [293], has also been proposed [301-303, 444, 
445] but the data is conflicting. Despite these findings, the interaction of these mechanisms 
and their direct effect on mycobacterial survival in the context of a Th2 response has not 
hitherto been explored. In order to investigate these mechanisms, a mycobacterial 
containment assay was performed where cells were stained for surface and intracellular 
markers then analysed by flow cytometry (chapter 7). IL-4-mediated subversion of M.tb 
containment was characterised by an increase in Treg (CD4+CD25+FoxP3+) expression and 
a concomitant decrease in CD4+ T-cell expression of Th1 cytokines (IFN-γ and TNFα). 
Blocking of IL-4 reverted Treg and CD4+ IFN-γ expression levels to those observed in cells 
stimulated with PPD alone (no IL-4). An increase in DC-SIGN expression, a marker of 
alternate macrophage activation that facilitates entry of M.tb into these cells [351, 609], was 
also observed on macrophages in IL-4-containing culture wells. These data implicate IL-4 as 
a mediator of multiple immune mechanisms in different cells involved in M.tb control. IL-4 
drives a Th2 response and simultaneously induces Treg proliferation resulting in the 
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dampening of a protective Th1 response. IL-4 also polarizes alternatively activated 
macrophages, characterised by increased DC-SIGN expression, to downregulate 
macrophage-specific anti-mycobacterial mechanisms. 
 
These data provide convincing evidence that IL-4 plays an active role in undermining 
protective immune mechanisms but whether the in vitro findings translate to what is 
happening within the body during active TB is not entirely certain. The inherent limitation of 
any in vitro model of infection is that it is a one-dimensional representation of the immune 
response and lacks the complex interaction of cytokines and cellular mechanisms occurring 
at the site of disease. Nevertheless, existing evidence does support the subversive role of IL-4 
in vivo. IL-4-deficient mice infected with TB exhibit reduced bacterial proliferation and 
immunopathology [256]. Biological findings in human TB show that high IL-4 levels 
correlate with radiological extent of disease [9, 18, 21, 421] and were able to predict 
progression to active TB [23]. Another concern is whether the concentration of IL-4 used in 
the mycobacterial containment assay is biologically relevant given that naturally occurring 
IL-4 is active at much lower concentrations. High rIL-4 concentrations were required in this 
model to observe a subversive effect on M.tb containment because recombinant protein, 
particularly those expressed in a non-mammalian system, tend to be less active and stable 
that their natural counterparts [554]. Furthermore, sIL-4R may considerably prolong the half-
life of IL-4 protein and enhance the bioactivity of IL-4 in vivo [362]. Thus, it is highly 
plausible that the high IL-4 levels consistently associated with active TB, are also causing 
immune dysfunction in vivo. 
 
10.3 What other Th2 or Th2-like cytokines play a potential role in 
disrupting protective TB immunity? 
The data presented thus far supports the notion that IL-4 can impair TB immunity but other 
cytokine factors are likely to be involved by either supporting IL-4 function or being a target 
of IL-4-induced immune dysregulation. Previous studies measuring soluble cytokines in TB 
have produced disparate results and few have evaluated expression in both the periphery and 
the site of disease (discussed in more detail in chapter 8). In order to determine what other 
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soluble mediators may be involved in impaired immunity within the context of a Th2 
response, M.tb antigen-specific cytokine and chemokine responses were evaluated in culture 
supernatants of cells from the periphery and the lungs by Luminex assay (chapter 8). A 
distinct compartment-specific cytokine profile was found in TB patients characterized by 
decreased Th1 responses in the blood (IFN-γ) and increased IL-9 in the lungs. The ratio of 
Th2-related cytokines and chemokines (IL-9 and MCP-1) to Th1 cytokines (IFN-γ and 
TNFα) suggest a mixed Th1/Th2 response similar to the mRNA expression patterns observed 
in chapter 3. However, IL-4 was undetectable in these antigen driven cultures, likely due the 
difficulty in measuring soluble IL-4 protein (discussed in chapter 3). 
 
The observation of an increased IL-9 response in the lungs of TB patients warranted further 
investigation into the cellular sources of this cytokine. Flow cytometric analysis revealed that 
CD4+ Th9 cells and CD8+ Tc9 cells were the predominant producers of IL-9 in TB. Th9 
cells are distinct from Th2 cells but are inherently linked because IL-4 is required for Th9 
development [49, 50] and Th9 cells have overlapping functions in Th2-driven allergic 
inflammatory diseases [324, 327, 332]. Tc9 cells are thought to exhibit a similar paradigm in 
the CD8+ population but have never been described in TB prior to this study. In both murine 
and human TB, increased levels of IL-4 and TGFβ are commonly found [16, 439], which 
provide the developmental conditions for induction of a Th9 response. Thus Th9 cells, and 
probably Tc9 cells as well, are likely to contribute to dysregulated immunity in TB by 
augmenting the Th2 response. 
 
10.4 Implication for vaccine design/immunotherapeutic interventions 
against TB  
The efficacy of BCG and MVA85A is based on their ability to prime the immune system by 
boosting a Th1 response, specifically CD4+IFN-γ producing T-cells. However, these 
vaccines offer limited protection in adults particularly in high burden settings where they are 
most needed. BCG efficacy is thought to be dampened in these settings due to a pre-existing 
Th1 immune response as a result of exposure to environmental mycobacteria [681].  Indeed, 
other studies and the data presented in chapter 3 reveal that a potent Th1 response is already 
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present in TB patients. Furthermore, animal studies show that manipulations to increase a 
Th1 response, above the response induced by BCG alone, failed to provide additional 
protection [682, 683]. These data suggest that it is the nature, rather than the magnitude, of 
the Th1 response that is important in inducing protective immunity. But targeting the Th1 
response alone may not be the only answer. Chronic helminth infection, common in TB 
endemic areas, may also contribute to the ineffectiveness of BCG by inducing the 
development of Th2 and Treg responses [451-453]. However, a Th1 is also induced by NTM 
and helminth infection and it is rather an unbalanced Th1/Th2 response that may be 
impairing protective immunity. Evidence of a pre-existing mixed Th1/Th2 response is 
commonly found in TB patients from developing countries [21, 288, 416-418] and the data 
presented here (chapter 3 and 8) supports these findings. Furthermore, artificially skewing 
the immune response to a Th2 phenotype can attenuate mycobacterial containment (chapter 
6) by inhibiting protective immune mechanisms (chapter 7).  
 
A large number of vaccine candidates are either in development or at various stages of 
clinical testing. The high cost of clinical trials and limited field testing sites makes 
prioritisation of the most promising candidates of paramount importance and there is an 
urgent need for reliable scientific data to inform vaccine designs. The two most important 
questions that need to be answered are (i) what antigens to target? and (ii) what type of 
immune response needs to be induced to confer protection?  The evidence presented here and 
elsewhere suggests that inducing a Th1 response is not enough and targeting the 
downregulation of Th2 responses and/or immunoregulatory mechanisms, including Th9, may 
also be required. As such, specific M.tb antigens that induce a Th2 or Th2-like response need 
to be identified so they can be excluded from existing and future vaccine preparations or 
administered with adjuvants that drive Th2 regulatory responses. One such candidate is M. 
vaccae, which promotes Th1 and simultaneously downregulates Th2 responses by inducing 
Th2-targeting regulatory cells, and has shown some promise as a multiple dose therapeutic 
and prophylactic vaccine in clinical trials [465-467]. Similarly, the hsp65 DNA vaccine 





The relevance of these data may also apply to the use of monoclonal antibodies in TB 
treatment. Neutralizing antibodies to Th2 and Th2-like cytokines or their receptors are 
commonly evaluated for their therapeutic use in asthma because they are simple to 
administer and well tolerated [684]. For example, anti-IL4 treatment has been shown to 
substantially reduce bacterial loads in murine models [685, 686] but its effect in humans is 
yet to be determined. Anti-IL-9 treatment reduces airway inflammation and hyper-
responsiveness in murine models and improved asthma symptoms in humans [687]. 
However, little is known about their efficacy in TB. In a murine model of TB, injection of a 
neutralizing antibody to IL-4 in BALB/c mice was largely therapeutic even when introduced 
late in infection [688]. Blocking of Treg immunoregulatory mediators was successful in 
tumour clearance in a murine model of mesothelioma [689] and, given the detrimental role of 
Tregs in TB (chapter 7, [293]), may also prove beneficial in TB in humans.  
 
10.5 Other Limitations 
Healthy unexposed individuals were not recruited in this study. The purpose of the study was 
to determine why some individuals exposed to TB develop progressive disease whereas 
others remain healthy. As such, healthy, asymptomatic LTBI individuals were chosen as 
controls because this group best represents exposure to TB but subsequent immune control of 
the infection. Indeed, it is possible that differences in the cytokine expression profile of 
unexposed controls, compared to TB patients, may have shown greater significance as was 
observed in other studies [9, 21, 397].    However, these studies were performed in low TB 
prevalence countries where exposure to other immune modulating pathogens, including 
helminthes, is not common [690]. Furthermore, in a high burden setting such as South Africa, 
it is impossible to definitively distinguish healthy controls from LTBI using the available T-
cell sensitization assays (TST and IGRA). Thus, due to the high rates of LTBI in the study 
setting and sample error, we did not recruit unexposed healthy controls. Nonetheless, it 
would be informative to determine the immune response to TB in these unexposed 





The higher percentage of males in the TB group and females in the LTBI group may have 
influenced cytokine expression patterns observed in the study. Indeed, the global TB 
notification rates are male biased, with a male to female ratio of ~1.8:1 [1]. In this study, the 
higher percentage of males recruited in the TB group is likely a reflection of the higher 
incidence of TB in males compared to females. On the other hand, the higher percentage of 
females in the LTBI group may have been an artifact of the recruitment strategy of the study. 
LTBI were primarily recruited from a healthcare worker study, which predominantly 
consisted of female nurses. Although gender differences can play a role in susceptibility to 
TB, it is unclear whether these sex differences are related to behavior, have a physiological 
component or a combination of these factors [691]). For instance, men tend to partake in 
more TB risk associated behavior (smoking, alcohol consumption) than women [691]. Sex 
hormones are also thought to play a role in the immune response to TB affecting various cell 
types including macrophages, neutrophils and T cells [691]. For example, estrogen and 
testosterone seem to have antagonistic effects on macrophage activation via TLR4 expression 
and programmed cell death via PGE2 and LXA4 production [8, 692, 693]. Furthermore, in 
mice, IFNγ production is downregulated by testosterone but enhanced by estrogen [694, 
695]. In contrast, high levels of estradiol can promote Th2 polarization and Tregs also seem 
to be influenced with changing levels of hormones, particularly during the menstrual cycle 
[692]. Given these findings, sex differences will be taken into account in future studies on 
TB immunity. 
 
TB patients recruited into the study had a microbiologically confirmed diagnosis and were on 
anti-TB treatment for less than 2 weeks. These criteria were chosen because it allowed for a 
definitive diagnosis of TB early in the disease time course after these patients presented at 
the clinic. However, the host immune response can vary depending on the clinical stage of 
TB and subsequently, the measured cytokine profile may be different depending on when 
samples were collected during the disease time course. For example, IL-4 tends to be highest 
at the onset of disease and decrease following treatment [9]. Furthermore, bacterial 
proliferation occurring early in untreated disease may also lead to increased IFNγ responses 
[8]. However, it is extremely difficult to ascertain exactly when infection was established 
post-exposure and the time taken for presentation of symptoms as patients usually only seek 
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medical attention once they have had TB symptoms for at least 2 weeks. Furthermore it was 
not possible to definitively determine if TB disease in these patients were the result of 
primary exposure or reactivation of latent infection. These considerations should be taken 
into account when interpreting the results of this study. 
 
10.6 Future work 
The detrimental role of IL-4 on the ability of effector T-cells and macrophages to effectively 
contain M.tb has been established in an in vitro model of TB infection. However the role of 
IL-4δ2, in relation to IL-4, remains unknown. It was not possible to test this protein in my 
model as insufficient quantities were obtained in a baculovirus system. Once IL-4δ2 
expression is optimized, either using an appropriate leader sequence for expression in insects 
cells or a different expression system altogether, further mycobacterial containment 
experiments using rIL-4δ2, either alone or together with rIL-4, will be performed to 
investigate its effect on mycobacterial survival. Given the higher expression of IL-9 in TB 
patients, similar experiments need to be performed using recombinant IL-9, to determine if it 
has a similar effect as IL-4 in this model. It will also be important to evaluate the impact of 
adding these cytokines (IL-4, IL-4δ2, IL-9) to other cell types, particularly those of the innate 
immune system and on lung resident macrophages, which tend to exhibit different degrees of 
mycobacterial uptake and anti-mycobacterial activities compared to blood derived 
macrophages [580, 581].  
 
IL-4 was shown to be associated with the induction of Tregs in the mycobacterial 
containment assay. Further experiments are required to assess the function, mechanisms of 
action and primary target of these Tregs and if blocking of Tregs will reverse the effect on 
mycobacterial containment. 
 
If a function for IL-4δ2 can be elucidated, the next step would be to determine if this protein 
occurs naturally and is present in TB or other diseases. Currently, detection of mRNA 
transcript by qPCR is the only reliable method to distinguish IL4 and IL-4δ2. There is limited 
evidence that IL-4δ2 exists as a protein in vivo but commercial antibodies that can effectively 
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distinguish it from IL-4 are not available. As such, work is currently being performed to 
generate monoclonal antibodies against these two isoforms.  
 
IL-4δ2 is not the only splice variant of IL-4 that has been discovered. IL4δ3, which lacks 
exon 3, has been observed in cattle and rabbits [388, 398, 399], and increased levels have 
been observed in cattle protected against M. bovis [399]. However, this cytokine has never 
been reported in humans. qPCR analysis will be performed to determine if the mRNA 
transcript of this variant is detectable in humans. If its existence is confirmed, then further 
experiments will be conducted to assess its function in relation to the other IL-4 isoforms. 
 
HIV infected participants were excluded from the study. However, it is important to 
determine the immune response to TB in the context of HIV, due to the high co-infection 
rates, especially in South Africa. High levels of IL-4 have been found in HIV infected 
individuals and these levels decrease upon commencement of HAART [696, 697]. 
Furthermore, HIV patients co-infected with TB express higher levels of IL-4 than those who 
are only HIV infected [415]. Therefore, more experiments are required to determine the 
extent of the IL-4 subversive effect in cells from HIV/TB co-infected patients. 
 
10.7 Conclusion 
TB patients express high levels of IL-4 and exhibit a skewed Th1/Th2 ratio, compared to 
LTBI controls, despite having a potent Th1 response. It has been shown, for the first time in a 
human in vitro model of TB infection, that IL-4 can subvert anti-mycobacterial mechanisms 
and subsequently undermine M.tb containment in monocyte derived macrophages. This 
likely occurs by downregulating a protective Th1 response, via induction of Treg activity, 
and driving alternate macrophage activation. Furthermore, other Th2 and Th2-like cytokines 
were also found to be associated with active TB. IL-9 in particular, which is produced 
predominantly by CD4+Th9 and CD8+ Tc9 cells, is increased in TB patients and may 




 Collectively, these data indicate a Th2 response plays an active role in undermining host 
immunity to pulmonary tuberculosis.  It is hoped that these data can contribute to the 
development of vaccines or immunotherapeutic interventions that downregulate or block a 
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12.1 Section A 
 
 
Figure A1. Example of a melt curve analysis to determine the IL-4 qPCR primer sequence 




Table A1. Cloning primers used to amplify cDNA regions containing the qPCR targets of 
interest for IFN-γ and HuPO. The amplified regions were used to generate the plasmid standards. 
Gene of Interest 
 
Sequence 
○ Forward cloning primer 5’ - 3’ 





















Figure A2. mRNA expression levels of (A) IFN-γ (B) IL-4 and (C) IFN-γ:IL-4 ratio stratified by 
sputum smear status in peripheral whole blood (Blood; red squares) from patients with 
pulmonary tuberculosis (TB; Blood n=23) as measured by quantitative real-time PCR. Data is 
shown on a log10 scale and copy numbers are expressed per million copies of HuPO. Statistical 











12.2 Section B 
12.2.1 Primers sequences 
This section describes the primers used to construct the vector sequences in chapter 3 
 









(ii) These primers were used to construct the pAP01-IL4-TEV-His vector: 
 
AP2_F 


















































12.2.2 Nucleotide sequences 
This section describes the full sequence of the plasmid vectors used in chapter 3 
 
(i) pAP01-IL4-TEV-His (5720bp)  
 
Boxed – start and stop codons 
Signal peptide sequence 
Exon 1 of IL-4 
Exon2 of IL-4 
Exon 3 of IL-4 
Exon 4 of IL-4 
TEV recognition sequence 
Decahistidine tag 
Restriction enzyme sites 
 
 
1      GGAACGGCTC CGCCCACTAT TAATGAAATT AAAAATTCCA ATTTTAAAAA ACGCAGCAAG 
61     AGAAACATTT GTATGAAAGA ATGCGTAGAA GGAAAGAAAA ATGTCGTCGA CATGCTGAAC 
121    AACAAGATTA ATATGCCTCC GTGTATAAAA AAAATATTGA ACGATTTGAA AGAAAACAAT 
181    GTACCGCGCG GCGGTATGTA CAGGAAGAGG TTTATACTAA ACTGTTACAT TGCAAACGTG 
241    GTTTCGTGTG CCAAGTGTGA AAACCGATGT TTAATCAAGG CTCTGACGCA TTTCTACAAC 
301    CACGACTCCA AGTGTGTGGG TGAAGTCATG CATCTTTTAA TCAAATCCCA AGATGTGTAT 
361    AAACCACCAA ACTGCCAAAA AATGAAAACT GTCGACAAGC TCTGTCCGTT TGCTGGCAAC 
421    TGCAAGGGTC TCAATCCTAT TTGTAATTAT TGAATAATAA AACAATTATA AATGCTAAAT 
481    TTGTTTTTTA TTAACGATAC AAACCAAACG CAACAAGAAC ATTTGTAGTA TTATCTATAA 
541    TTGAAAACGC GTAGTTATAA TCGCTGAGGT AATATTTAAA ATCATTTTCA AATGATTCAC 
601    AGTTAATTTG CGACAATATA ATTTTATTTT CACATAAACT AGACGCCTTG TCGTCTTCTT 
661    CTTCGTATTC CTTCTCTTTT TCATTTTTCT CTTCATAAAA ATTAACATAG TTATTATCGT 
721    ATCCATATAT GTATCTATCG TATAGAGTAA ATTTTTTGTT GTCATAAATA TATATGTCTT 
781    TTTTAATGGG GTGTATAGTA CCGCTGCGCA TAGTTTTTCT GTAATTTACA ACAGTGCTAT 
841    TTTCTGGTAG TTCTTCGGAG TGTGTTGCTT TAATTATTAA ATTTATATAA TCAATGAATT 
901    TGGGATCGTC GGTTTTGTAC AATATGTTGC CGGCATAGTA CGCAGCTTCT TCTAGTTCAA 
961    TTACACCATT TTTTAGCAGC ACCGGATTAA CATAACTTTC CAAAATGTTG TACGAACCGT 
1021   TAAACAAAAA CAGTTCACCT CCCTTTTCTA TACTATTGTC TGCGAGCAGT TGTTTGTTGT 
1081   TAAAAATAAC AGCCATTGTA ATGAGACGCA CAAACTAATA TCACAAACTG GAAATGTCTA 
1141   TCAATATATA GTTGCTGATC AGATCTGATC ATGGAGATAA TTAAAATGAT AACCATCTCG 
1201   CAAATAAATA AGTATTTTAC TGTTTTCGTA ACAGTTTTGT AATAAAAAAA CCTATAAATA 
1261   TAAAGCTTGG ATCCATGGGT CTCACCTCCC AACTGCTTCC CCCTCTGTTC TTCCTGCTGG 
1321   CATGTGCCGG CAACTTTGTC CACGGACACA AGTGCGATAT CACCTTACAG GAGATCATCA 
1381   AAACTTTGAA CAGCCTCACA GAGCAGAAGA CTCTGTGCAC CGAGTTGACC GTAACAGACA 
1441   TCTTTGCTGC CTCCAAGAAC ACAACTGAGA AGGAAACCTT CTGCAGGGCT GCGACTGTGC 
1501   TCCGGCAGTT CTACAGCCAC CATGAGAAGG ACACTCGCTG CCTGGGTGCG ACTGCACAGC 
1561   AGTTCCACAG GCACAAGCAG CTGATCCGAT TCCTGAAACG GCTCGACAGG AACCTCTGGG 
1621   GCCTGGCGGG CTTGAATTCC TGTCCTGTGA AGGAAGCCAA CCAGAGTACG TTGGAAAACT 
1681   TCTTGGAAAG GCTAAAGACG ATCATGAGAG AGAAATATTC AAAGTGTTCG AGCGAAAACC 
1741   TGTATTTTCA GGGTACCCAC CATCACCATC ACCATCACCA TCACCATTAG CCTAGGTAGC 
1801   TGAGCGCATG CAAGCTGATC CGGGTTATTA GTACATTTAT TAAGCGCTAG ATTCTGTGCG 
1861   TTGTTGATTT ACAGACAATT GTTGTACGTA TTTTAATAAT TCATTAAATT TATAATCTTT 
1921   AGGGTGGTAT GTTAGAGCGA AAATCAAATG ATTTTCAGCG TCTTTATATC TGAATTTAAA 
1981   TATTAAATCC TCAATAGATT TGTAAAATAG GTTTCGATTA GTTTCAAACA AGGGTTGTTT 
2041   TTCCGAACCG ATGGCTGGAC TATCTAATGG ATTTTCGCTC AACGCCACAA AACTTGCCAA 
2101   ATCTTGTAGC AGCAATCTAG CTTTGTCGAT ATTCGTTTGT GTTTTGTTTT GTAATAAAGG 
2161   TTCGACGTCG TTCAAAATAT TATGCGCTTT TGTATTTCTT TCATCACTGT CGTTAGTGTA 
2221   CAATTGACTC GACGTAAACA CGTTAAATAG AGCTTGGACA TATTTAACAT CGGGCGTGTT 
2281   AGCTTTATTA GGCCGATTAT CGTCGTCGTC CCAACCCTCG TCGTTAGAAG TTGCTTCCGA 
2341   AGACGATTTT GCCATAGCCA CACGACGCCT ATTAATTGTG TCGGCTAACA CGTCCGCGAT 
 
 285 
2401   CAAATTTGTA GTTGAGCTTT TTGGAATTAT TTCTGATTGC GGGCGTTTTT GGGCGGGTTT 
2461   CAATCTAACT GTGCCCGATT TTAATTCAGA CAACACGTTA GAAAGCGATG GTGCAGGCGG 
2521   TGGTAACATT TCAGACGGCA AATCTACTAA TGGCGGCGGT GGTGGAGCTG ATGATAAATC 
2581   TACCATCGGT GGAGGCGCAG GCGGGGCTGG CGGCGGAGGC GGAGGCGGAG GTGGTGGCGG 
2641   TGATGCAGAC GGCGGTTTAG GCTCAAATGT CTCTTTAGGC AACACAGTCG GCACCTCAAC 
2701   TATTGTACTG GTTTCGGGCG CCGTTTTTGG TTTGACCGGT CTGAGACGAG TGCGATTTTT 
2761   TTCGTTTCTA ATAGCTTCCA ACAATTGTTG TCTGTCGTCT AAAGGTGCAG CGGGTTGAGG 
2821   TTCCGTCGGC ATTGGTGGAG CGGGCGGCAA TTCAGACATC GATGGTGGTG GTGGTGGTGG 
2881   AGGCGCTGGA ATGTTAGGCA CGGGAGAAGG TGGTGGCGGC GGTGCCGCCG GTATAATTTG 
2941   TTCTGGTTTA GTTTGTTCGC GCACGATTGT GGGCACCGGC GCAGGCGCCG CTGGCTGCAC 
3001   AACGGAAGGT CGTCTGCTTC GAGGCAGCGC TTGGGGTGGT GGCAATTCAA TATTATAATT 
3061   GGAATACAAA TCGTAAAAAT CTGCTATAAG CATTGTAATT TCGCTATCGT TTACCGTGCC 
3121   GATATTTAAC AACCGCTCAA TGTAAGCAAT TGTATTGTAA AGAGATTGTC TCAAGCTCGG 
3181   ATCGATCCCG CACGCCGATA ACAAGCCTTT TCATTTTTAC TACAGCATTG TAGTGGCGAG 
3241   ACACTTCGCT GTCGTCGAGG TTTAAACGCT TCCTCGCTCA CTGACTCGCT GCGCTCGGTC 
3301   GTTCGGCTGC GGCGAGCGGT ATCAGCTCAC TCAAAGGCGG TAATACGGTT ATCCACAGAA 
3361   TCAGGGGATA ACGCAGGAAA GAACATGTGA GCAAAAGGCC AGCAAAAGGC CAGGAACCGT 
3421   AAAAAGGCCG CGTTGCTGGC GTTTTTCCAT AGGCTCCGCC CCCCTGACGA GCATCACAAA 
3481   AATCGACGCT CAAGTCAGAG GTGGCGAAAC CCGACAGGAC TATAAAGATA CCAGGCGTTT 
3541   CCCCCTGGAA GCTCCCTCGT GCGCTCTCCT GTTCCGACCC TGCCGCTTAC CGGATACCTG 
3601   TCCGCCTTTC TCCCTTCGGG AAGCGTGGCG CTTTCTCATA GCTCACGCTG TAGGTATCTC 
3661   AGTTCGGTGT AGGTCGTTCG CTCCAAGCTG GGCTGTGTGC ACGAACCCCC CGTTCAGCCC 
3721   GACCGCTGCG CCTTATCCGG TAACTATCGT CTTGAGTCCA ACCCGGTAAG ACACGACTTA 
3781   TCGCCACTGG CAGCAGCCAC TGGTAACAGG ATTAGCAGAG CGAGGTATGT AGGCGGTGCT 
3841   ACAGAGTTCT TGAAGTGGTG GCCTAACTAC GGCTACACTA GAAGGACAGT ATTTGGTATC 
3901   TGCGCTCTGC TGAAGCCAGT TACCTTCGGA AAAAGAGTTG GTAGCTCTTG ATCCGGCAAA 
3961   CAAACCACCG CTGGTAGCGG TGGTTTTTTT GTTTGCAAGC AGCAGATTAC GCGCAGAAAA 
4021   AAAGGATCTC AAGAAGATCC TTTGATCTTT TCTACGGGGT CTGACGCTCA GTGGAACGAA 
4081   AACTCACGTT AAGGGATTTT GGTCATGAGA TTATCAAAAA GGATCTTCAC CTAGATCCTT 
4141   TTAAATTAAA AATGAAGTTT TAAATCAATC TAAAGTATAT ATGAGTAAAC TTGGTCTGAC 
4201   AGTTACCAAT GCTTAATCAG TGAGGCACCT ATCTCAGCGA TCTGTCTATT TCGTTCATCC 
4261   ATAGTTGCCT GACTCCCCGT CGTGTAGATA ACTACGATAC GGGAGGGCTT ACCATCTGGC 
4321   CCCAGTGCTG CAATGATACC GCGAGACCCA CGCTCACCGG CTCCAGATTT ATCAGCAATA 
4381   AACCAGCCAG CCGGAAGGGC CGAGCGCAGA AGTGGTCCTG CAACTTTATC CGCCTCCATC 
4441   CAGTCTATTA ATTGTTGCCG GGAAGCTAGA GTAAGTAGTT CGCCAGTTAA TAGTTTGCGC 
4501   AACGTTGTTG CCATTGCTAC AGGCATCGTG GTGTCACGCT CGTCGTTTGG TATGGCTTCA 
4561   TTCAGCTCCG GTTCCCAACG ATCAAGGCGA GTTACATGAT CCCCCATGTT GTGCAAAAAA 
4621   GCGGTTAGCT CCTTCGGTCC TCCGATCGTT GTCAGAAGTA AGTTGGCCGC AGTGTTATCA 
4681   CTCATGGTTA TGGCAGCACT GCATAATTCT CTTACTGTCA TGCCATCCGT AAGATGCTTT 
4741   TCTGTGACTG GTGAGTACTC AACCAAGTCA TTCTGAGAAT AGTGTATGCG GCGACCGAGT 
4801   TGCTCTTGCC CGGCGTCAAT ACGGGATAAT ACCGCGCCAC ATAGCAGAAC TTTAAAAGTG 
4861   CTCATCATTG GAAAACGTTC TTCGGGGCGA AAACTCTCAA GGATCTTACC GCTGTTGAGA 
4921   TCCAGTTCGA TGTAACCCAC TCGTGCACCC AACTGATCTT CAGCATCTTT TACTTTCACC 
4981   AGCGTTTCTG GGTGAGCAAA AACAGGAAGG CAAAATGCCG CAAAAAAGGG AATAAGGGCG 
5041   ACACGGAAAT GTTGAATACT CATACTCTTC CTTTTTCAAT ATTATTGAAG CATTTATCAG 
5101   GGTTATTGTC TCATGAGCGG ATACATATTT GAATGTATTT AGAAAAATAA ACAAATAGGG 
5161   GTTCCGCGCA CATTTCCCCG AAAAGTGCCA CCTGACGCGC CCTGTAGCGG CGCATTAAGC 
5221   GCGGCGGGTG TGGTGGTTAC GCGCAGCGTG ACCGCTACAC TTGCCAGCGC CCTAGCGCCC 
5281   GCTCCTTTCG CTTTCTTCCC TTCCTTTCTC GCCACGTTCG CCGGCTTTCC CCGTCAAGCT 
5341   CTAAATCGGG GGCTCCCTTT AGGGTTCCGA TTTAGTGCTT TACGGCACCT CGACCCCAAA 
5401   AAACTTGATT AGGGTGATGG TTCACGTAGT GGGCCATCGC CCTGATAGAC GGTTTTTCGC 
5461   CCTTTGACGT TGGAGTCCAC GTTCTTTAAT AGTGGACTCT TGTTCCAAAC TGGAACAACA 
5521   CTCAACCCTA TCTCGGTCTA TTCTTTTGAT TTATAAGGGA TTTTGCCGAT TTCGGCCTAT 
5581   TGGTTAAAAA ATGAGCTGAT TTAACAAAAA TTTAACGCGA ATTTTAACAA AATATTAACG 
5641   TTTACAATTT CCCATTCGCC ATTCAGGCTG CGCAACTGTT GGGAAGGGCG ATCGGTGCGG 







(i) pAP01-IL-4δ2-TEV-His (5672bp)  
 
Boxed – start and stop codons 
Signal peptide sequence 
Exon 1 of IL-4 
Exon 3 of IL-4 
Exon 4 of IL-4 
TEV recognition sequence 
Decahistidine tag 
Restriction enzyme sites 
 
1      GGAACGGCTC CGCCCACTAT TAATGAAATT AAAAATTCCA ATTTTAAAAA ACGCAGCAAG 
61     AGAAACATTT GTATGAAAGA ATGCGTAGAA GGAAAGAAAA ATGTCGTCGA CATGCTGAAC 
121    AACAAGATTA ATATGCCTCC GTGTATAAAA AAAATATTGA ACGATTTGAA AGAAAACAAT 
181    GTACCGCGCG GCGGTATGTA CAGGAAGAGG TTTATACTAA ACTGTTACAT TGCAAACGTG 
241    GTTTCGTGTG CCAAGTGTGA AAACCGATGT TTAATCAAGG CTCTGACGCA TTTCTACAAC 
301    CACGACTCCA AGTGTGTGGG TGAAGTCATG CATCTTTTAA TCAAATCCCA AGATGTGTAT 
361    AAACCACCAA ACTGCCAAAA AATGAAAACT GTCGACAAGC TCTGTCCGTT TGCTGGCAAC 
421    TGCAAGGGTC TCAATCCTAT TTGTAATTAT TGAATAATAA AACAATTATA AATGCTAAAT 
481    TTGTTTTTTA TTAACGATAC AAACCAAACG CAACAAGAAC ATTTGTAGTA TTATCTATAA 
541    TTGAAAACGC GTAGTTATAA TCGCTGAGGT AATATTTAAA ATCATTTTCA AATGATTCAC 
601    AGTTAATTTG CGACAATATA ATTTTATTTT CACATAAACT AGACGCCTTG TCGTCTTCTT 
661    CTTCGTATTC CTTCTCTTTT TCATTTTTCT CTTCATAAAA ATTAACATAG TTATTATCGT 
721    ATCCATATAT GTATCTATCG TATAGAGTAA ATTTTTTGTT GTCATAAATA TATATGTCTT 
781    TTTTAATGGG GTGTATAGTA CCGCTGCGCA TAGTTTTTCT GTAATTTACA ACAGTGCTAT 
841    TTTCTGGTAG TTCTTCGGAG TGTGTTGCTT TAATTATTAA ATTTATATAA TCAATGAATT 
901    TGGGATCGTC GGTTTTGTAC AATATGTTGC CGGCATAGTA CGCAGCTTCT TCTAGTTCAA 
961    TTACACCATT TTTTAGCAGC ACCGGATTAA CATAACTTTC CAAAATGTTG TACGAACCGT 
1021   TAAACAAAAA CAGTTCACCT CCCTTTTCTA TACTATTGTC TGCGAGCAGT TGTTTGTTGT 
1081   TAAAAATAAC AGCCATTGTA ATGAGACGCA CAAACTAATA TCACAAACTG GAAATGTCTA 
1141   TCAATATATA GTTGCTGATC AGATCTGATC ATGGAGATAA TTAAAATGAT AACCATCTCG 
1201   CAAATAAATA AGTATTTTAC TGTTTTCGTA ACAGTTTTGT AATAAAAAAA CCTATAAATA 
1261   TAAAGCTTGG ATCCATGGGT CTCACCTCCC AACTGCTTCC CCCTCTGTTC TTCCTGCTGG 
1321   CATGTGCCGG CAACTTTGTC CACGGACACA AGTGCGATAT CACCTTACAG GAGATCATCA 
1381   AAACTTTGAA CAGCCTCACA GAGCAGAAGA ACACAACTGA GAAGGAAACC TTCTGCAGGG 
1441   CTGCGACTGT GCTCCGGCAG TTCTACAGCC ACCATGAGAA GGACACTCGC TGCCTGGGTG 
1501   CGACTGCACA GCAGTTCCAC AGGCACAAGC AGCTGATCCG ATTCCTGAAA CGGCTCGACA 
1561   GGAACCTCTG GGGCCTGGCG GGCTTGAATT CCTGTCCTGT GAAGGAAGCC AACCAGAGTA 
1621   CGTTGGAAAA CTTCTTGGAA AGGCTAAAGA CGATCATGAG AGAGAAATAT TCAAAGTGTT 
1681   CGAGCGAAAA CCTGTATTTT CAGGGTACCC ACCATCACCA TCACCATCAC CATCACCATT 
1741   AGCCTAGGTA GCTGAGCGCA TGCAAGCTGA TCCGGGTTAT TAGTACATTT ATTAAGCGCT 
1801   AGATTCTGTG CGTTGTTGAT TTACAGACAA TTGTTGTACG TATTTTAATA ATTCATTAAA 
1861   TTTATAATCT TTAGGGTGGT ATGTTAGAGC GAAAATCAAA TGATTTTCAG CGTCTTTATA 
1921   TCTGAATTTA AATATTAAAT CCTCAATAGA TTTGTAAAAT AGGTTTCGAT TAGTTTCAAA 
1981   CAAGGGTTGT TTTTCCGAAC CGATGGCTGG ACTATCTAAT GGATTTTCGC TCAACGCCAC 
2041   AAAACTTGCC AAATCTTGTA GCAGCAATCT AGCTTTGTCG ATATTCGTTT GTGTTTTGTT 
2101   TTGTAATAAA GGTTCGACGT CGTTCAAAAT ATTATGCGCT TTTGTATTTC TTTCATCACT 
2161   GTCGTTAGTG TACAATTGAC TCGACGTAAA CACGTTAAAT AGAGCTTGGA CATATTTAAC 
2221   ATCGGGCGTG TTAGCTTTAT TAGGCCGATT ATCGTCGTCG TCCCAACCCT CGTCGTTAGA 
2281   AGTTGCTTCC GAAGACGATT TTGCCATAGC CACACGACGC CTATTAATTG TGTCGGCTAA 
2341   CACGTCCGCG ATCAAATTTG TAGTTGAGCT TTTTGGAATT ATTTCTGATT GCGGGCGTTT 
2401   TTGGGCGGGT TTCAATCTAA CTGTGCCCGA TTTTAATTCA GACAACACGT TAGAAAGCGA 
2461   TGGTGCAGGC GGTGGTAACA TTTCAGACGG CAAATCTACT AATGGCGGCG GTGGTGGAGC 
2521   TGATGATAAA TCTACCATCG GTGGAGGCGC AGGCGGGGCT GGCGGCGGAG GCGGAGGCGG 
2581   AGGTGGTGGC GGTGATGCAG ACGGCGGTTT AGGCTCAAAT GTCTCTTTAG GCAACACAGT 
2641   CGGCACCTCA ACTATTGTAC TGGTTTCGGG CGCCGTTTTT GGTTTGACCG GTCTGAGACG 
2701   AGTGCGATTT TTTTCGTTTC TAATAGCTTC CAACAATTGT TGTCTGTCGT CTAAAGGTGC 
2761   AGCGGGTTGA GGTTCCGTCG GCATTGGTGG AGCGGGCGGC AATTCAGACA TCGATGGTGG 
2821   TGGTGGTGGT GGAGGCGCTG GAATGTTAGG CACGGGAGAA GGTGGTGGCG GCGGTGCCGC 
 
 287 
2881   CGGTATAATT TGTTCTGGTT TAGTTTGTTC GCGCACGATT GTGGGCACCG GCGCAGGCGC 
2941   CGCTGGCTGC ACAACGGAAG GTCGTCTGCT TCGAGGCAGC GCTTGGGGTG GTGGCAATTC 
3001   AATATTATAA TTGGAATACA AATCGTAAAA ATCTGCTATA AGCATTGTAA TTTCGCTATC 
3061   GTTTACCGTG CCGATATTTA ACAACCGCTC AATGTAAGCA ATTGTATTGT AAAGAGATTG 
3121   TCTCAAGCTC GGATCGATCC CGCACGCCGA TAACAAGCCT TTTCATTTTT ACTACAGCAT 
3181   TGTAGTGGCG AGACACTTCG CTGTCGTCGA GGTTTAAACG CTTCCTCGCT CACTGACTCG 
3241   CTGCGCTCGG TCGTTCGGCT GCGGCGAGCG GTATCAGCTC ACTCAAAGGC GGTAATACGG 
3301   TTATCCACAG AATCAGGGGA TAACGCAGGA AAGAACATGT GAGCAAAAGG CCAGCAAAAG 
3361   GCCAGGAACC GTAAAAAGGC CGCGTTGCTG GCGTTTTTCC ATAGGCTCCG CCCCCCTGAC 
3421   GAGCATCACA AAAATCGACG CTCAAGTCAG AGGTGGCGAA ACCCGACAGG ACTATAAAGA 
3481   TACCAGGCGT TTCCCCCTGG AAGCTCCCTC GTGCGCTCTC CTGTTCCGAC CCTGCCGCTT 
3541   ACCGGATACC TGTCCGCCTT TCTCCCTTCG GGAAGCGTGG CGCTTTCTCA TAGCTCACGC 
3601   TGTAGGTATC TCAGTTCGGT GTAGGTCGTT CGCTCCAAGC TGGGCTGTGT GCACGAACCC 
3661   CCCGTTCAGC CCGACCGCTG CGCCTTATCC GGTAACTATC GTCTTGAGTC CAACCCGGTA 
3721   AGACACGACT TATCGCCACT GGCAGCAGCC ACTGGTAACA GGATTAGCAG AGCGAGGTAT 
3781   GTAGGCGGTG CTACAGAGTT CTTGAAGTGG TGGCCTAACT ACGGCTACAC TAGAAGGACA 
3841   GTATTTGGTA TCTGCGCTCT GCTGAAGCCA GTTACCTTCG GAAAAAGAGT TGGTAGCTCT 
3901   TGATCCGGCA AACAAACCAC CGCTGGTAGC GGTGGTTTTT TTGTTTGCAA GCAGCAGATT 
3961   ACGCGCAGAA AAAAAGGATC TCAAGAAGAT CCTTTGATCT TTTCTACGGG GTCTGACGCT 
4021   CAGTGGAACG AAAACTCACG TTAAGGGATT TTGGTCATGA GATTATCAAA AAGGATCTTC 
4081   ACCTAGATCC TTTTAAATTA AAAATGAAGT TTTAAATCAA TCTAAAGTAT ATATGAGTAA 
4141   ACTTGGTCTG ACAGTTACCA ATGCTTAATC AGTGAGGCAC CTATCTCAGC GATCTGTCTA 
4201   TTTCGTTCAT CCATAGTTGC CTGACTCCCC GTCGTGTAGA TAACTACGAT ACGGGAGGGC 
4261   TTACCATCTG GCCCCAGTGC TGCAATGATA CCGCGAGACC CACGCTCACC GGCTCCAGAT 
4321   TTATCAGCAA TAAACCAGCC AGCCGGAAGG GCCGAGCGCA GAAGTGGTCC TGCAACTTTA 
4381   TCCGCCTCCA TCCAGTCTAT TAATTGTTGC CGGGAAGCTA GAGTAAGTAG TTCGCCAGTT 
4441   AATAGTTTGC GCAACGTTGT TGCCATTGCT ACAGGCATCG TGGTGTCACG CTCGTCGTTT 
4501   GGTATGGCTT CATTCAGCTC CGGTTCCCAA CGATCAAGGC GAGTTACATG ATCCCCCATG 
4561   TTGTGCAAAA AAGCGGTTAG CTCCTTCGGT CCTCCGATCG TTGTCAGAAG TAAGTTGGCC 
4621   GCAGTGTTAT CACTCATGGT TATGGCAGCA CTGCATAATT CTCTTACTGT CATGCCATCC 
4681   GTAAGATGCT TTTCTGTGAC TGGTGAGTAC TCAACCAAGT CATTCTGAGA ATAGTGTATG 
4741   CGGCGACCGA GTTGCTCTTG CCCGGCGTCA ATACGGGATA ATACCGCGCC ACATAGCAGA 
4801   ACTTTAAAAG TGCTCATCAT TGGAAAACGT TCTTCGGGGC GAAAACTCTC AAGGATCTTA 
4861   CCGCTGTTGA GATCCAGTTC GATGTAACCC ACTCGTGCAC CCAACTGATC TTCAGCATCT 
4921   TTTACTTTCA CCAGCGTTTC TGGGTGAGCA AAAACAGGAA GGCAAAATGC CGCAAAAAAG 
4981   GGAATAAGGG CGACACGGAA ATGTTGAATA CTCATACTCT TCCTTTTTCA ATATTATTGA 
5041   AGCATTTATC AGGGTTATTG TCTCATGAGC GGATACATAT TTGAATGTAT TTAGAAAAAT 
5101   AAACAAATAG GGGTTCCGCG CACATTTCCC CGAAAAGTGC CACCTGACGC GCCCTGTAGC 
5161   GGCGCATTAA GCGCGGCGGG TGTGGTGGTT ACGCGCAGCG TGACCGCTAC ACTTGCCAGC 
5221   GCCCTAGCGC CCGCTCCTTT CGCTTTCTTC CCTTCCTTTC TCGCCACGTT CGCCGGCTTT 
5281   CCCCGTCAAG CTCTAAATCG GGGGCTCCCT TTAGGGTTCC GATTTAGTGC TTTACGGCAC 
5341   CTCGACCCCA AAAAACTTGA TTAGGGTGAT GGTTCACGTA GTGGGCCATC GCCCTGATAG 
5401   ACGGTTTTTC GCCCTTTGAC GTTGGAGTCC ACGTTCTTTA ATAGTGGACT CTTGTTCCAA 
5461   ACTGGAACAA CACTCAACCC TATCTCGGTC TATTCTTTTG ATTTATAAGG GATTTTGCCG 
5521   ATTTCGGCCT ATTGGTTAAA AAATGAGCTG ATTTAACAAA AATTTAACGC GAATTTTAAC 
5581   AAAATATTAA CGTTTACAAT TTCCCATTCG CCATTCAGGC TGCGCAACTG TTGGGAAGGG 











(i) pAP01-GST-TEV-NSIL4δ2 (6257bp)  
 
Boxed – start and stop codons 
GST tag 
TEV recognition sequence 
Exon 1 of IL-4 
Exon 3 of IL-4 
Exon 4 of IL-4 
Restriction enzyme sites 
 
1      GGAACGGCTC CGCCCACTAT TAATGAAATT AAAAATTCCA ATTTTAAAAA ACGCAGCAAG 
61     AGAAACATTT GTATGAAAGA ATGCGTAGAA GGAAAGAAAA ATGTCGTCGA CATGCTGAAC 
121    AACAAGATTA ATATGCCTCC GTGTATAAAA AAAATATTGA ACGATTTGAA AGAAAACAAT 
181    GTACCGCGCG GCGGTATGTA CAGGAAGAGG TTTATACTAA ACTGTTACAT TGCAAACGTG 
241    GTTTCGTGTG CCAAGTGTGA AAACCGATGT TTAATCAAGG CTCTGACGCA TTTCTACAAC 
301    CACGACTCCA AGTGTGTGGG TGAAGTCATG CATCTTTTAA TCAAATCCCA AGATGTGTAT 
361    AAACCACCAA ACTGCCAAAA AATGAAAACT GTCGACAAGC TCTGTCCGTT TGCTGGCAAC 
421    TGCAAGGGTC TCAATCCTAT TTGTAATTAT TGAATAATAA AACAATTATA AATGCTAAAT 
481    TTGTTTTTTA TTAACGATAC AAACCAAACG CAACAAGAAC ATTTGTAGTA TTATCTATAA 
541    TTGAAAACGC GTAGTTATAA TCGCTGAGGT AATATTTAAA ATCATTTTCA AATGATTCAC 
601    AGTTAATTTG CGACAATATA ATTTTATTTT CACATAAACT AGACGCCTTG TCGTCTTCTT 
661    CTTCGTATTC CTTCTCTTTT TCATTTTTCT CTTCATAAAA ATTAACATAG TTATTATCGT 
721    ATCCATATAT GTATCTATCG TATAGAGTAA ATTTTTTGTT GTCATAAATA TATATGTCTT 
781    TTTTAATGGG GTGTATAGTA CCGCTGCGCA TAGTTTTTCT GTAATTTACA ACAGTGCTAT 
841    TTTCTGGTAG TTCTTCGGAG TGTGTTGCTT TAATTATTAA ATTTATATAA TCAATGAATT 
901    TGGGATCGTC GGTTTTGTAC AATATGTTGC CGGCATAGTA CGCAGCTTCT TCTAGTTCAA 
961    TTACACCATT TTTTAGCAGC ACCGGATTAA CATAACTTTC CAAAATGTTG TACGAACCGT 
1021   TAAACAAAAA CAGTTCACCT CCCTTTTCTA TACTATTGTC TGCGAGCAGT TGTTTGTTGT 
1081   TAAAAATAAC AGCCATTGTA ATGAGACGCA CAAACTAATA TCACAAACTG GAAATGTCTA 
1141   TCAATATATA GTTGCTGATC AGATCTGATC ATGGAGATAA TTAAAATGAT AACCATCTCG 
1201   CAAATAAATA AGTATTTTAC TGTTTTCGTA ACAGTTTTGT AATAAAAAAA CCTATAAATA 
1261   TAGGATCCAT GTCCCCTATA CTAGGTTATT GGAAAATTAA GGGCCTTGTG CAACCCACTC 
1321   GACTTCTTTT GGAATATCTT GAAGAAAAAT ATGAAGAGCA TTTGTATGAG CGCGATGAAG 
1381   GTGATAAATG GCGAAACAAA AAGTTTGAAT TGGGTTTGGA GTTTCCCAAT CTTCCTTATT 
1441   ATATTGATGG TGATGTTAAA TTAACACAGT CTATGGCCAT CATACGTTAT ATAGCTGACA 
1501   AGCACAACAT GTTGGGTGGT TGTCCAAAAG AGCGTGCAGA GATTTCAATG CTTGAAGGAG 
1561   CGGTTTTGGA TATTAGATAC GGTGTTTCGA GAATTGCATA TAGTAAAGAC TTTGAAACTC 
1621   TCAAAGTTGA TTTTCTTAGC AAGCTACCTG AAATGCTGAA AATGTTCGAA GATCGTTTAT 
1681   GTCATAAAAC ATATTTAAAT GGTGATCATG TAACCCATCC TGACTTCATG TTGTATGACG 
1741   CTCTTGATGT TGTTTTATAC ATGGACCCAA TGTGCCTGGA TGCGTTCCCA AAATTAGTTT 
1801   GTTTTAAAAA ACGTATTGAA GCTATCCCAC AAATTGATAA GTACTTGAAA TCCAGCAAGT 
1861   ATATAGCATG GCCTTTGCAG GGCTGGCAAG CCACGTTTGG TGGTGGCGAC CATCCTCCAA 
1921   AATCGGATCT GGAAGTTCTG TTCCAGGGGC CCCTGCTCGA GGAAAACCTG TATTTTCAGG 
1981   GCGCCCACAA GTGCGATATC ACCTTACAGG AGATCATCAA AACTTTGAAC AGCCTCACAG 
2041   AGCAGAAGAA CACAACTGAG AAGGAAACCT TCTGCAGGGC TGCGACTGTG CTCCGGCAGT 
2101   TCTACAGCCA CCATGAGAAG GACACTCGCT GCCTGGGTGC GACTGCACAG CAGTTCCACA 
2161   GGCACAAGCA GCTGATCCGA TTCCTGAAAC GGCTCGACAG GAACCTCTGG GGCCTGGCGG 
2221   GCTTGAATTC CTGTCCTGTG AAGGAAGCCA ACCAGAGTAC GTTGGAAAAC TTCTTGGAAA 
2281   GGCTAAAGAC GATCATGAGA GAGAAATATT CAAAGTGTTC GAGCTAGCCT AGGTAGCTGA 
2341   GCGCATGCAA GCTGATCCGG GTTATTAGTA CATTTATTAA GCGCTAGATT CTGTGCGTTG 
2401   TTGATTTACA GACAATTGTT GTACGTATTT TAATAATTCA TTAAATTTAT AATCTTTAGG 
2461   GTGGTATGTT AGAGCGAAAA TCAAATGATT TTCAGCGTCT TTATATCTGA ATTTAAATAT 
2521   TAAATCCTCA ATAGATTTGT AAAATAGGTT TCGATTAGTT TCAAACAAGG GTTGTTTTTC 
2581   CGAACCGATG GCTGGACTAT CTAATGGATT TTCGCTCAAC GCCACAAAAC TTGCCAAATC 
2641   TTGTAGCAGC AATCTAGCTT TGTCGATATT CGTTTGTGTT TTGTTTTGTA ATAAAGGTTC 
2701   GACGTCGTTC AAAATATTAT GCGCTTTTGT ATTTCTTTCA TCACTGTCGT TAGTGTACAA 
2761   TTGACTCGAC GTAAACACGT TAAATAGAGC TTGGACATAT TTAACATCGG GCGTGTTAGC 
2821   TTTATTAGGC CGATTATCGT CGTCGTCCCA ACCCTCGTCG TTAGAAGTTG CTTCCGAAGA 
2881   CGATTTTGCC ATAGCCACAC GACGCCTATT AATTGTGTCG GCTAACACGT CCGCGATCAA 
 
 289 
2941   ATTTGTAGTT GAGCTTTTTG GAATTATTTC TGATTGCGGG CGTTTTTGGG CGGGTTTCAA 
3001   TCTAACTGTG CCCGATTTTA ATTCAGACAA CACGTTAGAA AGCGATGGTG CAGGCGGTGG 
3061   TAACATTTCA GACGGCAAAT CTACTAATGG CGGCGGTGGT GGAGCTGATG ATAAATCTAC 
3121   CATCGGTGGA GGCGCAGGCG GGGCTGGCGG CGGAGGCGGA GGCGGAGGTG GTGGCGGTGA 
3181   TGCAGACGGC GGTTTAGGCT CAAATGTCTC TTTAGGCAAC ACAGTCGGCA CCTCAACTAT 
3241   TGTACTGGTT TCGGGCGCCG TTTTTGGTTT GACCGGTCTG AGACGAGTGC GATTTTTTTC 
3301   GTTTCTAATA GCTTCCAACA ATTGTTGTCT GTCGTCTAAA GGTGCAGCGG GTTGAGGTTC 
3361   CGTCGGCATT GGTGGAGCGG GCGGCAATTC AGACATCGAT GGTGGTGGTG GTGGTGGAGG 
3421   CGCTGGAATG TTAGGCACGG GAGAAGGTGG TGGCGGCGGT GCCGCCGGTA TAATTTGTTC 
3481   TGGTTTAGTT TGTTCGCGCA CGATTGTGGG CACCGGCGCA GGCGCCGCTG GCTGCACAAC 
3541   GGAAGGTCGT CTGCTTCGAG GCAGCGCTTG GGGTGGTGGC AATTCAATAT TATAATTGGA 
3601   ATACAAATCG TAAAAATCTG CTATAAGCAT TGTAATTTCG CTATCGTTTA CCGTGCCGAT 
3661   ATTTAACAAC CGCTCAATGT AAGCAATTGT ATTGTAAAGA GATTGTCTCA AGCTCGGATC 
3721   GATCCCGCAC GCCGATAACA AGCCTTTTCA TTTTTACTAC AGCATTGTAG TGGCGAGACA 
3781   CTTCGCTGTC GTCGAGGTTT AAACGCTTCC TCGCTCACTG ACTCGCTGCG CTCGGTCGTT 
3841   CGGCTGCGGC GAGCGGTATC AGCTCACTCA AAGGCGGTAA TACGGTTATC CACAGAATCA 
3901   GGGGATAACG CAGGAAAGAA CATGTGAGCA AAAGGCCAGC AAAAGGCCAG GAACCGTAAA 
3961   AAGGCCGCGT TGCTGGCGTT TTTCCATAGG CTCCGCCCCC CTGACGAGCA TCACAAAAAT 
4021   CGACGCTCAA GTCAGAGGTG GCGAAACCCG ACAGGACTAT AAAGATACCA GGCGTTTCCC 
4081   CCTGGAAGCT CCCTCGTGCG CTCTCCTGTT CCGACCCTGC CGCTTACCGG ATACCTGTCC 
4141   GCCTTTCTCC CTTCGGGAAG CGTGGCGCTT TCTCATAGCT CACGCTGTAG GTATCTCAGT 
4201   TCGGTGTAGG TCGTTCGCTC CAAGCTGGGC TGTGTGCACG AACCCCCCGT TCAGCCCGAC 
4261   CGCTGCGCCT TATCCGGTAA CTATCGTCTT GAGTCCAACC CGGTAAGACA CGACTTATCG 
4321   CCACTGGCAG CAGCCACTGG TAACAGGATT AGCAGAGCGA GGTATGTAGG CGGTGCTACA 
4381   GAGTTCTTGA AGTGGTGGCC TAACTACGGC TACACTAGAA GGACAGTATT TGGTATCTGC 
4441   GCTCTGCTGA AGCCAGTTAC CTTCGGAAAA AGAGTTGGTA GCTCTTGATC CGGCAAACAA 
4501   ACCACCGCTG GTAGCGGTGG TTTTTTTGTT TGCAAGCAGC AGATTACGCG CAGAAAAAAA 
4561   GGATCTCAAG AAGATCCTTT GATCTTTTCT ACGGGGTCTG ACGCTCAGTG GAACGAAAAC 
4621   TCACGTTAAG GGATTTTGGT CATGAGATTA TCAAAAAGGA TCTTCACCTA GATCCTTTTA 
4681   AATTAAAAAT GAAGTTTTAA ATCAATCTAA AGTATATATG AGTAAACTTG GTCTGACAGT 
4741   TACCAATGCT TAATCAGTGA GGCACCTATC TCAGCGATCT GTCTATTTCG TTCATCCATA 
4801   GTTGCCTGAC TCCCCGTCGT GTAGATAACT ACGATACGGG AGGGCTTACC ATCTGGCCCC 
4861   AGTGCTGCAA TGATACCGCG AGACCCACGC TCACCGGCTC CAGATTTATC AGCAATAAAC 
4921   CAGCCAGCCG GAAGGGCCGA GCGCAGAAGT GGTCCTGCAA CTTTATCCGC CTCCATCCAG 
4981   TCTATTAATT GTTGCCGGGA AGCTAGAGTA AGTAGTTCGC CAGTTAATAG TTTGCGCAAC 
5041   GTTGTTGCCA TTGCTACAGG CATCGTGGTG TCACGCTCGT CGTTTGGTAT GGCTTCATTC 
5101   AGCTCCGGTT CCCAACGATC AAGGCGAGTT ACATGATCCC CCATGTTGTG CAAAAAAGCG 
5161   GTTAGCTCCT TCGGTCCTCC GATCGTTGTC AGAAGTAAGT TGGCCGCAGT GTTATCACTC 
5221   ATGGTTATGG CAGCACTGCA TAATTCTCTT ACTGTCATGC CATCCGTAAG ATGCTTTTCT 
5281   GTGACTGGTG AGTACTCAAC CAAGTCATTC TGAGAATAGT GTATGCGGCG ACCGAGTTGC 
5341   TCTTGCCCGG CGTCAATACG GGATAATACC GCGCCACATA GCAGAACTTT AAAAGTGCTC 
5401   ATCATTGGAA AACGTTCTTC GGGGCGAAAA CTCTCAAGGA TCTTACCGCT GTTGAGATCC 
5461   AGTTCGATGT AACCCACTCG TGCACCCAAC TGATCTTCAG CATCTTTTAC TTTCACCAGC 
5521   GTTTCTGGGT GAGCAAAAAC AGGAAGGCAA AATGCCGCAA AAAAGGGAAT AAGGGCGACA 
5581   CGGAAATGTT GAATACTCAT ACTCTTCCTT TTTCAATATT ATTGAAGCAT TTATCAGGGT 
5641   TATTGTCTCA TGAGCGGATA CATATTTGAA TGTATTTAGA AAAATAAACA AATAGGGGTT 
5701   CCGCGCACAT TTCCCCGAAA AGTGCCACCT GACGCGCCCT GTAGCGGCGC ATTAAGCGCG 
5761   GCGGGTGTGG TGGTTACGCG CAGCGTGACC GCTACACTTG CCAGCGCCCT AGCGCCCGCT 
5821   CCTTTCGCTT TCTTCCCTTC CTTTCTCGCC ACGTTCGCCG GCTTTCCCCG TCAAGCTCTA 
5881   AATCGGGGGC TCCCTTTAGG GTTCCGATTT AGTGCTTTAC GGCACCTCGA CCCCAAAAAA 
5941   CTTGATTAGG GTGATGGTTC ACGTAGTGGG CCATCGCCCT GATAGACGGT TTTTCGCCCT 
6001   TTGACGTTGG AGTCCACGTT CTTTAATAGT GGACTCTTGT TCCAAACTGG AACAACACTC 
6061   AACCCTATCT CGGTCTATTC TTTTGATTTA TAAGGGATTT TGCCGATTTC GGCCTATTGG 
6121   TTAAAAAATG AGCTGATTTA ACAAAAATTT AACGCGAATT TTAACAAAAT ATTAACGTTT 
6181   ACAATTTCCC ATTCGCCATT CAGGCTGCGC AACTGTTGGG AAGGGCGATC GGTGCGGGCC 




12.3 Section C 
12.3.1 Preliminary optimization of mycobacterial containment assay 
Preliminary experiments were performed to determine the effect of adding IL-4 at different 
concentration and at different stages during the assay. Additionally, cells were harvested 48 
hours and 120 hours post co-culture to determine the optimal time for harvesting of cells.  In 
addition to the controls and interventions mentioned in Section 6.2.1, Figure 6.1 and Table 
6.1, the effect of pre-stimulating monocytes with IL-4 on mycobacterial containment was 
also performed (see below for description of experimental setup). 
 
IL-4 prestimulation of monocytes 
rIL4 was added to monocytes on Day 0 at concentrations of 5, 20 and 100 ng/ml. MDMs 
were then generated, infected and washed as described in 1.2.1.1. Concurrently, PBMCs 
were stimulated with PPD (12µg/ml) for 6 days to generate PPD effector cells. On day 6, 
these PPD effectors were co-cultured with the infected MDMs. 
 
12.3.2 Results: Preliminary optimization experiments 
Preliminary assays were performed on presumed LTBI controls (n=4) in order to determine 
the optimal time to add rIL-4 and time to harvest post co-culture and are shown in Figure C1. 
rIL-4 was added at 3 different concentrations (5, 20 and 100ng/ml) to PBMCs together with 
PPD to generate PPD/IL4 effectors (❹ in Figure 6.1 and Table 6.1), added together with 
PPD effectors to infected MDMs (❺ in Figure 6.1 and Table 6.1) or added to monocytes 
prior to infection with H37Rv (discussed above). Infected cells were harvested at 48 hours or 
120 hours post co-culture. At 48 hours post co-culture, the „PPD effectors‟ control (32.1 x 
103 CFU/ml) showed a 50% decrease in absolute CFU/ml compared to the „MDM only‟ 
control (60.4 x 103 CFU/ml). The most noteworthy effects of IL-4 were observed in the 
„PPD/IL-4 effectors‟ and „Exogenous IL-4‟ interventions. In the „PPD/IL-4 effectors‟, the 
absolute CFU/ml increased with increasing concentrations of rIL-4 from 32.7x103 CFU/ml 
(5ng/ml rIL-4) to 62.1x103 CFU/ml (100ng/ml rIL-4). Conversely, in the „Exogenous IL-4‟ 
intervention, there was a decrease in CFU/ml from 68x103 CFU/ml (5ng/ml rIL-4) to 
28.8x103 CFU/ml (100ng/ml rIL-4). There was no observable difference in CFUs in the „IL-4 
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pre-stimulation of monocytes‟ intervention at any concentration (13.2x103 at 5ng/ml rIL-4; 
9.5 x103 CFU/ml at 100ng/ml rIL-4) or compared to the PPD effector control (32.1x103 
CFU/ml). Furthermore, CFU counts decreased by a mean of 75% when harvesting was 
performed 120 hours post co-culture compared to 48 hours post co-culture. Results were not 
statistically significant. Based on these results, and due to limitations in the amount of blood 
that could be obtained from TB patients, only the  „PPD/IL-4 effectors‟  and „Exogenous IL-
4‟ interventions were performed in subsequent M.tb survival assays on TB patients and 











Figure C1. The effect of IL-4 on mycobacterial containment in monocyte derived macrophages 
(MDMs) when added at different time points in the mycobacterial containment assay. H37Rv-
infected MDMs were co-cultured with purified protein derivative (PPD) pre-primed peripheral blood 
mononuclear cells from latently infected healthy controls (n=4). Recombinant IL-4 (rIL-4) is added at 
different concentrations (5, 20 and 100ng/ml) and at various points in the mycobacterial survival 
assay (as described in Figure 6.1). Mycobacterial growth was assessed in cells harvested (A) 48 hours 
and (B) 120 hours after co-culturing of cells. Median values are expressed as colony forming 
units/ml. Statistical analysis was performed using the Wilcoxon matched-pairs signed rank test and 
p<0.05 was deemed significant. 
 
 
